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Abstract	
This	 thesis	 sets	 out	 to	 elucidate	 whether,	 in	 a	 lower	 dose	 MIA	 model	 of	 osteoarthritis	 (OA),	 the	previously	 observed	 adaptations	 in	 descending	 noradrenaline	 and	 serotonin	 (5hydroxytrptamine,	5HT)	 are	present.	We	 similarly	 aimed	 to	 ascertain	whether	 these	 adaptations	were	 reflected	 in	 the	firing	 patterns	 of	 ON	 cells	 in	 the	 Rostral	 Ventromedial	 Medulla	 (RVM),	 as	 has	 been	 seen	 in	 other	chronic	pain	models.	Finally,	the	role	of	Nav1.8	containing	peripheral	sensory	afferents	and	a	subset	of	mechanically	 sensitive	 TRPC	 ion	 channels	 were	 assessed	 by	 modeling	 osteoarthritis	 (OA),	 using	 a	0.5mg	dose	of	MIA,	in	knock-out	and	genetically	manipulated	mouse	lines.	
	in	vivo	electrophysiology	was	performed	in	rats	following	the	injection	of	1mg	MIA	to	the	left	knee	to	induce	OA.	 Following	behavioural	 assessment,	 single	unit	 recordings	 compared	 the	 effects	of	 spinal	ondansetron	 or	 spinal	 atipamezole	 on	 evoked	 responses	 of	 dorsal	 horn	 neurones	 to	 electrical,	mechanical	 and	 thermal	 stimuli	 in	 MIA	 or	 control	 rats	 under	 isoflurane	 anaesthesia.	 Separately,	single-unit	recordings	characterized	the	response	of	ON	cells	in	the	RVM	to	a	range	of	ipsilateral	and	contralateral	mechanical	stimulation	to	the	areas	of	primary	and	secondary	hypersensitivity	in	MIA	or	sham	animals.	
Given	 the	 absence	of	 effect	 of	 either	drug	on	 evoked	 responses	of	dorsal	 horn	neurones	during	 the	1mg	 MIA	 model,	 it	 seems	 possible	 that	 modifications	 to	 the	 extent	 of	 descending	 facilitation	 or	inhibition	 during	 the	 MIA	 model	 are	 dose	 and	 time	 dependent.	 Recordings	 in	 the	 brainstem,	 the	majority	 of	 which	 appear	 to	 be	 taken	 from	 the	 NGC,	 exhibited	 no	 significant	 adaptations,	 further	suggesting	a	 lack	of	 recruitment	of	descending	 control	 in	 this	1mg	MIA	model.	This	work	adds	 to	a	growing	body	of	evidence	suggesting	that	the	descending	control	of	pain	is	highly	adaptive,	depending	upon	both	 the	extent	and	profile	of	 the	 insult	during	 the	 initiation	and	maintenance	of	chronic	pain	conditions.	
No	clear	or	significant	sparing	effect	was	observed	through	the	KO	of	either	TRPC3,	TRPC6,	the	double	TRPC3/6	KO,	 or	 through	 the	 sensory	 ablation	 of	Nav1.8	 containing	neurones.	 This	may	 indicated	 a	role	 for	redundancy	within	 the	mechano-sensory	system	of	 the	periphery,	 rendering	 these	channels	poor	targets	of	analgesia	in	OA.	
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Chapter	1	–	General	Introduction	
1.1 		 	 Why	Study	Osteoarthritis	Pain?	
Pain	is	an	intrinsically	aversive	and	hugely	subjective	sensory	experience.	In	its	adaptive	form	pain	exists	as	an	innate	warning	system	for	potential	or	existing	damage,	but	in	its	chronic,	pathological	forms	it	can	result	in	a	severe	decline	in	quality	of	life.	Such	is	the	case	in	arthritis,	which	accounts	for	approx.	40%	of	chronic	pain	conditions	in	the	UK(Breivik,	Collett	et	al.	2006).		
Of	 the	 arthritic	 conditions,	 Osteoarthritis	 (OA)	 is	 the	 most	 common.	 8.5million	 individuals	 suffer	from	OA	in	at	least	one	joint	and	71%	of	them	are	in	almost	constant	pain,	while	1million	rate	their	pain	as	unbearable(Smith	2012).	A	further	2	in	5	say	that	the	analgesia	they	are	provided	is	either	not	 very	 effective	 or	 not	 at	 all	 effective(Smith	 2012).	 This	 has	 considerable	 consequences	 for	 the	quality	of	life	of	the	patient.	Pain	becomes	a	limiting	factor	on	the	ability	to	function	and	engage	in	day-to-day	 life,	 with	 a	 third	 of	 sufferers	 retiring	 early	 and	 1	 in	 5	 giving	 up	 hobbies	 and	 leisure	activities(Smith	 2012).	 OA	 pain	 similarly	 leads	 to	 degeneration	 in	mood,	 quality	 of	 sleep	 and	 the	development	 of	 psychological	 comorbidities(Nicholson	 and	 Verma	 2004,	 Power,	 Perruccio	 et	 al.	2005).		
Pain	is	also	a	primary	driver	behind	the	~164,000	knee	and	hip	replacement	surgeries	performed	on	the	NHS	each	year,	costing	in	excess	of	£1billion	per	annum(Mancuso,	Ranawat	et	al.	1996,	Cross	III,	Saleh	et	al.	2006,	Birrell	2011).	In	the	interim,	patients	are	reliant	upon	narcotic	analgesics,	whose	side	 effect	 profiles	 include	 constipation,	 nausea	 and	 vomiting,	where	 even	 total	 joint	 replacement	fails	to	resolve	joint	pain	fully	in	30%	of	patients(Wylde,	Hewlett	et	al.	2011).	
As	 such,	 OA	 is	 not	 simply	 a	 considerable	 source	 of	 suffering	 and	 disability	 for	 millions,	 but	 also	places	considerable	financial	strain	on	the	NHS,	while	OA	related	sick	days	are	thought	to	be	worth	millions	to	the	economy,	making	the	treatment	of	OA	of	great	social	and	economic	importance.	In	the	absence	of	disease	modifying	therapies,	agents	 that	might	slow	or	even	reverse	the	progression	of	structural	pathophysiology,	the	second	greatest	unmet	need	in	the	clinical	is	effective	and	tolerable	analgesia.		
For	a	period	the	anti-NGF	therapies,	namely	tanezumab,	 looked	to	provide	a	light	at	the	end	of	the	tunnel	 for	 OA	 patients	 in	 moderate	 to	 severe,	 chronic	 pain.	 The	 results	 from	 clinical	 trials	 were	compelling(Lane,	Schnitzer	et	al.	2010,	Brown,	Murphy	et	al.	2012,	Spierings,	Fidelholtz	et	al.	2013).	However,	 after	 2	 FDA	 mandated	 clinical	 holds	 and	 an	 anticipated	 total	 of	 32	 trials	 in	 >15,000	patients,	 even	once	 licensed	 tanezumab	 is	 expected	 to	be	 contraindicated	with	NSAIDs(Balanescu,	Feist	et	al.	2014,	Schnitzer,	Ekman	et	al.	2014),	due	to	the	risk	of	rapidly	progressing	OA	(RPOA),	and	
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restricted	 to	 those	 patients	 who	 have	 failed	 several	 lines	 of	 therapy	 (Phase	 3	 trial	 design:	NCT02528188).		To	date,	the	exact	relationship	between	anti-NGF	therapies	and	NSAIDs	that	might	provoke	 RPOA	 are	 still	 unclear	 and	 it	 is	 these	 limits	 to	 our	 present	 understanding	 of	 OA,	 the	mechanisms	 underlying	 pain	 and	 their	 relationship	 to	 overall	 joint	 health,	 which	 continually	challenge	the	successful	development	of	pharmacotherapy	for	OA.		
By	developing	a	more	comprehensive	understanding	of	the	mechanisms	underlying	pain	in	OA,	the	discreet	progression	and	adaptation	of	physiological	systems	over	time,	and	building	our	awareness	of	 the	 limitations	 of	 the	models	 we	 utilize,	 we	may	 be	 able	 to	 identify	 “cleaner”	 targets	 –	 whose	analgesia	successfully	outstrip	the	side	effect	burden.	The	work	presented	within	has	aimed	to	better	understand	the	time	and	dose	related	adaptations	of	descending	control	systems	 in	a	model	of	OA	pain	 in	 order	 to	 elucidate	 if	 and	 when	 pharmacological	 interferences	 with	 these	 systems	 might	provide	effective	analgesia	in	OA.		
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1.2				 	 Osteoarthritis	
Osteoarthritis	 is	 a	 degenerative	 condition	 characterized	 by	 the	 loss	 of	 function	 and	 integrity	 of	synovial	joints,	most	notably	of	the	hip	and	knee,	though	it	can	affect	a	wide	range	of	joints,	including	the	 hands,	 spine	 and	 shoulder.	 The	 condition	 can	 be	 viewed	 as	 the	 shared	 outcome	 of	 a	 range	 of	genetic,	metabolic	and	environmental	triggers,	though	the	mechanism	underlying	the	initiation	and	perpetuation	of	this	condition	are	not	yet	fully	understood.		
Clinically,	 OA	 is	 characterized	 by	 movement-evoked	 pain,	 tenderness,	 joint	 stiffness,	 muscle	weakness,	instability	and	episodic	inflammation.	Structurally,	OA	is	described	by	the	loss	of	cartilage,	bony	out	growths	and	sclerosis.	The	stumbling	block	 for	 the	early	diagnosis	of	OA,	based	on	these	criteria,	 is	 that	 while	 joints	 may	 show	 radiological	 changes,	 these	 changes	 are	 not	 necessarily	clinically	 relevant	 for	 a	 significant	 period	 of	 time,	 limiting	 reportage	 to	 GPs.	 Additionally,	 the	appearance	of	 both	 the	pain	 and	 radiological	 features	of	OA	are	 insidious.	Notably,	 there	 is	 also	 a	disparity	between	 the	 extent	of	 structural	 alteration	 and	 clinical	 outcomes	 in	patients,	which	may	complicate	matters.	
	
1.2.1			 The	Healthy	Joint	
A	joint	can	be	simply	defined	as	the	articular	meeting	point	of	two	or	more	bones,	 largely	with	the	aim	of	providing	 either	mechanical	 support	 and/or	movement	of	 the	 skeleton.	The	 true	picture	 is	slightly	 more	 complex,	 with	 three	 subcategories	 of	 joint	 based	 on	 their	 structure	 and	 function:	Fibrous,	Cartilaginous	and	Synovial.	The	synovial	joint	is	the	most	common	of	the	joints,	for	example	the	knees,	hips,	hands	and	shoulder,	and	 is	 the	category	of	 joint	most	commonly	affected	by	OA.	A	dense	fibrous	capsule	unites	these	joints,	where	the	synovial	fluid	held	in	this	the	synovial	cavity	of	this	 capsule	 acts	 to	 lubricate	 joint	 articulation.	 Given	 the	 prevalence	 of	 OA	 of	 the	 knee	 and	 the	methods	we	use	to	model	OA	(See	Chapter	3),	I	will	focus	on	the	knee	joint	to	demonstrate	synovial	joint	anatomy	and	pathology.	
As	 in	 all	 synovial	 joints,	 the	 articulating	 bony	 surfaces	 of	 the	 knee	 are	 not	 in	 direct	 contact.	 The	articular	surfaces	of	the	femur	and	tibia,	as	well	as	the	posterior	surface	of	the	patella,	are	covered	by	hyaline	articular	cartilage	to	cushion	the	joint	and	facilitate	smooth	movement.	This	cartilage	is	a	dense	extracellular	matrix,	composed	largely	of	type	II	collagen,	proteoglycans	and	water,	which	is	secreted	 and	maintained	 by	 the	 highly	 differentiated	mesenchymal	 cells,	 known	 as	 chondrocytes.		This	cartilage	is	both	a-vascular	and	lacking	innervation.	
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In	 addition	 to	 the	 cartilage,	 the	 joint	 is	 also	 cushioned	 and	 lubricated	 by	 the	 fluid	 of	 the	 synovial	cavity,	 the	 friction	 coefficient	 of	 which	 is	 low	 enough	 to	 facilitate	 much	 freer	 movement.	 This	synovial	 fluid	 is	 crucial	 to	 the	maintenance	 of	 cellular	 entities	within	 the	 cartilage,	 supplying	 the	necessary	 gases	 and	 nutrients	 for	 survival	 and	 continued	 cartilage	 maintenance.	 This	 fluid	 is	secreted	by	the	synoviocytes	that	line	the	inner	of	the	capsule,	forming	the	synovium.	These	cells	are	highly	metabolically	active,	 responsible	 for	both	 the	nourishment	of	 the	chondrocytes	but	also	 the	removal	 of	 metabolites	 and	 products	 of	 matrix	 degradation.	 In	 contrast	 to	 the	 cartilage,	 this	structure	is	highly	vascularized	and	innervated.		
The	 capsule	 itself	 is	made	 up	 of	 fibrous	 connective	 tissue	 emerging	 from	 the	 periosteum	 of	 each	bone,	 forming	 the	 boundaries	 of	 the	 joint.	 In	 other	 words,	 those	 areas	 within	 the	 capsule	 are	designated	as	intra-articular.	In	addition	to	this	capsule,	the	bones	of	the	joint	are	held	together	by	ligaments	 and	 stabilized	 by	 the	 surrounding	 muscle	 groups,	 which	 themselves	 are	 connected	 by	tendons	directly	to	the	bone.	This	structure	essentially	holds	the	joint	together	and	acts	to	limit	the	extent	and	direction	of	flexion	in	the	joint.	
	
1.2.2			 Structural	Changes	in	OA	
At	a	macroscopic	level,	the	characteristic	change	observed	in	OA	is	a	loss,	degradation	or	fibrillation	of	 the	 hyaline	 cartilage	 covering	 the	 epiphyses	 of	 the	 synovial	 joint(Poole	 1993).	 At	 a	 more	microscopic/molecular	 level,	 there	 are	 also	 chondrocyte	 cell	 clusters,	 matrix	 depletion	 and	composition	changes(Poole	1993).	Although	the	exact	mechanisms	vary	hugely	between	individuals,	the	cartilage	is	believed	to	be	one	of	the	principal	sites	of	initiation	of	OA.	Often	described	as	the	loss	of	equilibrium	in	the	joint,	it	is	believed	there	is	a	shift	of	the	discreet	balance	between	synthesis	and	break	down	of	this	hyaline	cartilage,	triggering	the	transformations	observed	in	OA.(Eyre	2004)		
Divergence	from	“healthy”	cartilage	structure	is	not	a	uniform	process.	There	is	a	huge	spectrum	of	change;	 from	 surface	 irregularities	 and	 alterations	 in	 matrix	 composition,	 which	 can	 only	 be	observed	at	the	microscopic	level;	to	the	loss	of	huge	swathes	of	cartilage	to	expose	the	subchondral	bone.		
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However,	OA	is	not	simply	a	disease	of	the	cartilage	but	has	diverse	effects	within	the	surrounding	tissues.	Notably	there	are	distinct	changes	 in	the	bone	crucial	 to	the	diagnosis	and	perpetuation	of	OA.	 These	 include	 increased	 density	 of	 the	 juxta-articular	 bone,	 subchondral	 trabecular	 bone	structure	 modifications,	 osteophyte	 (bony	 outgrowth)	 formation	 and	 sub-articular	 cysts(Kellgren	and	Lawrence	1957,	Kean,	Kean	et	al.	2004,	Wieland,	Michaelis	et	al.	2005).		
	
There	 is	 also	 evidence	 of	 neurovascularization	 of	 areas	 of	 bone	 remodeling,	 including	 infiltration	into	 the	 neighboring	 cartilage,	 promoting	 calcification	 or	 ossification	 to	 compromise	 the	 natural	barrier	between	the	articular	cartilage	and	subchondral	bone(Ghosh	and	Cheras	2001,	Suri,	Gill	et	al.	2007,	 Walsh,	 Bonnet	 et	 al.	 2007).	 Goldring	 and	 Goldring	 2010	 argue	 that	 an	 imbalance	 in	 the	adaptation	 of	 the	 cartilage	 and	 bone	 undermines	 the	 discrete	 tissue	 relationships	 leading	 to	pathology	 in	 OA,	 though	 it	 is	 largely	 believed	 that	 cartilage	 destruction	 precedes	 bone	pathology(Felson	and	Neogi	2004,	Goldring	and	Goldring	2010).	
OA	 is	 also	 a	 disease	 of	 the	 synovium.	During	OA	 this	 thin	 cell	 barrier	 becomes	both	 inflamed	 and	thickened(Fernandez-Madrid,	 Karvonen	 et	 al.	 1994,	 Wieland,	 Michaelis	 et	 al.	 2005),	 where	 acute	
Figure	 3.1:	 Synovial	 Joint	 Structures	 Affected	 in	 OA.	 Left|	 Healthy	 joint	 lacking	 cartilage	fissures	or	 joint	 inflammation.	 Right|	OA	joint	 -	cartilage	erosion/fibrillation,	episodic	synovitis,	bone	remodeling	and	muscle	weakness.	(Weiland,	Michaelis	et	al	2005)	
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messenger RNA and the protein levels, and strongly
stimulated the anabolic functions of chondrocytes, as
indicated by increased proteoglycan production44.
A change in the equilibrium of anabolic versus cata-
bolic processes can cause a net catabolic increase and,
therefore, cartilage degradation (FIG. 4). Lohmander et
al.46 reported an increase in the numbers of fragments
of collagen type II soon after injury and arthritis. One
of the major factors during breakdown is the pro-
inflammatory cytokine IL-1β, which is expressed by
both chondrocytes and synoviocytes. Intracellularly,
the pro-form of IL-1β is converted by interleukin-1
converting enzyme (ICE, also known as caspase 1) to
produce the active form of IL-1β. The pathophysiolog-
ical importance of IL-1β has been elucidated by both
pralnacasan (Vertex/Sanofi-Aventis), an ICE inhibitor
that reduced joint damage in two murine models of
OA47, and also by gene transfer of a biological IL-1β
receptor antagonist48. IL-1β activates proteases, such as
MMPs (FIG. 5a). These enzymes cleave collagen (MMP1,
MMP8 and MMP13) and proteoglycans (MMP3) and
also convert pro-MMPs into the active form (MMP3)
(FIG. 5a). They are differentially induced in human
osteoarthritic tissue and human synovial fibroblasts49,50,
as are other degradative proteases such as cathepsins and
aggrecanases (a disintegrin-like metalloprotease with
thrombospondin type motifs, ADAMTS1/ADAMTS4/
ADAMTS5). Peroxisome proliferator-activated receptor-γ
(PPARγ), a member of the nuclear hormone receptor
superfamily of ligand-dependent transcription factors,
can exert anti-IL-1β effects and downregulates
MMP151,52. IL-1β and tumour-necrosis factor-α (TNFα)
induce overexpression of COX2 and PGE2 in the joint
53,54.
COX2 expression is at least partly mediated by the nuclear
factor-κB (NF-κB) pathway in synovial fibroblasts55,56 and
in chondrocytes53, as shown by pharmacological inhibi-
tion57 and by overexpression of a dominant-negative
inhibitor of NF-κB (IκB) mutant58. Stimulation of the
NF-κB pathway by IL-1 or TNFα results in phosphory-
lation of the IκB kinase. The subsequent degradation of
this kinase unmasks the latent NF-κB, which translocates
into the nucleus, thereby again increasing the expression
of cytokines, MMPs and COX (FIG. 5a). As mentioned
before, disrupted homeostasis seems to result in a self-
sustaining vicious cycle, thereby inducing severe struc-
tural modification (FIG. 4). This account  leaves open the
nature of the ‘entry’ and ‘exit’ points of this vicious cycle,
neither of which are yet known. Nevertheless, the like-
lihood of identifying a disease-modifying drug is now
greater than ever because the pathophysiological jigsaw is
becoming more and more complete59.
Bony changes. One of the hallmarks of OA are the patho-
logical structural changes that occur in the subchondral
cortical and trabecular bone and subarticular structures
(FIG. 2). A significant increase in bone turnover and
remodelling (that is, both bone formation and resorp-
tion) of the bone–cartilage interface occurs early in the
course of the disease, especially in areas underlying
damaged cartilage areas. The cortical subchondral plate
thickens, and the trabecular bone becomes increasingly
homeostasis occur is influenced by trauma to the joint,
and hereditary and other factors (FIG. 4). As the cartilage
breaks down, changes occur i  the underlying bone,
which thickens with the formation of bony outgrowths
from the calcified cartilage layers and the bone surface.
Finally, the synovium becomes inflamed as a result of
cartilage breakdown. Chondrocytes produce mediators
associ te  with inflammation, for example, cytokines
and chemokines37,38, and proteolytic enzymes that can
cause further damage to the cartilage (FIGS 4,5a). Key con-
tributors to catabolic processes include, for example,
matrix metalloproteinases (MMPs) and interleukin-1β
(IL-1β), growth factors and free radicals, among
others37,39. Insulin growth factor 1 (IGF1) and bone
morphogenetic proteins (BMPs) are endogenous ana-
bolic factors that stimulate cartilage generation and
remodelling40–43. The endogenous attempt to repair the
cartilage defects can lead to the subsequent activation of
an overwhelming biochemical cascade; in particular
with increased amounts of growth factors. A compound
that mimicked cartilage-repair mechanisms in a dose-
dependent manner could act as a useful chondroprotec-
tive agent, provided it stimulated cartilage locally and
did not affect regions within intact cartilage.
LEPTIN and its receptor have been identified in human
cartilage and display stimulatory effects on proteoglycan
synthesis in rats44,45. The location and the extent of leptin
expression were related to the degree of cartilage damage
and paralleled the expression of the growth factors IGF1
and transforming growth factor-β (TGFβ)44. The intra-
articular injection of leptin into rat knee joints induced
the synthesis of IGF1 and TGFβ in cartilage at both the
LEPTIN
A polypeptide hormone ligand
related to the family of
interleukin-6 cytokines encoded
by the obese (ob) gene and
secreted by adipocytes.
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Figure 2 | Articular structures that are affected in osteoarthritis. a | Healthy tissue is shown:
normal cartilage without any fissures, no signs of synovial inflammation. b | Early focal degenerate
lesion and ‘fibrillated’ cartilage, as well as remodelling of bone, is observed in osteoarthritis. This
can lead to bony outgrowth and subchondral sclerosis. 
Normal	 Osteoarthritis		
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flares	 are	 characterized	 by	 effusion,	 warmth	 and	 tenderness,	 resulting	 in	 a	 degree	 of	inactivity/morning	stiffness(Bonnet	and	Walsh	2005).	This	synovitis	is	detectable	both	by	imaging,	arthroscopy	and	histology.		
Synovitis	 may	 be	 either	 a	 primary	 initiating	 factor	 (e.g.	 following	 injury)	 or	 secondary	 to	 other	changes	 occurring	 in	 the	 joint,	 including	 the	 removal	 of	 matrix	 degradation	 products,	 such	 as	hyaluronic	 acid,	 from	 the	 synovia	 or	 the	 presence	 of	 calcium	 pyrophosphate	 dehydrate	 (CPPD)	crystals(Bonnet	and	Walsh	2005).	This	debris	initiates	cell-mediated	immune	responses,	while	Uric	Acid	 released	by	damaged	and	dying	cells	of	 the	 joints	activates	 the	 inflammasome,	 leading	 to	 the	release	of	inflammatory	mediators	such	as	IL1β,	TNF-α,	IL-6,	IL-8,	NO	and	PGE2(Guerne,	Terkeltaub	et	al.	1989,	Liu,	O'Connell	et	al.	2000,	Sellam	and	Berenbaum	2010,	Denoble,	Huffman	et	al.	2011).	It	is	these	inflammatory	factors	mediating	synovitis	and	a	 large	degree	of	the	pain	and	tenderness	 in	OA(Sellam	and	Berenbaum	2010).	 These	 factors	 also	 perpetuate	 the	 changes	 already	 occurring	 in	the	 joint,	 including	 fibroblast	 proliferations,	 immune	 cell	 recruitment,	 cellular	 apoptosis,	angiogenesis	 and	 sensory	 innervation,	 starting	 a	 vicious	 cycle	 of	 OA	 progression(Walsh	 1999,	Haywood,	McWilliams	et	al.	2003,	Bonnet	and	Walsh	2005,	Sellam	and	Berenbaum	2010).	Despite	this,	OA	is	not	classified	as	an	inflammatory	disease.	
Classically,	 X-rays	 are	 used	 to	 assess	 changes	 in	 structural	 pathology	 in	 patients	 with	 OA.	 These	changes	are	then	quantified	using	scales	which	rate	the	radiographic	pathologies	observed,	such	as	the	previously	described	loss	of	joint	space,	osteophytes	or	bone	sclerosis,	for	example	the	Kellgren	Lawrence	Grade(Kellgren	and	Lawrence	1957).	 	In	addition	to	X-ray	however,	Magnetic	Resonance	Imaging	(MRI)	can	be	used	to	provide	enhanced	perspectives	on	the	modifications	occurring	in	the	joint	 as	 OA	 progresses.	 MRIs	 have	 the	 benefit	 of	 providing	 soft	 tissue	 contrast,	 allowing	 for	 the	assessment	of	effusions,	synovitis	and	changes	in	hyaline	cartilage	-	changes	that	may	often	precede	the	development	of	radiographic	changes	-	as	well	as	bone	marrow	lesioning.		Conversely	however,	MRIs	can	highlight	“abnormalities”	in	knees	rated	as	healthy,	i.e.	individuals	without	an	OA	diagnosis	and	scoring	0	on	the	Kellgren	Lawrence	grade,	who	suffer	no	pain	at	all.	This	was	demonstrated	in	the	Framingham	Osteoarthritis	Study,	in	which	86-88%	of	painless	knees	showed	at	least	one	type	of	pathology(Guermazi,	Niu	et	al.	2012).		
The	 difficulty	with	 the	 use	 of	 structural	 changes	 to	 assess	 OA	 is	 that,	 at	 present,	 the	 relationship	between	these	changes,	disease	progression	and	pain	are	poorly	understood.	It	is	not	yet	possible	to	identify	a	causal	relationship	between	specific	structural	changes	and	the	clinical	realities	of	pain	in	OA(Hunter,	 Guermazi	 et	 al.	 2013).	 As	 such	 these	measures	 are	 of	 limited	 use,	 since	 they	 lack	 the	sensitivity	required	to	assess	disease	progression,	clinical	outcomes	of	disease	modifying	drugs	and,	
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most	 importantly	 to	my	own	 research,	 they	 are	 poorly	 association	with	 joint	 pain	 (Buchanan	 and	Kean	2002,	Finan,	Buenaver	et	al.	2013).	
	
	
Figure	 1.2:	 Sagittal	 inversion	 recovery	 (A–C)	 and	 coronal	 fast	 spin-echo	 (D–F)	 magnetic	 resonance	
images	 of	 the	 knee	 joint	 illustrating	 the	 features	 of	 osteoarthritis.	 A)	 reactive	 synovitis	 (arrow),	 B)	subchondral	 cyst	 formation	 (arrow),	 C)	 bone	 marrow	 edema	 (arrows),	D)	 partial-thickness	 cartilage	 wear	(arrow),	 and	E	 and	 F),	 full-thickness	 cartilage	wear	 (thin	 arrows),	 subchondral	 sclerosis	 (arrowhead),	 and	marginal	osteophyte	 formation	(double-tailed	arrow).	Taken	 from	Loeser	et	al	2012.	 (Loeser,	Goldring	et	al.	2012)		
1.2.3			 Clinical	Features	and	Pain	in	OA	
As	informative	as	the	above	macro	and	microscopic	transformations	in	joint	structure	may	be	to	the	study	of	OA,	these	are	not	the	motives	which	drive	patients	to	seek	medical	advice	nor	their	primary	concern	 while	 receiving	 treatment.	 They	 are	 similarly	 not	 the	 primary	 diagnostic	 considerations.	Clinically	 we	 are	 concerned	 with	 symptomatic,	 not	 simply	 radiographic,	 osteoarthritis,	 which	 is	identified	by	the	presentation	of:	
• Joint	pain	and	tenderness.		
• Limitations	to	movement	and/or	joint	instability.	
programs, leading to matrix remodeling, inappropriate
hypertrophy-like maturation, and cartilage calcification (6).
The matrix-degrading enzymes found in the OA
joint include aggrecanases and collagenases, which are
members of the matrix metalloprot inase (MMP) fam-
ily, as well as several seri e and cysteine prot inas s (7).
Matrix degradation in e rly OA may be ue to MMP-3
and ADAMTS-5, which degrade aggrecan, followed by
increased activity of collagenases, in particular MMP-13,
which is highly efficient at degrading type II collagen.
Once the collagen network is degraded, it appears that a
state is reached that cannot be reversed.
Chondrocytes have receptors for extracellular
matrix components, many of which are responsive to
mechanical stimulation. Activation of these receptors
stimulates the production of matrix-degrading pro-
teinases and inflammatory cytokines and chemokines,
either as initiating or as feedback amplification events.
The type II collagen–containing network in the inter-
territorial region is normally not accessible to degra-
dation by proteinases because it is coated with pro-
teoglycans. The importance of proteoglycan depletion
in cartilage erosion was demonstrated in ADAMTS-5–
knockout mice, which are protected against progression
in the surgical OA model (8). However, aggrecan deple-
tion, by itself, does not drive OA progression, as sug-
gested by recent studies in MMP-13–knockout mice
showing that MMP-13 deficiency inhibits cartilage ero-
sion, but not aggrecan depletion (9).
Recent studies suggest that biomechanical stress
may initiate the disruption of the pericellular matrix
through the serine proteinase HTRA-1 (10). The recep-
tor tyrosine kinase discoid n domain receptor 2 is then
exposed to its ligand, native type II collagen (Figure 3),
and preferentially induces and activates MMP-13 (11).
Syndecan 4, a trans-membrane heparan sulfate proteo-
glycan involved in the maintenance of homeostasis, is a
positive effector of ADAMTS-5 activation through its
control of the synthesis of the stromelysin MMP-3 (12).
Chondrocytes in OA cartilage, especially those
in clonal clusters, express cytokine and chemokine re-
ceptors, MMPs, and a number of other genes that
enhance or modulate inflammatory and catabolic re-
sponses, including cyclooxygenase 2 (COX-2), micro-
somal prostaglandin E synthase 1, soluble phospholipase
A2, and inducible nitric oxide synthase (iNOS; or,
NOS-2). Activation of chondrocytes by mechanical and
inflammatory stimuli occurs primarily through the NF-
!B, stress-induced and MAPK pathways (6). Activation
of canonical NF-!B (p65/p50) signaling is required for
the chondrocytes to express MMPs, NOS-2, COX-2, and
interleukin-1 (IL-1). Upon activation, the ERK, JNK,
and p38 MAPK cascades coordinate the induction and
activation of transcription factors, such as activator
Figure 1. Sagittal inversion recovery (A–C) and coronal fast spin-echo (D–F) magnetic resonance images of the knee joint illustrating the features
of osteoarthritis. Shown are A, reactive synovitis (arrow), B, subchondral cyst formation (arrow), C, bone marrow edema (arrows), D,
partial-thickness cartilage wear (arrow), and E and F, full-thickness cartilage wear (thin arrows), subchondral sclerosis (arrowhead), and marginal
osteophyte formation (double-tailed arrow). Images courtesy of Drs. Hollis Potter and Catherine Hayter, Hospital for Special Surgery, New York,
NY.
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• Crepitus	-	a	grating,	crackling	or	popping	sound	or	sensation	produced	by	friction	between	bone	and	cartilage	or	the	fractured	parts	of	a	bone.	
• Effusions	–	the	build	up	of	intra-articular	fluid.	
• Morning	stiffness,	lasting	less	than	30minutes.	
• Some	low	level	inflammation,	in	the	absence	of	a	raised	white	blood	cell	count.	
Of	 these	symptoms,	pain	 is	of	greatest	significance	 to	patients.	The	quality	and	duration	of	painful	episodes	can	differ	greatly	from	patient	to	patient:	depending	on	how	advanced	the	disease,	which	joint	 structures	 are	 affected	 and	 patient-specific	 psychological	 vulnerabilities	 that	 may	 predict	 a	greater	pain	experience	in	certain	individuals.		
The	pain	 reported	 is	 largely	movement-evoked,	where	patients	 show	 increased	 sensitivity	 to	 load	bearing	 and	 movement	 in	 the	 normal	 range	 of	 the	 joint,	 a	 form	 of	 allodynia.	 Individuals	 also	experience	 heightened	 sensitivity	 to	 particularly	 strenuous	 movements	 or	 noxious	 stimulations,	described	 as	 mechanical	 hyperalgesia(Schaible,	 Richter	 et	 al.	 2009).	 In	 other	 words,	 there	 is	 a	leftward	shift	of	the	mechanical	stimulus-response	relationship,	where	the	threshold	at	which	pain	is	evoked	is	reduced	and	the	magnitude	of	the	response	to	suprathreshold	stimuli	increases.	Although	largely	resolved	upon	rest,	in	small	subsets	of	patients	there	is	also	ongoing	pain,	largely	indicative	of	a	more	advanced	pathophysiology(Hunter,	McDougall	et	al.	2008).	There	are	also	those	who	suffer	from	nighttime	based	resting	pain(Scott	2006).		
The	 descriptors	 commonly	 associated	 with	 OA	 pain	 include	 aching,	 burning,	 throbbing,	 sharp	 or	shooting	pains,	where	it	is	worth	considering	the	impact	this	ongoing	pain	has	on	the	quality	of	life	of	 patients(Hawker	 2009).	 Notably,	 beyond	 the	 obvious	 discomfort,	 pain	 is	 detrimental	 to	mood,	quality	 of	 sleep,	 appetite	 and	 concentration	 of	 these	 individuals,	 demonstrated	 by	 the	 ability	 of	effective	 analgesics	 to	 improve	 each	 of	 these	 co-morbidities(Hawker,	 Stewart	 et	 al.	 2008,	 Schein,	Kosinski	et	al.	2008).	
Many	 individuals	also	experience	referred	pain,	 the	experience	of	pain	 in	neighbouring,	unaffected	areas	of	 the	body.	Thus	patients	with	OA	 in	 their	hip,	who	classically	experience	pain	 in	 the	groin	region,	 may	 additionally	 experience	 pain	 referred	 to	 their	 knees	 and	 buttocks(Kean,	 Kean	 et	 al.	2004).	This	referred	pain	can	be	so	great	that	there	have	been	known	cases	of	individuals	reporting	severe	knee	pain	with	no	knee	pathology	but	significant	osteoarthritis	of	 the	hip(Kean,	Kean	et	al.	2004).	It	 is	suggested	this	referred	pain	may	be	the	effect	of	either	convergent	spinal	inputs	or	the	
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result	 of	 a	 central	 hypersensitivity	 indicative	 of	 more	 wide	 spread	 CNS	 changes	 (See	 Section	
1.5.4.4).	
Much	like	the	radiographic	changes,	these	symptoms	are	commonly	assessed	and	rated	using	a	scale	or	 index	 that	 allows	 for	 a	quantitative	 assessment	of	 severity,	 as	well	 as	 efficacy	and	outcomes	of	treatment	avenues	–	not	least,	physiotherapy,	joint	replacement	and	analgesia.	The	Western	Ontario	and	McMaster	Universities	Osteoarthritis	 Index	 (WOMAC)	 is	 perhaps	 the	most	 commonly	 used	 of	these	 scales(Bellamy	 2008).	 This	 survey	 is	 completed	 by	 patients,	 either	 in	 person	 or	 over	 the	phone,	 in	 approximately	 10mins	 and	 assesses	 pain,	 stiffness	 and	 physical	 function.	 The	 index	 is	composed	of	24	sections	divided	into	three	subclasses:	
• Pain	(5	items):	during	walking,	using	stairs,	in	bed,	sitting	or	lying,	and	standing.	
• Stiffness	(2	items):	after	first	walking	and	later	on	in	the	day.	
• Physical	Function	(17	items):	including	stair	use,	rising	from	sitting,	shopping,	putting	on	/	taking	off	socks,	rising	from	bed	and	light	household	duties.	
Patients	 answer	 these	 questions,	 either	 using	 a	 5	 point	 Likert-type	 or	 visual	 analogue	 format,	 to	produce	a	standardized	assessment	of	self-reported	severity,	which	crucially	relates	this	to	activities	relevant	 to	 the	 patient.	 The	 relative	 success	 of	 WOMAC	 as	 a	 measure	 of	 symptomatic	 OA	 are	demonstrated	 by	 the	 success	 of	 the	measure	 to	 predict	 physical	 function	 and	 pain	 scores	 2	 years	after	joint	replacement(Fortin,	Penrod	et	al.	2002,	Lingard,	Katz	et	al.	2004).		
The	significance	of	measures	such	as	WOMAC,	which	focus	on	symptoms	such	as	pain	and	mobility,	is	that	they	assess	issues	that	directly	affect	the	quality	of	life	of	patients.	While	there	may	be	value	in	halting	 the	progression	of	structural	pathology	 in	OA,	 the	significance	of	 these	changes	 to	patients	will	 be	 limited	 if	 they	do	not	 translate	 to	 improvements	 in	 scores	 such	 as	WOMAC.	As	 previously	mentioned,	 this	 is	 an	 entirely	 credible	 possibility,	 given	 the	 tenuous	 relationship	 between	radiographic	and	symptomatic	OA.		
It	has	also	been	documented	 that	OA	patients	use	similar	descriptors	 for	 their	pain	as	neuropathy	patients(Hawker,	Stewart	et	al.	2008,	Parsons,	Ingram	et	al.	2011),	such	as	burning,	electric	shock	or	numbness,	where	 the	use	of	 questionnaires	 such	 as	PainDETECT	 identify	patient	 sub	 groups	with	scores	 that	 indicate	 a	 neuropathic-like	 pain(Gwilym,	 Keltner	 et	 al.	 2009).	 However,	 it	 is	 worth	considering	 that	scales	 like	 this	have	been	developed	 to	 identify	neuropathic	elements	 to	patients’	pain	and	thus	may	have	an	inherent	bias,	where	neuropathy	may	not	be	the	exclusive	cause	of	such	sensation.		
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70%	of	knee	OA	patients	have	been	shown	to	exhibit	somatosensory	abnormalities(Wylde,	Palmer	et	al.	2012).	These	include	localized	thermal	and	tactile	hypoaestheisa	and	pressure	hyperalgesia	at	the	affected	 knee,	 as	 well	 as	 some	 tactile	 hypoaestheisa	 and	 pressure	 hyperalgesia	 in	 the	 pain	 free	forearm.	 Similarly,	 it	 has	 been	 documented	 that	OA	 patients	 exhibit	 loss	 of	 sensations,	 notably	 to	proprioception	and	vibration	sensitivity	at	cutaneous	sites(Oliveria,	Felson	et	al.	2005,	Hirsch,	Just	et	al.	 2013,	 Zavan,	 Ferroni	 et	 al.	 2013).	 Diagnosis	 of	 a	 neuropathic	 pain	 requires	 the	 “presence	 of	negative	or	positive	neurological	 signs	 concordant	with	 the	distribution	of	 pain”(Danziger,	Weil‐Fugazza	et	al.	2001).	These	sensory	losses	represent	negative	signs,	while	changes	to	pressure	pain	thresholds	in	these	patients	represent	positive	signs(Arendt-Nielsen,	Nie	et	al.	2010),	supporting	the	idea	that	a	small	subset	of	patients	may	have	a	neuropathic-like	pain	condition.	
	
1.2.	4			 Risk	Factors	
Osteoarthritis	 can	 be	 viewed	 as	 the	 shared	 outcome	 of	 a	 range	 of	 genetic,	 metabolic	 and	environmental	 triggers	 and	 risk	 factors,	 though	 the	 mechanism	 underlying	 the	 initiation	 and	perpetuation	 of	 this	 condition	 are	 not	 yet	 fully	 understood.	 Broadly	 speaking,	 the	 following	 are	considered	primary	risk	factors	in	the	development	of	OA:		
1. Aging	
• All	studies	indicate	that	the	incidence	of	OA	increase	severely	with	age,	across	all	joints(Arden	and	Nevitt	2006).	While	1	in	5	adults	aged	50-59	suffers	from	painful	OA	in	one	or	both	knees,	by	the	age	of	80+	this	incidence	increases	to	1	in	2	adults(Arthritis	Research	Nov	2008).		
• This	relationship	is	likely	the	result	of	a	convergence	of	age	related	factors,	not	least	declining	muscle	 function(Hurley	 1999),	 decreased	 joint	 stability(Sharma	 1999,	 Sharma,	 Lou	 et	 al.	1999),	 increased	 vulnerability	 of	 joint	 tissues	 to	 biomechanical	 insults	 and	 shift	 in	 the	equilibrium	 between	 catabolic	 and	 anabolic	 processes	 in	 the	 cartilage,	 altering	 the	 ultimate	cartilage	composition	and	thickness(Arden	and	Nevitt	2006).		
2. Bone	Density	and	Osteoporosis	
• Bone	 changes	 are	 a	 crucial	 part	 of	 OA	 pathophysiology	 (subchondral	 bone	 sclerosis	 and	osteophytes)	 and	 thus	 the	 health	 of	 the	 bones	 play	 a	 crucial	 role.	 It	 has	 been	 shown	 that	greater	bone	mineral	density	predisposes	women	to	OA,	while	osteoporosis	protects	against	–	though	 both	 of	 these	 may	 relate	 to	 Oestrogen(Hannan,	 Anderson	 et	 al.	 1993,	 Dequeker,	Boonen	et	al.	1996).	
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3. Gender	
• Women	are	more	prone	to	suffering	from	OA,	most	especially	of	the	knee,	hands	or	generalized	OA	(affecting	multiple	 joints).	Similarly,	hip	OA	has	been	shown	 to	progress	more	 rapidly	 in	women(Dougados,	Gueguen	et	al.	1996).		
• It	is	suggested	that	these	gender	differences	relate	to	various	levels	of	the	sex	hormones,	given	HRT	can	reduce	the	risk	of	OA(Arden	and	Nevitt	2006).	
4. Genetics	
• The	 combination	 of	 twin	 studies,	 epidemiology	 of	 family	 history	 and	 exploration	 of	 rare	genetic	diseases	have	assessed	the	heritability	of	OA	as	more	than	50%,	dependent	upon	the	joint.	Specifically,	studies	have	shown	heritability	of	Knee	OA	between	39	and	65%.	(Spector	and	MacGregor	2004)	
• Candidate	 gene	 studies	 and	 genome	wide	 linkage	 studies	 have	 suggested	 a	wide	 number	 of	possible	genetic	links	–	see	Valdes	and	Spector	2010	for	a	review	of	these(Valdes	and	Spector	2010).	Similarly,	our	understanding	of	 the	genetics	of	OA	pain	 is	growing	–	see	Thakur	et	al	2013	for	a	review(Thakur,	Dawes	et	al.	2013).	
5. Obesity	
• Obesity	is	the	major	risk	factor	associated	with	OA(Blagojevic,	Jinks	et	al.	2010),	where	weight	loss	is	often	advised	to	limit	the	progression	of	OA	pathology.	The	effect	of	obesity	appears	to	be	greater	in	women	and	there	is	a	tendency	towards	bilateral	over	unilateral	OA.	
• Recent	work	suggests	that	this	is	not	simply	a	byproduct	of	joint	loading,	since	there	is	a	two	fold	greater	risk	of	hand	OA	in	obese	vs.	normal	weight	patients.		It	is	proposed	that	there	is	a	more	complex	relationship	between	OA,	obesity	and	inflammation(Berenbaum,	Eymard	et	al.	2013).	
6. Race	
• Discreet	differences	in	risk	exist	by	race	and	climate.	For	example,	African	American	are	 less	likely	 to	 develop	 symptomatic	 hand	 OA	 but	 more	 likely	 to	 suffer	 knee	 only	 OA	 vs.	Caucasians(Nelson,	 Golightly	 et	 al.	 2013).	 In	 regards	 to	 OA	 pain,	 it	 is	 suggested	 that	 the	difference	between	Caucasian	and	African	Americans	may	be	the	result	of	differences	in	Vit	D	
		 36	
levels,	specifically	that	Vit	D	deficiency	may	be	a	risk	factor	for	greater	OA	Pain(Glover,	Goodin	et	al.	2012).	
• Evidence	suggests	that	the	prevalence	of	knee	OA	is	lowest	in	South	and	Southeast	Asia	while	hip	OA	 is	 lowest	 in	East	Asia(Cross,	 Smith	 et	 al.	 2014).	However,	 this	 is	 expected	 to	 change	rapidly	over	the	next	century	as	the	proportion	of	the	population	in	Asian	countries	becomes	increasingly	 aged.	 For	 example,	 by	2040	Singapore	will	 experience	 an	316%	 increase	 in	 the	population	over	65,	and	India	a	274%	increase(Fransen,	Bridgett	et	al.	2011).	This	will	likely	combine	 with	 increasing	 prevalence	 of	 obesity	 in	 these	 populations,	 combined	 with	 the	manual	heavy	occupations,	to	increase	prevalence	in	Asia	over	time.	
7. Smoking	
• Smoking	appears	to	have	a	moderately	protective	effect(Blagojevic,	Jinks	et	al.	2010),	though	there	is	little	to	no	biological	explanation	of	this.	It	is	possible	that	this	is	merely	a	correlate	of	the	effect	smoking	has	been	shown	to	be	linked	to	a	lower	BMI(Blagojevic,	Jinks	et	al.	2010).		
8. Trauma	
• A	history	of	 joint	 injury	or	trauma	is	a	central	risk	 factor	 for	the	development	of	OA.	50%	of	those	 diagnosed	 with	 anterior	 cruciate	 ligament	 or	 meniscus	 tears	 have	 symptomatic	 OA	within	 10-20years	 of	 injury(Lohmander,	 Englund	 et	 al.	 2007).	 Similarly,	 in	 another	 study,	while	only	6%	of	uninjured	participants	developed	knee	OA,	14%	of	those	with	history	of	knee	injury	in	adolescence	or	young	adulthood	developed	OA(Anderson,	Chubinskaya	et	al.	2011).	
• It	is	worth	noting	that	while	OA	is	more	common	in	former	athletes,	largely	as	a	consequence	of	intense	joint	loading	and	injury(Maffulli,	Longo	et	al.	2011),	this	by	no	means	outweighs	the	benefits	of	sport	given	the	protective	effects	of	exercise	on	patients	already	suffering	OA(Fries,	Bruce	et	al.	2012).	
	
1.2.5 		 Epidemiology	
Analysis	 of	 the	 Johnston	 County	 Osteoarthritis	 project,	 a	 longitudinal	 prospective	 study	 of	 OA	 in	Johnston	County,	North	Carolina,	estimated	that	the	lifetime	risk	of	developing	symptomatic	knee	OA	to	be	44.7%	overall(Murphy,	Schwartz	et	al.	2008).	Although	they	reported	no	significant	differences	by	 gender,	 the	 lifetime	 risk	 for	 women	 was	 7%	 points	 higher	 at	 46.8%,	 while	 both	 obesity	 and	history	of	injury	significantly	increased	the	lifetime	risk.	
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At	 present,	 roughly	 8.5million	 Britons	 have	 OA(Smith	 2012).	 It	 is	 predicted	 that	 OA	will	 become	more	 prevalent	 as	 the	 population	 ages,	 given	 incidence	 increases	 sharply	 at	 >50years	 of	age(Oliveria,	 Felson	 et	 al.	 1995),	 and	 obesity	 becomes	more	 prevalent.	 This	 is	 a	 pattern	 observed	clearly	 in	 the	 USA,	 where	 the	 number	 of	 Americans	 with	 OA	 in	 either	 a	 hip,	 knee	 or	 hand	 joint	increased	from	21million	in	1995	to	27million	in	2005(Lawrence,	Felson	et	al.	2008).		
The	 Framingham	 Study	 is	 perhaps	 one	 of	 the	 best-known	 studies	 of	 prevalence	 and	 risk	 factors	associated	 with	 OA.	 This	 population	 study,	 initially	 recruited	 as	 part	 of	 a	 prospective	 study	 of	
cardiovascular	risk	and	 incidents,	monitored	over	5,200	adults	over	a	35year	period,	where	of	 the	1,805	subjects	who	participated	in	examinations,	radiographs	were	obtained	from	1,424	(4	of	which	were	 excluded	 due	 to	 bilateral	 knee	 replacements)	 and	 graded	 using	 the	 Kellgren	 Lawrence	scale(Felson	 1990).	 Patients	 were	 also	 asked	 a	 series	 of	 questions	 about	 knee	 symptoms	 and	physical,	 functional	 disability.	 This	 allowed	 a	 comparison	 of	 the	 prevalence	 of	 radiographic	 or	symptomatic	knee	OA,	by	age	and	sex	–	the	results	of	which	are	given	in	the	Table	1,	below(Felson	1990).	
This	 data	 clearly	 demonstrated	 both	 the	 increasing	 prevalence	 of	 symptomatic	 and	 radiographic	knee	 OA	 with	 age,	 but	 also	 the	 increased	 prevalence	 in	 women.	 It	 also	 demonstrates	 that	 while	roughly	one	third	will	exhibit	radiographic	OA,	only	around	one	tenth	–	rising	to	16%	in	women	over	
Table	 3.1:	 Prevalence	 of	Knee	OA	by	 age	 and	 gender	 in	 the	 Framingham	OA	 study	 –	data	 from	Felson	1990(Felson	1990).	 	Prevalence	of	 radiographic	 and	symptomatic	Knee	OA	increases	with	age,	with	greater	prevalence	in	women		.	
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the	 age	 of	 80	 –	 suffer	 symptomatic	 OA,	 which	 involves	 pain,	 aching,	 stiffness	 and	 functional	impairment	in	addition	to	radiographic	changes.	
Ethnic	differences	in	the	prevalence	of	OA	have	also	been	noted,	as	briefly	discussed	in	risk	factors.	According	 to	 Nelson	 2013,	 African	 American	 are	 less	 likely	 to	 develop	 symptomatic	 hand	OA	 but	more	likely	to	suffer	knee	only	OA	vs.	Caucasians(Nelson,	Golightly	et	al.	2013).	This	is	also	shown	by	the	Johnston	County	OA	project,	which	observed	32.2%	vs.	23.8%	prevalence	of	radiographic	hip	OA	in	African	American	men	vs.	Caucasian	men(Jordan,	Helmick	et	al.	2009).	The	Beijing	Osteoarthritis	study	meanwhile	has	shown	that	both	hand	and	hip	OA	are	less	prevalent	in	Chinese	populations	vs.	white	America,	where	the	prevalence	of	hip	OA	is	Chinese	ages	60–89	years	was	0.9%	in	women	and	1.1%	in	men,	over	80%	less	frequent(Nevitt,	Xu	et	al.	2002,	Zhang,	Xu	et	al.	2003).	Conversely,	 the	Beijing	study	revealed	a	higher	prevalence	of	both	radiographic	and	symptomatic	knee	OA	in	women	compared	 to	 their	 white	 Framlington	 counterparts,	 while	 no	 difference	 was	 seen	 in	 male	groups(Zhang,	Xu	et	al.	2001).	
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1.3 		 Current	Treatments	of	OA	Pain	 	
The	primary	 complaint	of	OA	patients	 is	pain.	As	previously	described,	71%	of	OA	patients	 are	 in	almost	 constant	 pain,	 where	 1million	 rate	 their	 pain	 as	 unbearable(Smith	 2012).	Whether	 in	 the	early	stages	of	OA,	or	 the	 latter	stages	awaiting	 joint	replacement,	 it	 is	pain	that	drives	patients	 to	seek	out	their	GPs,	in	need	of	analgesia.	The	problem	facing	clinicians,	however,	is	that	2	in	5	say	the	analgesia	they	are	provided	is	either	not	very	effective	or	not	at	all	effective(Smith	2012).	Similarly,	because	 the	 majority	 of	 patients	 are	 among	 the	 more	 elderly,	 they	 are	 more	 likely	 to	 exhibit	concurrent	 conditions,	 such	 as	 CVD,	which	will	 complicate	 and	 limit	 the	 prescriptions	 the	 GP	 can	offer.	 Nevertheless,	 there	 are	 a	 number	 of	 interventions	 open	 to	 patients,	 ranging	 from	 non-pharmacological,	 pharmacological	 to	 surgical.	 I	 will	 be	 focusing	 on	 pharmacology	 and	 surgery,	where	the	non-pharmacological	interventions	are	outlined	in	Figure	1.4	and	1.5.	
	
1.3.1 		 Pharmacology	
Paracetamol	is	the	first	choice	of	oral	analgesia	for	patients,	whether	recommended	or	bought	over	the	counter	to	ease	pain	in	the	early	days	of	OA.	For	a	long	period,	paracetamol	(up	to	4g	per	day)	was	considered	the	analgesic	of	choice	in	the	mild	to	medium	stages	of	OA,	not	least	because	of	its	safety	and	effectiveness(Jordan,	Arden	et	al.	2003,	Zhang,	Doherty	et	al.	2005,	Zhang,	Moskowitz	et	al.	2008).	Most	literature	reviews	pointed	to	a	slightly	lesser	analgesia,	but	greater	safety	profile	of	paracetamol	vs.	NSAIDs,	thus	recommending	it	as	the	long-term	analgesic	of	choice(Zhang,	Jones	et	al.	 2004,	Zhang,	Doherty	et	 al.	 2005).	 	 Specifically,	 one	meta-analysis	of	10	 randomized	controlled	trials	 (RCTs)	 suggested	 that	 the	 safer	 profile	 of	 paracetamol,	 despite	 being	 less	 effective,	recommended	it	for	first	line	treatment	above	NSAIDs(Zhang,	Nuki	et	al.	2010).	
However,	findings	in	more	recent	literature	are	beginning	to	question	the	consensus.	A	recent	GDC	review	(The	NICE	Guideline	Development	Group)	has	pointed	 to	a	 smaller	efficacy	of	paracetamol	analgesia	in	OA	than	was	previously	believed	and	consequently	NICE	will	be	conducting	a	review	in	the	near	future	of	the	evidence	on	pharmacological	management	of	osteoarthritis(Excellence	2014,	Excellence	2014).		Further,	though	the	side	effect	profile	is	smaller	than	that	of	NSAIDs,	patients	are	still	 at	 increased	risk	of	upper	GI	 complications,	notably	bleeds(Rahme,	Barkun	et	al.	2008),	while	some	patients	may	exhibit	mild	loss	of	liver	function	or	hepatotoxicity(Zhang,	Nuki	et	al.	2010).	
NSAIDs	–	Non	Steroidal	Anti-Inflammatory	Drugs	–	are	prescribed	in	two	distinct	forms,	topical	and	oral.	 Topical	 NSAIDs,	 while	 effective	 on	 their	 own	 in	 mild	 OA,	 can	 make	 successful	 adjuncts	 to	paracetamol.	 The	 peripheral	 application	 has	 the	 notable	 benefit	 of	 avoiding	 cardiovascular	 and	gastrointestinal	(GI)	risks,	whose	impact	are	far	greater	in	the	largely	older	patient	pool(Baraf,	Gloth	
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et	al.	2011).	As	such,	it	is	only	after	paracetamol	and	topical	NSAIDs	have	been	insufficient	that	use	of	oral	NSAIDs	and	COX-2	inhibitors	are	recommended	by	NICE(Excellence	2014).		
	
Figure	 1.3:	 National	 Institute	 for	 Health	 and	 Care	 Excellence	 guidelines	 for	 the	 management	 of	
Osteoarthritis	(NICE	2014).	Following	a	diagnosis	of	OA	(1)	the	clinician	must	assess	the	impact	of	OA	on	the	patient’s	 function,	quality	of	 life,	mood,	occupation	and	relationships	(2).	Self-management	 interventions	are	then	suggested,	such	as	weight	loss,	exercise	and	suitable	foot	wear,	in	addition	to	treatments	in	line	with	the	severity	 of	 the	 patients	 OA.	 These	 will	 include	 prescription	 of	 pharmacological	 interventions,	 such	 as	paracetamol,	 NSAIDs,	 COX-2	 inhibitors	 and	 opioids	 (6),	 non-pharmacological	 interventions	 such	 as	
Management of osteoarthritis NICE Pathways
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thermotherapy,	TENS	and	assistive	devices	 (5),	or	 in	more	advanced	cases,	 referral	 for	 joint	 replacement	or	arthroplasty.		
NSAIDs	have	been	found	to	be	effective	analgesics	in	OA	across	a	range	of	studies,	both	in	patients	and	 animals(Zhang,	 Jones	 et	 al.	 2004,	 Towheed,	Maxwell	 et	 al.	 2006,	 Gallelli,	 Galasso	 et	 al.	 2013).		However,	 the	prevalence	of	serious	GI	effects	renders	NSAIDs	 less	 tolerable.	A	Cochrane	review	of	fifteen	RCTs	involving	5986	participants	found	19%	of	patients	experienced	an	adverse	GI	event,	vs.	13%	in	the	paracetamol	group(Towheed,	Maxwell	et	al.	2006).		As	such,	recommendations	focus	on	the	use	of	NSAIDs	at	the	lowest	possible	dose	for	the	shortest	period	of	time,	and	the	co-prescription	of	a	proton	pump	inhibitor	to	protect	the	GI	tract(Bijlsma,	Berenbaum	et	al.	2011,	Excellence	2014).	
The	 Coxibs,	 selective	 Cox-2	 inhibitors,	 can	 provide	 some	 respite	 from	 the	 gastric	 risks	 of	conventional	NSAIDs	with	the	same	or	greater	analgesic	efficacy(Sarzi-Puttini,	Cimmino	et	al.	2005).	Randomized	controlled	studies	have	shown	that	rofecoxib	and	celecoxib	produce	2	to	3	times	fewer	GI	 events	 and	 complications,	 such	 as	 perforations	 and	 bleeds,	 than	 ibuprofen	 or	 naproxen(Jones,	Rubin	 et	 al.	 2008).	 Similarly,	 Laine	 et	 al’s	 review	 of	 RCTs,	 meta-analyses,	 and	 literature	 review	demonstrated	a	74%	reduction	in	the	relative	risk	of	gastroduodenal	ulcers,	and	61%	reduction	in	ulcer	 complication	 using	 the	 coxib	 versus	 traditional	 NSAIDs(Laine,	White	 et	 al.	 2008).	 However,	contrary	 to	 this,	 their	 study	 also	 demonstrated	 a	 twofold	 increase	 in	 the	 risk	 of	 myocardial	infarctions	vs.	placebo(Laine,	White	et	al.	2008),	a	consideration	with	added	significance	given	the	average	age	and	weight	of	an	OA	patient.	
In	addition	to	the	use	of	oral	analgesics,	patients	may	also	be	prescribed	Capsaicin	creams	(0.025%,	4x	daily).	Capsaicin	is	the	lipophilic	alkaloid	agent	extracted	from	chilli	peppers,	responsible	for	the	hot	or	“spicy”	sensation	of	this	plant.	Capsaicin	binds	to	transient	receptor	potential	vanilloid	type1	(TRPV1)	ion	channels	to	cause	the	activation	and	sensitization	of	small	diameter	afferents,	termed	C	fibers,	 to	 produce	 a	 burning	 pain.	 However,	 the	 long	 term	 activation	 of	 TRPV1	 can	 cause	 the	desensitization	of	these	fibers,	and	eventually	the	“drawing	back”	of	the	afferent	terminals	from	the	site	of	application(Nolano,	Simone	et	al.	1999),	producing	loss	of	sensation	and	as	such	is	considered	an	adjunct	therapy	in	8/9	treatment	guidelines,	often	alongside	paracetamol(Zhang,	Moskowitz	et	al.	2007).	 While	 several	 studies	 show	 statistical	 significance	 in	 the	 efficacy	 of	 capsaicin	 cream	treatment(McCarthy	 and	 McCarty	 1992,	 Altman,	 Aven	 et	 al.	 1994,	 Schnitzer,	 Morton	 et	 al.	 1994,	Mason,	Moore	et	al.	2004),	it	is	worth	keeping	in	mind	the	inability	to	blind	participants	in	capsaicin	studies,	which	may	limit	these	studies.	
For	those	patients	prone	to	inflammatory	flares,	intra	articular	 injections	of	corticosteroids	can	supplement	 paracetamol/NSAIDs	 to	 provide	 long	 lasting	 (4-6week)	 anti-inflammatory	 action	 and	analgesia,	with	an	effect	size	of	0.58(Bijlsma,	Berenbaum	et	al.	2011),	for	those	patients	experiencing	
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moderate	 to	 severe	 pain(Excellence	 2014).	 A	 Cochrane	 review	 of	 28	 trials	 of	 1973	 participants,	comparing	intra	articular	corticosteroid	to	placebo,	found	these	injections	to	be	effective	analgesics	in	weeks	1-3,	with	a	numbers	needed	to	treat	of	 just	3-4(Bellamy,	Campbell	et	al.	2009).	However,	they	 found	no	significant	effect	beyond	week	4.	 IA	corticosteroid	may	represent	a	short	 term,	well	tolerated	analgesic	intervention	for	patients,	given	the	small	side	effect	profile	–	as	you	would	expect	from	a	peripherally	administered	therapy.	However,	given	the	short	term	nature	of	this	therapy,	for	what	is	a	chronic	pain	condition,	along	side	the	relatively	invasive	administration	vs.	oral	or	topical	analgesia,	IA	corticosteroids	are	rarer,	and	only	recommended	as	an	adjunct	to	the	core	therapeutic	pathway(Excellence	2014).	
For	 those	 patients	 experiencing	 moderate	 to	 severe	 pain,	 likely	 while	 waiting	 for	 surgical	intervention,	opioid	therapies	may	similarly	be	considered	where	paracetamol	alone	failed.	Opioids	are	 known	 as	 the	 “gold	 standard”	 analgesic	 across	 a	 range	 of	 chronic	 pain	 conditions.	 These	compounds	 provide	 a	 high	 standard	 of	 pain	 relief	 for	 patients	 with	 moderate	 to	 severe	 pain	conditions,	 providing	 analgesia	 where	many	 other	 compounds	 fail.	 This	 is	 the	 case	 in	 OA,	 where	opioids	 are	 recommended	 in	 patients	 where	 the	 conventional	 first	 choice	 therapies	 have	failed(Avouac,	Gossec	et	al.	2007).		
At	the	milder	end	of	the	Opioid	spectrum,	codeine	or	paracetamol-codeine	combinations	provides	a	superior	 level	 of	 analgesia	 than	 paracetamol	 for	 those	 patients	 for	 whom	 paracetamol	 alone	 or	NSAIDs	are	 insufficient(Bijlsma,	Berenbaum	et	al.	2011).	 	However,	 some	studies	have	questioned	whether	these	weaker	opioids	are	truly	more	effective	than	paracetamol	or	NSAIDs,	where	one	meta	analysis	 of	 opioids	 for	 chronic,	 non-cancer	 pain	 demonstrated	 that	 only	 the	 strong	 opioids	 were	more	effective(Center	2008).	
In	 more	 exceptional	 circumstances,	 patients	 may	 be	 prescribed	 stronger	 opioids	 like	 tramadol,	
oxycodone	or	morphine	for	short	periods,	which	have	been	shown	to	be	effective	across	a	range	of	RCTs	(Thorne,	Beaulieu	et	al.	2008,	Zhang,	Moskowitz	et	al.	2008,	Bijlsma,	Berenbaum	et	al.	2011).	Analysis	of	18	placebo-controlled	RCTs,	including	3244	patients	with	OA,	showed	a	moderate	effect	size	of	0.78	for	reduction	in	pain	intensity(Zhang,	Moskowitz	et	al.	2008).	However,	the	tolerability	of	this	class	of	drugs	is	extremely	poor.	Studies	report	withdrawal	rates	exceeding	30%	as	a	result	of	nausea,	 vomiting,	 dizziness,	 constipation	 and	 somnolence(Zhang,	 Moskowitz	 et	 al.	 2008,	 Bijlsma,	Berenbaum	et	al.	2011),	while	others	highlight	that	the	gains	in	function	through	analgesia	may	be	countered	by	 the	 functional	 impairments	of	 the	 side	 effects(Avouac,	Gossec	 et	 al.	 2007).	Crucially,	the	numbers	needed	to	harm	–	the	number	of	patients	you	must	treat	before	one	will	experience	an	adverse	effect	 and	withdraw	–	 can	be	as	 little	 as	4	 for	 strong	opioids(Avouac,	Gossec	et	 al.	2007).	
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Furthermore,	the	desirability	of	opioid	therapy	is	limited	for	long-term	use	by	strong,	not	unfounded	concerns	around	tolerance	and	addiction.		
	
Figure	 1.4:	 NICE	 Guidelines	 for	 the	 treatment	 of	 OA	 in	 adults(Conaghan,	 Dickson	 et	 al.	 2008).	Treatments	are	arranged	in	order	of	consideration,	starting	in	the	center,	taking	into	account	individual	needs	and	risk	factors.	Along	side	the	central	“core”	treatments,	the	next	major	consideration	is	paracetamol	and/or	topical	 NSAID.	 The	 outer	 circle	 also	 shows	 adjunctive	 treatments	 (both	 non-pharmacological	 and	 surgical),	which	have	 less	established	efficacy,	provide	 less	 symptom	relief,	or	 increased	 risk	 to	 the	patient	 compared	with	those	in	the	second	circle.	
	
A	 newer	 avenue	 of	 consideration	 for	 the	 pharmacological	 management	 of	 OA	 is	 the	 use	 of	
antidepressants.	 These	 drugs,	 which	 are	 already	 licensed	 for	 management	 of	 neuropathic	 pain	conditions	 such	 as	 diabetic	 neuropathy	 and	 fibromyalgia,	manipulate	 the	monoamine	 transmitter	systems	 to	produce	analgesia	and,	 at	higher	doses,	 combat	depression	and	anxiety.	One	particular	drug,	 duloxetine,	 has	 received	 particular	 attention	 following	 on	 from	 success	 in	 RCTs(Chappell,	Ossanna	et	al.	2009,	Sullivan,	Bentley	et	al.	2009,	Hochberg,	Wohlreich	et	al.	2012,	Pergolizzi,	Raffa	et	al.	 2013).	 Duloxetine	 is	 a	 selective	 serotonin	 noradrenaline	 reuptake	 inhibitor	 (SNRI)	 that,	 by	blocking	 reuptake	 of	 these	 monoamines,	 increases	 availability	 of	 these	 transmitters	 at	 the	 post	synaptic	 receptors.	 	 These	 RCTs	 have	 shown	 duloxetine	 to	 provide	 significant	 reduction	 in	 pain	scores,	 starting	 immediately	 and	 maintaining	 across	 the	 entirety	 of	 the	 studies	 durations,	 with	
! Offer paracetamol for pain relief—regular dosing
may be needed.
! For knee and hand osteoarthritis, consider para-
cetamol and/or topical non-steroidal anti-inflam-
matory drugs (NSAIDs) before oral NSAIDs,
cyclo-oxygenase-2 (COX 2) inhibitors, and
opioids.
! Consider topical capsaicin.
! If paracetamol or topical NSAIDs are insufficient
for pain relief, then consider adding opioid
analgesics or substituting with (or in addition to
paracetamol) an oral NSAID or COX 2 inhibitor.
! Use oral NSAIDs or COX 2 inhibitors at the
lowest effective dose for the shortest possible
period of time. The first choice should be either a
COX 2 inhibitor (other than etoricoxib 60 mg) or
a standard NSAID. In either case, prescribe these
alongside a proton pump inhibitor, choosing the
one with the lowest acquisition cost.
! All oral NSAIDs and COX-2 inhibitors have
analgesic effects of a similar magnitude but vary
in their potential gastrointestinal, liver, and
cardiorenal toxicity; therefore, when choosing
the agent and dose, take into account an
individual’s risk factors (including age) and
consider appropriate assessment and/or ongoing
monitoring of these risk factors.
! If a person with osteoarthritis needs to take low
dose aspirin, consider other analgesics before
substituting with or adding an NSAID or COX 2
inhibitor (plus a proton pump inhibitor) if pain
relief is ineffective or insufficient.
! Consider intra-articular corticosteroid injections
for the relief of moderate to severe pain.
Rubefacients and intra-articular hyaluronan injec-
tions are not recommended for the treatment of
osteoarthritis.
Referral for surgical interventions
! Referral for arthroscopic lavage and debridement
should not be routinely offered as part of
treatment for osteoarthritis, unless the person
has knee osteoarthritis with a clear history of
mechanical locking (therefore not for reasons
such as gelling (stiffness and pain associated with
prolonged immobility) “giving way,” or x ray
evidence of loose bodies—currently common
inappropriate reasons for referral).
! Before referring a patient for consideration of
joint surgery, ensure that he or she has been
offered at least the core treatment options.
! Consider referral for joint replacement surgery
for people with osteoarthritis who have joint
symptoms (pain, stiffness, and reduced function)
that substantially affect their quality of life and
are refractory to non-surgical treatment. Referral
should be made before there is prolonged and
established functional limitation and severe pain.
! Patient specific factors (including age, sex, smok-
ing, obesity, and comorbidities) should not be
barriers to referral for joint replacement surgery.
! Base decisions about referral thresholds on
discussions between patient representatives,
referring clinicians, and surgeons, rather than
on current scoring tools for prioritisation.
Overcoming barriers
Improved understanding, among healthcare profes-
sionals and people with osteoarthritis, of the range of
treatments available will reduce misconceptions and
negativity about osteoarthritis and its treatment.
Emphasising the recommended core treatments,
other simple, non-pharmacological treatments, and
relatively safe agents such as paracetamol and topical
NSAIDswill help to reduce drug toxicity and the focus
on pharmacological treatments.
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NSAIDs
Opioids
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Strengthening exercise,
aerobic fitness training
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Assistive
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Treatments for osteoarthritis in adults. Starting at the centre and working outwards, the
treatments are arranged in the order in which they should be considered, taking into account
individuals’ different needs, risk factors, and preferences. The core treatments (centre) should be
considered first for every person with osteoarthritis. If further treatment is required, consider the
drugs in the second circle before the drugs in the outer circle. The outer circle also shows
adjunctive treatments (both non-pharmacological and surgical), which have less well proved
efficacy, provide less symptom relief, or increased risk to the patient compared with those in the
second circle
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concomitant	improvements	in	function	and	WOMAC	scores(Chappell,	Ossanna	et	al.	2009,	Sullivan,	Bentley	 et	 al.	 2009,	 Hochberg,	 Wohlreich	 et	 al.	 2012).	 Of	 notable	 advantage	 is	 the	 ability	 of	 this	compound	 to	 ease	 affective	 comorbidities	 of	 chronic	 pain,	 which	 contributes	 further	 to	 the	improvement	 in	 quality	 of	 life.	 Crucially,	 these	 drugs	 seem	 far	 more	 tolerable,	 with	 a	 NNH	 of	8(Hochberg,	Wohlreich	 et	 al.	 2012),	 and	while	 50.2%	 of	 OA	 patients	 on	 duloxetine	 vs.	 36.7%	 on	placebo	reported	treatment	emergent	adverse	events	there	is	a	long	term	decline	in	their	incidence	–	for	example	nausea	occurs	in	31.8%	in	the	first	8	weeks	but	in	just	3.4%	from	the	8th	week	till	the	end	 of	 the	 year(Pergolizzi,	 Raffa	 et	 al.	 2013).	 Consequently,	 duloxetine	 is	 now	 licensed	 for	 the	treatment	on	OA	pain	in	the	USA,	though	NICE	does	not	currently	endorse	the	use	of	antidepressants	such	as	duloxetine	in	the	OA	treatment	pathway.	
	
1.3.2 		 Surgical	Intervention	
Joint	replacement	surgery	 is	 the	most	common	elective	surgical	procedure	performed	on	 the	NHS,	costing	over	£1billion	for	the	approx.	160,000	procedures	performed	in	the	UK	per	year[6-8].	This	is	the	removal	of	 the	articular	surfaces	 to	be	replaced	by	synthetic	materials	–	notably	metal,	plastic	and	 ceramic.	 It	 is	 universally	 accepted	 as	 the	 end	 point	 of	 the	 treatment	 pathway,	 when	pharmacological	and	non	pharmacological	interventions	have	failed	to	provide	adequate	pain	relief	and	improvement	in	function(Zhang,	Moskowitz	et	al.	2008,	Excellence	2014).	Not	only	do	all	studies	report	significant	 improvements	 in	pain	and	physical	 function	scores,	 joint	replacements	are	more	cost	 effective	 that	 current	 pharmacological	 therapies	 over	 the	 long	 term	 –	 where	 Rassanen	 et	 al	suggest	 that	 the	 cost	 per	 quality	 adjusted	 life	 year	 works	 out	 as	 €13,995	 for	 total	 knee	arthroplasty(Rasanen	P	2007).		
However,	 in	 a	 cruel	 twist	 of	 fate,	 these	 surgical	 procedures	 designed	 to	 alleviate	 pain	 can	 often	achieve	the	exact	opposite(Wylde,	Hewlett	et	al.	2011,	Beswick,	Wylde	et	al.	2012).	In	a	study	of	632	total	knee	replacement	(TKR)	patients	and	662	total	hip	replacements	(THR),	Wylde	et	al	found	44%	of	TKR	and	27%	of	THR	patients	experienced	some	form	of	persistent	post	surgical	pain,	while	14	and	8%	respectively	suffered	severe-extreme	persistent	pain(Wylde,	Hewlett	et	al.	2011).	Crucially,	those	patients	with	other	pain	and	health	problems,	pain	vulnerability/sensitivity	and	depression	or	poor	mental	health	scores	appear	to	be	at	high	risk	of	developing	this(Zhang,	Moskowitz	et	al.	2008,	Wylde,	Hewlett	et	al.	2011).	Similarly	this	 is	a	highly	invasive	procedure,	performed	under	general	anaesthetic.	Given	 the	average	age	and	weight	of	OA	patients	 reaching	 this	point	 in	 the	 treatment	pathway,	this	adds	extra	risk	to	the	procedure.		
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1.4 Modeling	Osteoarthritis	Pain	
In	 order	 to	 better	 understand	 the	 mechanisms	 underlying	 the	 generation,	 maintenance	 and	pharmacological	modulation	 of	 pain	 in	OA,	 there	 is	 a	 requirement	 to	model	 the	 disease	 in	 animals.	Researchers	have	 generated	 a	number	of	models	 that	 reliably	produce	OA-like	pain	 in	 animals,	 but	these	 models	 vary	 considerably	 –	 both	 in	 the	 means	 of	 induction,	 the	 symptom	 profile	 and	 the	pharmacological	 sensitivities.	 These	 include	 surgical	models,	 such	 as	 the	 anterior	 cruciate	 ligament	transection	model(Pond	and	Nuki	1973),	which	work	on	the	principal	of	destabilization	of	the	 joint;	Spontaneous	 arthritis,	 such	 as	 in	 aged	 Dunkin-Hartley	 guinea	 pigs(Jimenez,	 Glasson	 et	 al.	 1997),	which	 develop	 arthritis	 naturally	 in	 relation	 to	 their	 gain	 in	 body	 mass;	 Transgenic	 mice,	 such	 as	MMP-13	over-expressing	mice(Neuhold,	Killar	et	al.	2001),	which	have	a	metabolic	propensity	to	OA;	Enzymatically	induced	models,	such	as	intra-articular	injection	of	collagenases(Peter,	der	Kraan	et	al.	1990);	 and	 chemically	 induced	 models,	 such	 as	 the	 monosodium	 iodoacetate	 (MIA)	 model	 of	OA(Kalbhen	1987).		
	
1.4.1	 		 The	Monosodium	Iodoacetate	Model	
The	model	utilized	throughout	this	thesis	is	the	Monosodium	 Iodoacetate	 (MIA)	model	of	OA,	first	characterized	 in	 chickens	 in	 1977	 by	 Kahlben	 and	 Blum	 and	 finally	 used	 in	 rats	 in	 1987(Kalbhen	1987).	 This	 model	 involves	 the	 injection	 of	 MIA	 into	 the	 intra	 articular	 space	 of	 an	 anaesthetized	animal,	where	 the	 iodoacetate	acts	 to	 inhibit	 glycolysis	by	 the	 competitive	 inhibition	of	 the	enzyme	glyceraldehyde-3-phosphate	 dehydrogenase	 (GAPDH).	 Glycolysis,	 the	 key	 first	 stage	 of	 respiration,	enables	 cells	 to	 produce	 ATP	 in	 the	 absence	 of	 oxygen.	 Due	 to	 the	 A-vascular	 nature	 of	 cartilage,	chondrocytes	rely	heavily	on	diffusion	to	receive	both	glucose	and	oxygen,	leaving	them	reliant	almost	exclusively	on	glycolysis	to	respire.	As	such	MIA	limits,	if	not	halts	entirely,	the	production	of	ATP	in	chondrocytes	in	the	joint	to	cause	their	eventual	death,	followed	by	the	gradual	loss	of	proteoglycans,	fibrillation	 and	 thinning	 of	 the	 cartilage,	 along	 side	 osteophyte	 formation	 and	 thickening	 of	 the	subchondral	bone(Dunham,	Hoedt-Schmidt	et	al.	1992).	This	model	is	now	considered	to	be	the	most	common	for	modeling	OA	in	animals(Little	and	Zaki	2012).	
The	notable	advantages	provided	by	the	MIA	model	are	several	fold;	The	model	induces	rapidly,	with	pain	behaviour,	swelling	and	chondrocyte	degeneration	from	the	first	day,	and	bone	lesioning	by	day	14;	The	ease	of	 induction,	 given	 the	 simple	and	relatively	 trauma	 free	procedure	–	where	 the	 rat	 is	under	anesthesia	 less	 than	5mins;	The	model	produces	consistent	hypersensitivity,	both	at	 the	 joint	and	ipsilateral	paw,	across	numerous	labs,	where	it	is	notable	that	various	doses	used	can	be	selected	to	modify	 the	 progression	 and	 severity	 of	 the	 pain	 condition(Guingamp,	 Gegout-Pottie	 et	 al.	 1997,	
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Janusz,	Hookfin	et	al.	2001,	Schuelert	and	McDougall	2009);	But	the	crucial	feature	of	the	MIA	model	is	its	generation	of	both	joint	histopathology	and	pain	characteristics	that	are	not	dissimilar	from	those	observed	in	OA	patients(Guingamp,	Gegout-Pottie	et	al.	1997,	Mohan,	Perilli	et	al.	2011).		
	
1.4.2	Histopathology	in	the	MIA	model	
Within	24hrs	of	the	injection	of	MIA,	changes	are	occurring	within	the	joint.	The	process	begins	with	the	 reduction	 of	 proteoglycan	 staining	 as	 glycolysis	 inhibition	 limits	 the	 production	 of	 these	extracellular	matrix	 components(Guingamp,	 Gegout-Pottie	 et	 al.	 1997,	 Janusz,	 Hookfin	 et	 al.	 2001).	This	 is	 rapidly	 followed	by	observable	necrobiosis	of	 chondrocytes	over	 the	proceeding	1-5days,	 in	tandem	with	the	gradual	thinning	of	cartilage	as	the	extracellular	matrix	 loses	 its	 integrity(Dunham,	Hoedt-Schmidt	et	al.	1992,	Janusz,	Hookfin	et	al.	2001,	Guzman,	Evans	et	al.	2003).	Though	observed	across	the	joint,	the	effects	of	proteoglycan	and	cartilage	loss	are	most	marked	in	the	central	medial	tibial	plateau,	while	cartilage	degeneration	is	milder	on	the	lateral	side(Mohan,	Perilli	et	al.	2011).		
During	this	time	there	is	evidence	of	marked	inflammation.	This	is	observed	at	a	macroscopic	level	as	the	 thickening	 of	 the	 synovium	and	patellar	 fat	 pad,	 and	 swelling	 of	 the	 injected	 knee,	while	 at	 the	microscopic	 level	 there	 is	 observable	 infiltration	 of	 monocytes	 and	 neutrophils	 as	 part	 of	 a	
whereas the Tb.Sp decreased, in both the MIA-injected
knee and the control knee (Figure 3). This is in part due
to the normal growth of the rats at baseline, reaching
skeletal maturity. Similar age-related changes (increases)
in volumetric bone mineral density (vBMD) due to the
effect of normal animal growth have been reported in
the high-dose MIA rat model [21] and ACLT model
[22]. However, in our study the use of the contralateral
tibia as an internal control eliminates inter-animal varia-
bility for age-related changes and weight.
Pathologic subchondral plate changes are recognized
as a characteristic feature of OA. Previous studies have
looked at the subchondral plate changes in animal mod-
els of OA such as dogs, mice, cynomolgus macaques,
guinea pigs, and rabbits but not in rat models of OA.
Figure 7 Three-dimensional surface rendering obtained from micro-CT images of a control knee (A) and of a MIA-injected knee (B) at
ten weeks after injection. The control knee maintained the subchondral plate integrity with a smooth contour (A). The MIA-injected knee
showed erosion and pitting of the tibial subchondral plate, which was more severe in the medial tibial plateau, as indicated by arrow (B). Micro-
CT, micro-computed tomography; MIA, monosodium iodoacetate.
Figure 8 Macroscopic images of a control tibia (A-C) and of a
MIA-injected tibia (D-F), at ten weeks post injection. The control
tibia (A) had no cartilage lesions on the medial compartment (M)
and lateral compartment of the tibial plateau, whereas the MIA-
injected tibia (D) had severe cartilage lesions on the medial tibial
plateau (M). Fluorochrome images of the MIA-injected tibia showed
accumulation of calcein and xylenol orange along the margins of
the tibial plateau (E, F), suggesting osteophyte formation whereas
there was no accumulation of fluorochrome labels along the
margins of control tibia (B, C). MIA, monosodium iodoacetate.
Figure 9 Coronal sections stained with Safranin O and fast
green of a control tibia (A) and of a MIA-injected tibia (B-D)
showing the cartilage on the medial tibial plateau, at ten
weeks post injection. The control tibia (A) showed normal healthy
cartilage with normally distributed chondrocytes. The MIA-injected
tibia (B) showed loss of proteoglycans, loss of viable chondrocytes,
chondrocyte proliferation (arrow), and chondrocyte cluster
formation of variable sizes (arrowhead). The cartilage showed
fibrillation, vertical fissures (C, arrow) and delamination (D). The
subchondral trabecular bone architecture was altered with sclerosed
bone (C) and the cellular bone marrow was replaced by loosely
arranged spindl cells i fine fibrous s roma (D, arrow). Original
magnification ×100. MIA, monosodium iodoacetate.
Mohan et al. Arthritis Research & Therapy 2011, 13:R210
http://arthritis-research.com/content/13/6/R210
Page 10 of 14
Figure	1.5:	Coronal	sections	of	control	(A)	and	0.2mg	injected	MIA	tibia	(B-D)	at	10weeks	post	 injection,	stained	
with	Safranin	O	and	fast	green.	A)	The	control	tibia	exhibits	healthy	cartilage,	with	normally	distributed	chondrocytes.	MIA	injected	tibia	shows	loss	of	proteoglycan,	viable	chondrocytes	and	irregular	clusters	(B)	of	chondrocyte	proliferation,	fibrillation,	vertical	fissures	and	bone	sclerosis	(C),	delamination	and	 the	replacement	of	cellular	bone	marrow	by	spindle	cells	in	fibrous	stroma	(D).	Taken	from	Mohan	et	al	2011(Mohan,	Perilli	et	al.	2011).		
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proteinaceous	and	fibrin	rich	oedema(Bove	2003,	Guzman,	Evans	et	al.	2003,	Fernihough,	Gentry	et	al.	2004,	 Clements,	 Ball	 et	 al.	 2009).	 However	 it	 is	 worth	 noting	 that	 across	 these	 studies,	 this	inflammation	is	 largely	resolved	by	day	7,	peaking	during	days	1-3(Bove	2003,	Guzman,	Evans	et	al.	2003,	Fernihough,	Gentry	et	al.	2004,	Clements,	Ball	et	al.	2009).	Consistent	with	 this	 inflammation,	TNFα	IL-6	and	NGF	are	upregulated	in	the	joint(Orita,	Ishikawa	et	al.	2011),	Substance	P	expression	is	enhanced	in	the	synovium(Ahmed,	Li	et	al.	2012)	and	MIA	animals	exhibit	marked	hypersensitivity	to	ACh,	BK	and	5HT(Okamoto	and	Atsuta	2010).	
By	day	7,	 the	point	 at	which	we	are	witnessing	 the	 resolution	of	 inflammation,	we	begin	 to	 see	 the	progressive	 involvement	 of	 subchondral	 bone,	 with	 increasing	 numbers	 of	 osteoclasts	 along	 the	junction	 of	 necrotic	 cartilage	 and	 the	 bone(Guzman,	 Evans	 et	 al.	 2003).	 Progressively,	 the	 cartilage	becomes	 fibrillated	 and	 chondrocytes	 calcify	 and	 large	 osteophytes	 form,	 with	 bone	 sclerosis	 and	exposure	by	days	14-21(Dunham,	Hoedt-Schmidt	 et	 al.	 1992,	 Janusz,	Hookfin	 et	 al.	 2001).	Over	 the	longer	 term,	 there	 is	 also	 considerable	 remodeling	of	 the	bone	 structure,	with	 increased	 trabecular	thickness,	 reduced	 trabecular	 numbers	 and	 separation,	 cysts,	 and	 the	 replacement	 of	 marrow	 by	spindles(Guzman,	Evans	et	al.	2003,	Mohan,	Perilli	et	al.	2011).	
	
1.4.3	Pain-like	Behaviour	in	the	MIA	model	
As	this	study’s	focus	is	on	pain,	it	is	critical	that	the	MIA	model	produces	a	reliable	and	representative	pain	profile	in	animals,	representative	of	the	patient	experience.	MIA,	at	various	doses,	has	been	well	characterized	 as	 inducing	 a	 biphasic	 shift	 in	weight	 bearing,	 peaking	 in	 line	with	 the	 inflammatory	profile	at	day	3	and	regaining	 from	days	10	onwards(Bove	2003,	Pomonis,	Boulet	et	al.	2005,	Kelly,	Dunham	et	al.	2012,	Thakur,	Rahman	et	al.	2012).	Alongside	observed	adjustments	in	gait,	as	analysed	by	CatWalk	in	MIA	animals(Ferreira‐Gomes,	Adaes	et	al.	2010,	Ferland,	Laverty	et	al.	2011),	this	shift	in	weight	borne	to	the	contralateral	 limbs	is	 indicative	of	 joint	hypersensitivity,	where	both	animals	and	 patients	 minimize	 joint	 usage	 to	 shield	 themselves	 from	 the	 pain	 associated	 with	 knee	pathology(Zeni	and	Higginson	2011).	In	addition,	MIA	animals	also	exhibit	depressed	behaviours	such	as	wheel	running	and	nocturnal	exploration(Guingamp,	Gegout-Pottie	et	al.	1997,	Stevenson,	Mercer	et	al.	2011),	consistent	with	the	clinic	experience	that	pain	depresses	the	activity	e.g.	chores,	shopping	in	patients(Yelin,	Lubeck	et	al.	1987).	These	too	show	a	bilateral	pain	profile,	in	which	rats	exhibited	an	initial	peak	in	loss	of	nocturnal	mobility	in	the	first	3	days	following	injection,	a	period	of	recovery,	and	an	increasing	loss	of	activity	following	Day	11(Guingamp,	Gegout-Pottie	et	al.	1997).	
Beyond	the	knee	itself,	there	is	also	a	well-characterized	secondary	hypersensitivity	that	develops	in	areas	 distal	 to	 the	 knee,	 such	 as	 the	 hind	 paw	 and	 bicep	 of	 MIA	 animals.	 These	 include	 both	
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mechanical	hyperalgesia,	as	assessed	by	the	Randall	Selito	apparatus,	and	tactile	hypersensitivities,	as	assessed	by	von	Frey(Combe,	Bramwell	et	al.	2004,	Fernihough,	Gentry	et	al.	2004,	Rahman,	Bauer	et	al.	 2009,	 Vonsy,	 Ghandehari	 et	 al.	 2009,	 Thakur,	 Rahman	 et	 al.	 2012,	 Kelly,	 Dobson	 et	 al.	 2013).	Nociceptive	 reflexes	 serving	 the	 biceps	 femoris	 and	 tibialis	 anterior	 are	 similarly	 sensitized(Kelly,	Dobson	 et	 al.	 2013),	 though	 these	may	be	masked	by	 descending	 controls.	 As	with	 shifts	 in	weight	bearing	 and	 nocturnal	 activity,	 some	 studies	 have	 suggested	 that	 this	 secondary	 hypersensitivity	exhibits	 an	 initial	 peak	 around	 days	 2-3	 to	 coincide	 with	 the	 models	 initial	 inflammatory	 flare;	 a	baseline	 hypersensitivity	 profile,	 which	 may	 slowly	 build,	 is	 then	 established	 beyond	 ~day	 10	onwards	 once	 joint	 pathology	 becomes	 more	 established(Vonsy,	 Ghandehari	 et	 al.	 2009,	 Burnham	2012).	As	previously	discussed	(See	1.2.3),	 referred	pain	–	 the	pain	 in	a	secondary	area	such	as	 the	paw	–	is	a	common	feature	in	patients(Kean,	Kean	et	al.	2004,	Gwilym,	Keltner	et	al.	2009).	
	
1.4.4		Electrophysiology	in	the	MIA	model	
Electrophysiology	 in	 the	 MIA	 model	 has	 taken	 two	 main	 streams,	 the	 investigation	 of	 changes	 in	activity	and	evoked	responses	of	peripheral	fibers	serving	the	joint;	and	recordings	of	spinal	neurons,	serving	either	the	joint	or	areas	of	secondary	hypersensitivity.	
Single	unit	recordings	of	knee	joint	primary	afferents	have	established	a	dose	dependent	increase	in	the	 firing	 of	 these	 afferents	 in	 response	 to	 both	 non-noxious	 and	 noxious	 torque	 in	 MIA	animals(Schuelert	 and	 McDougall	 2006,	 Schuelert	 and	 McDougall	 2009).	 Similarly,	 mechanically	sensitive	A	 fibers	 have	 been	 shown	 to	 exhibit	marked	 decreases	 in	 their	mechanical	 threshold	 and	increased	 response	 to	 suprathreshold	 stimuli(Kelly,	 Dunham	 et	 al.	 2012).	 These	 studies	 have	 thus	contributed	to	our	understanding	of	peripheral	sensitization	in	the	MIA	model	but	also	suggests	this	peripheral	 sensitivity	 is	 proportional	 to	 pathology,	 given	 the	 links	 to	 dose.	 Interestingly,	 Kelly	 et	 al	2012	also	demonstrated	that	while	mechanosensitive	C	 fibers	did	not	exhibit	reduced	thresholds	or	increased	responses,	they	did	exhibit	an	increased	occurrence	and	rate	of	spontaneous	firing	in	MIA	animals	 vs.	 naïve	 that	was	 not	 observed	 in	A	 fibers	 and	which	 correlated	 to	 the	 changes	 in	weight	bearing	behaviour(Kelly,	Dunham	et	al.	2012).	Clinically,	 this	may	mean	C	 fibers	are	responsible	 for	pain	at	rest,	driving	central	sensitization,	while	A	fibers	are	responsible	for	movement	evoked	pain.	
Recordings	 of	 secondary	 neurons	 in	 the	 dorsal	 horn,	 which	 project	 to	 the	 brain,	 also	 indicate	modifications	 of	 spontaneous	 and	 evoked	 firing.	 Studies	 utilizing	 single	 unit	 recordings	 of	 WDRs	serving	 the	 ipsilateral	 hind	paw	have	 largely	 agreed	upon	 the	 enhanced	 evoked	 responses	 of	 these	neurons	to	graded	punctate	stimuli	in	MIA	vs.	shams,	including	at	both	the	early	and	late	stages	of	the	model(Harvey	and	Dickenson	2009,	Rahman,	Bauer	et	al.	2009,	Sagar,	Staniaszek	et	al.	2010,	Burnham	
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2012).	 There	 was	 similarly	 enhanced	 WDR	 spontaneous	 firing(Chu,	 Chandran	 et	 al.	 2011).	 These	findings	are	 in	 agreement	with	 the	observed	 changes	 in	mechanical	 sensitivity	 in	behavioural	 tests,	together	 indicating	 the	presence	of	a	central	sensitization	 in	MIA	animals.	 It	 is	highly	 likely	 that	 the	afore	mentioned	enhancements	in	peripheral	neuronal	activity	drive	this	central	sensitization	but	that	the	 overall	 pain	 profile	 observed	 in	 MIA	 is	 the	 collective	 result	 of	 both	 peripheral	 and	 central	plasticity.		
However,	 there	 is	 no	 clear-cut	 consensus	 on	 the	 effect	 of	 MIA	 on	 responses	 of	 deep	 dorsal	 horn	neurons.	 While	 much	 of	 the	 work	 in	 this	 lab	 has	 demonstrated	 potentiated	 mechanical	 responses	across	a	 range	of	punctate	 stimuli,	one	 thesis	 in	 this	 lab	saw	no	change	 in	either	Lamina	V	WDR	or	Lamina	 1	 NS	 cells,	 only	 observing	 a	 significant	 change	 from	 sham	 at	 8g	 vF	 in	 the	 Lamina	 1	WDRs(Thakur	 2012).	 The	 lack	 of	 increased	 baselines	 was	 similarly	 observed	 in	 Patel	 2012	 in	 her	thesis	evaluating	the	2mg	MIA	model,	in	which	she	had	similarly	demonstrated	enhanced	baselines	for	cancer	induced	bone	pain(Patel	2012).		
There	 is	similar	divergence	 in	 the	 literature	on	whether	responses	are	enhanced	to	 thermal	stimuli,	for	both	behaviour	and	electrophysiology.	Studies	using	high	dose	MIA	(4.8mg),	which	from	the	work	of	Thakur	et	al	2012	can	be	 inferred	to	be	a	neuropathic	model	of	OA(Thakur,	Rahman	et	al.	2012),	have	 previously	 demonstrated	 decreased	 paw	 withdrawal	 latencies	 to	 noxious	 thermal	 stimuli(*A.	OKUN1	 2011,	 Liu,	 Okun	 et	 al.	 2011).	 This	 is	 in	 agreement	with	 those	 electrophysiology	 studies	 by	Rahman	 et	 al	 and	 Burnham	 et	 al	 using	 a	 2mg	 dose	 that	 show	 enhanced	 thermally	 evoked	 WDR	responses(Rahman,	Bauer	et	al.	2009,	Burnham	2012).	However,	 in	direct	contrast,	 in	other	studies,	neither	 behaviour	 nor	 electrophysiology	 identified	 thermal	 hypersensitivity	 in	 the	 paw	 in	 other	studies	using	≤2mg	MIA	(Gwilym,	Keltner	et	al.	2009,	Harvey	and	Dickenson	2009,	Thakur	2012).	This	lack	of	thermal	hypersensitivity	appears	to	agree	with	clinical	observations,	where	Gwilym	et	al	2009	found	 no	 significant	 difference	 in	 the	 reported	 thermal	 pain	 or	 temperature	 detection	thresholds(Gwilym,	Keltner	et	al.	2009),	even	though	the	patients	assessed	reported	referred	pain	–	signifying	an	established	central	sensitization.	Similarly,	QST	characterized	only	7%	of	patients	with	thermal	hyperalgesia	but	31%	with	thermal	hypoaesthesia(Hochman,	Davis	et	al.	2013).		
These	 differences	 in	 observations	 in	 animal	 work	 are	 hard	 to	 explain.	 The	 fact	 that	 thermal	 (hot)	hypersensitive	behaviour	 is	only	exhibited	 in	the	high	dose,	4.8mg	model	may	suggest	this	 is	a	dose	related	symptom.	However,	the	differing	electrophysiology	profiles	of	MIA	animals	discussed	all	come	from	 trials	 using	 a	 2mg	model	 so	 differences	 cannot	 be	 attributed	 to	 dose.	 It	 is	 possible	 this	 is	 the	result	 of	 inter-experimenter	 effects,	 given	 differences	 are	 also	 observed	 in	 the	 baseline	 profiles	 of	naïve	and	sham	animals	too,	where	the	response	profile	of	cells	selected	by	different	experimenters	may	lead	to	these	observed	differences	in	evoked	responses.		
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In	 addition	 to	 these	 evoked	 changes,	 spinal	 electrophysiology	 has	 also	 elucidated	 a	 change	 in	 the	receptive	filed	size	of	spinal	neurons	serving	the	ipsilateral	paw	in	MIA,	but	only	in	the	NS	and	WDR	cells	of	Lamina	 I	 (Not	 lamina	V)(Thakur	2012).	 In	other	words,	 these	secondary	projecting	neurons	are	responding	to	inputs	from	a	wider	array	of	primary	afferents	and	thus	a	larger	number	of	Lamina	I	neurons	are	activated	by	any	given	stimulus,	 indicative	of	central	 sensitization	and	a	process	which	may	underlie	a	degree	of	the	hypersensitivity	observed	in	MIA	animals.	
Though	 less	well	characterized,	studies	of	WDR	cells	serving	the	knee	have	additionally	revealed	an	increased	 spontaneous	 rate	 of	 firing(McGaraughty,	 Chu	 et	 al.	 2010),	 though	 evoked	 responses	 to	mechanical	stimuli	do	not	appear	to	differ	from	shams(McGaraughty,	Chu	et	al.	2010,	Chu,	Chandran	et	al.	2011).	However,	it	is	possible	that	the	increased	peripheral	inputs	and	central	sensitization	we	would	 expect	 to	 see	 from	 these	 WDR	 recordings	 are	 masked	 by	 moderating	 descending	 controls	which	may	provide	analgesia	to	the	primary	site.		
This	 thesis	will	engage	both	behavioural	and	electrophysiological	 techniques	to	profile	 the	extent	of	hypersensitivity	 induced	 following	 the	 injection	 of	 a	 1mg	 dose	 of	 MIA	 to	 the	 knee	 and	 the	consequential	development	of	an	OA	like	condition.	As	such,	it	is	important	to	understand	that	while	the	expected	behavioural	profile	of	this	model	is	relatively	uncontroversial	in	the	published	literature,	there	 is	 no	 clear	 consensus	 in	 the	 literature	 on	 the	 expected	 evoked	 electrophysiological	 profile	 of	WDR	cells	in	these	rats.	Given	this	forms	the	baseline	readings	for	the	pharmacological	investigation	of	 descending	 control	 of	 pain	 in	 this	model	 of	 OA,	 it	 will	 be	 particularly	 important	 to	 characterize	clearly	what	difference,	if	any,	is	observed	between	the	punctate	and	thermally	evoked	MIA	and	sham	animals	at	the	time	points	investigated.	
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1.5 An	Overview	of	Nociception	
When	 viewed	 simply,	 pain	 can	 be	 regarded	 as	 the	 consequence	 of	 a	 three	 major	 stages:	 The	translation	of	tissue	damage	or	noxious	stimuli	information	by	peripheral	afferents;	the	modulation	and	 transmission	 of	 information	 from	 peripheral	 afferents	 to	 second	 order	 neurons	 in	 the	 spinal	cord;	and	the	generation	of	a	contextual,	subjective	pain	experiences	by	the	brain.	These	processes	are	 consequence	 of	 complex	 layers	 of	 inputs	 and	 modulation,	 while	 the	 systems	 themselves	 are	highly	plastic,	not	least	during	a	chronic	pain	condition	such	as	OA.	
	
1.5.1 		 Peripheral	Nociception	
Though	 the	 cartilage	 itself	 is	 not	 innervated,	 at	 least	 in	 healthy	 joints,	 the	 surrounding	 tissues,	notably	 the	 synovium	 and	 bone,	 are	 well	 served	 by	 a	 diverse	 population	 of	 sensory	 afferents.	Meanwhile,	 vascularization	 and	 neuronal	 infiltration	 provide	 sensation	 from	 the	 previously	insensitive	cartilage.	
At	 the	most	 basic	 level,	 OA	 is	 a	 nociceptive	 pain	 condition,	where	mechanoreceptors	 are	 directly	activated	by	increased	friction	elicited	upon	movement,	by	bone	compression,	lesions,	fractures	and	increased	intra-osseous	pressure.	These	high	threshold	mechanical	stimuli	activate	primary	sensory	afferents	projecting	to	the	spinal	cord.		
	
1.5.1.1		 The	Fibers	
Peripheral	afferents	convey	sensory	information	to	the	CNS.	They	are	most	commonly	sub-classified	on	the	basis	of	their	conduction	velocity,	which	itself	is	a	function	of	their	distinct	morphologies	and	myelination(Harper	and	Lawson	1985):		
• Aβ	fibers:	Highly	myelinated,	wide	diameter	neurons	which	conduct	at	roughly	20-65ms-1.	
• Aδ	fibers:	Medium	diameter,	myelinated	neurons	conducting	in	the	range	of	2.2-	8ms-1.	
• C	 fibers:	Small	diameter,	un-myelinated	fibers	with	the	slowest	conduction	velocity,	at	 less	than	1.4ms-1.	
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While	it	is	possible	to	generalise	the	roles	of	these	fibers	it	is	noteworthy	that	even	these	sub	classes	exhibit	 considerable	heterogeneity,	most	notably	 in	 terms	of	 the	 thresholds	 to	activation,	 stimulus	specificity,	transmitters	and	molecular	markers.	
	
1.5.1.2	 Subdivision	by	Sensation	
As	part	 of	 an	 experiment	 to	 define	whether	 intraepidermal	 electrical	 stimulation	 (IES)	 provides	 a	fully	selective	nociceptive	 input,	Mouraux	et	al	defined	some	of	 the	sensational	subdivisions	 found	between	 Aβ,	 Aδ	 and	 C	 fibers(Mouraux,	 Iannetti	 et	 al.	 2010).	 Namely,	 that	 activation	 of	 C	 fibers	elicited	prickling,	 tingling,	warming	and	burning	sensations,	while	selective	Aδ	selective	activation	resulted	 in	tingling,	prickling	and	 light	 touch.	While	such	sensations	relating	to	Aβ	activation	were	expected,	 it	 is	most	 notable	 that	 these	 fibers	were	 also	 responsible	 for	 shock	 like	 sensations.	 The	study	highlights	 that	while	 there	 is	 some	subdivision	of	 sensation	at	 this	 superficial	 level,	 there	 is	also	considerable	cross	over	–	for	example	between	prickling	and	tingling	sensations	between	C	and	Aδ	fiber	populations.		
	
1.5.1.3	 Molecular	Markers	Defining	Subpopulations	
Studies	 in	cutaneous	nociceptors	proposed	that	at	the	simplest	 level	this	broad	peripheral	afferent	population	can	be	subdivided	into	two	classes:	those	nociceptors	that	contain	peptides	transmitters	(SP,	CGRP)	and	those	nociceptors	that	do	not(Snider	and	McMahon	1998).	These	peptidergic	fibers	
Figure	 1.6	 –	 Pie	 chart	 summarizing	 the	 subdivision	 of	 DRGs	
according	to	molecular	markers,	taken	from	Priestley	et	al	2002.		
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concomitantly	express	TrkA	receptors,	denoting	the	importance	of	NGF	for	fiber	survival(Snider	and	McMahon	1998),		and	are	estimated	to	make	up	approximately	half	of	all	C	fibers	and	about	20%	of	Aδ	 fibers(McCarthy	and	Lawson	1989,	Lawson	1996,	Priestley,	Michael	et	al.	2002).	The	remaining	80%	 of	 non	 peptidergic	 Aδ	 receptors	 bind	 the	 plant	 lectin	 IB4(Silverman	 and	 Kruger	 1988),	 and	express	FRAP(Silverman	and	Kruger	1988),	GFRα1-4	and	Ret	for	glial	cell	line	derived	nerve	growth	factor(Priestley,	Michael	 et	 al.	 2002)	 –	 further	 emphasizing	 the	 difference	 in	 neurotropic	 reliance	between	these	fiber	subgroups.	
However,	 there	 are	 a	 multitude	 of	 additional	 structural	 and	 neurochemical	 markers	 that	 denote	potential	subpopulations,	some	examples	of	which	are	summarized	in	the	Table	1.2.	
	
Table	1.4	-	Structural	and	neurochemical	markers	of	DRG	subpopulations	(Silverman	and	Kruger	1988,	Silverman	
and	 Kruger	 1988,	 Lawson	 and	Waddell	 1991,	 Lawson,	 Crepps	 et	 al.	 1997,	 Zylka,	 Rice	 et	 al.	 2005,	 Brumovsky,	
Watanabe	et	al.	2007,	Zylka,	Sowa	et	al.	2008,	Seal,	Wang	et	al.	2009,	Lagerström,	Rogoz	et	al.	2011,	Li,	Rutlin	et	al.	
2011,	Shields,	Ahn	et	al.	2012,	Vrontou,	Wong	et	al.	2013)	The	 subdivision	 of	 peripheral	 afferents	 by	 their	 molecular	 markers,	 while	 diverse,	 is	 relatively	simpler.	For	example,	the	binding	of	IB4	and	FRAP	content	in	non-peptidergic	fibers(Silverman	and	Kruger	 1988,	 Silverman	 and	 Kruger	 1988),	 or	 VGLUT3	 in	 a	 non-peptidergic	 LTM	 C	 fiber	subpopulation(Seal,	Wang	et	al.	2009).	The	functional	relevance	of	these	subdivisions	has	historically	been	 less	 clear,	 with	 work	 ongoing	 to	 attribute	 specific	 sensations	 to	 specific	 fiber	 populations	 –	largely	using	ablation	techniques.	
Molecular	marker	 Population	 Reference	
NF200	 Large-medium	myelinated	fibers	 Lawson	and	Waddell	1991	
VGLUT1	 Large-medium	myelinated	fibers	 Brumovsky	et	al	2007	
VGLUT2	 Medium	and	small	afferents	
Brumovsky	et	al	2007;	
Lagerström	et	al	2011	
VGLUT3	 Non-peptidergic	LTM	C	fibre	subpopulation	 Seal	et	al	2009	
Tyrosine	hydroxylase	 Non	peptidergic	LTM	C	fibre	subpopulation		 Li	et	al	2011	
CGRP,	SP	 Peptidergic	nociceptors	 Lawson	1997	
Prostatic	Acid	
Phosphatase	 Non-peptidergic	nociceptors	 Zylka	et	al	2008	
IB4	binding	 Non-peptidergic	nociceptors	 Silverman	and	Kruger,	1988a	
MrgprD	
Non-peptidergic	nociceptor	population	
exclusively	serving	the	epidermis	 Zylka	et	al	2005	
MrgprdB4	
Non-peptidergic	C	fibre	population	mediating	
pleasant	touch	 Vrontou	et	al	2013	
Nav1.8	
Subset	of	sensory	afferents	-	~90%	nociceptors,	
LTM	C	Fibers	and	RA	Aβ	LTM	afferents	 Shields	et	al	2012	
FRAP	 Non-peptidergic	nociceptors	 Silverman	and	Kruger,	1988b	
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When	considering	the	role	of	non-peptidergic	nociceptors	in	peripheral	sensation,	one	of	the	clearest	potential	markers	for	targeting	neurones	for	ablation	is	IB4	binding,	as	engaged	by	Vulchanova	et	al	and	Tarpley	et	al	 respectively	 in	studies	using	 IB4	conjugated	 to	saporin	(IB4-SAP).	Previous	work	had	 already	 suggested	 that	 these	 neurones	were	 involved	 in	 nociceptive	 transmission,	 though	 the	role	 in	heat	 transmission	appeared	 to	be	much	 smaller	 than	 their	peptidergic	 counterparts(Stucky	and	Lewin	1999),	but	ablation	studies	provided	a	somewhat	clearer	picture.	These	IB4-SAP	studies	suggested	a	role	for	non-peptidergic	nociceptors	in	both	mechanical	and	thermal	nociception,	while	similarly	 pointing	 to	 a	 role	 for	 these	 fibers	 in	 mechanical	 allodynia	 in	 neuropathy	 and	 thermal	hyperalgesia	following	NGF(Vulchanova,	Olson	et	al.	2001,	Tarpley,	Kohler	et	al.	2004).	 	In	so	doing	these	studies	pointed	to	a	degree	of	functional	distinction	between	the	roles	of	peptidergic	and	non	peptidergic	 nociceptors	 –	 though	 later	 studies	 raised	 concerns	 around	 the	 true	 specificity	 of	 IB4-SAP(Cavanaugh,	Lee	et	al.	2009).		
Looking	further	into	the	discreet	differences	between	molecularly	defined	receptor	sub	populations,	later	studies	 turned	 to	TRPV1.	This	polymodal	nociceptor	has	been	characterized	as	 localized	on	a	subpopulation	 of	 small	 to	medium	diameter	 nociceptors	 projecting	 to	 the	 superficial	 layers	 of	 the	dorsal	 horn(Caterina,	 Schumacher	 et	 al.	 1997,	 Tominaga,	 Caterina	 et	 al.	 1998,	 O'Neill,	 Brock	 et	 al.	2012).	 It	 is	worth	noting	 the	discrete	 expression	differences	between	 rats	 and	mice	–	namely	 that	TRPV1	is	distributed	in	both	peptidergic	and	non-peptidergic	peripheral	afferents	in	the	rat,	but	that	expression	becomes	restricted	to	peptidergic	 fibers	 in	the	mouse	by	adulthood(Cavanaugh,	Chesler	et	 al.	 2011).	 Though	TRPV1-/-	mice	 demonstrated	 only	 a	mild	 reduction	 in	 inflammatory	 thermal	hyperalgesia	and	deficits	to	thermal	nociception	above	50°C(Caterina,	Leffler	et	al.	2000),	speaking	to	the	redundancy	of	receptor	mechanisms,	work	in	mice	in	which	the	entire	TRPV1	containing	primary	afferent	 population	 is	 ablated	 have	 characterized	 insensitivity	 to	 noxious	 heat,	 a	 lack	 of	discrimination	 between	 30	 and	 45	 °C	 in	 temperature	 preference	 assays,	 failure	 to	 develop	 a	 Fos	signal	 following	 	 55°C	 thermal	 stimulus,	 and	 an	 absence	 of	 thermal	 hyperalgesia	 associated	 with	either	 capsaicin	 or	 CFA	 treatment(Cavanaugh,	 Lee	 et	 al.	 2009,	 Mishra,	 Tisel	 et	 al.	 2011,	 Zhang,	Cavanaugh	et	al.	2013).	Meanwhile	the	mice	in	these	studies	maintained	normal	mechanosensation,	highlighting	 the	 distinct	 role	 of	 this	 peptidergic	 nociceptors	 population	 in	 thermosensation	 and	hypersensitivity	in	mice.	
To	 further	 investigate	 the	 distinct	 sensory	 profiles	 of	 peptidergic	 and	 non-peptidergic	 nociceptors	subpopulations,	 studies	by	Cavanaugh	and	by	Zhang	have	sought	 to	 compare	 the	modalities	of	 the	TRPV1	positive	and	MrgprD	positive	fibers,	given	this	latter	population	is	an	exclusively	cutaneous,	non	peptidergic	afferent	population(Cavanaugh,	Lee	et	al.	2009,	Zhang,	Cavanaugh	et	al.	2013).	Using	behaviour	 and	 spinal	 cord	 electrophysiology	 respectively,	 in	 MrgprdDTR	 mice,	 intrathecal	 (IT)	
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capsaicin	 treated	 wild	 type	 mice,	 and	 IT	 Capsaicin	 treated	 MrgprdDTR	 mice	 these	 studies	demonstrated	that:		
• MrgprD	 positive	 afferents	 are	 required	 for	 full	 behavioural	 sensitivity	 to	 noxious	mechanosensation	 and	mechanical	 hyperalgesia,	 but	 not	 thermal	 nociception;	 and	 reduced	the	evoked	responses	of	superficial	dorsal	horn	NS	neurons,	with	limited	effect	on	the	evoked	responses	 of	WDR	 neurons	 –	 suggesting	 a	 degree	 of	 redundancy	 between	 the	 nociceptive	mechanical	inputs	to	the	deep	dorsal	horn	
• As	 discussed	 already,	 TRPV1	 positive	 afferents	 are	 required	 for	 behavioural	 sensitivity	 to	thermal	nociceptive	stimuli.	Further,	that	loss	of	this	TRPV1	positive	population	abolishes	the	evoked	responses	of	superficial	and	deep	dorsal	horn	neurons	to	noxious	heat		
• The	loss	of	both	afferent	populations	was	additive,	with	no	further	behavioural	deficits	
Overall,	 these	 studies	 emphasized	 modality	 discrimination	 within	 the	 periphery	 deriving	 from	distinct	and	non-overlapping	peripheral	afferent	populations.	It	might	be	estimated	that	many	more	such	discreet	populations	might	exist,	encoding	specific	sensory	modalities	before	their	 integration	in	the	dorsal	horn	
	
1.5.1.4	 Efferent	Function	
In	addition	to	the	standard	transmission	of	sensory	information	to	the	dorsal	horn,	these	peptidergic	fibers	discussed	above	also	have	antidromic	function.	While	the	activation	of	this	subpopulation	of	fibers	will	lead	to	the	release	of	both	glutamate	and	neuropeptides,	largely	in	the	superficial	laminae,	in	the	dorsal	horn	it	also	triggers	the	release	of	substance	P,	CGRP	and	Neurokinin	A	(NKA)	into	the	periphery.		
The	effect	of	these	neuropeptides	in	the	periphery	is	diverse,	but	ultimately	leads	to	the	initiation	of	neurogenic	 inflammation	 through	 vasodilation,	 plasma	 extravasation	 and	 immune	 cell	migration(Richardson	and	Vasko	2002).	These	peptides	bind	to	their	receptors	to	act	either	directly	on	the	vasculature	or	on	immune	cells	to	trigger	secondary	effects,	such	as	mast	cell	degranulation	or	 leukocyte	migration.	This	 is	demonstrated	by	 the	ability	of	 intradermal	administration	of	 these	peptides	to	trigger	a	wheel	and	flare	response(Hägermark,	Hökfelt	et	al.	1978,	Brain,	Williams	et	al.	1985).	 These	 peptides	 similarly	 have	 their	 role	 to	 play	 in	 the	 generation	 of	 pain,	 through	 the	activation	or	perpetuation	of	the	inflammatory	cascade,	as	demonstrated	by	the	attenuation	of	pain	responses	in	knock	out	mice(Zhang,	Hoff	et	al.	2001).	
		 56	
Notably,	heightened	 levels	of	SP	are	 found	 in	 the	synovial	membrane	of	OA	rats(Calza,	Pozza	et	al.	1997),	while	back-labeling	of	knee	afferents	in	MIA	rats	shows	knee	specific	enrichment	of	CGRP	and	TRPV1	 in	 the	DRG	neurons(Fernihough,	Gentry	et	al.	2005),	mirroring	directly	 the	observations	 in	the	 clinic(Saito	 and	Koshino	2000).	 This	 indicates	 a	 potential	 role	 for	 SP,	 CGRP	 and	TRPV1	 in	 the	manifestation	of	pain	in	OA,	possibly	through	both	contributions	to	the	joint	effusions	and	peripheral	sensitization.	 Electrophysiological	 studies	 using	 peripheral	 administration	 of	 CGRP	 antagonist	BIBN4096BS,	in	which	plasma	concentrations	never	exceeded	nanomolar	levels,	also	demonstrated	attenuation	 of	 WDR	 neuronal	 activity	 following	 CFA	 induced	 inflammation,	 where	 spinal	 drug	application	 had	 no	 effect,	 indicating	 the	 importance	 of	 peripheral	 (not	 central)	 CGRP	 in	inflammatory	pain(Hirsch,	Just	et	al.	2013).		
1.5.1.5	 Joint	Innervation	
Morphological	analysis	of	the	innervation	of	the	knee	indicates	that	approximately	20%	of	articular	afferents	 are	 myelinated,	 where	 the	 majority	 of	 this	 group	 are	 Aδ	 fibers,	 while	 the	 remaining	unmyelinated	 80%	 are	 roughly	 half	 C	 fibers,	 half	 efferent	 sympathetic	 neurons(Grubb	 2004).	 The	use	 of	 intra-articular	 tracers	 confirm	 that	 these	 fibers	 largely	 project	 to	 levels	 L3,	 L4	 and	 L5	DRG/sympathetic	ganglia(Edoff,	Grenegard	et	al.	2000),	with	two	major	terminal	sites	in	the	dorsal	horn	–	Lamina	I	and	Lamina	V(Craig,	Heppelmann	et	al.	1988).		
	
1.5.1.6	 Spinal	terminations	of	primary	afferents	
Just	 as	 these	 defined	 afferent	 populations	 show	 distinct,	 modality	 specific	 functions,	 these	populations	also	have	characteristic	termination	patterns	within	the	dorsal	horn.	 Broadly	 speaking	the	myelinated	and	lower	threshold	mechanoreceptive	afferent	populations	innervate	deeper	in	the	dorsal	 horn,	 from	 lamina	 II-V,	 while	 the	 nociceptive	 populations	 of	 Aδ	 and	 C	 fibers,	 notably	peptidergic	fibers,	terminate	in	the	more	superficial	lamina(Todd	2010).		
At	a	more	granular	 level,	work	is	ongoing	to	 identify	where	specific	subsets	of	afferents	terminate.	Using	mice	designed	to	express	the	farnesylated	enhanced	green	fluorescent	protein	at	the	TRPM8	locus,	 Dhaka	 et	 al	 demonstrated	 that	 TRPM8	 containing,	 and	 thus	 cooling	 sensitive,	 peripheral	afferents	 terminate	 in	 the	 superficial	 layer,	 lamina	 I(Dhaka,	 Earley	 et	 al.	 2008).	 Using	 a	 similar	technique,	 in	 which	 placental	 alkaline	 phosphatase	 was	 targeted	 to	 the	 MrgprB4	 locus,	 Liu	 et	 al	demonstrated	 that	 the	 population	 of	 C-fibres	 innervating	 hairy	 skin	 to	 convey	 tactile	 information	terminate	in	lamina	IIo,	as	part	of	large	arborisations,	and	co-terminate	with	IB4	positive	fibres(Liu,	Vrontou	et	al.	2007).		
		 57	
	
	
Figure	1.7	–	Primary	afferent	termination	in	the	dorsal	horn,	taken	from	Todd	2010	-	Left)	NeuN	immunolabeled	rat	dorsal	horn,	demonstrating	the	laminar	boundaries	described	by	Rexed.	Note	the	density	of	small	neurons	in	lamina	I	and	II.	 Right)	 Todd	 2010	 describes	 a	 laminar	 termination	 pattern	 based	 on	 fiber	 diameter	 and	 function.	 Namely	 that	 Aβ	afferents	terminate	in	lamina	III–V,	with	some	extension	into	lamina	Iii;	Aδ	hair	follicle	afferents	terminate	at	the	border	of	lamina	II	and	lamina	III;	Aδ	nociceptors	terminate	in	lamina	I,	with	some	neurones	additionally	branching	to	lamina	V	and	lamina	X;	Peptidergic	primary	afferents	(mainly	C,	with	some	20%	of	Aδ	nociceptors)	terminate	 in	 lamina	I	and	IIo,	with	some	divergence	into	deeper	lamina;	Non-peptidergic	C	fibers	terminate	in	the	central	part	of	lamina	II.	(Todd	2010)See	the	body	of	text	for	more	details.		
However,	the	location	of	termination	is	not	the	only	variable	–	but	the	nature	of	the	secondary	cell	to	which	the	afferent	primarily	targets.	There	are	considerations	of	whether	projection	or	interneurons	are	the	post-synaptic	target,	and	given	interneurons	are	most	commonly	the	target(Todd	2010),	it	is	important	 to	consider	 the	 	considerable	segmentation	of	 the	 interneuron	population.	For	example,	the	islet	and	central	cells	of	lamina	II	will	receive	direct	inputs	from	C	and	Aδ,	however	only	C	fibers	will	provide	monosynaptic	excitatory	 inputs	 to	 these	 interneurons,	while	 islets	received	 inhibitory	inputs	 from	Aδ	only(Yasaka,	Kato	et	al.	2007).	Meanwhile	 the	C	 fibers	expressing	both	TRPA1	and	TRPV1	 synapse	 to	 vertical	 and	 radial	 cells	 of	 lamina	 II(Uta,	 Furue	 et	 al.	 2010).	 This	 peptidergic	nociceptor	population	 is	 also	 the	major	 synaptic	 input	 to	NK1	expressing	projecting	population	of	secondary	order	neurones	 in	 lamina	I(Todd	2002),	 though	these	afferent	may	additionally	provide	some	synaptic	input	to	lamina	II	and	IV(Naim,	Spike	et	al.	1997).	The	consequence	of	this	segmented	input	is	that	the	specific	ablation	of	NK1	positive	neurones	(both	projecting	and	interneuron),	using	saporin	 linked	 substance	 P,	 significantly	 reduces	 the	 behavioural	 shifts	 associated	 with	inflammatory	 and	 neuropathic	 pain	models	 (Hunt	 and	Mantyh	 2001)-	 as	 a	 direct	 consequence	 of	abolishing	a	major	route	of	transmission	of	information	from	peptidergic	nociceptors.		
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1.5.1.7	 Modulating	influences	on	primary	afferents	
As	peripheral	 afferents	progress	 through	 the	DRG	and	 into	 the	dorsal	 horn	 a	number	of	 potential	interactions	may	take	place	before	synapsing	with	the	secondary	neuron.	In	experiments	using	a	cre-dependent	rabies	virus	to	 trace	 inputs	onto	primary	sensory	neurons	 in	neonatal	mice	Zhang	et	al	suggested	 that	 sensory	 neurones	 likely	 partook	 in	 extra-synaptic	 regulation	 of	 neighbouring	afferents	 within	 the	 DRG,	 likely	 via	 Glutamatergic	 transmission	 onto	 the	 soma(Zhang,	 Zhao	 et	 al.	2015).	 This	 is	 aligned	 to	 earlier	 studies	 identifying	 intraganglia	 release	 of	 neurotrasmitters(Bráz,	Ackerman	et	al.	2011,	Kung,	Gong	et	al.	2013),	and	potentially	represents	a	mechanism	driving	the	spread	of	sensitization	that	contributes	to	allodynia(Zhang,	Zhao	et	al.	2015).	This	acts	in	contrast	to	the	 axo-axonic	 and	 dendro-axonic	 GABAergic	 inputs	 driving	 peripheral	 afferent	 depolarization	(PAD)	 (Todd,	 Watt	 et	 al.	 1996,	 Kullmann,	 Ruiz	 et	 al.	 2005),	 which	 ultimately	 act	 to	 reduce	 the	number	of	action	potentials	reaching	the	synapse.	Notably,	peptidergic	nociceptors	appear	to	receive	much	fewer	axo-axonic	synapses(Ribeiro‐Da‐Silva,	Tagari	et	al.	1989).	 It	 is	suggested	that	these	pre-synaptic	 interactions	 can	 similarly	 segmented	 by	 fibre	 type,	with	 Glycine	 enriched	GABAergic	input	 to	 Aδ	 and	 Aβ	 hair	 follicle	 afferents,	 where	 as	 there	 is	 no	 or	 limited	 glycine	 to	 the	 non	peptidergic	C	fibers(Todd,	Watt	et	al.	1996,	Watson,	Hughes	et	al.	2002).		
The	characterization	of	receptor	populations	on	the	terminals	of	primary	afferents	in	the	dorsal	horn	further	speaks	to	the	segmentation	of	 the	 influences	of	 intraspinal	and	supraspinal	 influences.	The	central	 terminals	 of	 small	myelinated	Aδ	 and	 the	 non-peptidergic	 C	 fibers	 express	 both	 5HT3	 and	muscarinic	receptors	M2	and	M3(Li,	Chen	et	al.	2002,	Zeitz,	Guy	et	al.	2002),	while	TRPV1	positive,	peptidergic	populations	have	been	characterized	as	expressing	α2A,	5HT1A,	5HT1D,	5HT7	and	nicotinic	receptors(Cardenas,	Del	Mar	et	al.	1997,	Stone,	Broberger	et	al.	1998,	Birder	and	Perl	1999,	Potrebic,	Ahn	et	al.	2003,	Haberberger,	Bernardini	et	al.	2004,	Doly,	Fischer	et	al.	2005).	As	such,	despite	the	role	 of	 volume	 transmission	 in	 modulating	 these	 fiber	 populations,	 the	 discreet	 expression	 of	specific	receptor	populations	determines	the	balance	of	inhibition	and	excitatory	influences	exerted.	
Recent	work	by	Zhang	et	al	has	emphasized	the	predominance	of	pre-synaptic	inhibition	of	primary	afferents	 by	 descending	 GABAergic	 modulation	 from	 the	 RVM.	 In	 this	 work,	 the	 spread	 of	 a	peripherally	injected,	cre-dependent	rabies	virus	in	advallin-cre	P1	pups	into	RVM	cells	positive	for	one	of	either	GLAD2,	GlyT2	or	Tph2	confirmed	 these	neurones	were	~80%	GABA/Glycinergic	and	~17%	serotonergic.	Further,	 the	 inhibition	of	 this	population	of	RVM	neurones	suggested	 that	 the	GABA	 released	 by	 this	 population	 is	 required	 to	 suppress	 hypersensitivity	 to	 noxious	 heat	 under	normal	conditions(Zhang,	Zhao	et	al.	2015).	
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Similarly,	Kim	and	colleagues	characterized	the	importance	of	descending	serotonin	for	sensitizing	the	central	terminals	of	primary	afferents	during	nerve	injury,	via	the	activation	of	the	5HT3	receptor	and	the	facilitation	of	TRPV1(Kim,	Chu	et	al.	2014).		Specifically,	in	Vc	slices	from	GCaMP3	knock-in,	chronic	 constriction	 injury	 of	 the	 infraorbital	 nerve	 (CCI-ION)	 mice,	 treatment	 with	 a	 5-HT3AR	antagonist	reduced	the	capsaicin	evoked	GCaMP3	signals	at	the	central	terminals	to	levels	equivalent	to	the	signals	observed	in	the	contralateral	side.	Similarly,	the	5-HT3AR	agonist	mediated	increase	in	ESPC	observed	in	Vc	slices	could	be	partially	reversed	by	pretreatment	with	a	TRPV1	antagonist.	As	part	of	a	much	broader	set	of	experiments,	this	was	taken	to	suggest	that	descending	5HT,	acting	via	the	 5-HT3AR,	 recruits	 and	 sensitizes	 TRPV1	 to	 mediate	 an	 enhancement	 of	 glutamine	 release	 at	these	 central	 terminals(Kim,	 Chu	 et	 al.	 2014).	 This	 again	 emphasizes	 the	 important	 role	 of	 pre-synaptic	regulation	of	peripheral	afferent	input	to	the	dorsal	horn.	
Further	discussion	of	descending	controls	of	spinal	cord	excitability	can	be	found	in	Section	1.5.6.	
	
1.5.1.8	 Distinct	Contributions	to	Hyperalgesia	and	Allodynia	
As	 might	 be	 expected,	 given	 the	 distinct	 subdivisions	 of	 sensation	 between	 peripheral	 afferents,	there	is	a	growing	picture	of	the	distinct	roles	of	the	fiber	subtypes	in	allodynia	and	hyperalgesia.	
While	 findings	 have	 in	 part	 been	 contradictory,	 a	 number	 of	 studies	 have	 sought	 to	 classify	 the	potential	 role	 of	 the	 Aβ	 population	 in	 tactile	 allodynia	 during	 inflammation	 and	 neuropathy,	suggesting	 that	abnormal	activity	and	access	of	 these	 low	 threshold	mechanosensory	 fibers	 to	 the	ascending	 nociceptive	 pathways	 could	 underlie	 this	 pathology.	 These	 theories	 have	 included	 the	sprouting	of	Aβ	 fibers	 into	 lamina	 I	 and	 II(Lekan,	 Carlton	 et	 al.	 1996),	 and	 a	potential	 phenotypic	switch	 of	 these	 fibers	 to	 express	 peptidergic	 transmitters(Noguchi,	 Dubner	 et	 al.	 1994,	Neumann,	Doubell	et	al.	1996).	
As	 discussed	 above,	 SP	 expression	 has	 been	 characterized	 as	 nociceptors	 specific	characteristic(Lawson,	 Crepps	 et	 al.	 1997),	 however	 following	 inflammation	 Neumann	 and	colleagues	characterized	the	co-expression	of	SP	and	GM1	ganglioside	in	the	sciatic	nerve	DRG	using	immunohistochemistry	and	B	 fragment	cholera	 toxin	binding	respectively(Neumann,	Doubell	et	al.	1996).	 The	 study	 suggested	 that	 this,	 along	 side	 the	 increased	 release	 of	 SP	 in	 the	 dorsal	 horn	following	 inflammation,	 and	 the	 increased	diameter	of	SP	positive	 cell	profiles	after	 inflammation,	suggested	a	phenotypic	switch	had	occurred	 in	which	Aβ	afferents	were	expressing	SP,	potentially	contributing	to	the	increased	excitability	of	ascending	neurones	via	volume	transmission(Neumann,	Doubell	 et	 al.	 1996).	 A	 similar	 suggestion	 was	 made	 by	 work	 characterizing	 increased	 SP	 in	 the	
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dorsal	 horn	 following	 electrical	 stimulation	of	Aβ	 fibers	 after	 SNL	 (Malcangio,	Ramer	 et	 al.	 2000).	However,	more	recent	work	by	Hughes	has	contradicted	this,	observing	neither	 increased	staining	for	peptidergic	transmitters	in	myelinated	fibers,	nor	internalization	of	the	NK1	receptors	when	Aβ	fibers	are	stimulated	electrically	in	various	neuropathic	models(Hughes,	Scott	et	al.	2003).	There	is	also	 a	 suggestion	 that	 injured	 C	 fibers	 also	 bind	 B	 fragment	 of	 cholera	 toxin(Shehab,	 Spike	 et	 al.	2003)	 -	 similarly	 serving	 to	 contradict	 earlier	 work	 in	 which	 had	 suggested	 the	 sprouting	 of	 Aβ	fibers	after	nerve	injury	(Lekan,	Carlton	et	al.	1996).	
While	 the	 exact	 mechanism	 is	 unclear,	 that	 the	 abnormal	 central	 processing	 of	 inputs	 from	 this	population	 of	 low	 threshold	 mechanoreceptive	 A	 fibers	 is	 responsible	 for	 allodynia	 has	 been	demonstrated	 by	 intra	 neural	 micro	 stimulation(Torebjörk,	 Lundberg	 et	 al.	 1992).	 Following	treatment	with	capsaicin,	 the	 intraneural	microstimulation	that	had	previously	 induced	light	touch	sensations	 became	 painful,	 and	 A	 fiber	 blockade	 could	 completely	 abolish	 this	 pain	 (Torebjörk,	Lundberg	et	al.	1992).	Similarly,	in	a	patient	lacking	low	threshold	mechanosensitive	A	fibers,	Treede	and	 Cole	 described	 the	 failure	 of	 the	 patient	 to	 develop	 hypersensitivity	 to	 light	 touch	 following	capsaicin	injection,	despite	the	usual	burning	pain,	punctate	hypersensitivity	and	flare	(Treede	and	Cole	1993),	supporting	the	role	of	Aβ	fibers	in	allodynia	during	central	sensitization.		
Using	capsaicin	and	nerve	compression	to	selectively	block	A	fiber	conduction,	a	number	of	studies	have	 sought	 to	 distinguish	 the	 distinct	 roles	 of	 different	 fiber	 populations	 during	 hyperalgesia.	Following	capsaicin	injection,	the	A	fiber	block	abolished	allodynia	to	stroking,	reduced	but	did	not	abolish	 punctate	 (pricking)	 mechanical	 hyperalgesia,	 and	 left	 the	 “burning”	 pain	unchanged(Torebjörk,	Lundberg	et	al.	1992,	Ziegler,	Magerl	et	al.	1999).	If	a	capsaicin	pre-treatment	was	 engaged	 instead,	 to	 cause	 the	 selective	 “silencing”	 of	 TRPV1+	 peripheral	 afferents(Nolano,	Simone	et	al.	1999),	the	stimulus	response	for	pinprick	was	reduced	by	32%	(versus	82%	reduction	with	A	fiber	block)	while	laser	evoked	pain	was	eliminated(Magerl,	Fuchs	et	al.	2001).	Only	when	the	A	 block	 was	 combined	 with	 the	 capsaicin	 pre-treatment	 was	 sensitivity	 to	 pinprick	 eliminated	completely(Magerl,	Fuchs	et	al.	2001).		
Combined	 these	 studies	 built	 a	 picture	 in	 which,	 during	 central	 sensitization,	 low	 threshold	mechanoreceptive	A	fibers	are	the	sole	transducer	of	stroke/tactile	allodynia,	while	TRPV1	negative	A	 fibers	 are	 the	major	 contributor	 to	 pin	 prick	 hyperalgesia,	with	 some	 small	 contributions	 from	TRPV1	 positive	 C	 and	 A	 fibers.	 	 Given	 this,	 it	 is	 perhaps	 interesting	 to	 note	 that	 following	 CFA	induced	inflammation	the	incidence	and	magnitude	of	monosynaptic	Aδ	fiber,	but	not	monosynaptic	C-fiber,	 input	 to	 lamina	 I	 NK1	 positive	 projecting	 neurons	 is	 increased(Torsney	 2011).	 Crucially,	these	 studies	 suggest	 that	 punctate	 hyperalgesia	 is	 facilitated	 by	 C	 fibers,	 a	 hetereosynaptic	
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facilitation,	but	require	the	activity	of	A	fibers(Torebjörk,	Lundberg	et	al.	1992,	Ziegler,	Magerl	et	al.	1999,	Magerl,	Fuchs	et	al.	2001,	Torsney	2011).		
Henrich	and	colleagues	used	high	frequency	electrostimulation,	capsaicin	pre	treatment	and	A	fiber	nerve	block	to	look	further	into	the	respective	roles	of	C	and	A	fibers	in	homotropic	and	heterotropic	long	term	potentiation	(LTP),	or	increased	synaptic	strength,	in	the	dorsal	horn	(Henrich,	Magerl	et	al.	2015).	This	work	classified	an	equivalent	role	for	TRPV1	positive	and	negative	fiber	populations	in	homotropic	LTP,	while	homotropic	and	heterotropic	LTP,	observed	as	secondary	hyperalgesia	to	pinprick,	required	a	much	greater	contribution	of	C	 fibers	over	A	 fibers.	 In	other	words,	 this	work	demonstrated	 the	 subdivisions	 of	 contribution	 of	 different	 peripheral	 afferent	 populations	 to	 the	generations	of	increased	synaptic	strength	and	the	consequential	hyperalgesia.	 	
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1.5.2 			 Stimulus	Transduction	and	Transmission	
As	 previously	 described,	 afferent	 endings	 are	 either	 associated	 directly	 to	 stimulus	 transduction	machinery,	such	as	Merkel	cells,	or	exist	as	free	endings	in	the	superficial	layers	and	the	joint.	These	free	 endings	 are	 reliant	 on	 receptors,	 largely	 ion	 channels,	 to	 transduce	mechanical,	 thermal	 and	chemical	information	from	their	environment	into	depolarizing	sensory	potentials.	These	potentials	may	either	directly	activate	 the	afferent,	by	activating	voltage	gated	sodium	channels	 to	 trigger	an	action	potential,	or	sensitize	the	cell,	contributing	to	a	shift	in	the	resting	potential	of	the	cell	to	make	exceeding	 the	 activation	 threshold	more	 likely.	 These	 action	 potentials	 are	 then	 conducted	 to	 the	dorsal	horn	of	the	spinal	cord.	
	
1.5.2.1 Mechano	and	Thermal	Transduction	
As	 the	 conduction	 machinery	 of	 the	 lipid	 membrane,	 ionophores	 are	 crucial	 components	 of	 the	transduction	 and	 transmission	 of	 sensory	 information.	 Both	 inflammation	 and	 neuropathy	 elicit	plasticity	in	the	function	and	expression	of	these	channels,	the	result	of	which	is	the	enhanced	and	spontaneous	 afferent	 drive.	 To	 date,	 the	 full	 range	 of	 somatosensory	 machinery	 are	 as	 yet	 fully	characterized,	 but	 can	 crudely	 be	 broken	 down	 into	 light	 touch,	 proprioception,	 thermosensation	and	nociception	(Gardner,	Martin	et	al.	2000),	where	nociception	itself	can	also	similarly	be	broken	down	into	thermal,	mechanical	and	chemical.		
Across	 a	 thermal	 gradient,	 9	 different	 receptors	 within	 the	 Transient	 Receptor	 Potential	 (TRP)	family	become	active	and	change	conformation	to	increase	cation	permeability,	causing	nociceptors	depolarization:	 TRPV1-4,	 TRPM2,	 4,	 5	 and	 8	 and	 TRPA1(O'Neill,	 Brock	 et	 al.	 2012).	 At	 the	 most	noxious	end	of	the	scale,	TRPV2	is	activated	at	temperatures	exceeding	52°C(Caterina,	Rosen	et	al.	1999),	though	TRPV1	is	believed	to	be	faster	acting	with	a	threshold	of	42°C(Dhaka,	Viswanath	et	al.	2006).	
At	the	cool	end,	TRPM8	and	TRPA1	are	well-characterized	transducers	of	cooling,	cold	sensation	and	nociception(Bautista,	Siemens	et	al.	2007,	Karashima,	Talavera	et	al.	2009).	However	the	presence	of	these	 receptors	 alone	 is	 not	 sufficient	 for	 cold	 sensation	 given	 the	 inactivation	 of	 voltage	 gated	sodium	 channels	 by	 cooling.	 As	 such,	 only	 Nav1.8	 containing	 afferents,	 which	 are	 insensitive	 to	cooling	 inactivation,	 may	 convey	 sensory	 information	 related	 to	 cold	 and	 cooling(Zimmermann,	Leffler	et	al.	2007).	
Across	 these	 thermo-TRPs,	 there	 is	 additional	 receptivity	 to	 a	 range	 of	 chemical	 and	 mechanical	stimuli.	 The	 sensitivity	 of	 TRPV1	 to	 pH	 and	 capsaicin	 is	 perhaps	 one	 of	 the	 best	
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characterized(O'Neill,	 Brock	 et	 al.	 2012),	 along	 side	 TRPA1	 as	 a	 polymodal	 receptor	 and	 the	“gatekeeper	for	inflammation”(Bautista,	Pellegrino	et	al.	2013),	where	both	have	direct	and	indirect	roles	 in	 the	 sensitization	 of	 primary	 afferents.	 While	 TRPA1	 is	 activated	 by	 a	 range	 of	 chemical	stimuli,	including	mustard	oil,	TRPA1	ablated	mice	exhibit	deficits	in	responses	to	both	low	and	high	intensity	mechanical	stimuli(Kwan,	Allchorne	et	al.	2006),	and	TRPA1	antagonist	attenuated	C	fiber	activation	to	high	intensity	mechanical	stimulation(Kerstein,	del	Camino	et	al.	2009).		
TRPs	are	becoming	 increasingly	recognised	 for	 their	role	 in	mechanotransduction,	 though	 it	 is	not	yet	 fully	 understood.	 TRPV4	 is	 one	 such	 candidate.	 When	 knocked	 out	 this	 Ca2+	 permeable	osmomechano-TRP	channel	reduced	mouse-tail	sensitivity	to	noxious	pressure(Suzuki,	Mizuno	et	al.	2003).	 TRPV4,	 which	 is	 highly	 expressed	 in	 articular	 chondrocytes,	 has	 similarly	 been	 shown	 to	convey	 load	 bearing	 information	 to	 allow	 the	 regulation	 of	 extracellular	 matrix	 and	 joint	 health,	whereby	loss	of	this	mechnoceptor	is	associated	with	joint	arthropathy	and	osteoarthritis(O’Conor,	Leddy	et	al.	2014).		
Attention	 is	 also	 being	 assigned	 to	 the	 TRPC	 family	 of	 receptors.	 A	 study	 utilizing	 antisense	oligonucleotides	 showed	 that	TRPC1	and	TRPV4	are	 required	 for	mechanical	hyperalgesia	but	are	not	 required	 for	 baseline	 mechanosensation,	 whilst	 TRPC6	 plays	 a	 role	 in	 both	 mechanical	 and	thermal	hyperalgesia(Alessandri-Haber,	Dina	et	al.	2009).	Dual	knock	out	of	both	TRPC3	and	TRPC6	silenced	 a	 subpopulation	 of	 small	 diameter	 afferents	 expressing	 rapidly	 adapting	 mechanically	sensitive	 currents,	 and	 additionally	 resulting	 in	 sensory	 deficits	 in	 light	 touch(Quick,	 Zhao	 et	 al.	2012).	
As	 with	 cold	 sensation,	 the	 presence	 of	 these	 receptors	 in	 the	membrane	 is	 not	 enough	 alone	 to	produce	mechanosensation,	with	 increasing	 support	 for	 the	 importance	 of	 Piezo	 proteins	 in	 both	noxious	 and	 innocuous	 sensation(Delmas	 and	 Coste	 2013).	 Indeed,	 there	 are	 questions	 as	 to	whether	mechanosensation	 is	 directly	 transduced	 by	 these	 channels	 above,	with	 suggestions	 TRP	may	merely	modulate	or	amplify	the	activity	of	other	unknown	mechanosensitive	 ionophores(Xiao	and	Xu	2010).	In	line	with	this	concept	of	indirect	mechanotransduction	MrgprD,	a	G	protein	coupled	ATP	receptor,	has	been	proposed	 to	 indirectly	 transduce	 touch	sensation	 through	 the	detection	of	ATP	release	in	the	skin(Dussor,	Zylka	et	al.	2008).	
	
1.5.2.2 Voltage	Gated	Sodium	Channels	
Ionophores	 also	 control	 the	 electrophysiological	 properties	 of	 the	 primary	 afferents,	 not	 least	 the	threshold	 for	 action	 potential	 generation,	 inter	 spike	 intervals	 and	 burst	 duration.	 Of	 particular	
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import	to	the	transmission	of	pain	signals	are	the	voltage	gated	sodium	channels	(VGSC)	Nav1.3,	1.7,	1.8	and	1.9.	Indeed,	the	differential	transmission	qualities	of	the	afferent	fiber	subtypes	are	in	part	dependent	on	the	distinct	VGSC	expression	patterns.	While	A	fibers	produce	narrow,	high	frequency	APs	 as	 a	 result	 of	 the	 predominance	 of	 the	 TTX-S	 Nav	 1.6	 and	 1.7,	 C	 fibers	 have	 wider,	 lower	frequency	action	potential	firing	patterns	due	to	the	predominance	of	TTX-R	Nav1.8	and	1.9.	
The	 importance	 of	 these	 specific	 VGSC	 in	 pain	 is	 clearly	 demonstrated	 by	 specific	 genetic	polymorphisms,	 knock	 out	 studies	 and	 pharmacology.	 These	 will	 be	 discussed	 in	 more	 depth	 in	Chapter	6.	
In	 addition	 to	 baseline	 conductance	 in	 healthy	 animals,	 as	 has	 previously	 been	 alluded	 to,	 these	channels	are	pivotal	to	the	generation	of	sensitization	in	the	periphery	during	injury,	inflammation	and	 neuropathy.	 Their	 currents,	 thresholds,	 distribution	 and	 inclusion	 are	 highly	 plastic,	 altering	greatly	to	produce	hyperalgesia	and	allodynia,	as	discussed	below,	to	contribute	to	the	adaptive	pain	experience	of	OA.	
	
1.5.2.3 Ion	Channels,	Chemical	Stimuli	and	Inflammatory	Pain	
Following	 injury	 and	 while	 inflammation	 is	 ongoing,	 the	 activation	 of	 signaling	 cascades	 by	inflammatory	messengers	lead	to	the	phosphorylation	of	VGSC.	Alteration	in	the	threshold,	current	magnitude	and	kinetics	of	Nav1.7,	1.8	and	1.9	currents	follow,	increasing	membrane	excitability	and	thus	 the	 likelihood	 that	 a	 given	 stimulus	will	 evoke	an	action	potential(Liu	and	Wood	2011).	This	peripheral	sensitization	can	be	limited	by	the	use	of	COX	inhibitors,	as	previously	described	for	OA	management,	but	the	effects	of	 these	 interventions	are	narrow	if	 the	pain	 is	 largely	neuropathic	 in	nature.	
In	addition	 to	 these	post-translational	 changes	 to	 ionophore	proteins	evoked	by	 the	 inflammatory	milieu,	 there	 is	 dynamic	 regulation	 of	 sodium	 channel	 expression,	 both	 of	 their	 distribution	 and	population.	Transcriptional	regulation,	triggered	by	both	inflammatory	cascades	and	nerve	damage,	lead	to	both	up	and	down	regulation	of	VGSC	populations.	Crucially,	 following	nerve	damage	there	appears	 to	 be	 a	 renewed	 expression	 of	 Nav1.3,	 despite	 restricted	 expression	 in	 normal	 adult	 rat	DRG(Dib-Hajj,	 Cummins	 et	 al.	 2010).	 It	 is	 suggested	 that	 this	 novel	 expression	 of	 Nav1.3	 in	 adult	sensory	afferents	results	in	ectopic	firing	and	consequently	spontaneous	pain,	symptoms	which	can	be	reversed	by	the	application	of	GDNF	which	normalizes	Nav1.3	expression(Dib-Hajj,	Cummins	et	al.	2010,	Liu	and	Wood	2011).		
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Similarly,	 the	 usually	 abundant	 Nav1.8	 and	 1.9	 have	 been	 shown	 to	 be	 down-regulated	 following	nerve	injury(Dib-Hajj,	Cummins	et	al.	2010,	Liu	and	Wood	2011).	However,	results	are	contradictory	given	alternate	studies	exhibit	a	 role	 for	Nav1.8	 in	spontaneous	activity	 in	sensory	afferents(Roza,	Laird	 et	 al.	 2003).	 Gold	 et	 al	 argue	 that	 while	 Nav1.8	 is	 down-regulated	 in	 the	 injured	 neurons,	expression	 is	 redistributed	 to	uninjured	counterparts	 to	produce	aberrant	activity(Gold	MS	2003),	which	consequently	maintains	an	afferent	drive.		
Consideration	 must	 also	 be	 made	 to	 the	 enhanced	 action	 of	 sodium	 channel	 populations	 within	sympathetic	 neurons.	 Nav1.7	 containing	 sympathetic	 and	 sensory	 neuron	 populations	 have	 been	shown	 to	work	 in	 concert	 to	 enhance	 pain	 sensation(Minett,	 Nassar	 et	 al.	 2012).	While	 the	 exact	mechanism	 of	 a	 sympathetic	 drive	 in	 acute	 and	 neuropathic	 pain	 is	 not	 yet	 clear,	 this	 system	 is	already	being	targeted	for	analgesia	in	postoperative	pain(McDonnell,	Finnerty	et	al.	2011).		
	
1.5.3 		 Peripheral	Sensitization	
As	 previously	 stated,	 the	 onset	 and	 maintenance	 of	 OA	 provides	 considerable	 activation	 of	 the	immune	 cells	 in	 and	 around	 the	 joint,	 producing	 episodic	 flares	 of	 inflammation	 as	 tissue	 injury	progresses.	 Similarly,	 the	 damaged	 and	 dying	 cells	 (such	 as	 the	 chondrocytes)	 release	 distress	signals,	 including	 ATP(Burnstock	 1996),	 K+	 and	 H+,	 which	 alter	 the	 tissue	 pH(McMahon	 and	Koltzenburg	2006),	and	prostanoids(Vignon,	Balblanc	et	al.	1993),	in	and	around	the	joint.		
The	accumulation	of	pro	inflammatory	cytokines	in	the	knee	during	OA	is	well	characterized(Vignon,	Balblanc	et	al.	1993,	Cameron,	Fu	et	al.	1994,	Abramson	2004,	Gallelli,	Galasso	et	al.	2013).	TNFα,	the	major	 pro	 inflammatory	 cytokine	 driving	 cartilage	 catabolism	 and	 degradation(Haseeb	 and	Haqqi	2013),	 has	 been	 detected	 in	 96.1%	 of	 patients	 tested,	 while	 84.6%	 exhibited	 IL-6	 in	 their	synovium(Vignon,	Balblanc	et	al.	1993).	It	has	additionally	been	suggested	that	the	levels	of	IL-6	can	be	indicative	of	the	stage	of	OA(Kaneko,	Satoh	et	al.	2000).		It	is	this	accumulation	of	cytokines	and	inflammatory	 mediators	 which	 is	 targeted	 by	 NSAID	 analgesia,	 where	 treatment	 with	 celecoxib,	diclofenac	 or	 ibuprofen	 not	 only	 produced	 significant	 improvement	 in	 WOMAC	 scores,	 but	significant	 decrease	 in	 the	 IL-6,	 VEGF	 and	TNFα	 concentration	 in	 the	 synovial	 fluid,	where	 higher	doses	produced	better	reductions	to	both	criteria(Gallelli,	Galasso	et	al.	2013).	
This	inflammatory	milieu	serves	dual	purposes-	not	only	do	these	inflammatory	mediators	directly	activate	 nociceptors,	 through	 ligand	 gated	 ion	 channels	 (LGIC),	 these	 mediators	 can	 bind	 to	metabotropic	 receptors,	 including	 G-protein	 coupled	 receptors	 (GPCR),	 to	 produce	 sensitization	through	 the	 initiation	 of	 intracellular	 signaling	 cascades,	 many	 of	 which	 converge	 on	 common	
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targets.	 Consequences	 are	 diverse,	 but	 largely	 involve	 post	 translational	 modifications,	 direct	 ion	channel	 modulation,	 altered	 protein	 trafficking	 and	 expression,	 and	 intracellular	 calcium	mobilization.	Consequently,	there	is:		
• An	 observable	 increase	 in	 the	 response	 of	 low	 threshold	 Aδ	 afferents	 to	 noxious	 and	innocuous	stimuli;		
• High	threshold	Aδ	and	C	fibers	display	a	decrease	in	the	mechanical	stimulus	threshold	and	increase	responsiveness;		
• The	 silent,	mechanically	 insensitive	 nociceptors	 become	mechanically	 sensitive,	 increasing	input	 to	 the	 spinal	 cord	 in	 response	 to	mechanical	 stimuli	 (i.e.	 fiber	 recruitment)(Schaible	and	Schmidt	1985,	Grigg,	Schaible	et	al.	1986,	Schaible	and	Schmidt	1988).		
These	changes	significantly	contribute	to	the	allodynia	and	mechanical	hyperalgesia	observed	in	OA	patients	and	are	termed	peripheral	sensitization.	Outlined	below	are	some	example	mechanisms	of	peripheral	sensitization	by	specific	mediators	involved	in	OA	pain	pathophysiology.	
	
1.5.3.1 Activation	of	LGIC	
LGICs	are	hydrophilic	pores	in	the	membrane	of	the	cell	whose	confirmations	change	from	open	to	closed	upon	the	binding	of	an	agonist.	This	is	the	basic	mechanism	through	which	neurotransmitters	such	 as	 Glutamate	 generate	 depolarizing	 potentials	 to	 trigger	 action	 potentials	 in	 neurons.	 It	 is	similarly	 the	 mechanism	 used	 by	 several	 of	 these	 inflammatory	 agents	 to	 shift	 the	 membrane	potential	 and	 sensitize	 primary	 afferents.	 Key	 transmitter-LGIC	 relationships	 in	 peripheral	sensitization	include	5HT	released	from	platelets	and	mast	cells	at	5HT3(Sommer	2004),	ATP	at	P2X	family	receptors	,	and	protons	at	acid	sensing	ion	channels	(ASICs).	
To	 give	 one	 example,	 ATP	 has	 been	 shown	 to	 be	 elevated	 in	OA	 knees(Ryan,	 Rachow	 et	 al.	 1991,	Park,	Masuda	et	al.	1996),	where	it	has	been	characterized	that	nociceptors	(C	and	Aδ)	in	the	knee	joint	produce	rapid,	short	acting	excitation	following	introduction	of	ATP	or	P2X	agonist	–	an	effect	which	may	similarly	be	antagonized(Dowd,	McQueen	et	al.	1998).	As	such	is	it	is	purported	by	Dowd	that	the	increased	presence	of	ATP	in	the	synovial	fluid	during	the	degradation	of	the	joint	directly	activates	 these	 P2X	 LGIC	 to	 contribute	 to	 the	 initiation	 of	 nociception	 and	 sensitization	 of	nociceptors(Dowd,	McQueen	et	al.	1998).	It	is	of	note,	however,	that	these	LGIC	may	have	actions	on	non-neuronal	 tissues	 which	may	 contribute	 to	 sensitization	 –	 where	 P2X4	 activation	 on	 synovial	
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fibroblasts	 induces	 the	 release	 of	 BDNF(Klein,	 Aeschlimann	 et	 al.	 2012),	 whose	 levels	 are	 also	elevated	in	OA(Barthel,	Yeremenko	et	al.	2009).	
	
1.5.3.2 Activation	of	GPCR	
GPCR	are	a	broad	family	of	receptor	proteins	characterized	by	a	7-transmembrane	receptor	that	acts	in	 association	with	 a	 heterotrimer	 of	 nucleotide	 binding	 proteins.	 GPCRs	 are	 the	 transducers	 of	 a	number	 of	messengers,	 not	 least	 5HT,	 bradykinin	 and	 the	 prostaglandins.	 It	 is	 this	mechanism	 of	peripheral	sensitization	targeted	during	NSAID	therapy.	
These	 metabotropic	 receptors	 drive	 the	 excitability	 of	 nociceptors	 during	 inflammation	 by	 the	initiation	of	cascades	that	result	in	post	translational	modifications,	largely	utilizing	either	Adenylate	Cyclase	(AC)	and	Phospholipase	C	(PLC).		
• Actions	through	AC	
For	 example,	 the	binding	of	PGE2	at	 its	EP2/EP4	,	Gs	 coupled	 receptor,	would	 stimulate	AC,	resulting	 in	 the	 production	 of	 cAMP.	 This	 activates	 Protein	 Kinase	 A	 (PKA),	 which	phosphorylates	 serine	 or	 threonine	 residues	 of	 receptors	 and	 ion	 channels	 within	 the	nociceptors	 to	 alter	 their	 activity.	 Affected	 proteins	 include	 both	 those	 involved	 in	 action	potential	generation,	such	as	Nav1.7	and	1.8,	whose	threshold	and	kinetics	become	altered	to	increase	membrane	 excitability	 and	 thus	 increase	 the	 likelihood	 that	 a	 given	 stimulus	will	evoke	 an	 action	 potential(England,	 Bevan	 et	 al.	 1996,	 Gold,	 Reichling	 et	 al.	 1996);	 and	receptor	proteins	like	TRPV1,	whose	phosphorylation	results	in	the	reduction	in	the	thermal	activation	 threshold	 so	 that	 the	 receptor	 can	 activate	 at	 body	 temperature,	 leading	 to	 the	burning	pain	associated	with	inflammation(Moriyama,	Higashi	et	al.	2005).	
• Actions	through	PLC		
For	 example,	 the	 binding	 of	 BK	 at	 the	 B2	 receptor,	 a	 Gq	 coupled	 receptor,	 results	 in	 the	activation	 PLC.	 This	 mediates	 the	 liberation	 of	 Ca2+	 from	 intracellular	 stores,	 which	 may	activate	 Ca2+	 sensitive	 ion	 channels(Gold	 and	 Gebhart	 2010)	 or	 similarly	 activate	 Calcium	sensitive	 enzymes,	 including	 both	 Protein	 Kinase	 C	 (PKC)	 isozymes	 and	 Ca-Calmoduin-dependant	 Protein	 Kinase	 II	 (CAMKII).	 This	 can	 result	 in	 both	 the	 phosphorylation	 of	nociceptive	 proteins	 like	 TRPV1,	 whose	 gating	 is	 consequently	 enhanced(Cesare	 and	McNaughton	1996).	
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It	 is	worth	 noting	 there	 are	multiple	 points	 of	 convergence,	 explaining	 the	 impressive	 synergy	 of	PGE2	 and	 BK,	 which	 together	 produce	 far	 greater	 mechanical	 hyperalgesia	 than	 either	 would	alone(Schaible	2009).	Similarly,	there	is	considerable	redundancy	–	it	is	not	enough	to	simply	knock	out	EP2	to	prevent	the	phosphorylation	of	TRPV1	during	inflammation.	
Additionally,	 while	 G	 proteins	 make	 considerable	 contributions	 to	 sensitization,	 they	 may	 also	provide	analgesia.	PGE2	at	its	EP3	subtype	receptor	can	provide	anti-nociceptive	actions,	where	EP3	agonist	has	been	shown	 to	reduce	neuronal	 responses	of	 rat	knee	afferents	 in	 inflamed	 joints,	but	had	no	effect	in	un-inflamed	joints(Natura,	Bär	et	al.	2013).	It	is	these	endogenous	pain	control	GPCR	systems	that	are	utilized	by	many	analgesics,	not	least	opioids.	
	
	
1.5.3.3 Tyrosine	Kinase	Receptor	Activation	
Receptor	Tyrosine	Kinases	(RTK)	are	crucial	to	the	generation	of	peripheral	sensitization,	as	this	is	the	 receptor	 family	 primarily	 responsible	 for	 the	 effects	 of	 cytokines,	 where	 notable	 examples	include	TNF-α	at	p55/60.	
These	receptors	dimerise	and	recruit	p38	MAPK,	Janus	Kinase	(JAK)	and	Stat	transcription	factors,	to	directly	alter	gene	expression	and	post-translational	modification.	These	receptors	also	recruit	PKC	to	 have	more	 immediate	 effects	 on	 sensory	 neurons,	 where	 IL-1β	 can	 produce	 heat	 sensitization	
Figure	1.8	 -	Mechanisms	of	peripheral	sensitization	at	 the	peripheral	 terminal	of	a	sensory	afferent	 |	 Inflammatory	mediators,	 such	 as	prostaglandin	E2	 (PGE2),	 bradykinin	 and	nerve	 growth	 factor	 (NGF),	 activate	 intracellular	 kinases	 that	phosphorylate	transducer	channels	to	reduce	their	threshold	or	sodium	channels	to	increase	excitability.	(LGIC	–	ligand	gated	ion	 channel;	GPCR	–	G	protein	coupled	 receptor;	RTK	–	Receptor	 tyrosine	 kinase;	 PKA	–	Protein	Kinase	A;	AC	–	Adenylate	Cyclase;	PLC	–	Phospholipase	C;	PKC	–	Protein	Kinase	C;	CaMKII	-	Ca-Calmoduin-dependant	Protein	Kinase	II;		
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within	a	minute	of	peripheral	injection	through	it’s	RTK(Sommer	and	Kress	2004).	While	targeting	these	mechanisms,	e.g.	using	antibodies	for	TNF-α	such	as	infliximab,	provide	successful	analgesia	in	conditions	with	 a	more	pronounced	 inflammatory	 component,	 such	as	Rheumatoid	Arthritis	 (RA),	they	 have	 little	 effect	 in	 OA,	 probably	 due	 to	 the	 smaller	 role	 played	 by	 inflammation	 in	 this	condition(Feldmann	and	Maini	2003).	
	
1.5.3.4 NGF	at	TrkA	
The	 neurotrophin	 family,	 containing	 both	 NGF	 and	 BDNF,	 is	 a	 critical	 contributor	 to	 peripheral	sensitization	in	inflammation	and	OA.	These	mediators	were	originally	characterized	for	their	role	in	the	 survival	 of	 neurons,	 but	 were	 later	 recognised	 for	 their	 role	 in	 pain	 and	 hyperalgesia.	 The	injection	of	NGF	to	the	Masseter	muscle	produces	prolonged	reduction	in	pressure	pain	thresholds	(PPTs),	 without	 alterations	 in	 sensations	 governed	 by	 large	 diameter	 mechanoreceptive	fibers(Svensson,	Wang	et	al.	2008),	characteristic	of	the	expression	of	NGF	receptors	in	peptidergic	nociceptors.	 Similarly,	mutations	 to	 the	NGF	 receptors	 have	 been	 demonstrated	 in	 3	 independent	patients	with	congenital	insensitivity	to	pain(Indo,	Tsuruta	et	al.	1996).	
Neurotrophin	receptors	can	be	split	into	two	groups:	The	low	affinity	p75	receptor,	which	will	bind	to	any	neurotrophin;	and	the	high	affinity	Trk	receptors	that	bind	selectively	–	NGF	at	TrkA,	BDNF	and	NT-4	at	TrkB,	and	NT-3	at	TrkC.	 	When	NGF	binds,	 to	cause	 the	dimerization	of	TrkA,	 several	signaling	 pathways	 are	 recruited,	 including	 mitogen	 activated	 protein	 kinase	 (MAPK),	phosphoinositide	3-kinase	(PI3K),	extracellular	signal	regulated	kinase	(ERK)	and	PLC	(Bonnington	and	McNaughton	2003,	Hefti,	Rosenthal	et	al.	2006,	Pezet	and	McMahon	2006).	Recruited	signaling	cascades	and	their	effects	include:	
• Activation	of	PI3K,	leading	to	phosphorylation	of	TRPV1,	enhancing	its	trafficking	to	the	membrane	 and	 enhancing	 the	 depolarizing	 current	 of	 this	 channel(Huang,	 Zhang	 et	 al.	2006).	
• Regulation	of	 the	activity	of	several	 transcription	 factors	by	NGF-TrkA	complex,	and	 its	recruited	 proteins,	 to	 alter	 the	 expression	 of	 a	 range	 of	 nociceptive	 genes	 in	 the	 DRG	neurons,	including	the	peptide	transmitters	SP	and	CGRP,	ion	channels	including	TRPV1	and	Nav1.8,	BK	receptors	and	BDNF	(McMahon	and	Koltzenburg	2006,	 Ji	and	Kawasaki	2009).			
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• Non-transcriptional	regulation,	altering	the	rate	of	mRNA	translation	through	p38	MAPK	signaling	 pathways,	 allowing	 for	 a	 more	 rapid	 increase	 in	 expression	 of	 nociceptive	proteins(Ji	and	Kawasaki	2009).	
As	 such,	 NGF	 not	 only	 alters	 the	 currents	 and	 trafficking	 of	 ion	 channels	 in	 the	 nociceptors	membrane,	 it	 also	 alters	 the	 expression	 of	 nociceptive	 genes	 to	 increase	 excitability.	 This	 acts	 in	concert	 with	 the	 effects	 of	 NGF	 at	 immune	 cells,	 triggering	 degranulation,	 cytokine	 release,	proliferation	and	recruitment.	
It	 is	 has	 been	 demonstrated	 that	 NGF	 is	 increased	 during	 OA(Aloe,	 Tuveri	 et	 al.	 1992,	 Walsh,	McWilliams	et	al.	2010),	where	NGF	is	released	by	activated	macrophages	which	have	infiltrated	the	joint.	The	role	of	NGF	in	OA	has	gained	considerable	interest	following	the	experimental	and	clinical	success	of	Tanezumab	in	mitigating	OA	pain(Lane,	Webster	et	al.	2005,	Lane,	Schnitzer	et	al.	2010,	McNamee,	 Burleigh	 et	 al.	 2010,	 Schnitzer,	 Lane	 et	 al.	 2011,	 Brown,	 Murphy	 et	 al.	 2012).	Unfortunately,	this	drug	has	been	on	clinical	hold	under	the	FDA	twice	since	2010,	following	reports	of	serious	adverse	effects	in	a	minority,	not	limited	to	rapidly	advancing	OA(Garber	2011).	
	
1.5.3.5 Evidence	for	Peripheral	Sensitization	in	OA		
In	 the	 context	of	 the	 joint,	 peripheral	 sensitization	 is	observed	as	pain	 from	previously	 innocuous	joint	movements,	 strain	and	 torque,	while	noxious	stimuli	 (such	as	weight	placed	on	an	unnatural	joint	angle)	generate	greater	pain,	considered	allodynia	and	hyperalgesia	respectively.	While	OA	is	not	 considered	 an	 inflammatory	 disease,	 the	 presence	 of	 peripheral	 sensitization	 is	 well	documented.	
Consider	first	animal	work:	It	has	been	shown,	using	single	unit	electrophysiology,	that	the	induction	of	OA	 using	 the	MIA	model	 induces	 a	 significant	 increase	 in	 the	 rate	 of	 firing	 of	 joint	 afferents	 in	response	 to	 increasing	 noxious	 and	 non-noxious	 knee	 torque	 (Schuelert	 and	 McDougall	 2006,	Schuelert	 and	McDougall	 2009);	Mechanically	 sensitive	 A	 fibers	 exhibit	marked	 decrease	 in	 their	mechanical	threshold	and	increased	response	to	suprathreshold	stimuli(Kelly,	Dunham	et	al.	2012);	In	an	acute	arthritis	model,	utilizing	carrageenan	and	kaolin,	both	nociceptors	and	non	nociceptors	showed	 enhanced	 mechanosensation,	 with	 the	 additional	 recruitment	 of	 previously	 silent	 knee	afferents(Schaible	 and	Schmidt).	However,	 this	 study	by	 Sciable	&	Schmidt	1988	points	 to	 limited	role	of	Type	II	(Aβ	fibers)	in	the	enhanced	responses	of	the	arthritic	knee,	additionally	demonstrated	by	Dorn,	Schiable	&	Schmidt	1991,	where	Type	II	 fibers	showed	normal	proprioceptive	function	in	
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arthritic	 joints(Dorn,	 Schaible	 et	 al.	 1991).	 As	 such,	 animal	 evidence	 seems	 to	 point	 to	 the	predominant	role	of	Aδ	and	C	fibers	in	OA	related	changes	in	peripheral	sensitivity.	
In	humans	these	changes	 in	peripheral	 fiber	excitability	are	much	harder	to	characterize.	The	best	evidence	of	 the	 role	of	peripheral	 sensitization	 in	OA	clinically	 is	 the	efficacy	of	anti-inflammatory	analgesics,	as	discussed	in	Section	1.3.1.	These	compounds,	by	blocking	the	inflammatory	cascades	responsible	 for	 sensitizing	 peripheral	 fibers,	 provide	 effective	 analgesia(Zhang,	 Jones	 et	 al.	 2004,	Towheed,	Maxwell	et	al.	2006,	Gallelli,	Galasso	et	al.	2013).			
	
	
1.5.4 		 The	Dorsal	Horn	
While	pain	 is	 initially	 the	product	of	peripheral	 sensitization	 in	OA,	 the	sustained	sensory	barrage	produced	 results	 in	 alterations	 in	 synaptic	processing,	 termed	 central	 sensitization,	which	make	a	significant	contribution	to	the	overall	pain	experience	during	OA(Mease,	Hanna	et	al.	2011).	Central	sensitization	 is	 activity-dependent	 and	 characterized	 by	 reduced	 threshold,	 increased	responsiveness	 and	 enlargement	 of	 the	 receptive	 field	 (Ji,	 Kohno	 et	 al.	 2003).	 In	 other	 words,	 it	enhances	and	facilitates	the	synaptic	 transfer	of	nociceptive	 information	from	primary	afferents	to	the	ascending	neurons	in	the	dorsal	horn.		
	
	
1.5.4.1 Organization		
Sensory	 afferents	 from	 the	 joints	 enter	 the	 spinal	 cord,	 via	 the	 dorsal	 root,	 to	 synapse	within	 the	dorsal	horn	of	L3,	L4	and	L5(Widenfalk	and	Wiberg	1989,	Ferreira‐Gomes,	Adaes	et	al.	2010).	It	is	here	 that	 the	 full	 range	 of	 sensory	 information	 is	 integrated	 before	 ascension	 to	 the	 brain.	 These	joint	afferents	 largely	project	 to	either	Lamina	 I/II	and	Lamina	V/VI(Sugiura,	Lee	et	al.	1986)[49],	where	 they	may	 form	either	monosynaptic	or	polysynaptic	 connections	 to	 ascending	neurons	and	interneurons.	Unlike	afferent	populations,	which	are	heavily	sub	populated	into	sensory	categories	(See	discussion	in	section	1.5.1),	these	ascending	fibers	convey	a	more	integrated	signal,	which	is	the	result	of	a	convergence	of	multiple	afferent	sub-types	onto	common	ascending	pathways.	
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1.5.4.1.1 Superficial	Layers		
Interneurons	
The	large	majority	of	the	superficial	layers,	 laminas	I	and	II,	are	interneurons	–	most	especially	the	inner	 layer	 of	 lamina	 II,	which	 contains	 a	 dense	 population	 of	 roughly	 95%	 interneuron,	many	 of	which	 project	 deeper	 into	 the	 dorsal	 horn(Spike,	 Puskar	 et	 al.	 2003).	 	 As	 such	 it	 is	 perhaps	 no	surprise	 that	 the	 major	 post	 synaptic	 target	 for	 the	 peripheral	 afferents	 are	 the	 interneurons	 (A	discussion	of	the	peripheral	afferent	terminations	can	be	found	in	section	1.5.1.)	
The	majority	of	 these	 locally	arborizing	interneurons	are	 inhibitory	(ININs).	These	cells	commonly	utilize	GABA	and/or	Glycine	–	making	up	approximately	25-40%	of	the	cells	of	the	superficial	dorsal	horn	(Todd	and	Sullivan	1990,	Polgar,	Hughes	et	al.	2003).	GABA	at	the	GABAA	receptor	appears	to	provide	 a	 tonic	 level	 of	 inhibition,	 as	 suggested	 by	 the	 efficacy	 of	 the	 antagonist	 bicuculline	 to	potentiate	NS	neuronal	responses(Seagrove,	Suzuki	et	al.	2004).		
Attempts	have	been	made	 to	 sub-classify	 the	 ININ	populations,	where	 recent	work	by	Polgar	et	al	2013	 propose	 sub-classification	 based	 on	 the	 expression	 of	 Galanin,	 NPY,	 nNOS	 and	Paravalbumin(Polgár,	Sardella	et	al.	2013).	These	sub-classifications	highlight	functional	differences,	for	example	that	nNos	containing	 ININs	upregulated	FOS	following	noxious	thermal	stimulation	or	Formalin,	but	not	capsaicin,	denoting	segregated	sensory	inputs	to	these	interneurons.	They	suggest	that	 that	nNOS	and	NPY	containing	 ININs	directly	 inhibit	projecting	nociceptors	 to	attenuate	pain.		Perhaps	the	most	widely	accepted	classifications	are	as	islet,	central,	vertical	and	radial	cells,	which	are	differentiated	by	their	dendritic	morphology	(Lu	and	Perl	2005).	
Similarly,	 a	 population	 of	 excitatory	 interneurons,	 expressing	 vesicular	 glutamate	 transporter	 2	(VGLUT2)	 have	 been	 characterized.	 These	 are	 directly	 engaged	 by	 primary	 afferents	 to	 transmit	nociceptive	information	to	the	deep	dorsal	horn(Millan	2002,	D'Mello	and	Dickenson	2008).	
	
Contribution	of	interneurons	to	hyperalgesia	and	allodynia	
Given	 that	 interneurons	are	most	 commonly	 the	post	 synaptic	 target	of	peripheral	 afferents(Todd	2010),	 it	 is	perhaps	not	surprising	 that	 this	neuronal	population	are	hypothesized	 to	play	a	major	role	 in	 the	 development	 of	 allodynia.	 Transmission	 of	 Aβ	 fibre	 input	 to	 the	 superficial	 laminae	 is	increased	during	pain	states(Baba,	Doubell	et	al.	1999,	Okamoto,	Baba	et	al.	2001,	Kohno,	Moore	et	al.	 2003,	 Schoffnegger,	 Ruscheweyh	 et	 al.	 2008),	 an	 effect	 which	 can	 be	 replicated	 by	 GABA	 and	Glycine	 receptor	 antagonists	 (Torsney	 and	 MacDermott	 2006,	 Schoffnegger,	 Ruscheweyh	 et	 al.	
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2008).	 Consequently,	 suggestions	 center	 on	 the	 concept	 of	 disinhibition	 -	 the	 lost	 inhibition	 of	excitatory	 interneurons	 –	 though	 studies	 are	 in	 disagreement	 on	whether	 this	 is	 due	 to	 a	 loss	 of	GABA/Glycine,	neuronal	death	or	aberrant	activity	of	ININs(Todd	2010).			
Candidate	interneuron	populations	include	those	PKCγ	containing	EXINs	which	receive	their	inputs	from	 low	 threshold	 afferents(Miraucourt,	 Dallel	 et	 al.	 2007,	Neumann,	 Braz	 et	 al.	 2008)	 and	 have	been	shown	to	be	the	subject	of	parvalbumin	(PV)	ININ	population	modulation,	recently	termed	the	gatekeepers	 of	 touch	 evoked	 pain	 (Petitjean,	 Pawlowski	 et	 al.	 2015).	 Crucially,	 within	 this	 study	Petitjean	demonstrated	that	during	neuropathy	there	are	fewer	side-by-side	positionings	of	PV	and	PKCγ	 containing	 interneurons	 in	 the	dorsal	 horn	 vs.	 naïve	mice(Petitjean,	 Pawlowski	 et	 al.	 2015).	Hypothesizing	 that	 this	might	 constitute	 a	 disinhibition	 of	 this	 EXIN	 population,	 Petitjean	 further	demonstrated	that	 intrathecal	 treatment	of	 these	neuropathic	mice	with	a	selective	PKCγ	 inhibitor	significantly	 attenuated	 mechanical	 allodynia	 with	 no	 effect	 in	 naïve	 mice,	 while	 the	 selective	ablation	 of	 PV	 interneurons	 induced	 allodynia	 in	 naïve	mice	 that	 could	 be	 reversed	with	 a	 PKCγ	inhibitor	(Petitjean,	Pawlowski	et	al.	2015)	.	As	such,	it	seems	likely	that	a	loss	of	inhibition	of	PKCγ	containing	EXINs	by	PV	ININs	may	contribute	to	the	development	of	mechanical	(tactile)	allodynia.	
	
Projecting	Neurones	
The	 projection	 neurones	 of	 the	 superficial	 lamina	 predominantly	 project	 from	 lamina	 I,	 with	 a	limited	 number	 arising	 from	 lamina	 II(Todd	 2010).	 As	 a	 whole,	 the	 lamina	 is	 largely	 considered	nociceptive	specific,	given	the	nature	of	the	innervation	received,	however	much	like	the	peripheral	afferents	that	activate	them,	the	projecting	neurones	can	also	be	sub-classified	on	the	basis	of	their	molecular	 markers	 and	 physiological	 role.	 	 For	 example,	 using	 intracellular	 stains	 and	electrophysiology,	 Han	 et	 al	 suggested	 that	 lamina	 I	 populations	 could	 be	 subdivided	 to	 include	populations	 of	 fusiform	 cells,	 responsive	 only	 to	 pinch	 and/or	heat;	 innocuous	 cooling	 responsive	pyramidal	cells;	and	polymodal	multipolar	cells,	responsive	to	heat,	pinch	and	cold(Han,	Zhang	et	al.	1998).		
Using	combinations	of	retrograde	and	anterograde	tracing	the	projections	and	termination	of	lamina	I	neurones	have	been	classified	as	crossing	the	midline	to	pass	within	contralateral	white	matter	to	the	 brainstem	 and	 thalamic	 nuclei,	 notably	 to	 the	 lateral	 parabrachial	 area	 (LPB),	 periaqueductal	grey	(PAG),	caudal	ventral	medulla,	nucleus	of	the	solitary	tract	(NTS)	and	the	thalamus(Burnstein,	Dado	 et	 al.	 1990,	 Gauriau	 and	 Bernard	 2004,	 Todd	 2010).	 As	 part	 of	 these	 projections	 there	 is	similarly	 a	 large	 degree	 of	 collateralization,	 allowing	 projections	 to	 multiple	 nuclei	 and	 thus	
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accounting	for	the	relative	proportions	of	projection	destinations	as	95%	LPB,	33%	PAG,	25%	NTS	and	<5%	to	the	thalamus(Al‐Khater	and	Todd	2009).	
The	consequence	of	such	rich	innervation	to	the	brainstem	is	the	capacity	for	these	projecting	fibers	from	 lamina	 I	 to	 recruit	 descending	 controls	 (see	 Section	 1.4.5.2).	 	We	 have	 previously	 discussed	how	the	SAP-SP	ablation	of	NK1	projecting	neurones	attenuated	the	behavioural	hypersensitivities	associated	with	neuropathic	and	inflammatory	pain(Hunt	and	Mantyh	2001).	Interestingly	this	is	an	effect	 replicated	 by	 the	 blockade	 of	 descending	 serotonergic	 facilitation	 (Suzuki,	Morcuende	 et	 al.	2002),	further	suggesting	these	projecting	fibers	recruit	descending	controls.		
	
1.5.4.1.2 Deep	Dorsal	Horn	
In	 the	 deep	 dorsal	 horn,	 at	 laminas	 V-VII,	 projecting	 afferents	 receive	 both	 direct	 and	 indirect	sensory	 inputs	–	both	 from	 the	myelinated	A	 fibers	 from	 the	knee,	 cutaneous	and	deeper	 sources,	plus	 interneurons	 receiving	 nociceptive	 inputs	 in	 the	 superficial	 layers(Craig,	 Heppelmann	 et	 al.	1988,	Light	and	Kavookjian	1988,	Craig	2003,	D'Mello	and	Dickenson	2008).	These	cells	of	the	deep	dorsal	horn	can	be	largely	grouped	into	nociceptive	specific,	as	seen	in	the	superficial	laminae,	and	wide	 dynamic	 range	 cells	 (WDRs)	 which	 gain	 their	 names	 through	 their	 propensity	 to	 fire	 in	 a	graded	manner	across	a	broad	range	of	stimuli(Ritz	and	Greenspan	1985,	Willis	1985).	This	includes	pressure,	noxious	and	innocuous	heat	and	cold.		
These	WDR	cells	are	the	site	of	a	great	degree	of	convergence,	since	a	single	cell	could	theoretically	have	 inputs	relating	to	cutaneous,	muscular	and	 joint	stimuli(Schaible,	Schmidt	et	al.	1987),	which	may	in	part	explain	the	referral	of	pain(Vecchiet,	Vecchiet	et	al.	1999).	A	proportion	of	WDRs	then	cross	 over	 to	 the	 anterior	 spinothalamic	 tract(Willis,	 Kenshalo	 et	 al.	 1979),	 where	 they	 project	onward	 to	 the	 thalamus,	 namely	 to	 the	 central	 lateral	 thalamic	 nucleus,	 globus	 palladus	 and	somatosensory	 cortex(Carstens	 and	 Trevino	 1978,	 Gauriau	 and	 Bernard	 2004),	 with	 additional	projections	to	the	PB	and	hypothalamus(Kitamura,	Yamada	et	al.	1993,	Giesler,	Katter	et	al.	1994),	suggesting	a	number	of	routes	are	additionally	used.	
The	most	notable	characteristic	of	WDR	cells	is	their	propensity	to	“wind	up”.	This	is	a	form	of	short-term	 sensitization	where	 by	 high	 frequency	 inputs	 of	 constant	 intensity	 evoke	 increasing	 outputs	from	 the	WDR	 cell,	 in	 contrast	 to	 adaptation	 as	 one	might	 expect.	 This	 is	 possibly	 to	 allow	 great	differentiation	by	the	WDR	between	innocuous	and	noxious	 inputs,	since	Wind-up	may	only	result	from	 the	 recruitment	 of	 C	 fibers(Herrero,	 Laird	 et	 al.	 2000).	 This	 process	 has	 been	 shown	 to	 be	
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NMDA	 and	 NK1	 receptor	 dependent(Dickenson	 and	 Sullivan	 1987,	 Herrero	 and	 Cervero	 1996,	Herrero,	Laird	et	al.	2000),	which	is	discussed	in	more	detail	below	(1.4.4.2).		
	
1.5.4.2 The	Synapse	and	Neurotransmitters	involved	in	Transmission	
This	 synaptic	 transfer	 of	 acute	 nociceptive	 information	 from	 the	 primary	 afferents	 to	 dorsal	 horn	neurons	relies	on	ionotropic	glutamatergic	transmission	at	AMPA	and	Kainate	receptors.		In	the	case	of	an	acute	noxious	stimulus	the	membrane	depolarization	produced	will,	more	likely	than	not,	fail	to	generate	an	action	potential,	 instead	producing	varying	degrees	of	sub-threshold	depolarization	in	 the	WDR	 (Li	 and	 Zhuo	 1998).	 Prior	 to	 the	 onset	 of	 central	 sensitization,	 action	 potentials	 for	noxious	inputs	are	only	generated	by	several	EPSPs	summating	in	time	or	space	(Stephen	McMahon	2006).	Thus,	in	healthy	states,	Glutamate	acting	at	AMPA	sets	a	baseline	response	for	noxious	stimuli	(D'Mello	and	Dickenson	2008).		
However,	when	these	dorsal	horn	neurons	are	presented	with	a	barrage	of	nociceptive	information,	as	in	OA,	this	synaptic	transfer	is	enhanced	by	a	number	of	distinct	mechanism	(Stephen	McMahon	2006).	 	 The	 first	 to	 manifest	 is	 Wind-up,	 defined	 as	 the	 frequency	 dependent	 build	 up	 of	 spinal	neuronal	 responsiveness	 in	 the	WDR	neurons(Mendell	1984,	Dickenson	and	Sullivan	1987).	 	High	frequency	 firing	 of	 nociceptors	 results	 in	 the	 co-release	 of	 peptide	 transmitters	 from	nociceptors,	including	 SP	 and	CGRP,	which	bind	 to	 post	 synaptic	GPRCs,	most	 notably	 SP	 at	NK1,	 to	 produce	 a	slow	and	building	membrane	depolarization	(De	Koninck	and	Henry	1991,	Budai	and	Larson	1996,	Khasabov,	Rogers	 et	 al.	 2002,	 Suzuki,	Hunt	 et	 al.	 2003).	These	 slow	EPSPs,	 lasting	 for	100s	of	ms,	readily	 summate	 during	 high	 frequency	 inputs	 to	 produce	 a	 membrane	 voltage	 capable	 of	“unleashing”	 the	 voltage-dependent	 Mg2+	 block	 of	 the	 NMDA	 Glutamate	 receptor	 (Dickenson	 and	Sullivan	 1987).	 	 This	 receptor	 is	 highly	 calcium	 permeable	 and	 thus,	 upon	 binding	 of	 Glutamate,	produces	a	sizable	depolarization	of	the	membrane	capable	of	triggering	high	frequency	firing	in	the	WDR,	with	some	help	from	recruited	voltage	gated	Calcium	channels	(Stephen	McMahon	2006).	This	activity	dependent	plasticity	presents	rapidly	during	high	frequency	stimulation	(See	Figure	1.9)	but	terminates	 equally	 rapidly	 once	 the	 stimulus	 is	 removed,	 thus	playing	 a	 crucial	 role	 in	movement	evoked	pain	of	OA.	
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Both	 AMPA	 and	 NMDA	 receptors	 are	 involved	 in	 the	transmission	of	sensory	information	in	the	joint,	where	NMDA’s	 role	 is	 more	 exclusive	 to	 nociception.	 The	application	of	antagonists	for	these	receptors,	CNQX	and	ketamine	 respectively,	 reveal	 the	 role	of	AMPA	 in	both	innocuous	 and	noxious	 sensation	but	 an	 exclusive	 role	for	 NMDA	 in	 nociceptive	 sensations	 from	 the	joint(Neugebauer,	 Lücke	 et	 al.	 1993).	 Ketamine	 could	similarly	 prevent	 the	 development	 of	 hyperalgesia	during	OA,	further	demonstrating	the	importance	of	this	LGIC	to	pain	in	OA(Boettger,	Weber	et	al.	2010).	
Likewise,	 peptides	 play	 a	 crucial	 role	 in	 nociceptive	transmission.	The	small	and	medium	diameter	afferents,	most	notably	 those	 from	muscles	and	 joints,	utilize	 the	peptides	SP	and	CGRP	at	both	the	superficial	and	deeper	dorsal	layers(Gibson,	Polak	et	al.	1984,	Duggan,	Hendry	et	al.	1988,	O'Brien,	Woolf	et	al.	1989,	Lawson,	Perry	et	al.	1993).	These	peptides	facilitate	the	generation	of	ESPSs	in	the	dorsal	horn,	as	is	seen	by	the	ability	of	 co-administration	 of	 SP	 to	 facilitate	 NMDA	 action	 to	 facilitate	 Aδ	 evoked	 responses	 and	 wind	up(Chapman,	 Dickenson	 et	 al.	 1994),	 or	 the	 reduction	 of	 WDR	 cell	 responses	 to	 noxious	 and	innocuous	stimulation	of	inflamed	knees	following	CGRP	antagonism(Neugebauer,	Rümenapp	et	al.	1996).		
	
1.5.4.3 Non-neuronal	Contributions	to	Transmission	
As	is	the	case	in	the	periphery	(See	1.5.3),	the	migration,	proliferation	and	release	of	inflammatory	mediators	by	glia	–	the	immune	cells	of	the	CNS	–	trigger	sensitization	of	neuronal	cells.	It	has	been	observed	 that	microglia	become	activated	during	 the	development	of	OA	pain,	where	 inhibition	of	glial	 cell	 activation	 by	 nimesulide	 significantly	 attenuated	 OA	 pain(Sagar,	 Burston	 et	 al.	 2011).	Gibson	et	al	suggest	 this	may	 in	part	be	due	to	 the	 loss	of	microRNA-146a	 from	DRGs	 in	OA,	since	miRNA-146a	 acts	 to	 regulate	 and	 limit	 inflammatory	 factors	 in	 human	 glial	 cells,	 including	 TNFa,	iNOS	and	COX-2(Li,	Gibson	et	al.	2011).	
	
Figure	1.9	-	Electrically	evoked	responses	of	a	
Lamina	V	WDR	neuron	
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1.5.4.4 Central	Sensitization	
In	addition	to	wind-up,	synaptic	processing	in	the	dorsal	horn	is	also	subject	to	the	effects	of	post-translational	 processing	 of	 ion	 channels,	 receptors	 and	 regulatory	 proteins,	 altered	expression/trafficking	 of	 receptors,	 and	 transcriptional	 changes	 –	 much	 like	 those	 seen	 in	 the	periphery.	These	changes	are	part	of	 the	process	of	 central	 sensitization,	 seen	as	 the	expansion	of	receptive	 fields,	 prolonged	 reduction	 in	 threshold	 and	 increased	 responsiveness	 of	 neurons(Cook,	Woolf	 et	 al.	 1987,	 Hylden,	 Nahin	 et	 al.	 1989,	 Woolf	 2011).	 What	 crucially	 differentiates	 central	sensitization	 from	 peripheral	 sensitization,	 since	 both	 may	 result	 in	 hyperalgesia,	 allodynia	 and	spontaneous	pain,	is	the	ability	of	central	sensitization	to	sensitize	secondary	sites	neighbouring	the	insult	(secondary	hyperalgesia),	to	refer	pain	to	entirely	unaffected	areas,	the	experience	of	dynamic	allodynia	(relating	to	Aβ	input)	and	temporal	summation(Woolf	2011).		
	
1.5.4.4.1 Central	Sensitization:	Mechanisms	
During	pain	 states,	 the	dorsal	 horn	 is	 bombarded	with	 sensory	 inputs	 and	 awash	with	 glutamate,	peptides	 and	 inflammatory	 mediators	 such	 a	 PGE2	 and	 NGF.	 The	 consequence	 of	 this	 is	 both	 an	increase	 in	 intracellular	 calcium	 concentrations	 and	 activation	 of	 GPCRs,	 such	 as	 TrkB	 by	 BDNF	(Balkowiec	and	Katz	2000),		which	lead	to	the	activation	of	protein	kinases	(Malinow,	Madison	et	al.	1988,	Malinow,	Schulman	et	al.	1989),	nitric	oxide	synthase	and	ERK	(Kitto,	Haley	et	al.	1992,	Budai,	Wilcox	et	al.	1995)	(Ji,	Befort	et	al.	2002,	Kawasaki,	Kohno	et	al.	2004).	Specifically,	NMDA	subunits	NR1,	NR2A	and	NR2B	become	phosphorylated	by	PKC	and	Src	to	remove	the	voltage	dependent	Mg2+	block	and	increase	open	time	and	kinetics	(Zou,	Lin	et	al.	2000,	Guo	and	Huang	2001,	Guo,	Zou	et	al.	2002,	Brenner,	Ji	et	al.	2004,	Woolf	2004),	while	AMPA	receptor	GluR1	subunits	are	phosphorylated	by	CaMKII	to	increase	single	channel	conductance	(Wang,	Wu	et	al.	2010).		
This	 is	 accompanied	 by	 alterations	 in	 the	 trafficking	 of	 glutamate	 receptors	 in	 the	 synaptic	membrane	 –	 GluR2	 AMPA	 subunits	 are	 internalized,	 through	 binding	 to	 GRIP,	 to	 allow	 a	predominance	 of	 higher	 calcium	 permeable	 GluR1	 containing	 receptors,	 which	 themselves	 show	increased	inclusion	(Derkach,	Barria	et	al.	1999,	Park,	Voitenko	et	al.	2009,	Wang,	Wu	et	al.	2010).	There	 is	also	an	overall	 increase	 in	 the	number	of	AMPA	receptors	 in	 the	synaptic	membrane	as	a	result	 of	 their	 increased	 insertion	 from	 intracellular	 stores	 (Galan,	 Laird	 et	 al.	 2004,	 Larsson	 and	Broman	2008).	These	changes	alone	constitute	a	significant	 increase	in	synaptic	efficacy,	as	can	be	observed	from	the	ability	of	knock	down	or	knock-out	of	GluR1	or	NR1	and	receptor	antagonism	to	halt	 the	 appearance	 of	 central	 sensitization	 (Chizh,	Headley	 et	 al.	 2001,	 South,	 Kohno	 et	 al.	 2003,	Hartmann,	Ahmadi	et	al.	2004).	
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In	 addition	 to	 these	 Glutamatergic	 alterations	 there	 are	 significant	 changes	 in	 gene	 transcription.	The	 phosphorylation	 and	 activation	 of	 ERK1	 and	 2	 has	 both	 acute	 effects,	 such	 as	 the	 direct	regulation	of	potassium	currents	through	phosphorylation	of	Kv4.2	(Hu,	Carrasquillo	et	al.	2006),	or	chronic	effects,	 through	 the	activation	of	 cAMP	responsive	element	 (CREB)(Kawasaki,	Kohno	et	al.	2004).	This	leads	to	the	expression	of	a	range	of	nociceptive	proteins,	including	c-Fos,	NK1	and	Trk-B	receptors,	dynorphin,	DREAM	and	COX-2	(Anderson	and	Seybold	2000,	Ji,	Befort	et	al.	2002,	Kuner	2010).	 Increased	 transcription	 of	 COX-2	 ultimately	 results	 in	 elevated	 PGE2	 in	 the	 CNS,	 which	facilitates	exocytosis	of	excitatory	neurotransmitter	and	directly	activates	ascending	neurons	(Vasko	1995,	Baba,	Kohno	et	al.	2001).	 	As	 such,	 the	 synapses	of	 the	dorsal	horn	become	geared	 towards	increased	transmission,	contributing	to	the	enhanced	perception	of	pain.	
Central	 sensitization	also	 involves	a	 loss	of	 inhibition	at	a	 local	 level.	Melzack	and	Wall,	 as	part	of	their	Gate	Control	Theory,	suggest	that	loss	of	this	inhibition	would	result	in	allodynia	in	the	healthy	subject	(Melzack	and	Wall	1965).	During	OA	the	PGE2	produced	centrally,	as	observed	in	acute	rat	models	of	OA(Ebersberger,	Grubb	et	al.	1999),	leads	to	inhibition	of	glycine	receptors	containing	an	α3	 unit	 (EP	 GPCR	 –	 PKA	 dependent	 mechanism)	 preventing	 inhibitory	 signaling	 by	 glycine	interneurons	 (Ahmadi,	 Lippross	 et	 al.	 2002,	 Harvey,	 Depner	 et	 al.	 2004).	 As	 such,	 there	 is	additionally	a	loss	of	inhibition	during	OA,	contributing	to	the	reported	hyperalgesia	and	allodynia.	
The	 feature	 that	 critically	 identifies	 central	 sensitization	 is	 the	 development	 of	 secondary	hyperalgesia.	This	is	the	reduction	in	threshold	and	increased	response	to	mechanical	stimuli	in	an	area	 neighbouring	 injury,	 but	 not	 itself	 damaged.	 This	 is	 clearly	 demonstrated	 by	 the	 capacity	 of	intradermal	 capsaicin	 to	 induce	mechanical	hyperalgesia	 and	dynamic	 tactile	 allodynia	 for	 several	hours,	 even	 beyond	 a	 tight	 band	 which	 prevents	 local	 spread	 of	 capsaicin	 or	 inflammatory	mediators(LaMotte,	 Shain	 et	 al.	 1991).	 	 This	 is	 not	 just	 a	 demonstration	 of	 clear	 heterosynapic	facilitation,	 whereby	 inputs	 from	 C	 fibers	 (capsaicin	 responsive)	 are	 conditioning	 increased	responses	 to	A	 fiber	 sensory	 inputs	 (note	 that	windup	 is	 a	 form	of	homosynaptic	 facilitation),	but	also	of	the	expansion	of	the	receptive	field	of	spinal	neurons.	As	explained	by	Schaible	and	Richter	2004	 (See	Figure	1.7	below),	 neurons	 from	neighbouring	 areas	may	 share	projecting	neurons	but	under	 healthy	 conditions	 fail	 to	 evoke	 a	 suprathreshold	 response.	 Upon	 peripheral	 injury/insults	like	 capsaicin,	 the	 barrage	 of	 sensory	 information	 sensitizes	 the	 spinal	 neuron,	 lowering	 the	threshold	for	activation,	so	that	previously	innocuous	inputs,	such	as	dynamic	brush	from	the	silent	edges	of	the	receptive	filed,	are	sufficient	to	trigger	action	potentials	–	thus	expanding	the	receptive	field	and	accounting	for	secondary	hyperalgesia(Schaible	and	Richter	2004).	
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Central	sensitization	is	similarly	responsible	for	the	generation	of	referred	pain,	as	demonstrated	by	the	 inability	of	 local	anaesthesia	and	compression	block	to	prevent	the	generation	of	referred	pain	from	 intramuscular	electrical	 stimulation(Laursen,	Graven-Nielsen	et	 al.	1999,	Graven-Nielsen	and	Arendt-Nielsen	 2003).	 However,	 there	 still	 remains	 a	 divisions	 in	 the	 field	 regarding	 how	 exactly	pain	 becomes	 referred.	 On	 the	 one	 hand,	 the	 expansion	 of	 receptive	 fields	 discussed	 above	 may	account	 for	pain	 in	healthy	 tissue.	Many	 similarly	 cite	 the	 likely	 role	of	 convergence	of	peripheral	inputs,	 where	 a	 co-localization	 of	 cells	 allow	 a	 cross	 talk(Fernihough,	 Gentry	 et	 al.	 2004),	 while	synapses	to	shared	ascending	cells	lead	to	simple	misinterpretation	by	higher	centers	regarding	the	location	 of	 the	 input(Schaible,	 Schmidt	 et	 al.	 1987,	 Giamberardino	 2003,	 Gwilym,	 Keltner	 et	 al.	2009).	However,	many	 reject	 this	 convergence-facilitation	 theory	 for	 referred	muscle	pain,	 stating	there	 is	 little	 convergence	 onto	 dorsal	 horn	 neurons	 from	 deep	 tissues	 such	 as	 joints	 and	muscles(Mense	 1994,	 Vecchiet,	 Vecchiet	 et	 al.	 1999),	 though	 there	 may	 be	 convergence	 with	cutaneous	 inputs.	 It	 further	 fails	 to	 account	 for	 the	 time	 delay	 of	 referred	 pain	 or	 the	 stimulus	intensity	dependence	of	referral.		
Instead	referred	pain	can	be	attributed	to	the	spreading	of	the	state	of	central	sensitization(Arendt-Nielsen,	Nie	 et	 al.	 2010,	 Graven-Nielsen	 and	Arendt-Nielsen	 2010),	which	 explains	 both	 the	 delay	
Figure	 1.10	 -	 Development	 of	 Secondary	 Hyperalgesia	 following	 capsaicin	 injection,	 as	 a	 consequence	 of	
development	 central	 sensitization	 in	a	 spinal	 cord	neuron.	 Top:	Action	potentials	are	generated	by	stimulation	of	normal	receptive	field	(shaded	region)	during	healthy	state,	but	not	stimulation	of	surrounding	areas	from	which	spinal	neuron	also	receives	 inputs.	Bottom:	Following	insult	 in	the	primary	receptive	filed,	not	only	is	the	elicited	response	of	the	spinal	neuron	greater	to	the	stimulation	of	the	normal	receptive	filed,	but	the	sensitization	of	the	spinal	neuron	allows	generation	of	action	potentials	from	the	neighbouring	regions	from	which	it	had	previously	been	insensitive.	As	such	the	total	receptive	field	expands	resulting	in	a	secondary	hyperalgesia.	(Taken	from	Schaible	and	Richter	2004		(Schaible	and	Richter	2004))	
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and	 the	 intensity-dependence.	 This	 is	 the	 idea	 that	 the	 peripheral	 drive	 from	 the	 joint	 sensitizes	adjacent	dorsal	 horn	 segments	without	 synapsing	 to	 them	directly,	 possibly	 through	 interneurons	and/or	 volume	 transmission.	 There	 is	 additionally	 a	 role	 for	 descending	 controls	 in	 this	 referral,	discussed	 later,	which	creates	a	 facilitated	environment	 in	surrounding	spinal	segments	that	could	account	for	pain	referral.	
	
1.5.4.4.2 Central	Sensitization:	Evidence	in	OA	
While	 it	 is	 impossible	 to	 directly	 measure	 changes	 in	 synaptic	 efficacy	 or	 evoked	 responses	 in	patients	to	demonstrate	central	sensitization,	there	are	also	numerous	studies	documenting	changes	in	sensory	and	nociceptive	processing	 in	OA	patients,	which	along	with	 the	prevalence	of	 referred	pain	in	these	patients,	point	to	a	CS	contribution	to	OA	pain.		
Consider	resultant	pain	profiles	 following	 the	 intramuscular	 injection	of	hypertonic	saline	 into	 the	tibialis	anterior	muscle	of	OA	patients	and	healthy	controls.	OA	patients	experienced	pain	of	greater	duration	 and	 intensity	 compared	 to	 controls,	 with	 increased	 referred	 and	 radiating	 pain(Bajaj,	Graven-Nielsen	 et	 al.	 2001).	 This	 muscle	 hyperalgesia	 in	 the	 absence	 of	 peripheral	 sensitization	suggesting	 that	 long	 term	nociceptive	 inputs	 from	 the	OA	knee	 induce	 central	 sensitization	 in	 the	spinal	 cord	 which	 facilitate	 messages	 from	 the	 muscle.	 This	 would	 account	 for	 the	 reduced	threshold,	 increased	responsiveness	and	enlargement	of	 the	 radiating	pain	area	observed	 in	 these	individuals(Woolf,	Thompson	et	al.	1988,	Neugebauer	and	Schaible	1990,	Bajaj,	Graven-Nielsen	et	al.	2001).		
Experimenters	have	similarly	demonstrated	enhanced	temporal	summation	of	pain	 in	patients	(an	analogue	of	wind-up),	using	assessment	of	pressure	pain	thresholds	across	the	knee,	 leg	and	arms,	and	 impaired	 diffuse	 inhibitory	 controls	 (DNIC)	 compared	 to	 controls(Arendt-Nielsen,	 Nie	 et	 al.	2010).	Sensory	profiling	of	healthy	tissue,	often	using	QST,	likewise	reveals	shifts	in	the	sensitivity	of	OA	 patients	 to	 mechanical	 stimuli	 –	 revealing	 both	 reductions	 in	 pressure	 pain	 thresholds	 and	mechanical	hyperalgesia(Bradley,	Kersh	et	al.	2004,	Imamura,	Imamura	et	al.	2008,	Suokas,	Walsh	et	al.	 2012,	 Wylde,	 Palmer	 et	 al.	 2012).	 Brain	 imaging	 studies	 have	 shown	 significantly	 greater	activation	 in	 the	 brainstem	 of	 OA	 patients	 in	 response	 to	 punctate	 hyperalgesia	 compared	 to	controls,	 including	 significant	 Periaqueductal	 Grey	 activation,	 which	 are	 considered	 to	 be	 brain	biomarkers	 of	 central	 sensitization	 from	 previous	 studies(Zambreanu,	 Wise	 et	 al.	 2005,	 Lee,	Zambreanu	et	al.	2008,	Gwilym,	Keltner	et	al.	2009);	
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While	joint	replacement	resolves	OA	pain	and	the	related	sensory	abnormalities	for	the	majority	of	patients	(Kosek	and	Ordeberg	2000)	–	highlighting	the	importance	of	the	peripheral	drivers	from	the	joint	in	OA	pain	–	a	minority	of	patients	continue	to	suffer	following	surgery,	suggesting	long	term,	dysfunctional	changes	 in	 the	 transmission	of	sensory	 information	 in	 the	CNS(Wylde,	Hewlett	et	al.	2011).	It	has	been	suggested	that	the	failure	of	joint	replacement	to	resolve	chronic	pain	has	a	direct	relationship	 to	 pre	 surgery	 severity,	 whereby	 patients	 with	 more	 severe	 symptoms	 had	 poorer	outcomes(Fortin,	Penrod	et	al.	2002,	Lim,	Luscombe	et	al.	2006).	This	not	only	reinforces	the	clinical	importance	 of	 replacement	 before	 it	 is	 too	 late,	 but	 also	 emphasizes	 the	 role	 played	 by	 central	sensitization	in	chronic	OA	pain.	
Finally,	in	one	study,	lidocaine	to	one	knee	in	patients	with	bilateral	OA	produced	a	decrease	in	the	VAS	scores	for	both	knees(Creamer,	Hunt	et	al.	1996)	–	indicating	that	a	peripheral	drive	from	one	side	was	contributing	to	the	hyperalgesia	of	the	other	through	central	sensitization.		
Alternately,	 if	 we	 look	 to	 the	 animal	models	 of	 OA	 they	 report	 expanded	 receptive	 fields(Thakur	2012),	 PGE2	 release	 and	 COX-2	 up-regulation	 in	 the	 spinal	 cord(Ebersberger,	 Grubb	 et	 al.	 1999),	increased	 excitability	 of	 ascending	 neurons(Rahman,	 Bauer	 et	 al.	 2009)	 and	 a	 pharmacological	efficacy	of	pregabalin	to	attenuate	mechanical	hyperalgesia(Thakur,	Rahman	et	al.	2012),	all	widely	accepted	to	be	indicators	of	central	sensitization.	The	changes	observed	in	animal	models	of	OA	are	discussed	further	in	Chapter	3.	
	
1.5.5 														 Ascending	Projections	
1.5.5.1 Spinothalamic	Tract	
The	spinothalamic	tract	 is	one	of	 the	major	path	through	which	sensory	 information	ascends	 from	the	 dorsal	 horn	 to	 the	 brain,	 where	 retrograde	 tracers	 injected	 into	 the	 thalamus	 identify	 inputs	originating	 in	 both	 Lamina	 I,	 Lamina	 V	 and	 lamina	 VII/VIII	 in	 primates	 and	 cats(Carstens	 and	Trevino	1978,	Willis,	Kenshalo	et	al.	1979).	These	studies	also	suggested	that	the	majority,	~	90%	of	STT	cells,	ascend	contralaterally.	Similarly,	anterograde	labeling	in	rats,	using	injections	of	Phaseolus	vulgaris-leucoagglutinin	at	the	superficial	 lamina,	has	demonstrated	that	 lamina	I	neurones	project	extensively	 to	 ventral	 posterolateral,	 posteromedial	 and	 the	 posterior	 group	 (Po)	 thalamic	nuclei(Gauriau	and	Bernard	2004).	
Attempts	 have	 been	 made	 to	 manipulate	 pain	 and	 nociception	 through	 either	 the	 stimulation	 or	interruption	of	the	STT,	causing	or	blocking	burning	pain	respectively(Craig	2003).	However,	these	
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manipulations	 themselves	 could	 result	 in	 the	 development	 of	 chronic	 pain	 while	 individual	differences	in	localities	of	the	STT	make	this	an	unattractive	target	for	analgesia.	
	
1.5.5.2 Spino-bulbo-spinal	Loop	
As	 in	 the	 STT,	 cells	 project	 from	 Lamina	 I,	 V	 and	 VII	 in	 the	 spinoparabrachial	 and	spinomesencephalic	 tracts	 to	 the	brainstem	(Cechetto,	Standaert	et	al.	1985,	Panneton	and	Burton	1985,	Kitamura,	Yamada	et	al.	1993),	 to	allow	the	 integration	of	nociceptive	 information	to	 inform	behaviour	 and	 homeostasis.	 While	 their	 functional	 properties	 and	 projection	 paths	 are	 similar,	unlike	 the	STT	these	projections	are	bilateral(Hylden,	Hayashi	et	al.	1986,	Kitamura,	Yamada	et	al.	1993),	and	arise	most	frequently	from	Lamina	I(Andrew,	Krout	et	al.	2003).	
This	spinobulbar	route	terminates	in	four	main	regions:	the	brain	stem	reticular	formation,	PB,	PAG,	and	 the	 catecholamine	 cell	 groups	 A1-7(Hylden,	 Hayashi	 et	 al.	 1986,	 Hylden,	 Hayashi	 et	 al.	 1986,	Wiberg,	 Westman	 et	 al.	 1987,	 Westlund	 and	 Craig	 1996).	 These	 nuclei	 have	 a	 range	 of	 effects	including	homeostasis,	autonomic	integrations,	emotion,	behaviour	and	continued	projection	of	pain	information	to	the	hypothalamus,	 fore	brain	and	amygdala.	Crucially	this	pathway	is	part	of	a	 loop	that	projects	back	to	the	dorsal	horn	to	provide	modulation	of	spinal	excitability,	where	the	tone	of	modulation	 is	 a	 consequence	 of	 both	 the	 level	 of	 peripheral	 drive	 and	 facilitations	 or	 inhibitions	from	other	proximal	centers(Kuner	2010).	
	
1.5.6 		 The	Brain,	Descending	Controls	and	Pain	
The	context	in	which	injury	and	inflammation	occur	play	a	large	role	in	determining	the	extent	of	the	pain	 we	 actually	 experience.	 	 This	 is	 the	 direct	 result	 of	 the	 integration	 of	 contextual	 cues	 and	psychological	factors,	such	as	attention	and	mood,	into	the	processing	of	nociceptive	information	in	the	 brain	 stem.	 	 These	 supraspinal	 sites	 contain	 populations	 of	 neurons	 that	 project	 down	 to	 the	dorsal	horn,	providing	a	mechanism	for	modulating	synaptic	transmission	in	the	spinal	cord(Kwiat	and	Basbaum	1992,	Clark	and	Proudfit	1993).	
The	 importance	 of	 supraspinal	 influences	 on	 pain	 and	 transmission	 in	 the	 spinal	 cord	 is	 well	documented,	 with	 experiments	 ranging	 from	 transections(Danziger,	 Weil‐Fugazza	 et	 al.	 2001),	reversible	 spinalizations(Schaible,	 Neugebauer	 et	 al.	 1991,	 Herrero	 and	 Cervero	 1996,	 Ren	 and	Dubner	1996),	electrical	 stimulations	and	 lesioning	of	 relevant	brain	regions	 (Tsuruoka	and	Willis	1996,	 Urban,	 Zahn	 et	 al.	 1999,	 Wei,	 Dubner	 et	 al.	 1999,	 Terayama,	 Guan	 et	 al.	 2000,	 Terayama,	
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Dubner	et	al.	2002)	and	pharmacology	at	both	 the	brain	and	spinal	cord(Green,	Lyons	et	al.	1998,	Urban,	Coutinho	et	al.	1999,	Green,	Scarth	et	al.	2000,	Rahman,	Suzuki	et	al.	2004)	confirming	their	importance	in	spinal	excitability,	behaviour	and,	crucially,	the	dynamic	changes	observed	following	damage	and	inflammation.		
	
1.5.6.1 Key	Pain	Centers	
1.5.6.1.1 Periaqueductal	Gray	
The	 PAG,	 which	 quite	 literally	 surrounds	 the	 midbrain	 aqueduct,	 plays	 a	 pivotal	 role	 in	 the	integration	and	modulation	of	pain.	As	early	as	1969	it	was	acknowledges	that	electrical	stimulation	(ES)	of	 the	PAG	produces	profound	analgesia	(Reynolds	1969),	 leading	to	 it’s	 licensing	as	a	Cancer	Pain	 therapy	 for	 a	 period(Young	 and	 Brechner	 1986).	 The	 PAG	 feeds	 into	 and	 through	 the	 RVM,	forming	 a	 crucial	 PAG-RVM	 pain	 axis.	 Microinjection	 of	 lidocaine	 to	 the	 RVM	 has	 been	 shown	 to	abolishes	the	effect	of	PAG	ES	(Sandkuhler	and	Gebhart	1984),	demonstrating	the	importance	of	the	RVM	as	the	relay	point	for	PAG	controls	on	pain.		
This	 PAG-RVM	 axis	 acts	 as	 an	 integration	 site	 for	 inputs	 from	 various	 brain	 regions	 with	 those	directly	ascending	from	the	superficial	laminae(Hylden,	Hayashi	et	al.	1986,	Kuner	2010),	providing	the	 basis	 for	 the	 role	 of	 context	 on	 descending	 controls.	 	 Neurons	 feed	 into	 the	 PAG	 from	 areas	including	 the	 Amygdala,	 Hypothalamus,	 Frontal	 Lobe	 and	 the	 Anterior	 Cingulate	 Cortex	 (ACC)	 to	modulate	activity	based	on	attention,	emotion,	stress	and	setting	(Lovick	1993,	Bandler	and	Shipley	1994,	Ossipov,	Dussor	et	al.	2010).	These	contributions	set	the	level	of	input	into	the	nucleus	raphe	magnus	(NRM)	and	nucleus	gigantocellularis	(NGC)	before	these	neurons	descend	to	the	dorsal	horn	via	the	dorsolateral	and	ventrolateral	funiculi.		In	addition,	the	PAG	and	RVM	communicate	with	the	Noradrenergic	nuclei,	most	notably	the	locus	coeruleus	(LC),	A5	and	A7,	recruiting	them	to	provide	their	own	direct	noradrenergic	modulation	in	the	dorsal	horn	(Holden	and	Proudfit	1998,	Bajic	and	Proudfit	1999).	
Interestingly,	the	PAG	has	been	shown	to	differentially	modulate	myelinated	vs.	unmyelinated	fibers	inputs.	 Specifically,	 descending	 inhibition	 from	 the	 rostrocaudal	 extent	 of	 the	 dorsolateral/lateral	and	ventrolateral	columns	of	the	PAG	preferentially	target	WDRs	with	C	fiber	inputs(McMullan	and	Lumb	2006,	Waters	and	Lumb	2008).	The	 functional	 implication	 is	 that	PAG	may	 limit	 the	slower,	less	well	localized	burning	pains	conveyed	by	C	fibers,	and	could	in	part	be	important	in	limiting	the	effect	of	wind	up	in	these	WDR	cells,	given	this	summation	is	similarly	C	fiber	dependent.	
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1.5.6.1.2 Rostral	Ventromedial	Medulla		
It	is	now	very	well	established	that	neurons	descend	from	the	Rostral	Ventromedial	Medulla	(RVM)	to	modulate	 transmission	 in	 the	dorsal	horn,	with	 converging	evidence	highlighting	 the	ability	 for	these	 controls	 to	 either	 enhance	 or	 diminish	 nociceptive	 processing(Fields,	 Basbaum	 et	 al.	 1977,	Fields,	Bry	et	al.	1983,	Mokha,	McMillan	et	al.	1985,	Mokha,	McMillan	et	al.	1986,	Heinricher,	Barbaro	et	al.	1989,	Heinricher,	Morgan	et	al.	1994,	Ren	and	Dubner	1996,	Wei,	Dubner	et	al.	1999,	Burgess,	Gardell	 et	 al.	 2002,	Neubert,	 Kincaid	 et	 al.	 2004,	 Bee	 and	Dickenson	2007,	De	 Felice,	 Sanoja	 et	 al.	2011).	 This	 dichotomy	 of	 function	 is	 best	 observed	 in	 studies	 using	 electrostimulation	 (ES)	 and	microinjections	 of	 Glutamate	 to	 the	 RVM	 –	 where	 small	 doses	 of	 Glutamate	 or	 low	 intensity	 ES	produces	 facilitation	 in	 the	 dorsal	 horn	 while	 high	 dose	 Glutamate	 or	 high	 intensity	 ES	 inhibits	transmission	(Zhuo	and	Gebhart	1992,	Zhuo	and	Gebhart	1997).		
Evidence	 suggests	 that	 both	 inhibitory	 and	 facilitatory	 systems	 are	 activated	 during	 acute	nociception	but	that	the	discreet	balance	between	these	outputs	may	change	over	time	to	determine	the	extent	of	nociceptive	transmission	and	pain	experienced	(Porreca,	Ossipov	et	al.	2002,	Vanegas	and	 Schaible	 2004).	 Lesioning	 studies	 have	 suggested	 that	 while	 the	 NRM	 is	 responsible	 for	descending	 inhibition	 of	 spinal	 excitability,	where	 lesioning	 enhanced	 thermal	 hyperalgesia	 in	 the	first	 24hrs	 of	 inflammation,	 this	 is	 counterbalanced	 by	 the	 NGC,	 which	 provides	 descending	facilitation	and	whose	lesioning	entirely	attenuated	thermal	hyperalgesia(Wei,	Dubner	et	al.	1999).	Crucially,	the	discreet	balance	between	these	opposing	systems	is	dynamic	and	shifts	during	the	time	
investigation of how descending systems interface with
nociceptive circuitry of the dorsal horn. There is nevertheless
much conflicting information, and many unknowns: to what
extent and under what conditions are descending controls
mediated by presynaptic versus postsynaptic mechanisms;
what neurotransmitters/neuromodulators prevail under dif-
ferent conditions and what are the interactions between
them; and finally, do descending controls discriminate
between different sensory qualities including different com-
ponents of the pain signal and, if so, is this control
dynamically regulated? Issues relating to the last question
are the subject of this part of the review, which will consider
descending control by the PAG of spinal processing of noxious
versus non-noxious inputs, and of different components of
the pain signal.
Initial reports of behavioral analgesia following stimulation
in the PAG concluded that the effects of central stimulation
were highly selective for behaviors evoked by noxious stimuli,
and that animals continued to respond to non-noxious,
tactile, stimuli and other non-aversiv cues (Mayer et al,
1971). This finding was at odds with early electrophysiological
studies in which activation of the PAG was often found to
produce a non-selective inhibition of both non-nociceptive
and nociceptive responses of dorsal horn neurons (Bennett
and Mayer, 1979; Duggan and Morton, 1983; Gray and
Dostrovsky, 1983; Kajander et al, 1984). It is likely that non-
selective effects of electr cal stimulation reflected activation of
fibers of passage and/or antidromic activation of spinal
neurons that project to the PAG. This is because activation of
neuronal cell bodies in other studies revealed that PAG control
of dorsal horn responses is highly selective for noxious inputs:
comparison of electrical and chemical stimulation at the same
sites in the PAG revealed non-selective and selective effects,
respectively (Waters and Lumb, 1997). From a behavioral
perspective it was concluded that selective descending control
might operate as part of an integrated response to stressful or
threatening stimuli. Selective suppression of nociception
would allow an organism to respond in an appropriate
manner to a life-threatening situation without the distraction
or counterproductive motor responses that might be evoked
by noxious input. The likelihood of survival would be further
heightened as responses to potentially important non-nox-
ious cues would be left intact.
The realization that descending control from the midline
PAG-RVM system is specific for noxious relative to non-
noxious input raises the question of whether selectivity in
descending control extends further, to different aspects of the
noxious signal. Information about actual or potential tissue
damage in the periphery is conveyed to the spinal dorsal horn
in A- a d C-fiber nociceptors. These two classes of nociceptor
have different electrophysiological properties, various chemi-
cal phenotypes (see Lawson, 2002 for review), signal different
qualities of acute pain (Schady et al, 1983; Torebjork and
Ochoa, 1990) and have distinct roles in the development and
maintenance of chronic pain (Fuchs et al, 2000; Magerl et al.,
2001; Pertovaara, 1998). Given the importance of descending
control in defining the pain experience, together with the
diff rent roles of A- and C-fiber nociceptors in acute and
chronic pain, it is important to determine how information
flow in pathways activated by these distinct afferents is
modulated from supraspinal sites.
The question of descending control of A- versus C-
nociceptor-evoked responses in the spinal dorsal horn has
been the subject of a number of studies (for example, Jurna,
1980). However, most of these studies have employed
electrical stimulation to activate afferents, which could
confound interpretation of the data. Electrical stimulation of
peripheral nerves evokes un-physiological, synchronous
inputs to the spinal cord, which may be resistant to modula-
tion. It also simultaneously activates afferents innervating
excitatory and inhibitory receptive fields of spinal neurons.
One approach to overcoming these limitations is to establish
the profile of A- and C-fiber input to an individual neuron
using electrical stimulation, which enables assumptions
about the fiber types mediating the naturally evoked
responses of that cell. Thus, dorsal horn neurons can be
Fig. 1 – Schematic illustrates main topics of this review: midline PAG-RVM system, which exerts bidirectional control over
dorsal horn nociceptive processing, and the DRt and VLM in the caudal medulla. DRt is thought to be facilitating, and VLM
primarily inhibitory, although it may, like the RVM, have both an inhibitory and facilitatory influence. The PAG especially, but
also the RVM, DRt and VLM (not shown) receive important direct and indirect inputs from limbic forebrain areas including
anterior cingulate cortex (ACC), amygdala (AMY), dorsomedial nucleus of the hypothalamus (DMH), and medial prefrontal
cortex (MPC).
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Figure	1.11	-	Schematic	diagram	of	descending	controls	in	the	rat	brain:	The	Periaqueductal	Gray	(PAG)	receives	direct	and	indirect	inputs	 fro 	limbic	forebrain	areas	including	anterior	cingulate	cortex	(ACC),	amygdala	(AMY),	dorsomedia 	nucleus	of	the	hypothalamus	(DMH),	 and	medial	 prefrontal	cortex	 (MPC).	 This	 then	 feeds	 into	 the	Rostral	Ventromedial	Medulla	 (RVM),	which	 additionally	 received	 inputs	 from	DMH,	 and	 descends	 to	 the	dorsal	 horn	 to	 exert	 bidirectional	 control.	 	 DRt	 and	 VLM	additionally	 receive	 these	 inputs	 (not	 shown),	where	DRt	 is	 thought	 to	 be	 facilitating,	 and	VLM	primarily	 inhibitory.	 (Taken	
from	Heinricher	2009	(Heinricher,	Tavares	et	al.	2009))	
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course	 of	 injury/disease,	 as	 well	 as	 differing	 depending	 on	 the	 extent	 and	 kind	 of	 insult	 (See	
1.4.6.2).	
This	bi-directional	control	of	pain	is	observed	in	the	firing	patterns	of	3	distinct	classes	of	cells	found	within	the	RVM:	ON	cells,	OFF	cells	and	Neutral	cells(Fields,	Bry	et	al.	1983,	Heinricher,	Barbaro	et	al.	1989).		ON	cells	increase	their	firing	just	prior	to	the	initiation	of	nociceptive	reflex	(such	as	tail	flick	in	 the	 rat)	 while	 OFF	 cells	 are	 tonically	 active	 and	 decrease	 firing	 prior	 to	 nociceptive	 reflexes.	Neutral	cells	show	no	real	change	in	activity	prior	to	or	during	the	nociceptive	reflex.	Crucially,	the	activity	of	ON	and	OFF	cells	has	been	 linked	 to	 the	 facilitation	and	 inhibition	of	pain	 transmission	respectively.	 Thus	during	periods	 of	 increased	OFF	 cell	 activity	 there	 is	 an	 observable	 increase	 in	latency	 to	 tail	 flick	 and	 conversely	 increases	 ON	 cell	 activity	 shortens	 this	 latency	 (Barbaro,	Heinricher	et	al.	1989,	Heinricher,	Barbaro	et	al.	1989).		
The	 key	 characteristic	 of	 the	 RVM	 and	 these	 ON/OFF	 cells	 is	 their	 role	 in	 opioid	 analgesia.	 The	administration	of	morphine	causes	significant	reduction	in	the	firing	of	ON	cells	while	enhancing	the	activity	of	OFF	cells(Heinricher,	Morgan	et	al.	1994).	During	normal/acute	pain	states	this	activation	of	OFF	cells	is	both	necessary	and	sufficient	for	opiate	analgesia,	while	inhibition	of	ON-cells	alone	is	insufficient	 (Fields;,	 Basbaum;	 et	 al.	 2006).	 However,	 during	 chronic	 pain	 states	 such	 as	inflammation	 the	 direct	 opioid	 inhibition	 of	 ON	 cells	 has	 a	 much	 greater	 impact	 on	 hyperalgesia	(Porreca,	Ossipov	et	al.	2002),	a	result	of	the	increases	activity	of	ON-cells	during	inflammatory	pain.	
Controls	descending	from	the	RVM	utilize	5HT	(Serotonin)	as	the	major	transmitter	by	which	they	control	excitability,	along	side	some	GABA	and	Glycine(Kato,	Yasaka	et	al.	2006)	and	Noradrenaline	(NA)	from	the	LC	to	modulate	spinal	excitability.	These	transmitters	bind	to	the	presynaptic	boutons	of	 the	 primary	 afferents	 to	 affect	 neurotransmitter	 release	 or	 bind	 to	 post	 synaptic	 sites	 on	secondary	 or	 ascending	 neurons	 to	 modulate	 excitability	 and	 firing.	 While	 NA	 produces	 a	 direct	inhibitory	effect	on	neurons	through	α2	adrenoceptor(Millan	2002),	5HT	can	be	either	inhibitory	or	excitatory,	depending	on	the	receptor	subtype.	Dogrul	and	colleagues	demonstrated	that	serotonin	at	 5HT7	 will	 inhibit	 transmission	 and	 provide	 analgesia	 while	 5HT3	 enhances	 transmission	 to	induce/sustain	hyperalgesia(Dogrul,	Ossipov	et	al.	2009).		
While	 the	 role	 of	 enhanced	 or	 diminished	 serotonergic	 controls	 in	 the	 dorsal	 horn	 in	 acute,	inflammatory,	and	neuropathic	pain	conditions	are	well	confirmed	by	pharmacology(Green,	Scarth	et	al.	2000,	Suzuki,	Rahman	et	al.	2004,	Suzuki,	Rygh	et	al.	2004,	Rahman,	Bauer	et	al.	2009,	Sikandar,	Bannister	 et	 al.	 2012,	Burnham	and	Dickenson	2013,	Wang,	King	 et	 al.	 2013),	 it	 is	 suggested	 that	these	dynamic	changes	may	need	a	sufficiently	large	peripheral	drive	to	cause	a	shift.	For	example,	a	model	of	carrageenan	inflammation	did	not	alter	levels	of	descending	facilitation	from	those	seen	in	
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naïve	animals	but	facilitation	was	enhanced	in	both	stages	of	the	formalin	response,	as	revealed	by	the	5HT3	 antagonist	 ondansetron(Green,	 Scarth	 et	 al.	 2000,	Rahman,	 Suzuki	 et	 al.	 2004).	This	 is	 a	reasonable	suggestion	if	we	consider	descending	control	to	be	a	form	of	brain	stem	sensitization,	as	is	suggested	by	Miki	(Miki,	Zhou	et	al.	2002).	As	in	the	dorsal	horn,	where	central	sensitization	is	a	frequency	 dependent	 build	 up	 in	 responsiveness,	 it	 may	 be	 that	 the	 intervention	 of	 descending	controls	is	frequency	dependent,	relying	on	a	certain	level	of	ascending	input.	This	has	been	verified	by	Suzuki	and	colleagues,	who	demonstrated	 that	 the	analgesic	effect	of	selective	ablation	of	NK1-containing	 ascending	 neurons	 could	 be	 reproduced	 by	 ondansetron	 during	 the	 second	 phase	 of	formalin	response	(Suzuki,	Morcuende	et	al.	2002).	Thus	these	ascending	NK1	containing	neurons	of	lamina	I/III	are	driving	descending,	serotonergic	controls	
This	bi	directional	control	of	pain	by	the	RVM	presents	an	interesting	target	for	pain	control,	given	the	 position	 of	 the	 discreet	 balance	 will	 determine	 the	 overall	 pain	 experience.	 It	 is	 similarly	 of	considerable	interest	to	define	where	the	balance	lies	during	chronic	pain	conditions	such	as	OA,	to	help	 better	 our	 understanding	 of	 this	 condition.	 Preliminary	 work	 has	 suggested	 there	 is	 an	increased	 descending	 serotonergic	 facilitation	 during	 an	 MIA	 model	 of	 OA(Rahman,	 Bauer	 et	 al.	2009),	but	how	this	changes	over	time	and	with	disease	severity	is	as	yet	unclassified.	
	
1.5.6.1.3 Dorsolateral	Pontine	Nuclei		
The	dorsolateral	pontine	(DLP)	noradrenergic	cell	groups	are	a	rich	source	of	NA	in	the	spinal	cord,	most	 especially	 from	 the	 locus	 coeruleus	 (A6),	 A5	 and	 A7	 nuclei(Westlund,	 Bowker	 et	 al.	 1983,	Westlund,	 Bowker	 et	 al.	 1984,	 Kwiat	 and	 Basbaum	 1992),	 where	 projections	 appear	 to	 largely	terminate	 in	 the	 deeper	 laminae	 of	 the	 dorsal	 horn(Clark	 and	 Proudfit	 1991).	 It	 is	 here	 that	 the	release	of	noradrenaline	provides	inhibition	of	spinal	excitability	–	as	has	been	well	characterized	by	the	 spinal	 application	 of	NA(Engberg	 and	Ryall	 1966,	Headley,	 Duggan	 et	 al.	 1978).	 Similarly,	 the	application	 of	 NA	 antagonists	 has	 been	 shown	 to	 be	 hyperalgesic(Sagen	 and	 Proudfit	 1984),	including	reversing	the	analgesic	effects	of	systemic	morphine(Proudfit	and	Hammond	1981).	
As	in	the	PAG,	the	ES	of	the	DLP	produced	strong	inhibition	of	tail	flick	in	lightly	anaesthetized	rats,	an	 effect	most	potent	when	directly	 stimulating	 the	LC(Jones	 and	Gebhart	1986).	This	descending	inhibition	 was	 effectively	 blocked	 by	 the	 intrathecal	 introduction	 of	 α2	 receptor	 antagonists	Yohimbine,	pointing	to	a	α2	mediated	noradrenergic	 inhibition	descending	from	the	DLP(Jones	and	Gebhart	 1986).	 	 This	 anti-nociceptive	 and	 anti-hyperalgesic	 control	 of	 spinal	 excitability	 by	 the	DLP/LC	is	now	very	well	characterized(Segal	and	Sandberg	1977,	Jones	and	Gebhart	1986,	Mokha,	
		 87	
McMillan	 et	 al.	 1986,	 Jones	 and	 Gebhart	 1988,	 Clark	 and	 Proudfit	 1991,	 Clark	 and	 Proudfit	 1993,	West,	Yeomans	et	al.	1993).	
It	 is	 suggested	 that	 nociceptive	 inputs	 activate	 descending	 inhibition,	 where	 the	 extent	 of	 the	inhibition	 is	 both	 intensity	 dependent,	 surmountable	 and	 dynamic	 over	 the	 time	 course	 of	injury(Stanfa	 and	 Dickenson	 1994,	 Tsuruoka	 and	 Willis	 1996,	 Tsuruoka	 and	 Willis	 1996,	 Green,	Lyons	et	al.	1998,	Tsuruoka,	Hitoto	et	al.	1999,	Malmberg,	Hedley	et	al.	2001,	Molina	and	Herrero	2006).	It	is	apparent	across	the	breadths	of	these	studies,	which	utilize	lesioning,	knock	out	animals	and	pharmacology,	that	this	descending	inhibition	requires	“switching	on”	as	it	is	not	active	in	naïve,	uninjured	animals	-	with	the	exception	of	responses	to	high	intensity	noxious	inputs	in	naïve	animals	(such	 as	 tail	 flick).	 This	 is	 a	 pain	 protection	 system	 that	 becomes	 switched	 on	 by	 the	 barrage	 of	nociceptive	information	and	as	such	is	an	attractive	target	for	clinical	pain	management.	Hughes	et	al	2013	suggest	that	this	descending	noradrenergic	system	spatially	restricts	and	temporally	delays	the	expression	of	neuropathic	pain,	but	 loses	 influence	once	neuropathic	pain	 is	establish	–	as	seen	by	the	lost	effect	of	α2	receptor	antagonism	and	using	this	to	explain	the	lost	efficacy	of	NA	therapies	in	neuropathic	pain	(Hughes,	Hickey	et	al.	2013).	The	suggestion	is	that	neuropathic	pain	may	be	better	managed	by	earlier	interventions	with	therapies	designed	to	manipulate	NA	systems,	notably	SNRIs	and	tricyclics,	before	descending	noradrenergic	inhibition	loses	its	influence.	This	has	already	been	effective	in	the	prevention	of	progression	of	shingles	to	post	herpatic	neuralgia(Bowsher	1997),	and	the	implications	of	this	to	the	management	of	advanced	OA	pain	could	be	interesting.	
	
1.5.6.2 Changes	to	Descending	Controls	during	Inflammation	
While	changes	to	descending	controls	and	supraspinal	processing	in	OA	are	as	yet	not	fully	classified,	it	is	perhaps	most	informative	to	consider	the	changes	in	these	descending	systems	during	acute	and	chronic	inflammation.		
	
Initiation	of	Inflammatory	Pain	
It	 has	 been	 shown	 that	 during	 the	 initial	 hours	 of	 inflammation	 descending	 controls	 gear	 towards	facilitation.	Terayama	and	colleagues	showed	that	at	3hrs	after	the	induction	of	inflammation	there	is	a	rightward	shift	in	the	ES	stimulus–response	curve	compared	to	1hr	time	points	(Terayama,	Guan	et	al.	2000).	In	other	words,	a	greater	ES	is	required	to	gain	the	same	increase	in	paw	withdrawal	latency	(PWL),	 indicating	a	shift	 in	the	balance	of	descending	control	towards	facilitation,	where	this	shift	 is	shown	 to	 relate	 to	plasticity	of	 the	NMDA	 receptor	population(Terayama,	Dubner	 et	 al.	 2002).	This	
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shift	was	not	observed	when	ES	was	applied	directly	to	the	dorsolateral	funiculus,	indicating	that	the	change	is	 located	in	the	RVM	and	not	at	the	spinal	 level.	These	studies	suggest	the	predominance	of	facilitation	during	the	onset	of	inflammatory	pain,	driven	by	NMDA	receptor	sensitivity	in	the	RVM.	
It	 is	proposed	 that	 this	 initial	 facilitation	originates	within	 the	NGC,	a	site	previously	shown	to	be	a	point	 of	 origin	 of	 descending	 facilitation(Zhuo	 and	 Gebhart	 1992,	 Wei,	 Dubner	 et	 al.	 1999).		Consequently,	lesioning	of	the	NGC	reduces	the	current	intensity	of	ES	to	the	RVM	required	to	produce	complete	 inhibition	of	 inflammatory	hyperalgesia(Terayama,	Dubner	et	al.	2002).	 It	has	additionally	been	shown	that	molecular	depletion	of	5HT	from	these	NGC	neurons	attenuates	the	development	of	mechanical	 hyperalgesia	 and	 allodynia	 after	 CFA	 injection,	 suggesting	 serotonergic	 neurons	 have	 a	significant	role	in	facilitating	the	development	of	hyperalgesia	following	inflammation(Wei,	Dubner	et	al.	2010).		
Given	this	information,	it	seems	feasible	that	in	the	initial	hours	of	inflammation	the	sensory	barrage	ascending	 to	 the	 brain	 stem	 activates	 facilitatory	 descending	 controls.	 As	 with	 peripheral	sensitization,	this	early	facilitation	is	beneficial	as	a	mechanism	for	limiting	the	use	of	injured	tissue.	
	
Modulation	of	Established	Inflammatory	Pain	
It	 is	 now	 established	 that	 during	 inflammation,	 beyond	 this	 initial	 facilitation	 on	 day	 1,	 there	 is	 a	superseding	 shift	 towards	 descending	 inhibition	 of	 the	 site	 of	 primary	 hyperalgesia,	 which	 acts	 to	limit	the	impact	of	accumulating	peripheral	and	central	sensitization.	First	suggested	by	Schiable	and	colleagues,	 who	 reversibly	 spinalized	 cats	 using	 cooling	 of	 the	 spinal	 cord,	 it	 was	 shown	 that	inflammation	 induced	 a	progressive	 enhancement	 of	 descending	 inhibition(Schaible,	Neugebauer	 et	al.	1991).	This	effect	was	similarly	replicated	using	lidocaine	to	block	descending	controls	during	CFA	induced	paw	inflammation	(Ren	and	Dubner	1996).	
Terayama	and	 colleagues	 showed	 that	 this	predominance	of	 inhibition	does	not	occur	 immediately,	rather	developing	 after	 an	 initial	 period	of	 facilitation.	After	 the	 initial	 increase	 in	 current	 intensity	required	 for	 complete	 inhibition	 of	 PW	 observed	 at	 the	 3rd	 hour	 of	 CFA	 inflammation	 there	 is	 a	decrease	over	the	next	21hours,	shifting	the	stimulus	response	curve	to	the	left,	indicating	the	switch	to	 a	 net	 descending	 inhibition	 (Terayama,	 Guan	 et	 al.	 2000,	 Terayama,	 Dubner	 et	 al.	 2002).	 This	leftward	 shift	 is	 similarly	 replicated	 in	 NMDA	 and	 AMPA	 dose-response	 curves	 24hrs	 post	inflammation	 (Guan,	Terayama	et	 al.	2002).	This	 is	 indicative	of	 a	 switch	 in	 the	RVM	 to	descending	inhibition,	 originating	 from	 plasticity	 at	 glutaminergic	 synapses(Vanegas	 2004).	 This	 plasticity	similarly	increases	the	sensitivity	of	the	RVM	to	opiates(Zhang	and	Hammond	2010).	
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Single	unit	recordings	from	the	RVM	similarly	support	the	idea	of	a	shift	towards	inhibition	from	the	RVM(Miki,	 Zhou	 et	 al.	 2002).	 Continuous	 recordings	 over	 the	 3-6	 hours	 after	 CFA	 identified	 a	phenotypic	switch	of	neutral	cells	to	pain	modulating	on-like	or	off-like	cells,	as	was	not	seen	in	naïve	animals.	This	was	confirmed	with	a	population	study.	There	was	similarly	a	reduction	in	the	number	of	 off-like	 cells	 showing	 a	 pause	 of	 activity	 after	 noxious	 stimulation	 after	 inflammation,	 which	together	 lead	 to	 a	 suggestion	 that	 RVM	 neurons	 may	 switch	 to	 favour	 descending	 inhibition(Miki,	Zhou	et	al.	2002).	
This	 enhancement	 of	 descending	 inhibition	 is	 not	 limited	 to	 the	 RVM	 however	 but	 involves	 the	noradrenergic	 system	 too.	 Using	 lesioning,	 Tsuruoka	 et	 al	 suggests	 that	 inflammation	 activates	inhibitory	 controls	 originating	 from	 the	 LC	 to	 restrict	 the	 development	 of	 hyperalgesia	 during	inflammation(Tsuruoka	 and	Willis	 1996).	However,	 the	 effect	 of	 lesioning	 are	 lost	 by	 the	7th	 day	of	inflammation,	whereby	 no	 difference	 is	 observed	 between	 the	 hyperalgesia	 between	 the	 sham	 and	lesion	 groups(Tsuruoka	 and	 Willis	 1996).	 This	 suggests	 that	 the	 LC	 and	 NA	 are	 only	 involved	 in	descending	 inhibition	during	a	short	 initial	window	of	 inflammation,	as	 is	observed	 in	both	the	MIA	model	of	OA	and	tibial	nerve	injury	neuropathic	pain	model(Hughes,	Hickey	et	al.	2013).		
In	 considering	 the	 plasticity	 of	 these	 systems	other	 experiments	 have	 shown	 that,	much	 like	 in	 the	dorsal	 horn,	 there	 are	 significant	 alterations	 in	 gene	 expression	 and	 receptor	 populations	 over	 the	course	 of	 inflammation.	 Miki	 and	 colleagues,	 in	 proposing	 the	 concept	 of	 brainstem	 sensitization,	identified	peripheral	 inflammation	 induced	 changes	 in	NMDA	 receptor	 gene	 expression	 in	 the	RVM	(Miki,	 Zhou	 et	 al.	 2002).	 	 They	 identified	 a	 significant	 increase	 in	 NMDA	 subunit	 mRNA	 over	 the	proceeding	1-7days	after	CFA	 injection,	with	 the	greatest	 increase	 in	NR2A	unit	mRNA	and	protein.	Similarly,	 inflammation	 induces	 a	 significant	 increase	 in	 AMPA	 receptor	 subunit	 mRNA,	 with	significant	up-regulation	of	GluR1-flip	protein	over	24hr-3days	after	CFA(Guan,	Guo	et	al.	2003).		It	is	well	 established	 that	 Glutamate	 plays	 a	 prominent	 part	 in	 excitatory	 transmission	 in	 the	 RVM	 and	activation	of	descending	control	from	brainstem	sites(Aimone	and	Gebhart	1986,	Beitz	1990,	Spinella,	Cooper	 et	 al.	 1996),	where	we	 have	 discussed	 above	 the	 shift	 in	 the	 dose	 response	 curves	 for	 this	transmitter	during	 inflammation(Guan,	Terayama	et	 al.	 2002).	As	 such,	 these	 results	would	 suggest	that	part	of	the	increase	in	descending	control	observed	during	inflammation	may	originate	from	an	increase	 in	 NMDA	 and	 AMPA	 receptor	 populations,	 composed	 of	 subunits	 with	 high	 conductance	properties	(NR2A)	and	a	reduced	rate	of	desensitization	(GluR1-flip),	which	increase	excitability	and	activation	of	RVM	neurons.	 Since	 the	 activation	of	AMPA	 receptors	 in	 the	RVM	mediate	descending	inhibition(Urban,	Coutinho	et	al.	1999),	the	growth	of	this	receptor	population	in	the	RVM	during	the	first	week	of	inflammation	goes	some	way	to	explain	the	increased	descending	inhibition	observed	to	be	limiting	acute	inflammatory	pain.	However,	the	leftward	shift	in	the	dose	response	curve	of	AMPA	and	 NMDA	 in	 descending	 inhibition	 was	 significant	 as	 early	 as	 5hrs	 after	 the	 induction	 of	
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inflammation	when	these	protein	changes	only	reach	significance	after	24hrs(Guan,	Guo	et	al.	2003),	pointing	to	additional,	faster	acting	mechanisms	of	plasticity	in	the	brain	stem.		
The	complexity	of	 the	overall	pain	profile	during	 inflammation	 is	added	 to	by	evidence	suggesting	that	primary	and	secondary	sites	of	hyperalgesia	may	be	differentially	controlled(Vanegas	2004).	It	is	suggested	that	 there	 is	an	 inhibitory	drive	 to	 the	area	of	primary	hyperalgesia,	but	a	 facilitatory	drive	 in	 the	 surrounding	 spinal	 segments	 that	 underlie	 secondary	hyperalgesia	 and	 referred	pain.	This	is	demonstrated	by	the	ability	of	lidocaine,	NMDA	receptor	or	neurotensin	receptor	antagonists	in	 the	 RVM	 to	 attenuate	 the	 development	 of	 secondary	 thermal	 hyperalgesia	 during	 paw	inflammation(Ren	and	Dubner	1996,	Urban,	Coutinho	et	al.	1999,	Wei,	Dubner	et	al.	1999).	On	the	basis	of	this	evidence	we	would	expect	a	descending	facilitation	of	noxious	transmission	from	areas	of	secondary	hyperalgesia,	 for	example	the	rat	paw	in	a	model	of	knee	OA,	and	 inhibitory	controls	presiding	over	the	joint	itself.	
When	 we	 consider	 OA	 specifically,	 much	 is	 yet	 to	 be	 understood	 about	 the	 role	 of	 supraspinal	controls	 in	 OA	 pain.	 While	 some	 work	 has	 been	 done	 to	 characterize	 how	 these	 influences	 may	change	 during	 OA,	 and	 the	 consequences	 this	 may	 have	 on	 OA	 pain,	 the	 picture	 is	 by	 no	 means	complete.	 Early	work	 using	 either	 cold	 block	 spinalizations	 or	 transection	 to	 elucidate	 the	 role	 of	descending	controls	in	inflammatory	joint	pain	revealed	the	increase	in	descending	inhibition	which	followed	 in	 the	 initial	24hrs(Schaible,	Neugebauer	et	al.	1991,	Danziger,	Weil-Fugazza	et	al.	1999).	Brain	 imaging	 has	 similarly	 suggested	 greater	 activation	 of	 the	 PAG	 in	 OA	 patients	 receiving	punctate	stimulation	to	areas	of	referred	pain	vs.	controls(Gwilym,	Keltner	et	al.	2009),	suggesting	these	spinally	projecting	brain	stem	centers	may	be	highly	relevant	to	the	generation	of	the	overall	OA	pain	profile.	More	recently,	work	from	this	lab	has	characterized	the	chronic	shifts	in	descending	controls	during	the	MIA	model	of	OA.	They	showed	adaptive	changes	 in	serotonergic	controls	 that	may	 underlie	 increased	 evoked	 responses	 to	 dynamic	 brush	 and	 innocuous	 punctate	stimuli(Rahman,	Bauer	et	al.	2009),	along	side	work	revealing	a	time	sensitive	effects	of	atipamezole	or	 milnacipran	 plus	 atipamezole	 on	 evoked	 responses	 in	 the	 early	 stages	 of	 MIA	 induced	OA(Burnham	and	Dickenson	2013).	These	 fall	 in	 line	with	expectations	provided	by	 inflammatory	pain	models.	We	would	expect	a	prolonged	descending	facilitation	of	noxious	transmission	from	the	paw	to	maintain	a	secondary	hyperalgesia	in	OA,	as	well	as	a	time	sensitive	noradrenergic	inhibition	of	transmission,	which	resolves	by	day	7.	However,	questions	remain	about	how	these	findings	may	change	 in	 a	 lower	 dose	 MIA	model,	 or	 what	 may	 be	 observed	 regarding	 serotonin	 in	 the	 earlier	stages.		
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1.6		 Thesis	Aims	
For	patients	with	 symptomatic	OA	 the	unmet	needs	 are	 still	 clear	 –	 efficacious,	 safe	 and	 tolerable	analgesia.	If	we	are	to	address	these	to	provide	superior	quality	of	life	for	patients,	it	is	crucial	that	we	 continue	 to	 expand	 our	 knowledge	 of	 the	 mechanisms	 underlying	 pain	 during	 OA	 so	 we	 can	better	manipulate	and	target	these	mechanisms	to	mitigate	their	impact.	
	
The	experiments	described	in	this	thesis	aimed	to:	
Ø Characterize	 differences	 in	 the	 pain	 phenotype	 and	 extent	 of	 descending	 control,	 both	serotonergic	and	noradrenergic,	in	the	early	and	later	stages	of	a	1mg	MIA	model	of	OA	pain	versus	previously	published	work	in	a	2mg	neuropathic	model	of	OA	pain,	using	behaviour	and	 spinal	 cord	 electrophysiology;	 And	 relate	 these	 differences	 and	 the	 pharmacological	implications	back	to	the	clinic.	
Ø Identify	 whether	 a	 low	 dose	 MIA	 model	 of	 OA	 pain	 induced	 adaptations	 in	 the	 response	properties	of	the	pain	responsive	cells	of	the	RVM	using	electrophysiology.	
Ø Evaluate	 the	 role	 of	 a	 specific	 sub-population	 of	 sensory	 afferents	 and	 a	 population	 of	mechanosensory	receptors	in	the	development	of	pain	during	OA	in	mice.	
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Chapter	2	–	Methods	
All	procedures	were	approved	by	the	UK	home	office	and	followed	the	guidelines	of	the	International	Association	for	the	Study	of	Pain(Zimmermann	1983).	
	
2.1	 		 Animals	
2.1.1	 		 Rats	All	 work	was	 conducted	 in	Male	 Sprague	 Dawley	 rats,	 bred	 and	 housed	 in	 the	 Central	 Biological	Services	 Unit	 at	 University	 College	 London.	 Experimental	 animals	 can	 be	 split	 into	 six	 distinct	groups:		
• Arthritic:	Those	animals	 in	which	the	OA	pain	state	was	 induced	by	the	 injection	of	MIA.	For	spinal	electrophysiology,	 these	animals	were	 investigated	either	at	 the	early	stages	of	OA	 pain	 development,	 at	 days	 3-5	 after	 injection,	 or	 late	 stages,	 at	 days	 10-14	 after	injection.	For	RVM	electrophysiology,	animals	were	investigated	14-16	days	after	injection.	Induction	 weights	 differed	 to	 ensure	 behaviour	 and	 electrophysiology	 was	 conducted	 in	animals	of	the	same	weight	and	age,	in	the	range	of	220-250g	for	spinal	electrophysiology,	and	250-300g	for	brain	electrophysiology:	
o Early:	MIA	injection	into	animals	weighing	160-180g.		
o Late:	MIA	injection	in	animals	weighing	120-140g.	
o Brain	Recording:	MIA	injection	into	animals	weighing	160-180g	
• Shams:	Those	animals	in	which	OA	was	not	induced	but	instead	received	an	intra-articular	injection	 of	 Saline.	 Sham	 animals	 were	 investigated	 across	 the	 same	 time	 scale,	 to	 track	time	dependent	changes	resulting	from	the	procedure	itself.	These	animals	were	similarly	age	 and	 weight	 matched	 so	 that	 all	 behaviour	 and	 electrophysiology	 was	 conducted	 in	animals	of	the	same	weight	and	age,	in	the	range	of	220-250g	for	spinal	electrophysiology	and	250-300g	for	brain	electrophysiology.	
o Early:	Saline	injection	into	animals	weighing	160-180g.		
o Late:	Saline	injection	in	animals	weighing	120-140g.	
o Brain	Recording:	MIA	injection	into	animals	weighing	160-180g	
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Animals	were	housed	at	a	maximum	of	five	per	cage	with	ad	libitum	food	and	water,	on	a	12hour	day	and	night	cycle.		
Naïve	controls,	where	used,	were	procured	directly	from	BSU	stock	at	a	weight	in	the	range	of	220-250g.	
	
2.1.2	 		 Mice	Work	was	 conducted	 in	male	 and	 female	mice	 from	 four	different	 genetic	 lines,	 all	 of	which	were	bred	 and	 housed	 in	 the	 Cruciform	 Biological	 Services	 Unit	 at	 University	 College	 London.	 Animals	were	housed	as	a	maximum	of	6	per	cage,	with	ad	libitum	food	and	water,	on	a	12hour	day	and	night	cycle.	 Mice	 aged	 6-8weeks	 were	 used	 for	 induction	 of	 OA	 pain	 state,	 induced	 by	 intra-articular	injection	of	MIA.	
Mouse	Lines:	
• “DTA	Mice”:	This	mouse	line	was	generated	by	crossing	heterozygous	Nav1.8	Cre	mice	with	homozygous	eGFP-DTA	mice.	This	generated	a	litter	of	half	controls	(wild	type,	WT)	and	half	DTA	mice,	 where	 DTA	mice	 have	 all	 the	 post-mitotic	 sensory	 neurons	 containing	 Nav1.8	eradicated	 through	 the	 expression	 of	 diphtheria	 toxin	 A(Ivanova,	 Signore	 et	 al.	 2005,	Stirling,	Forlani	et	al.	2005,	Abrahamsen,	Zhao	et	al.	2008).	A	full	sensory	profile	is	described	in	Abrahamsen	et	al	2008.	
• TRPC	knock	out	mice:	Quick	et	al	2012	generated	three	mouse	lines	for	use(Quick,	Zhao	et	al.	2012):	
o TRPC3	SKO	
o TRPC6	SKO	
o TRPC3/6	DKO	
A	double	knock	out	mouse	had	originally	been	generated	by	Birnbaumer	and	colleagues	at	the	 NIEHS.	 Their	 DKO	 mice	 were	 crossed	 with	 C57BL/6	 mice	 to	 create	 heterozygous	TRPC3+/-;TRPC6+/-	mice.	These	 could	 then	be	 crossed	 together	 to	 create	DKOs,	 single	KOs	and	WT	controls.	A	full	sensory	profile	is	described	by	Quick	et	al.	
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2.2	 		 Induction	of	OA	
2.2.1	 		 Rats	The	dose	selected	for	this	protocol	was	based	upon	findings	of	Thakur	et	al	2012,	which	described	differential	 pain	 profiles	 between	 1mg	 and	 2mg	MIA	 rats.	 Previous	 work	 in	 this	 lab	 had	 already	characterized	descending	controls	for	the	2mg	profile,	so	we	sought	to	characterize	this	less	severe,	non-neuropathic	1mg	MIA	model(Thakur,	Rahman	et	al.	2012).	
Male	Sprague	Dawley	rats,	weighing	either	160-180g	(early	group)	or	120-140g	(late	group),	were	anaesthetized	using	3.5%	isoflurane	in	a	2:1	mixture	of	Oxygen	and	Nitrous	Oxide	until	animals	were	a-reflexive.	Animals	were	then	placed	on	their	backs,	on	a	heat	mat,	and	maintained	on	a	nose	cone	at	 2%	 isoflurane.	 The	 absence	 of	 reflexes	was	 re-assessed.	 The	 entire	 ventral	 surface	 of	 the	 hind	limb,	from	paw	up	to	mid	thigh,	was	then	clipped	of	hair	and	cleaned	using	clorhexidine.	This	both	minimized	 the	 risk	 of	 infection	 but	 rendered	 the	 skin	 more	 soft,	 malleable	 and	 translucent	 for	visualizing	 the	 injection	 site.	 Reflexes	 were	 checked	 one	 final	 time	 before	 OA	 was	 induced	 by	injecting	 1mg	 MIA	 in	 25μl	 of	 0.9%	 saline	 into	 the	 left	 knee	 of	 the	 flexed	 joint.	 The	 MIA	 was	administered	using	a	27G	needle	 through	 the	 left	patellar	 tendon,	which	was	held	 in	place	 for	30s	and	withdrawn	slowly	to	minimize	 leakage.	The	 limb	was	then	flexed	and	extended	a	few	times	to	distribute	MIA,	re-cleaned	and	the	animal	placed	in	an	incubator	to	recover.	Sham	animals	received	saline	injection	only.	Once	animals	had	recovered	they	were	returned	to	their	cages	and	monitored	over	the	proceeding	24-72	hours	by	trained	staff	in	the	animal	unit.	The	injection	day	is	considered	day	0	for	the	subsequent	studies.	
	
2.2.2	 		 Mice	
The	protocol	for	establishing	OA	in	mice	using	MIA	is	less	well	established,	at	least	in	comparison	to	the	rat.	Total	doses	range	from	0.025mg	to	1mg,	as	do	the	volumes	used	–	normally	between	5μl	and	10μl(van	der	Kraan,	Vitters	et	al.	1989,	Van	Osch,	Van	Der	Kraan	et	al.	1994,	Harvey	and	Dickenson	2009,	 Ogbonna,	 Clark	 et	 al.	 2012).	 Before	 beginning,	 a	 preliminary	 test	 was	 completed	 using	0.025mg,	0.2mg	and	0.5mg.	Based	on	the	results	of	these	across	two	mouse	strains,	the	0.5mg	dose	was	selected	as	it	produced	the	most	reliable	and	robust	change	in	PWT.	
Procedure	was	carried	out	as	described	above	for	rats,	except	using	0.5mg	monosodium	iodoacetate	in	 5μl	 of	 0.9%	 saline	 using	 a	 30G	 needle.	 Mice	 were	 aged	 6-8	 weeks,	 weighing	 between	 20-35g	depending	on	gender	and	mouse	strain.	
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2.3	 		 Behaviour	
2.3.1	 		 Assessment	Days	
Rats:	Animals	were	assessed	on	either	day	3	(early),	day	10	(late)	or	day	14	(for	RVM)	post	injection,	preceding	electrophysiology.	
Mice:	Animals	were	assessed	on	day	0,	on	the	morning	prior	to	the	injection,	and	on	the	mornings	of	day	3,	7,	14	and	21	there	after.	If,	at	any	time	point,	mice	displayed	obvious	pain	or	physical	damage	relating	to	fighting	or	over-scratching	(as	appeared	in	a	minority	of	DTA	mice)	these	animals	were	excluded.	
	
2.3.2	 			 Acclimatization	
Before	measurements	began,	 all	 animals	were	given	a	period	 in	which	 to	acclimatize	 to	 their	new	settings	–	namely	a	rack	of	Perspex	boxes	open	at	the	bottom	and	top	and	sat	upon	a	wire	grid.	This	wire	grid	allowed	access	to	the	paws	of	the	animal.		
• For	 the	 rats,	 the	 tops	 of	 the	 Perspex	 chamber	 were	 topped	 by	 cardboard	 to	 provide	 a	degree	of	cover	and	given	a	period	of	20	minutes	in	which	to	acclimatize.		
• For	the	mice,	black	plastic	coverings	were	placed	around	the	sides	and	as	a	lid	to	entirely	black	out	the	chambers	and	the	mice	left	for	1hr	–	in	acknowledgement	of	their	enhanced	acclimatization	requirements.		
During	this	time,	the	rooms	were	off-access	to	other	experimenters	to	allow	a	quiet	and	undisturbed	setting.			
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2.3.3	Mechanical	Hypersensitivity	
Rat	–	Punctate	Mechanical	Hypersensitivity	
	
Mechanical	 sensitivity	 was	 assessed	 through	 the	 placement	 of	 von	 Frey	 filaments	 to	 the	 plantar	surface	of	the	hind	paw	and	subsequent	withdrawal,	or	not,	by	the	rat.	The	usually	innocuous	hairs	1g,	6g	and	8g	were	each	applied	ten	times	–	once	to	each	toe	and	once	each	to	the	pads	on	the	paw-	and	the	number	of	withdrawals	out	of	ten	recorded.	Each	hair	was	applied	for	2	seconds,	such	that	the	 fiber	 bent,	 and	 a	 withdrawal	 classified	 as	 the	 active	 removal	 of	 the	 paw	 from	 the	 stimulus,	including	full	bodily	removal	from	the	stimulus;	turning	to	lick	the	paw;	or	shaking	the	paw.	Should	the	fiber	slip	off	the	toe	before	bending	this	touch	was	not	considered	a	test,	as	full	force	would	not	have	been	applied.	
These	 tests	were	done	 to	both	 the	 ipsilateral	and	contralateral	paws	 in	ascending	order,	 such	 that	the	10x1g	stimuli	would	be	performed	on	each	paw	(contralateral	first)	and	then	followed	by	a	one-minute	break,	cold	hypersensitivity	test	plus	additional	one	minute	break	before	commencing	the	6g	test.	
	
Rat	and	Mouse	–	Paw	Withdrawal	Threshold	
The	assessment	of	 change	 in	 touch	withdrawal	 threshold	was	used	 in	both	mice	and	 the	group	of	rats	to	be	used	in	RVM	recordings.	This	technique	was	adopted,	in	preference	to	the	one	described	
Figure	2.1	–	Behavioural	testing	for	punctate	mechanical	hypersensitivity:	Animals	were	placed	in	a	clear	Perspex	box,	sat	atop	a	metal	grid	through	with	hind	paws	could	be	reached	by	vF	hairs.	vF	hairs	were	applied	ten	times	for	each	fiber	force,	once	to	each	of	the	red	spot		locations	( )	on	the	hind	paw.	
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above,	as	 it	reduced	the	number	of	application	of	 the	vF	hairs	while	 increasing	the	accuracy	of	 the	measurement	–	to	give	an	value	for	threshold	for	withdrawal.	
The	protocol	matches	that	described	above,	except	that	instead	of	using	number	of	withdrawals	out	of	 ten	 to	 three	separate	vF	 fibers,	a	paw	withdrawal	 threshold	was	calculated	using	 the	 “up-down	method”,	 as	 described	by	Chaplan	 et	 al(Chaplan,	Bach	 et	 al.	 1994).	 In	 brief,	 vF	hairs	 of	 sequential	increasing	 or	 decreasing	 force	 are	 applied,	 based	 on	 the	 response	 to	 the	 previous	 stimuli	(withdrawal	 or	 lack	 there	 of).	 The	 statistical	 formula	 described	 by	 Dixon	 et	 al	 is	 then	 utilized	 to	calculate	 the	 50%	 withdrawal	 threshold(Dixon	 1980)	 –	 which	 describes	 the	 force	 at	 which	 the	animal	will	withdraw	50%	of	the	time.		
	
Weight-bearing	Assessment	
The	assessment	of	resting	joint	discomfort	is	made	using	the	incapacitance	test.	This	was	performed	in	both	rats	and	mice,	however	a	different	brand	of	equipment	was	used	–	given	the	different	sizes	of	the	 animal.	 Regardless	 of	 animal	 or	 machinery,	 all	 weight	 bearing	 was	 performed	 in	 only	 those	animals	deemed	calm	enough	–	 for	example,	any	rat	exhibiting	stress	 induced	hiccoughs	would	be	returned	to	his	cage	to	recover	and	tested	at	a	later	time	point.		
Rat:	Rats	were	placed	 in	 the	angled	Perspex	 chamber	 so	 that	each	hind	paw	rested	on	a	 separate	force	platform,	the	front	paws	rested	on	the	Perspex	and	the	tail	projected	out	of	the	box	as	seen	in	Figure	2.2.	Animals	were	 given	2	minutes	 to	 acclimatize	 and	once	 stood	 in	 the	position	described	above,	so	 that	each	platform	had	 just	one	paw	in	contact,	 the	 force	exerted	by	each	hind	 limb	was	measured	over	a	5s	period	to	give	an	average,	in	grams,	for	each	side.	The	percentage	weight	borne	of	 the	 ipsilateral	 limb	was	 then	 calculated.	 This	was	 repeated	 3	 times	 and	 averaged.	 (Equipment:	Linton	Instrumentation,	Norfolk,	UK)	
Mice:	Mice	were	placed	on	the	incapacitance	tester	such	that	they	“hide”	their	head	and	front	paws	in	 the	 presented	 nose	 cone	 of	 their	 own	 free	 will.	 Some	 natural	 degree	 of	 exploration	 of	 the	equipment	was	allowed	to	prevent	the	animal	feeling	forced	into	position	but	gentle	tugging	of	the	tail	would	be	used	to	encourage	hiding	if	necessary.	The	cone	naturally	positioned	the	mouse	such	that	each	paw	rested	on	a	separate	plate,	with	front	paws	elevated.		The	tail	was	held	gently	during	this	 time	 to	 prevent	 breaks	 for	 freedom	 or	 entire	 submersion	 into	 the	 nose	 cone	 tube.	 Once	 the	mouse	was	considered	to	be	calm	and	still,	the	force	exerted	by	each	hind	limb	was	measured	over	a	10s	period,	to	give	an	average,	 in	grams,	for	each	side.	The	percentage	weight	borne	of	the	IL	limb	was	then	calculated.	This	was	repeated	3	times	and	averaged.	(Linton	Instrumentation,	Norfolk,	UK).	
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Please	 note	 that	 this	 measure	 was	 not	 performed	 in	 rats	 used	 for	 brain	 recording	 following	 the	
inadvertent	 disposal	 of	 the	 angled	 Perspex	 box	 required	 to	 operate	 the	 incapacitance	machine.	 As	 a	
result,	only	PWTs	were	used	to	measure	behavioural	changes	in	these	animals.		
	
Figure	2.2	-	Weight	bearing	assessment	using	an	incapacitance	tester,	as	describe	by	Bove	et	al(Bove	
2003).	The	animal	sits	in	a	perspex	box	that	orientates	it	so	that	one	hindpaw	is	on	each	platform,	the	front	paws	 are	 elevated	 and	 resting	 on	 the	 Perspex,	 and	 the	 tail	 is	 projecting	 out	 of	 the	 box.	 Once	 the	 animal	 is	settled	and	still	a	reading	is	taken	which	measures	the	weight	borne	by	each	hind	paw	on	each	platform.	
	
2.3.4	 		 Cooling	Hypersensitivity	
Cooling	hypersensitivity	was	measured	as	the	number	of	withdrawals	out	of	five	to	the	placement	of	a	drop	of	acetone	to	the	plantar	surface	of	the	paw.	The	drop	was	placed	using	a	1ml	syringe	with	plastic	 tubing	 attached	 at	 the	 nozzle	 with	 which	 to	 administer.	 The	 tubing	was	 never	 allowed	 to	touch	the	animal’s	paw.	Each	application	was	spaced	out	by	at	least	one	minute,	including	between	application	to	the	ipsilateral	and	contralateral	paws.		
It	should	be	noted	that	the	syringe	was	always	filled	prior	to	the	introduction	of	the	animals	to	the	behaviour	 room,	 as	 the	 smell	 of	 opening	 the	 acetone	 container	 catches	 their	 attention	 and	sometimes	unsettles	 them.	This	measure	was	only	performed	 in	early	and	 late	rats,	not	 in	mice	or	rats	 to	be	used	 for	brain	recordings,	as	no	change	 in	cooling	sensitivity	was	noted	 in	 these	earlier	experiments.	
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2.4	 		 Spinal	Cord	Electrophysiology	(Rat	only)	
This	protocol	has	been	previously	described	(Urch	and	Dickenson	2003).	
2.4.1	 		 Animal	Preparation	
Animals	were	 placed	 in	 a	 perspex	 box	 and	weighed.	 This	 box	was	 then	 connected	 to	 receive	 4%	isoflurane	in	a	2:1	mixture	of	Oxygen	and	Nitrous	Oxide.	Once	rats	had	become	unconscious	and	a-reflexive	 they	 were	 removed	 from	 the	 box	 and	 placed	 on	 a	 nose	 cone,	 on	 their	 backs,	 and	 the	anaesthetic	reduced	to	3%.	A	rectal	probe	was	 inserted	to	provide	 feedback	control	of	 the	heating	mat,	such	that	body	temperature	was	maintained	at	37°C	in	all	animals.	
Reflexes	were	checked	before	 the	exposure	of	 the	 trachea	by	blunt	dissection.	A	 tracheotomy	was	then	 performed,	 involving	 the	 insertion	 of	 a	 cannula	 to	 the	 trachea,	which	was	 securing	with	 silk	thread.	 Anaesthesia	 delivery	 was	 transferred	 across	 to	 this	 cannula	 and	 reduced	 to	 2.5%.	 The	animals	were	then	fitted	into	ear	bars	in	a	stereotaxic	frame,	on	their	ventral	side.	An	incision	was	then	made	down	 the	middle	of	 the	animal’s	dorsal	 side,	 starting	between	 the	shoulder	blades	and	down	 to	 approximately	 the	 top	of	 the	hips	 –	 the	 smaller	 the	 incision	 the	better.	A	mark	was	 then	made,	through	a	small	scratch,	to	mark	the	point	at	which	the	ribs	met	the	spine.	Above	this	point,	incisions	of	approximately	2cm	in	length	were	made	on	either	side	of	the	spine	and	a	clamp	placed	here	and	tightened	onto	the	vertebrae.	This	served	the	dual	purpose	of	holding	the	thoracic	region	sufficiently	high	for	easy	breathing	and	held	the	spine	securely	in	place.	
At	 the	 point	 of	 the	marker,	where	 the	 ribs	meet	 the	 spine,	 the	muscle	 and	 connective	 tissue	was	removed	in	a	strip	of	roughly	0.5cm	in	width	and	~0.5cm	above	and	below	the	marker	in	order	to	reveal	 spinal	 segments	 L4-6.	 A	 laminectomy	 was	 performed.	 Any	 meninges	 still	 in	 place	 were	carefully	 removed	with	 fine	 (watchmakers)	 tweezers.	 Finally,	 incisions	were	made	 (as	 before)	 on	either	side	of	the	spine	just	below	the	laminectomy	and	a	clamp	tightened	onto	the	vertebrae,	such	that	 the	 spinal	 cord	was	 held	 level,	 straight,	 tight	 (cranial-dorsal)	 and	 secure.	 This	 overall	 set	 up	formed	a	natural	well	around	the	exposed	cord	to	allow	the	spinal	application	of	drugs	without	drip	off.	Saline	was	applied	when	necessary	to	keep	the	cord	moist	throughout	the	procedure.		
Once	 this	 set	 up	 was	 complete	 the	 anaesthesia	 was	 reduced	 to	 ~1.6%	 Isoflurane,	 such	 that	 the	animal	 remained	 a-reflexive	 and	 the	 breathing	 rate	 steady.	 Throughout	 the	 experiment	 the	 depth	and	 rate	 of	 breathing	was	monitored	 visually,	 along	 side	 the	 colour	 of	 the	 rat	 ears	 and	 tail	 –	 the	pinkness	of	which	was	a	good	indicator	of	wellbeing.	
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Figure	 2.4	 -	 Schematic	 of	 the	 Neurolog	 recording	 system,	 adapted	 from	 Urch	 and	 Dickenson	 2003(Urch	 and	
Dickenson	2003).	 	 Input	 from	the	spinal	cord	is	transmitted	by	the	electrode	through	the	head	stage	and	into	the	AC	Pre-Amp.	The	 signal	 is	processed	such	that	 “noise”	 is	 subtracted,	 the	signal	amplified	and	 filtered,	 sending	outputs	 to	both	 the	oscilloscope	 and	speaker.	Action	potentials	with	an	amplitude	 that	exceed	the	 set	 threshold	 are	 outputted	 to	 the	CED	and	filtered	 to	 the	 computer.	 Pre-set	 frequency	 electrical	 stimuli	 are	 applied	 to	 the	 paw	 by	 the	 pulse	 buffer	 via	 stimulating	electrodes,	 where	 all	 resultant	 electrical	 outputs	 are	 captured	 and	 plotted	 by	 the	 computer	 into	 a	 post-stimulus	 time	histogram	which	separates	activity	related	to	fiber	types	based	on	latency.	
!
Ground
Animal
Homeothermic Heat Matt
Figure	2.3	-	Stereotaxic	set	up	of	the	rat	for	spinal	electrophysiology	–	Rat	is	held	in	position	by	a	combination	of	ear	bars	and	2	sets	of	clamps	above	and	below	the	laminectomy.	A	feedback	thermometer	sits	in	the	rectum	to	control	the	heat	mat	upon	which	the	rat	sits.	The	electrode	is	inserted	just	lateral	to	the	central	vessel	and	lowered	to	Lamina	V.	Grounding	cables	are	similarly	connected	to	both	the	frame	and	the	animal.	
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2.4.2	 		 Single	Cell	Recordings	
Recordings	 were	 made	 by	 the	 insertion	 of	 a	 parylene-coated	 tungsten	 electrode	 (AM	 Systems,	Washington,	 exposed	 tip	 0.1mm,	 2MΩ)	 into	 the	 spinal	 cord	 of	 the	 rat	 at	 a	 depth	 of	 approx.	 500-1000µm	 –	 corresponding	 to	 Lamina	 V	 –	 using	 a	 micromanipulator	 to	 visualize	 the	 depth.	 The	electrode	was	held	by	a	head	stage	which	also	received	connections	from	two	grounding	cables	–	one	attached	to	the	animal,	 to	collate	electrical	activity	 in	the	animal	not	related	to	spinal	cord	activity	(e.g.	 heart	 beat),	while	 the	 other	 collected	 background	 electrical	 noise	 through	 attachment	 to	 the	stereotaxic	frame.	This	information	was	then	all	fed	into	the	Neurolog	AC	recording	system.	
The	Neurolog	 recording	 system	was	 operated	 on	 the	 A-B	 setting,	 signifying	 differential	 recording	where	 by	 signals	 from	 the	 grounding	 cables	 is	 subtracted	 from	 those	 of	 the	 electrode	 to	 give	 a	cleaner	signal.	The	neurolog	system	amplifies	and	filters	this	signal,	feeding	it	to	both	an	oscilloscope	and	speakers	to	allow	audiovisual	demonstration	of	the	spinal	cord	outputs.	Action	potentials	were	counted	 by	 the	 CED1401	 system	 and	 fed	 into	 a	 computer	 for	 collation,	 where	 they	 were	 then	presented	as	histograms.	
Finding	a	cell	from	which	to	record	
The	electrode	was	inserted	gently,	using	a	micromanipulator,	to	the	ipsilateral	side	of	the	spinal	cord	such	that	the	electrode	would	enter	just	lateral	to	the	central	vessel.	The	electrode	was	then	moved	upwards	 and	 downwards	 slowly	 in	 the	 search	 region	 (500-1000µm	 from	 the	 surface	 when	 not	puckered)	while	tapping	on	the	paw.	This	allowed	for	the	 literal	sounding	out	of	cells,	which	were	also	visualized	on	the	oscilloscope.	WDR	cells	were	identified	and	selected	on	the	following	criteria:	
• Responding	to	8g	vF	(light	touch)	and	dynamic	brush	with	a	minimum	of	50	action	potentials	
• Strong	responses	to	noxious	inputs	(pinch	and	48°C	water	jet.);		
• Responded	to	natural	stimuli	in	a	graded	manner,	coding	increasing	intensity.	
• Exhibited	prolonged	firing	to	a	continuing	noxious	mechanical	stimulus,	such	as	pinch.	
• A	 clear	 signal,	 which	 could	 be	 recorded	without	 collecting	 data	 on	 neighbours	 –	 this	 was	often	solvable	by	fractional	movements	of	the	electrode	to	become	more	proximal	to	the	cell	of	 interest	 and	 further	 from	 the	 neighbour.	 The	 signal	 to	 noise	 ratio	 for	 stable	 optimal	recording	was	~4:1.	
• Receptive	field	which	included	at	least	one	toe.	
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Figure	 2.5	 –	 Electrical	 evoked	 responses	 from	 an	 example	WDR	 cell.	 A)	 Evoked	 responses	 to	 sequential	 electrical	stimuli	delivered	by	stimulating	electrodes	within	the	WDR	receptive	field.	Each	vertical	line	is	an	action	potential,	where	each	 dot	 above	 denotes	 that	 the	 computer	 has	 “counted”	 this	 output.	 Note	 the	 increase	 in	 evoked	 responses	 between	stimulus	numbers	1,	3,	 10	and	14.	B,	 C)	Graphical	depictions	of	 the	actual	versus	predicted	action	potential	evoked	by	a	train	of	16	electrical	stimuli	at	3	times	C	fiber	threshold	for	activation.	(B	=	Total	generated,	C	=	per	stimulus).	Shaded	areas	indicate	 the	basis	 of	 the	 Input	 (red)	 and	Wind-up	(Red)	metrics.	 	 The	 first	 stimulus	evoked	19	action	potential,	 the	16th	evoked	58.	D)	Histogram	 separating	 electrically	 evoked	 responses	by	 latency	 	 -	 where	 action	 potentials	 from	Aβ	 arrive	much	faster	than	C.	Note	that	the	WDR	exhibits	input	from	all	three	fiber	classes.		
Aβ	 Aδ	 C	Fiber	 Post	Discharge	
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Electrically	Evoked	Responses	
Upon	selection	of	a	cell,	 two	simulating	electrodes	were	inserted	into	the	receptive	field	of	the	cell	such	 that	 they	 were	 near	 but	 not	 touching.	 The	 threshold	 for	 C	 fiber	 activation	 was	 determined,	based	on	the	latency	of	response	to	electrical	stimuli	from	these	electrodes.	A	train	of	16	stimuli,	at	three	 times	 this	 threshold	 stimulating	 current,	 were	 then	 delivered	 at	 0.5Hz,	 generating	 a	 post	stimulus	 time	histogram	 (PSTH)	of	 electrically	 evoked	 responses	 (Figure	 2.5	 D).	Responses	were	separated	into	fiber	classes,	such	that	each	action	potential	could	be	attributed	to	Aβ,	Aδ,	C	fiber	of	post	discharge	based	on	their	latency,	where	post	discharges	are	those	responses	occurring	beyond	the	C	fiber	latency	period(Urch	and	Dickenson	2003,	Lane,	Schnitzer	et	al.	2010)		
During	this	train	of	electrical	impulses,	the	total	number	of	action	potentials	generated	so	far	at	each	stimulus	 (as	 displayed	 on	 the	 neurolog	 counter)	 is	 collected.	 A	 value	 for	 a	 predicted	 no	 windup	response	is	calculated	as	the	number	of	responses	to	the	first	stimulus	multiplied	by	sixteen,	known	as	the	input.	This	is	then	subtracted	from	the	final	total	number	of	action	potentials	counted	by	the	final	16th	stimulus	to	give	a	figure-denoted	wind-up.	For	example	–	the	first	stimulus-response	is	10	potentials,	while	 the	16th	 is	1000.	Thus	 the	 input	 is	10x16	=	160.	The	wind-up	 is	1000-160	=	840.	(See	figure	2.5	B	and	C)	This	is	confirmation	of	a	WDR	cell	that	winds	up,	completing	the	final	criteria	for	selection.	Note	that	this	is	a	final	selection	barrier	only	performed	on	cells	already	deemed	WDR	–	 pinning	 and	 stimulating	 before	 this	would	 create	 unnecessary	 tissue	 damage	 and	 consequential	peripheral	sensitization	throughout	the	(often	lengthy)	search	process.	
This	electrical	stimulation	was	performed	at	 the	beginning	of	ever	test	run,	such	that	stimuli	were	delivered	 in	 the	 order	 [electrical	 –>	 2minute	 pause	 –>	 mechanical	 –>	 thermal].	 This	 pause	 was	normally	covered	by	the	time	taken	recording	readings	but	primarily	allowed	a	brief	recovery	period	for	the	cell,	especially	in	those	showing	vigorous	after	firing.	A	test	run	was	completed	every	20mins	until	 three	 sets	 of	 consecutive,	 consistent	 recordings	 had	 been	 collected.	 This	 would	 then	 be	followed	by	pharmacology	(discussed	below)	and	the	test	runs	repeated	at	specific	time	points.	
	
Mechanical	and	Thermally	Evoked	Responses	
Following	the	2min	pause	post	electrical	stimulation,	the	natural	stimuli	are	then	applied,	in	order	of	ascending	 severity,	 for	 10seconds	 at	 one	 minute	 intervals	 to	 the	 center	 of	 the	 receptive	 field	 –mechanical	stimuli	preceding	thermal.	This	order	and	temporal	spacing	is	designed	to	prevent	any	sensitization	and	allow	the	recovery	from	any	after	firing.	The	stimuli	applied,	in	order,	are	dynamic	brush	 (ten	 stroked	 over	 the	 receptive	 field);	 8,	 15,	 26,	 60g	 vF	 hairs	 applied	 to	 the	 center	 of	 the	
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receptive	field;	35,	40,	45	and	48°C	water	jet	delivered	at	a	constant	force	through	a	21G	needle.	The	number	 of	 action	 potentials	 generated	 over	 the	 10s	 stimulation	 period	 was	 collected	 by	 the	computer.	
	
	
Figure	2.6	–	Naturally	evoked	responses	of	 lamina	V	WDR	neuron.	Note	the	graded	response	to	stimuli	of	increasing	magnitude.	The	number	of	action	potentials	are	plotted	in	1second	bins,	where	the	black	bars	above	denote	the	10second	stimulation	period.		These	stimuli	are	brushing	of	the	receptive	field	(ten	strokes	–	dynamic	mechanical	stimulation),	von	Frey	 hairs	 and	 thermal	water	 jets.	 This	 cell	was	 selected	 specifically	 as	 it	was	 considered	 broadly	 representative,	 since	many	cells	characterized	exhibited	limited	response	to	non-noxious	thermal	stimulation	(fewer	than	150	action	potentials	to	35	and	40°C),	but	respond	vigorously	at	45	and	48°C.		
Once	full	recordings	had	been	completed	the	anaesthesia	was	increased	to	5%	and	death	confirmed	by	cervical	dislocation.	
	
2.4.3	 		 Pharmacology	
All	drugs	and	controls	used	during	 these	spinal	electrophysiology	protocols	were	applied	spinally.	This	 involves	 the	 direct	 application	 to	 the	 surface	 of	 the	 cord.	 In	 order	 to	 ensure	 maximum	penetrance,	the	surface	of	the	cord	was	kept	clear	of	blood	clots	that	could	be	obstruct	access.	Once	drugs	 had	 been	 applied,	 test	 runs	 were	 completed	 at	 10,	 30	 and	 50minutes	 post	 application.	Specifics	of	the	drugs	used	and	their	dilution	will	be	discussed	in	individual	chapters.	
	
		 107	
2.5	 		 Electrophysiological	Recordings	from	the	RVM	(Rat	only)	
2.5.1	 		 Animal	Preparation	
Because	the	coordinates	used	to	locate	the	RVM	are	based	on	a	rat	brain	atlas	for	rats	between	250-350g,	only	rats	weighed	and	exceeding	250g	could	be	used	in	this	procedure.	Rats	found	to	fall	just	under	this	were	returned	to	the	animal	house	for	an	additional	day	or	two	of	growth,	on	a	wet	mash	diet.	
Animals	were	anaesthetized	and	a	tracheotomy	performed	as	previously	described.	 Isoflurane	was	reduced	 to	2.5%	and	 rats	 secured	 in	 a	 stereotaxic	 frame.	An	 incision	was	made	along	 the	head	of	approximately	2cm	 in	 length	and	 the	skull	 cleared	of	muscle	and	connective	 tissue.	Once	 the	skull	had	 “dried	 out”	 somewhat,	 so	 that	 bregma	 and	 lambda	 were	 clearly	 visible,	 the	 incisor	 bar	 was	adjusted	such	that	these	two	markers	lay	equal	and	the	skull	was	flat.	Using	a	blunt	electrode	and	the	micromanipulators,	 an	 area	 corresponding	 to	 the	 center	 of	 the	 RVM	was	marked	 on	 the	 skull,	 at	0.5mm	mediolateral	 and	 11mm	 caudal	 from	 bregma.	 This	was	 then	 slowly	 drilled,	 using	 a	 dental	drill,	such	that	a	hole	through	to	the	brain	of	approximately	4mm	in	diameter	was	created.	The	dura	was	 then	 removed	 using	 fine	 tweezers,	 if	 it	 had	 not	 already	 been	 by	 the	 drilling,	 and	 saline	dampened	gauze	placed	over	 the	opening	 to	help	cease	any	subsequent	bleeding.	Anaesthesia	was	immediately	 dropped	 to	 1.8%	 with	 oxygen	 alone	 (i.e.	 no	 more	 nitrous	 oxide).	 This	 was	 then	continuously	lowered,	in	small	increments,	to	1.3%	over	the	next	hour.	This	was	considered	a	level	sufficient	to	maintain	clear	reflex	withdrawal	from	paw	and	tail	pinch	without	spontaneous	activity.	However,	animals	were	closely	and	continually	monitored	throughout	for	any	signs	that	anesthesia	was	 too	 light,	 such	 as	 paw	 withdrawals	 independent	 of	 stimulus,	 and	 isoflurane	 subsequently	increased	till	this	was	resolved.	As	previously,	depth	and	rate	of	breathing	was	monitored	visually,	alongside	the	colour	of	the	rat	ears	and	tail	–	the	pinkness	of	which	was	a	good	indicator	of	wellbeing	–	while	 body	 temperature	was	 controlled	 by	 a	 heat-blanket,	 controlled	 by	 feedback	 from	 a	 rectal	probe.	
	
2.5.2	 		 Single	Cell	Recording	
Recordings	 were	 made	 by	 the	 insertion	 of	 a	 parylene-coated	 tungsten	 electrode	 (AM	 Systems,	Washington,	exposed	tip	0.1mm,	2MΩ)	into	an	area	corresponding	to	the	RVM,	as	mapped	by	the	rat	atlas:	 0.0-0.9mm	mediolateral,	 10.5-11.5mm	caudal	 and	9.0-11.0mm	dorsal	 of	 the	dura	matter.	As	described	 for	 spinal	 recordings,	 the	 electrode	 was	 held	 by	 a	 head	 stage,	 which	 also	 received	connections	 from	 two	 grounding	 cables,	 and	 fed	 into	 the	 Neurolog	 AC	 recording	 system	 which	
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filtered,	 amplified	 and	 visualized	 neuronal	 activity	 on	 an	 oscilloscope,	 made	 audible	 through	speakers,	and	mapped	wave	patterns	in	the	Spike	5	software	on	the	computer.	
Cells	were	identified	and	classified	as	either	ON-,	OFF-	or	neutral	cells	based	on	change	in	firing	just	prior	to	tail	flick,	as	induced	by	8cm	immersion	in	50°C	water,	as	described	by	Fields	et	al(Fields,	Bry	et	al.	1983).	This	 temperature	was	selected	 to	prevent	sensitization	 through	repetitive	 immersion.	Briefly,	cells	were	characterized	as	ON	cells	if	they	displayed	an	increased	rate	of	firing	just	prior	to	tail	 flick;	 OFF	 by	 a	 pause	 just	 prior	 to	 tail	 flick;	 and	 neutral	 if	 they	 did	 not	 change	 at	 all.	 This	classification	was	based	upon	a	change	in	rate	of	firing	of	7	action	potentials	per	second,	and	not	a	percentage	 as	 had	 previously	 be	 utilized	 in	 this	 lab	 simply	 by	 virtue	 of	 many	 ON	 cells	 having	 a	resting	rate	of	firing	of	zero,	from	which	a	percentage	cannot	be	calculated.	This	change	in	rate	was	calculated	by:	
Rate	of	Firing	due	to	tail	flick	-	Mean	Baseline	Rate	
Where	the	rate	of	firing	due	to	tail	flick	was	the	average	rate	over	a	5	second	period	composed	of	the	one	second	before	and	4	seconds	after	tail	flick;	and	Mean	baseline	rate	was	the	mean	rate	over	a	50	second	sample	period	prior	to	the	application	of	the	noxious	stimulus.	Some	example	cells	are	given	in	Figure	2.7.	
	
While	the	identification	of	a	single	cell,	isolated	visually	on	the	oscilloscope	and	audibly	through	the	speakers,	was	ideal	-	cells	were	analysed	and	followed	based	upon	waveform	shape	(See	2.5.4).	This	allowed	several	cells	to	be	followed	in	tandem,	for	example	both	an	ON-cell	and	neutral	cell,	unlike	in	spinal	recordings	where	individual	cells	were	entirely	isolated	for	recording.	
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Figure	2.7		 -	Example	ON-	(A),	OFF-	(B)	and	Neutral	(C)	cells	displaying	characteristic	change	 in	reflex	related	firing	
following	 noxious	 thermal	 stimulation	 of	 the	 tail	 -	 Histograms	 demonstrating	 the	 change	 in	 rate	 of	 firing	 (spikes	 per	second)	of	individual	ON,	OFF	and	Neutral	cells	in	response	to	heat	evoked	tail	flick.	
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2.5.3	 		 Experimental	Protocol	
Once	a	cell	was	identified	and	classified,	it	was	characterized	through	three	phases	of	testing:	
1. Change	in	rate	of	firing	in	response	to	tail	flick.		
2. Mean	resting	activity	over	15minutes.	
3. Change	 in	 rate	 of	 firing	 in	 response	 to	 ipsilateral	 and	 contralateral	 stimulation	 of	 the	 paw	and	knee.	
	
Change	in	tail	flick	reflex	related	firing	
Once	a	cell	was	identified,	the	tail	flick	reflex	and	changes	in	related	RVM	firing	were	characterized.	This	 involved	 three	 rounds	 of	 tail	 flicks,	 spaced	 5mins	 apart.	 All	 time	 point	markings	were	made	manually	onto	the	spike	system,	based	on	experimenter	observation:	H	notified	the	point	at	which	the	 tail	 was	 immersed,	 to	 8cm,	 in	 50°C	 water.	 T	 notified	 the	 point	 at	 which	 tail	 flick	 could	 be	observed	to	have	begun.	The	time	elapsed	between	H	and	T	was	denoted	the	latency	to	tail	flick,	and	is	given	as	 the	mean	of	 these	 three	 tail	 flicks.	Change	 in	rate	of	 firing	was	calculated,	as	described	above,	and	the	greatest	change	in	rate	of	the	three	trials	used	for	analysis.	
	
Mean	resting	activity	
The	 rat	was	allowed	5mins	 following	 the	 third	 tail	 flick.	Resting	activity	was	 then	recorded	as	 the	rate	 of	 firing	 (spikes	 per	 second)	 in	 1minute	 segments	 and	 averaged	 to	 give	 a	mean	 rate,	 termed	baseline	firing.	
	
Knee	and	Paw	Stimulation	
The	mechanical	 stimuli	were	 applied,	 in	 ascending	 order	 of	 force,	 first	 to	 the	 ipsilateral	 paw	 and	knee,	and	then	to	the	contralateral	side.	The	von	Frey	fibers	were	applied	at	one	minute	intervals	to	the	middle	toe	such	that	the	fiber	was	in	contact	and	bent	for	20	seconds.	If	observable	changed	in	firing	continued	beyond	the	one-minute	 interval,	additional	 time	was	 left	 for	 the	cell	 to	recover	 to	baseline	rate	of	firing.	Fibers	used	were:	8,	15,	26,	60	and	100g.	Following	these,	the	knee	joint	was	
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clamped	for	20seconds	by	calibrated	forceps	set	to	close	to	a	point	smaller	than	the	knee	diameter.	This	protocol	was	repeated	three	times,	with	10minute	pauses	between	each	round	of	stimulation.	
Changes	in	rate	of	firing	were	calculated	as:	
Rate	of	Firing	During/After	stimulus	-	Mean	Baseline	Rate	
Where	baseline	was	calculated	as	the	mean	rate	of	 firing	for	the	20	seconds	directly	preceding	the	stimulus;	Rate	of	firing	during	was	calculated	as	the	mean	rate	of	firing	for	the	20seconds	during	von	Frey	or	clamp	application;	and	the	rate	of	firing	after	stimulus	was	the	mean	rate	in	the	20seconds	after	 the	 stimulus.	 The	 greatest	 change	 in	 rate	 of	 firing	 over	 the	 three	 rounds	was	 then	 used	 for	analysis.	 This	 measure	 of	 after	 stimulus	 change	 in	 rate	 of	 firing	 was	 calculated	 following	observations	that	the	increase	or	pause	in	firing	sometimes	followed	the	release	of	the	more	noxious	stimuli,	namely	the	clamp	and	60	and	100g	von	Frey	hairs.	
	
2.5.4	 		 Data	extraction	
During	 these	 experiments	 Spike	 2	 recorded	 all	 raw	 data	 as	 individual	 waveforms.	 Once	 the	experiment	was	complete,	Spike2	was	used	 to	analyse	 these	waveforms	 into	 individual	wavemark	channels.	These	channels	use	the	shape	of	the	waveform	(including	amplitude	and	duration)	to	form	templates,	where	any	spike	that	fits	within	this	template	is	classed	as	originating	from	the	same	cell.	In	some	instances,	two	templates	are	created	that	may	look	like	the	same	cell	based	on	the	template	shape,	 identical	 activity	 of	 the	 two	 cells	 and	 the	 waveform	 heights.	 In	 these	 instances,	 the	 two	separate	 templates	were	 compared	using	 a	principal	 components	 analysis	 and	 if	 considered	 to	be	the	 same,	 through	mostly	 overlapping	 components,	 these	 templates	 were	 merged	 into	 one.	 Each	individual	wave	mark	was	then	converted	to	rate	(spikes/second)	and	data	extracted.	
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Figure	 2.8	 –	 Depiction	 of	 the	 process	 through	 with	 Spike	 2	 waveform	 data	 is	 sorted	 and	 filtered	 to	 identify	
individual	 cells	 for	 extraction	 and	 analysis:	The	original	waveform	 is	 analysed	 to	produce	wavemark	 templates	 that	allow	spikes	to	be	attributed	to	individual	cells.	These	templates	are	based	on	the	shape	of	the	action	potentials	detected,	which	vary	both	because	of	the	individual	cell	ion	channel	populations	and	proximity.	These	similarity	of	these	templates	can	then	be	assessed	by	principal	components	analysis	to	ensure	all	templates	represent	different	individual	cells.	
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2.6	 		 Analysis	
All	graphs	were	drawn	up	using	Graph	Pad	Prism	5.0,	as	were	all	statistical	analyses.	Please	refer	to	individual	Chapter	methods	for	the	individual	stats	protocols	used.	
Note:		
• In	behavioural	studies,	data	is	either	expressed	as	mean	difference	(e.g.	Ipsi	Withdrawals	out	of	 ten	–	Contra	Withdrawals	out	of	 ten),	 the	mean	percentage	 incapacitance	or	as	PWT,	as	calculated	by	Dixons	non	parametric	statistical	analysis.		
• Where	baseline	is	referred	to	in	spinal	electrophysiology	data,	these	are	the	measurements	taken	 prior	 to	 drug	 administration	 and	 represent	 the	mean	 of	 three	 stable	 test	 runs.	 The	effect	 of	 each	 drug	 is	 expressed	 as	 the	 maximum	 change	 from	 this	 baseline	 value	 per	individual	 drug	dose	 across	 all	 time	points.	 Graphs	 are	 expressed	 as	 raw	action	potentials	±SEM.		
• Where	 baseline	 is	 referred	 to	 in	 RVM	 recordings,	 this	 is	 the	 rate	 of	 firing	 prior	 to	 the	application	of	somatic	stimuli.	For	both	tail	flick,	paw	and	knee	stimulation	related	changes	in	 rate	 of	 firing,	 the	 value	 given	 is	 the	maximum	 change	 from	 baseline	 value.	 Graphs	 are	expressed	as	either	rate	of	firing	(spikes	per	second)	or	change	of	rate	in	firing.	
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Chapter	3	–	Baseline	Profile	of	1mg	MIA	Rats	As	discussed	in	section	1.5	of	the	introduction,	there	remain	inconsistencies	in	the	literature	around	the	exact	expected	profile	of	evoked	spinal	cord	electrophysiology	in	this	selected	model	of	OA	pain,	the	MIA	model.		As	I	am	using	a	lower	dose	of	MIA	than	has	traditionally	been	used	to	model	OA	pain	in	 spinal	 electrophysiological	 investigations	 in	 this	 lab,	 it	 seemed	 doubly	 important	 to	 clearly	characterize	 the	 baseline	 behaviour	 and	 evoked	 spinal	 cord	 electrophysiology	 of	 the	 rats	 used	 to	investigate	 changes	 in	 descending	 controls	 in	 OA.	 As	 such,	 this	 chapter	 is	 a	 precursor	 to	 the	pharmacology	work	in	Chapter	4,	in	which	the	baseline	readings	(pre-pharmacology	recordings)	of	all	animals	used	in	Chapter	4	have	been	merged	to	provide	an	overview	of	the	baseline	profile	of	these	animals.	The	baseline	readings	have	been	merged	into	one	of	four	experimental	cohorts	–	Early	MIA,	Late	 MIA,	 Early	 Sham	 and	 Late	 Sham	 –	 in	 the	 hope	 of	 providing	 greater	 space	 to	 focus	 on	 the	pharmacology	outcomes	in	Chapter	4.	
	
3.1.1 		 The	importance	of	dose	
As	discussed	in	section	1.5,	it	is	well	established	that	the	MIA	model	has	a	dose	dependent	effect	in	the	induction	of	 both	histopathology	 and	pain	 like	behaviour	 in	 animals(Guingamp,	Gegout-Pottie	 et	 al.	1997,	Janusz,	Hookfin	et	al.	2001,	Thakur	2012,	Udo,	Muneta	et	al.	2016).	While	this	is	logical,	since	a	larger	dose	will	provoke	the	more	rapid	and	wide	spread	changes,	 it	also	raises	questions	about	the	basis	for	the	pain	we	are	modeling	and	whether	this	is	representative	of	patient	groups.		
Within	 this	 thesis	 a	dose	of	1mg	of	MIA	has	been	 selected	 to	 investigate	 adaptations	 to	descending	controls,	 and	 later	 to	 RVM	 activity	 in	 rats,	 the	 results	 of	 which	 are	 presented	 in	 Chapter	 4	 and	 5	respectively.	The	reasoning	behind	the	selection	of	this	dose	is	three	fold:	
1. A	1mg	dose	 of	MIA	has	 been	 shown	 in	 past	 literature	 to	 produce	 a	 robust,	 reliable,	 OA-like	histopathological	and	pain	profile		
2. Previous	literature	has	characterized	a	neuropathic	profile	in	the	higher,	2mg	dose	of	MIA	
3. Previous	literature	characterizing	changes	in	descending	controls	in	the	MIA	model	have	used	this	higher,	2mg	model	of	OA	pain		
In	considering	 these	 factors,	discussed	 further	below,	 it	became	clear	 that	 there	could	be	 important	differenced	between	the	changes	in	descending	controls	observed	in	the	1mg	model	of	MIA	which	had	yet	to	be	characterized.	
		 114	
3.1.1.1 The	1mg	MIA	model:	a	reliable	and	robust	model	of	OA	pain	and	pathophysiology	
While	a	consensus	may	not	exist	for	the	expected	adaptations	observed	to	lamina	V	WDR	cell	evoked	activity	 in	 the	1mg	MIA	model	of	OA,	 there	 is	 a	much	greater	degree	of	 consensus	around	 the	 time	course	and	extent	of	structural	changes	in	this	model	-	changes	which	also	show	a	relationship	with	the	dose	administered	in	both	the	time	course	and	severity	of	changes(Guingamp,	Gegout-Pottie	et	al.	1997,	Janusz,	Hookfin	et	al.	2001,	Thakur	2012,	Udo,	Muneta	et	al.	2016).			
The	choice	 to	pursue	 the	1mg	dose	 flowed	out	of	 recent	work	 conducted	by	M.	Thakur	 in	his	2012	thesis,	 which	 in	 part	 looked	 to	 characterize	 the	 physiological	 and	 structural	 differences	 between	 a	1mg	 and	 2mg	 MIA	 model(Thakur,	 Rahman	 et	 al.	 2012).	 This	 work	 characterized	 a	 neuropathic	component	in	the	2mg	but	not	1mg	model	(see	3.1.1.2	below),	with	measures	including	assessments	of	 histology	 and	 proteoglycan	 loss	 (Figure	 3.1),	 DRG	 immunohistochemistry,	 quantification	 of	 total	DRG	ATF-3	expression,	quantification	of	 intra-epidermal	nerve	fibre	density	 in	plantar	hindpaw	and	quantification	of	microglial	activation,	along	side	the	additional	behavioural,	electrophysiological	and	pharmacological	measures.	From	this	work	there	was	a	clear	conclusion	that	a	1mg	dose	had	a	robust	OA	like	profile,	with	significant	proteoglycan	loss	in	both	the	1mg	and	2mg	MIA	models,	in	addition	to	the	development	of	a	robust	OA	pain	like	profile(Thakur,	Rahman	et	al.	2012).	
	
Figure	3.4	–	Articular	histology	taken	from	Thakur	et	al	2012,	comparing	the	relative	effect	of	saline,	1mg	
or	2mg	MIA	on	articular	cartilage	at	14days	after	injection.	Sagittal	sections	are		stained	with	toluidine	blue	to	visualize	cartilage	proteoglycan	content.	Fem=	femoral	condyl,	Tib	=	tibial	condyl.	Ant	=	anterior	aspect	of	knee,	Post	=	posterior	aspect.	A)	2mg	B)	1mg	C)	Saline(Thakur,	Rahman	et	al.	2012)		
However,	numerous	other	1mg	MIA	studies	have	characterized	 further	components	of	 the	1mg	MIA	model	at	the	time	points	investigated,	including:	
• The	development	of	an	initial	inflammation	(Bove	2003,	Guzman,	Evans	et	al.	2003,	Clements,	Ball	et	al.	2009,	Mapp,	Sagar	et	al.	2013)	
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• Proteoglycan	 loss	 and	 chondrocyte	 death	 (Guingamp,	 Gegout-Pottie	 et	 al.	 1997,	Gencosmanoglu,	Eryavuz	et	al.	2001,	Pomonis,	Boulet	et	al.	2005,	Ivanavicius,	Ball	et	al.	2007,	Sagar,	Staniaszek	et	al.	2010,	Strassle,	Mark	et	al.	2010,	Stevenson,	Mercer	et	al.	2011,	Thakur,	Rahman	et	al.	2012)	(Bove	2003,	Guzman,	Evans	et	al.	2003,	Clements,	Ball	et	al.	2009,	Mapp,	Sagar	et	al.	2013)	
• Cartilage	 fibrillation	 (Guingamp,	 Gegout-Pottie	 et	 al.	 1997,	 Gencosmanoglu,	 Eryavuz	 et	 al.	2001,	Guzman,	Evans	et	al.	2003,	Ivanavicius,	Ball	et	al.	2007)	
• Subchondral	bone	sclerosis	and	osteophytes	(Pomonis,	Boulet	et	al.	2005,	Ivanavicius,	Ball	et	al.	2007,	Clements,	Ball	et	al.	2009,	Nagase,	Kumakura	et	al.	2012)	(Guingamp,	Gegout-Pottie	et	al.	1997,	Gencosmanoglu,	Eryavuz	et	al.	2001,	Guzman,	Evans	et	al.	2003,	Ivanavicius,	Ball	et	al.	2007,	Mapp,	Sagar	et	al.	2013)		
• Development	of	pain	 like	behaviour,	 including	 shifts	 in	WB,	 reduced	PWT,	gait	 adjustments	and	lost	of	spontaneous	activities	(Guingamp,	Gegout-Pottie	et	al.	1997,	Guzman,	Evans	et	al.	2003,	 Ivanavicius,	 Ball	 et	 al.	 2007,	 Clements,	 Ball	 et	 al.	 2009,	 Sagar,	 Staniaszek	 et	 al.	 2010,	Strassle,	 Mark	 et	 al.	 2010,	 Stevenson,	 Mercer	 et	 al.	 2011,	 Nagase,	 Kumakura	 et	 al.	 2012,	Thakur,	Rahman	et	al.	2012)	
Some	of	these	changes	and	their	time-course	are	visualized	in	Figure	3.2,	taken	from	Ivanavicius	et	al	2007.	Further	detail	and	a	discussion	of	the	time	course	can	also	be	found	in	section	1.4.		
The	characterization	and	publication	of	such	outcomes	in	a	1mg	model	of	MIA	consequently	gives	us	confidence	that	the	1mg	MIA	model	is	just	as	robust	and	reliable	a	model	of	OA	pain	as	the	2mg	MIA	model,	where	the	 joint	histopathology	and	pain	characteristics	appear	broadly	 translatable	to	OA	in	patients.	
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3.1.1.2 Neuropathic	profile	of	2mg	MIA	rats	
The	 development	 of	 a	 neuropathic-like	 pain	 component	 in	 the	 MIA	 model	 has	 been	 identified	recently(Ivanavicius,	Ball	et	al.	2007,	Thakur,	Rahman	et	al.	2012),	though	some	debate	remains	as	to	whether	this	is	a	flaw	of	the	model	as	opposed	to	effective	characterization	of	OA	pain	pathology.	As	mentioned,	recent	work	from	this	lab	has	indicated	that	larger	concentrations	can	induce	neuropathic	like	changes(Thakur,	Rahman	et	al.	2012).		In	this	study,	in	which	1mg	and	2mg	MIA	rat	groups	were	compared,	 it	was	 found	 that	 the	2mg	animals	 showed	a	 significant	 reduction	 in	 fiber	density	 in	 the	plantar	hind	paw	skin,	a	significant	increase	in	ATF-3	expression	and	microgliosis	in	the	spinal	cord,	which	was	not	observed	 in	 the	1mg	animals,	 indicating	that	 the	 larger	dose	could	 induce	significant	axonal	 injury(Thakur,	Rahman	et	al.	2012).	These	suggestions	of	mild	neuropathy	 in	 the	MIA	model	have	been	made	before	in	previous	studies(Ivanavicius,	Ball	et	al.	2007,	Orita,	Ishikawa	et	al.	2011).		
Figure	 3.2	 –	 Articular	 histology	 taken	 from	 Ivanavicius	 et	 al	 2007	 displaying	 the	 time	 course	 of	 the	
histopathology	 of	a	1mg	MIA	 injection,	 (f,	 femoral	 condyle;	 t,	 tibial	 condyle).	a)	saline	control	knee	at	8	days,	where	the	*	highlights	normal,	healthy	cartilage	overlying	the	subchondral	bone	plate	and	cancellous	bone	of	 the	epiphysis	 (arrowhead)	which	 is	 interspaced	by	marrow	cavity	 (arrow)	b)	MIA	 injected	knee	at	8	days,	highlighting	the	pallor	of	the	intact	articular	cartilage	and	ghosting	of	chondrocytes,	with	some	degeneration	of	the	underlying	subchondral	bone	(arrowheads).	The	arrow	highlights	where	fibrous	tissue	is	developing	in	the	marrow	cavity	c)	MIA	injected	knee	at	12	days,	where	*	highlights	erosion	of	the	articular	cartilage	with	marked	subchondral	bone	degeneration	and	loss	(arrowhead)	d)	MIA	injected	knee	14	days	–	pronounced	ulceration	of	the	 articular	 cartilage	 (*)	 and	 superficial	 subchondral	 bone	 with	 ongoing	 degeneration	 and	 remodeling	 of	deeper	cancellous	epiphyseal	bone	(arrowheads).	(Ivanavicius,	Ball	et	al.	2007)		
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It	 seems	 likely	 that	 all	 MIA	 animals	will	 eventually	 develop	 a	 neuropathic	 pain	 state,	 as	 pathology	advances	and	 lesions	affect	nerve	endings	 in	the	bone.	However,	dose	 is	pivotal	 to	when	this	switch	from	a	nociceptive	and	inflammatory	pain	to	a	neuropathy	driven	pain	occurs.	This	work	by	Thakur	et	al	would	 indicate	 that	 in	 the	 2mg	model	 this	 switch	 to	 neuropathy	 is	 already	 underway	 at	 14days,	while	the	1mg	model	is	predominantly	nociceptive	pain(Thakur,	Rahman	et	al.	2012).	
The	 important	 implication	 is	 that	 the	dose	and	time	points	 investigated	may	define	the	relevance	of	findings	 from	animal	models.	Consider	 the	efficacy	of	pregabalin	 to	attenuate	behaviour	and	reduce	the	WDR	evoked	neuronal	responses	in	animals	treated	with	2	mg	MIA,	but	not	1	mg	or	sham	treated	groups(Rahman,	Bauer	et	al.	2009,	Vonsy,	Ghandehari	et	al.	2009,	Thakur,	Rahman	et	al.	2012).	This	suggests	that	gabapentinoids	are	effective	pain	relief	 in	OA	pain	with	neuropathic	contributions,	but	not	 in	all	patients.	This	would	explain	why	 these	 results	have	not	 translated	 to	 clinical	use	of	 these	drugs	 in	 OA	 management,	 since	 the	 majority	 (between	 68-80%)	 of	 patients’	 OA	 pain	 is	 non	neuropathic(Hochman,	Davis	et	al.	2013,	Oteo‐Álvaro,	Ruiz‐Ibán	et	al.	2014).	This	would	similarly	explain	 the	 progressive	 loss	 of	 efficacy	 of	 celecoxib	 or	 diclofenac,	 but	 not	 opiates,	 during	 more	advanced	time	points	in	the	higher	doses	of	the	MIA	model(Fernihough,	Gentry	et	al.	2004,	Pomonis,	Boulet	et	al.	2005).		
The	presence	of	potential	neuropathy	in	the	higher	dose	models	is	not	necessarily	a	limitation	of	the	MIA	model,	since	patients	with	neuropathic	pain	relating	to	their	OA	are	becoming	increasingly	well	characterised.	 OA	 patients	 use	 similar	 descriptors	 for	 their	 pain	 to	 neuropathy	 patients	 (Hawker,	Stewart	et	al.	2008,	Shigemura,	Ohtori	et	al.	2011),	such	as	burning,	electric	shock	or	numbness,	and	on	 questionnaires	 like	 PainDETECT	 and	 Douleur	 Neuropathique	 in	 4	 questions	 (DN4)	 patient	 sub	groups	 are	 identified	 as	 having	 neuropathic-like	 pain(Gwilym,	 Keltner	 et	 al.	 2009,	 Oteo‐Álvaro,	Ruiz‐Ibán	et	al.	2014).	The	use	of	QST	to	document	symptoms	such	as	loss	of	sensations,	notably	to	proprioception	 and	 vibration	 sensitivity	 at	 cutaneous	 sites,	 has	 provided	 further	 evidence	 of	 a	neuropathic	 like	 component(Hurley,	 Scott	 et	 al.	 1997,	 Sharma	 1999,	 Shakoor,	 Agrawal	 et	 al.	 2008,	Felson,	Gross	et	al.	2009,	Hochman,	Davis	et	al.	2013).	In	light	of	this,	the	PainDETECT	survey	has	been	modified	 (mPD-Q)	 to	 try	 to	 more	 accurately	 identify	 this	 cohort	 with	 a	 view	 to	 providing	 better	analgesia(Hochman,	Gagliese	 et	 al.	 2011).	 The	 combined	uses	 of	mPD-Q	 and	QST	point	 to	 a	 patient	population	of	~20%	with	neuropathic	contributions	to	their	pain(Hochman,	Davis	et	al.	2013),	though	more	 recent	work	has	 suggested	 this	 could	be	 as	high	as	52%	(or	33%	once	potential	 confounders	were	excluded)(Oteo‐Álvaro,	Ruiz‐Ibán	et	al.	2014).		
	
		 118	
As	such,	the	OA	patient	population	is	clearly	composed	of	sub	groups	whose	pain	can	be	differentially	attributed	 to	 mixtures	 of	 nociception,	 inflammation	 and	 sometimes	 neuropathy.	 Identifying	 where	patients	 fit	 may	 enable	 clinicians	 to	 identify	more	 suitable	 and	 effective	 analgesics	 e.g.	 pregabalin,	Tricyclics,	duloxetine	etc.	 (Hochman,	Davis	et	al.	2013),	but	similarly	knowing	where	on	 this	sliding	scale	 of	 OA	 pain	mechanisms	 each	 dose	 and	 time	 point	 of	 the	MIA	model	 represents	may	 produce	more	clinically	 informative	conclusion.	As	such	there	appears	value	in	investigating	the	mechanisms	contributing	to	pain	in	OA	in	both	the	1mg	and	the	2mg	model.	
	
3.1.1.3 Previous	 literature	 has	 characterized	 changes	 in	 descending	 controls	 in	 a	 2mg	
MIA	model	of	OA	pain	
As	 is	 discussed	 in	 much	 greater	 detail	 in	 the	 introduction	 and	 discussion	 sections	 of	 Chapter	 4,	previous	work	 in	 this	 laboratory	and	others	has	 sought	 to	 characterize	 the	potential	 adaptations	of	descending	serotonergic	and	noradrenergic	controls	in	the	2mg	MIA	model	of	pain	(see	Section	4.1.1	and	 4.1.2).	 	 Specifically,	 this	 work	 identified	 time-dependent	 changes	 in	 the	 noradrenergic	 and	serotonergic	 descending	 controls	 mediating	 spinal	 excitability,	 and	 thus	 pain	 perception,	 in	 a	 2mg	model	 of	 OA	 pain	 compared	 to	 sham	 and	 naïve	 controls(Rahman,	 Bauer	 et	 al.	 2009,	 Burnham	 and	Dickenson	 2013).	 As	 we	 have	 discussed	 above,	 this	 dose	 of	 MIA	 has	 been	 suggested	 to	 be	 driving	neuropathy(Ivanavicius,	 Ball	 et	 al.	 2007,	 Thakur,	 Rahman	 et	 al.	 2012).	 This	 then	 raises	 questions	about	 the	potential	 differences	 in	modulation	between	a	neuropathic	 and	non-neuropathic	MIA	 rat,	given	the	extent	of	adaptation	of	descending	controls	has	been	shown	to	be	variable	between	different	pain	conditions(Green,	Scarth	et	al.	2000,	Rahman,	Suzuki	et	al.	2004).	It	is	hypothesized	that,	at	this	lower,	non-neuropathic	dose	of	MIA,	modifications	in	the	descending	control	on	spinal	excitability	by	NA	 and	 5HT,	 as	 revealed	 by	 the	 spinal	 application	 of	 various	 antagonists,	may	 also	 differ.	 In	 other	words,	the	conclusions	drawn	previously	regarding	the	descending	control	of	the	2mg	model	of	pain	may	only	be	applicable	and	translatable	to	a	neuropathic	sub	population	of	OA	patients	–	but	this	will	only	become	more	apparent	once	any	changes	have	been	characterized	in	a	non-neuropathic	MIA	OA	pain	rat.	
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3.1.2	 	 Chapter	Aims	
In	order	 to	understand	better	 the	differences	 in	pain	mechanisms	 that	may	operate	between	a	1mg	and	2mg	MIA	model	of	OA,	this	thesis	has	used	a	1mg	dose	of	MIA	in	all	rat	work.	I	took	the	view	that	a	1mg	model	could	be	considered	a	model	of	milder	OA,	representing	non-neuropathic	earlier	stage	OA	patients,	and	sought	 to	confirm	similarities	or	highlight	differences	 in	descending	modulation	of	OA	pain	which	had	previously	be	defined	by	this	lab	in	the	2mg	model	(See	Chapter	4).		
However,	 the	 pain	 profile	 of	 the	 1mg	 MIA	 model	 is	 not	 as	 well	 established,	 though	 mechanical	sensitivities	at	the	hind	paw	withdrawal	have	been	documented(Sagar,	Staniaszek	et	al.	2010,	Thakur,	Rahman	 et	 al.	 2012,	 Sagar,	 Nwosu	 et	 al.	 2015).	 When	 additionally	 taking	 into	 account	 the	inconsistencies	 in	 the	 electrophysiological	 profiles	 in	 published	 literature	 (See	 Section	 1.4)	 it	appeared	valuable	to	clearly	characterize	the	baseline	behavioural	and	electrophysiological	profile	of	these	1mg	MIA	rats.	
The	 aim	 of	 this	 chapter	 is	 to	 present	 the	 collective	 baselines	 of	 experimental	 work	 discussed	 in	Chapter	 4,	 with	 a	 view	 to	 evaluating	 the	 overall	 behavioural	 and	 electrophysiological	 changes	observed	 at	 two	 stages	 of	 a	 lower	 dose,	 1mg	 MIA	 model:	 The	 early	 phase	 –	 where	 pain	 is	characteristically	 driven	 more	 by	 inflammation	 and	 peripheral	 effects	 of	 MIA	 injections;	 The	 late	phase	–	where	pain	is	characteristically	driven	more	by	chronic	nociception	and	central	sensitization,	but	 crucially	not	neuropathy	 in	 this	 dose,	 at	 this	 time.	This	would	 then	provide	more	 space	 for	 the	evaluation	of	pharmacological	outcomes	in	Chapter	4.		 	
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3.2	 		 Methods	
3.2.1			 Animals	
All	 work	 was	 conducted	 in	 Male	 Sprague	 Dawley	 rats,	 bred	 and	 housed	 in	 the	 Central	 Biological	Services	 Unit	 at	 University	 College	 London.	 As	 described	 in	 Chapter	 2,	 behaviour	 and	electrophysiology	was	conducted	either	at	the	early	stages	of	OA	pain	development,	at	days	3-5	after	injection,	or	 late	stages,	at	days	10-14	after	 injection	 in	animals	 in	 the	range	of	220-250g,	such	 that	they	were	injected	at	either:	
o Early:	MIA	(OA)	or	Saline	(sham)	injection	into	animals	weighing	160-180g.		
o Late:	MIA	(OA)	or	Saline	(sham)	injection	in	animals	weighing	120-140g.	
As	 such,	 four	populations	of	 experimental	 animals	were:	Early	MIA,	Early	 Sham,	Late	MIA	and	Late	Sham.	
	
3.2.2	 		 Induction	of	the	model	
As	detailed	in	Section	2.2,	rats	were	injected	with	1mg	MIA	(Sigma,	UK)	to	the	left	knee.	
	
3.2.3	 		 Behavioural	Assessment		
Rats	were	 assessed	 at	 either	 Day	 3	 (Early)	 or	 Day	 10	 (Late)	 following	 injection	 to	 assess	 punctate	mechanical	hypersensitivity,	 cooling	hypersensitivity	 and	 incapacitance.	The	protocol	 sequence	was	as	follows:	
Acetone	à	vF	1g	à	Acetone	à	vF	6g	à	Acetone	à	vF	8g	à	Acetone	à	Acetone	à	Incapacitance	
All	 tests	 were	 performed	 at	 one-minute	 intervals	 such	 that	 contralateral	 and	 ipsilateral	 paws	 in	tandem,	where	the	contralateral	paws	were	always	tested	first,	with	a	one-minute	interval	before	the	ipsilateral	 test.	 In	 other	words:	Acetone	 (CL)	à	Acetone	 (IL)	à	 vF	1g	 (CL)	 and	 so	 on.	 Details	 of	 the	exact	protocol	and	withdrawal	criteria	are	given	in	Section	2.3.3	and	2.3.4.	
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3.2.4	 		 Electrophysiological	Assessment	
Spinal	electrophysiology	was	carried	out	in	rats	weighing	220-250g	at	either	days	3-5	(Early)	or	days	10-14	 (late)	 after	 injection	of	 either	MIA	or	Saline,	 as	described	 in	detail	 in	Section	2.4.	The	 results	presented	in	this	chapter	are	the	collated	baseline	recordings	of	all	WDR	spinal	electrophysiology	in	MIA	 or	 sham	 rats,	 both	 early	 and	 late,	 used	 in	 this	 thesis,	where	 the	 baseline	 is	 the	mean	 of	 three	rounds	of	20minute	recordings	of	electrical,	mechanical	and	thermally	evoked	stimuli.	
	
3.2.5	 		 Data	Analysis	
All	data	is	presented	as	the	mean	±	SEM.		
Behaviour	
• Punctate	mechanical	and	cooling	hypersensitivity:	Data	expressed	as	the	mean	difference	in	the	 number	 of	 withdrawals	 out	 of	 ten.	 Difference	 between	 groups	 analysed	 using	 a	 non-parametric	Mann-Whitney	U	test.	
• Incapacitance:	Data	expressed	as	the	percentage	of	total	weight	borne	on	the	ipsilateral	side.	Analysed	using	an	un-paired	student’s	T	test.	
Electrophysiology	
• Naturally	 evoked	 (mechanical	 and	 thermal)	 responses:	 Data	 expressed	 as	 number	 of	 action	potentials.	 Difference	 between	 groups	 analysed	 using	 a	 two-way	 ANOVA	 followed	 by	Bonferroni	post-hoc	tests.	
• Electrically	 evoked	 and	 dynamic	 brush	 responses:	 Data	 expressed	 as	 number	 of	 action	potentials.	Difference	between	groups	analysed	using	unpaired	student’s	T	test.	
	
Values	were	deemed	significant	at	p<0.05.	
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3.3	 		 Result	
3.3.1			 Behavioural	hypersensitivity	in	the	MIA	model	of	OA	
Punctate	mechanical	 and	 cooling	hypersensitivity	 and	 incapacitance	was	 assessed	 in	Rats	 following	the	intra-articular	injection	of	MIA	and	compared	to	sham	controls,	which	received	saline.	These	tests	revealed	 the	 development	 of	 a	 significant	 ipsilateral	 punctate	 mechanical	 hypersensitivity	 and	reduction	in	percentage	weight	borne	in	MIA	animals	versus	shams	in	both	early	and	late	groups.		
While	 no	 difference	was	 observed	 to	 vF1g,	 vF6g	 or	 acetone	 between	MIA	 and	 Sham	 in	 either	 time	group,	at	vF8g	MIA	animals	from	both	early	and	late	groups	showed	a	significantly	greater	propensity	to	withdraw	 the	 IL	 paw	 than	 sham	 equivalents	 (Figure	 3.3	 A	 and	B;	 n=13-15;	Mann	Whitney-U;	 **	p≤0.01;	*	p≤0.05).			
Similarly,	MIA	animals	exhibited	a	 reduction	 in	 the	percentage	 total	weight	borne	on	 the	 ipsilateral	paw	compared	to	time	matched	shams,	such	that	in	the	early	animals:	43.2±1.9%	vs.	51.8±1.7%	MIA	vs.	 Sham;	 and	 in	 late	 animals:	 	 42.7±2.7%	 vs.	 53.1±1.5%	 MIA	 vs.	 Sham	 (Figure	 3.3	 E;	 Unpaired	Students	T-test;	**	p≤0.01).		
No	differences	 in	withdrawals	to	punctate	stimuli,	acetone	or	 incapacitance	were	observed	between	either	Early	vs.	Late	MIA	animals	or	Early	vs.	Late	Sham	animals	(Figure	3.3	C,	D	and	E;	n=13-15).		
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Figure	3.3	–	Monosodium	Iodoacetate	 induced	OA	produced	 significant	punctate	mechanical	hypersensitivity	and	a	
reduction	in	ipsilateral	weight	bearing	versus	shams	in	both	early	and	late	stages:	A)	At	day	3	following	injection,	MIA	animals	show	significant	hypersensitivity	to	vF8g	compared	to	sham	animals	(Sham	n=13,	MIA	n=14).	This	effect	is	replicated	at	day	10	following	injection	(B)	(Sham	n=15,	MIA	n=14).	C)	Arthritic	animals	receiving	1mg	MIA	injection	show	no	difference	at	days	3	or	 to	 animals	at	day	10	 in	withdrawal	 from	punctate	stimuli.	 (Early	MIA	n=14,	Late	MIA	n=14).	D)	Sham	animals	receiving	 saline	 injection	 show	 no	 difference	 across	 all	 behavioural	 measures	 at	 days	 3	 or	 10.	 E)	 At	 both	 day	 3	 and	 10	following	MIA	 injection	a	 reduction	 in	 ipsilateral	weight	bearing	versus	sham	is	observed,	with	no	different	between	either	early	MIA	early	and	late,	or	Sham	early	and	late	animals.	
A	 B	
C	 D	
E	
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3.3.2	 		 Spinal	Neuronal	Hypersensitivity	in	the	MIA	model	of	OA	
Evoked	responses	of	WDR	cells	following	electrical,	mechanical	and	thermal	stimuli	of	the	IL	hind	paw	were	 assessed	 in	 MIA	 and	 Sham	 animals	 at	 either	 the	 early	 or	 later	 stages.	 	 These	 tests	 revealed	enhanced	 responses	 of	 Early	 MIA	 animals	 to	 mechanical,	 both	 dynamic	 brush	 and	 punctate,	 and	thermal	stimulation	in	comparison	to	Early	Sham	animals.	
Electrically	Evoked	Responses	
Across	all	groups	of	animals,	no	significant	effect	was	observed	on	the	electrically	evoked	responses	of	Lamina	V	WDR	cells	(Figure	3.4A).	There	is	a	trend	towards	a	greater	C	fiber	count	and	input	in	Early	MIA	animals	compared	to	Early	Sham	animals,	but	 this	 trend	 is	not	mirrored	 in	Late	MIA	and	Sham	animals,	as	there	is	similarly	a	trend	towards	greater	C	fiber	count	and	input	in	Late	Sham	compared	to	Early	Sham.		
Dynamic	Brush	Evoked	Responses	
Early	 MIA	 animals	 exhibited	 a	 significant	 increased	 in	 the	 number	 of	 action	 potentials	 evoked	 in	response	to	a	dynamic	brush	stimulus	to	the	receptive	field	in	comparison	to	Early	Sham	(Figure	3.4B.	Un-paired	Student’s	T	 test;	 *	p≤0.05).	While	no	difference	 is	observed	between	Late	MIA	and	Sham	groups,	the	difference	between	Early	MIA	and	Late	MIA	nears	significance	at	p=0.058.	 	
Figure	3.4-	Comparison	of	electrically	and	dynamic	brush	evoked	responses	of	Lamina	V	WDR	cells	in	MIA	and	
Sham	animals	at	either	Early	or	Late	stages	after	injection.	A)	No	difference	in	the	electrically	evoked	responses	of	WDR	cells	is	observed	in	either	the	Early	or	Late	MIA	animals	versus	shams.	B)	Dynamic	brush	evoked	responses	are	significantly	enhanced	in	Early	MIA	animals	versus	Early	Sham	(*p≤0.05)	(n=13-15).	
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	Punctate	Stimulation	Evoked	Responses	
The	evoked	 responses	of	 Lamina	V	WDR	cells	 following	 the	application	of	 vF	hairs	 to	 the	 receptive	field	in	the	IL	paw	produced	a	stimulus-response	curve,	whereby	the	increasing	force	evoked	a	greater	number	 of	 action	 potentials.	 Two-way	 ANOVA	 found	 that	 this	 stimulus	 response	 relationship	 was	significantly	 enhanced	 in	 Early	 MIA	 animals	 compared	 to	 their	 Sham	 counterparts	 (Figure	 3.5A:	p=0.015),	 where	 Bonferroni	 post	 hoc	 tests	 indicated	 that	 these	 evoked	 action	 potentials	 were	significantly	 greater	 in	 response	 to	 noxious	 punctate	 stimulation.	 The	 number	 of	 action	 potentials	evoked	by	vF26g	and	vF60g	was	significantly	greater	 in	 these	Early	MIA	animals	compared	to	early	Sham	(Figure	3.5A:	**	p≤0.01;	*	p≤0.05;).	This	trend	was	observed	to	lower	force	punctate	stimulation,	where	both	vF8g	and	vF15g	near	significance	(p=0.077;	p=0.052	respectively).	
No	 difference	was	 observed	 in	 the	 number	 of	 action	 potentials	 evoked	 in	 Late	MIA	 and	 Late	 Sham	animals	 (Figure	 3.5B).	 Similarly	 no	 difference	 was	 observed	 between	 Early	 and	 Late	 MIA	 animals,	
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Figure	3.5	 -	Comparison	of	mechanically	evoked	responses	of	Lamina	V	WDR	cells	 in	MIA	and	Sham	animals	at	
either	Early	or	Late	stages	after	injection.	A)	Early	MIA	animals	exhibited	significantly	enhanced	evoked	responses	to	punctate	mechanical	stimuli	versus	Early	Sham	animals	(**	p≤0.01;	*	p≤0.05)	(Sham	n=13,	MIA	n=14).	B)	No	difference	was	 observed	 between	 Late	 MIA	 and	 Late	 Sham	 animals	 in	 response	 to	 punctate	 mechanical	 evoked	 responses.	 C)	Comparison	of	mechanically	evoked	responses	across	all	animal	groups	–	no	significant	difference	was	observed	between	Early	vs.	Late	MIA,	Late	MIA	vs.	Late	Sham	or	Early	vs.	Late	Sham.	
A	 B	
C	
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however	 a	 trend	 to	 enhanced	 evoked	 responses	 in	Late	 Sham	animals	 versus	Early	 Sham	was	 seen	though	 this	 wasn’t	 significant	 (2way	 ANOVA;	 p=0.088).	When	 comparing	 all	 baseline	mechanically	evoked	 responses	 across	 all	 four	 groups	 of	 animals,	 it	 seems	 apparent	 that	 there	 is	 a	 trend	 to	enhanced	 evoked	 responses	 in	 MIA	 animals	 but	 that	 this	 is	 not	 distinguishable	 between	 the	 late	groups	as	Late	Shams	exhibit	a	similar	enhancement	in	evoked	responses,	where	the	Early	stage	MIA	animals	exhibit	 the	greatest	enhancement	of	WDR	evoked	responses.	As	 such,	while	 the	MIA	model	appears	 to	 provoke	 a	 greater	 than	 normal	 response	 relationship	 to	 punctate	 stimuli	 at	 both	 time	points,	the	sham	model	additionally	seems	to	develop	an	mild	increased	response	to	punctate	stimuli	in	the	later	days	after	injection	of	saline	that	does	not	exceed	that	produced	by	MIA.	
	
Thermally	Evoked	Responses	
The	evoked	responses	of	Lamina	V	WDR	cells	 following	 the	application	of	 thermal	water	 jets	 to	 the	receptive	 field	 in	 the	 IL	 paw	 produced	 a	 stimulus-response	 curve,	 whereby	 the	 increasing	temperature	evoked	a	greater	number	of	action	potentials.	Two-way	ANOVA	found	that	this	stimulus	response	 relationship	 was	 significantly	 enhanced	 in	 Early	 MIA	 animals	 compared	 to	 their	 Sham	counterparts	 (Figure	 3.6A:	 p=0.018),	 where	 Bonferroni	 post	 hoc	 tests	 indicated	 that	 these	 evoked	action	potentials	were	significantly	greater	in	response	to	water	jets	at	the	temperature	35°C	and	48°C	(Figure	 3.6A:	 *	 p≤0.05;),	 innocuous	 and	 strongly	 noxious	 respectively.	 This	 trend	 was	 strongly	observed	across	all	temperatures	in	the	Early	MIA	animals.		
No	difference	was	observed	 in	 the	responses	of	Late	MIA	and	Late	Sham	animals	 (Figure	3.6B),	nor	between	Early	MIA	and	Late	MIA	(2way	ANOVA;	Figure	3.6c).	Notably	however,	a	significantly	greater	number	of	action	potentials	were	evoked	by	thermal	stimuli	in	the	Late	Sham	compared	to	Early	Sham	(2way	 ANOVA	 p=0.018),	 where	 Bonferroni	 post	 hoc	 tests	 indicated	 that	 these	 evoked	 action	potentials	were	significantly	greater	in	response	to	water	jets	at	the	temperature	35°C	and	this	trend	carried	 across	 the	 temperatures	 (Figure	 3.6C;	 #	 p≤0.05).	 As	 observed	 for	 the	mechanically	 evoked	responses,	there	is	an	observable	trend	by	which	all	MIA	animals	and	Late	Sham	responses	are	greater	than	 those	observed	 in	 the	Early	 Sham	 in	 response	 to	 thermal	 stimulation.	 	As	 such,	while	 the	MIA	model	appears	to	provoke	a	greater	than	normal	response	relationship	to	thermal	stimuli	at	both	time	points,	 the	sham	model	additionally	developed	an	increased	response	to	thermal	stimuli	 in	the	 later	days	after	injection	of	saline.	
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Figure	3.6	-	Comparison	of	thermally	evoked	responses	of	Lamina	V	WDR	cells	in	MIA	and	Sham	animals	at	either	
Early	or	Late	stages	after	injection.	A)	Early	MIA	animals	exhibited	significantly	enhanced	evoked	responses	to	thermal	stimuli	versus	Early	Sham	animals	(*	p≤0.05)	(Sham	n=13,	MIA	n=14).	B)	No	difference	was	observed	between	Late	MIA	and	Late	Sham	animals	in	response	to	thermal	water	jet	(Sham	n=15;	MIA	n-14).	C)	Comparison	of	mechanically	evoked	responses	across	all	animal	groups	–	no	significant	difference	was	observed	between	Early	vs.	Late	MIA,	Late	MIA	vs.	Late	Sham	or	Early	vs.	Late	Sham.	(n=13-15)		
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3.4	 		 Discussion	
The	MIA	model	of	OA	is	one	of	the	most	common	rat	models	of	OA(Little	and	Zaki	2012),	as	a	result	of	the	 ease	 of	 induction,	 reliable	 histopathology	 and	 pain	 like	 hypersensitivities	 observed	 across	 both	behaviour	and	electrophysiology.	However,	the	doses	most	commonly	utilized	are	≥2mg	(See	Thakur	et	al	2012,	Table	S2	for	a	summary),	doses	that	have	recently	been	identified	as	provoking	neuropathy	and	a	pain	state	that	may	only	represent	a	specific	subset	of	patients.	The	aim	of	this	chapter	was	to	confirm	a	behavioural	and	electrophysiological	profile	 indicative	of	 the	 induction	of	an	OA	 like	pain	state	in	these	animals	at	a	dose	of	MIA	that	dose	not	cause	neuropathy.	
Here	 we	 demonstrate	 that	 in	 the	 1mg	 MIA	 model	 animals	 develop	 both	 a	 punctate	 mechanical	hypersensitivity	 at	 the	 paw	 and	 a	 shift	 in	weight	 distribution	 from	 the	 ipsilateral	 limb,	 at	 both	 the	early	and	late	stages	of	the	model	versus	sham	animals.	Similarly,	electrophysiology	in	these	animals	identified	increased	activity	in	response	to	both	dynamic	brush,	punctate	and	thermal	stimulation	of	the	hind	paw	in	the	Lamina	V	WDR	cells	of	Early	MIA	animals	compared	to	Early	Shams.	While	similar	differences	were	not	 identified	between	Late	MIA	and	Late	Sham,	 it	seems	possible	that	this	may	be	due	 to	 the	 increased	baseline	 responses	observed	 in	Late	 Shams	 compared	 to	Early	 Shams,	 to	both	punctate	and	thermal	stimuli.	
	
3.4.1	 		 Behavioural	Hypersensitivity	
Shifts	in	weight	bearing	are	indicative	of	established	joint	discomfort	
The	assessment	of	weight	bearing	as	a	measure	of	joint	discomfort	in	the	study	of	OA	is	common.	It	is	well	established	at	both	2mg	and	1mg	MIA	doses	that	a	shift	occurs	onto	the	contralateral	paw	which	peaks	 in	 the	 early	 days	 of	 the	model,	 and	 becomes	 consistent	 around	 10	 days	 after	 injection(Bove	2003,	Pomonis,	Boulet	et	al.	2005,	Kelly,	Dunham	et	al.	2012,	Thakur,	Rahman	et	al.	2012),	where	no	difference	was	 observed	 between	 these	 two	 doses(Thakur,	 Rahman	 et	 al.	 2012).	 The	 present	work	confirms	 this,	 demonstrating	 that	 at	 both	 time	 points	 the	 1mg	 MIA	 model	 produced	 a	 shift	 in	percentage	weight	 borne	 not	 observed	 in	 shams	 at	 the	 equivalent	 time	 point,	 where	 there	was	 no	difference	observed	between	day	3	and	day	10	in	MIA	animals.		
Theories	differ	as	to	the	exact	relation	of	weight	bearing	deficits	to	clinical	pain	 in	OA.	Many	equate	this	measure	 to	a	primary	hypersensitivity	or	mechanical	allodynia	of	 the	 joint,	where	 the	normally	innocuous	use	of	the	knee,	namely	placing	pressure	on	it,	becomes	painful,	resulting	in	weight	being	shifted	 to	 the	 unaffected	 side.	 This	 discomfort	 could	 result	 from	 either	 peripheral	 or	 central	
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sensitization	mechanisms,	 though	 the	 rectification	 of	 this	 shift	 in	weight	 bearing	 by	NSAID	 therapy	suggests	a	significant	contribution	of	peripheral,	inflammatory	factors(Bove	2003,	Pomonis,	Boulet	et	al.	 2005).	 Others,	 such	 as	 Kelly	 et	 al	 2012,	 suggest	 that	 these	 weight	 bearing	 deficits	 correlate	 to	increased	spontaneous	C	 fiber	activity	 in	 these	animals,	both	 indicative	of	a	peripheral	sensitization	but	 also	 an	 increased	 likelihood	 of	 central	 sensitization(Kelly,	 Dunham	 et	 al.	 2012).	 As	 such,	 this	suggests	 the	 measure	 equates	 more	 to	 pain	 at	 rest	 or	 ongoing	 pain(Mogil	 and	 Crager	 2004),	 also	observed	in	patient	pools(Hunter,	McDougall	et	al.	2008).	
	
Secondary	Mechanical	Hypersensitivity,	But	No	Cooling	Hypersensitivity	
Though	changes	in	weight	bearing	are	informative	measures	of	joint	discomfort,	they	do	not	provide	discriminatory	 evidence	 as	 to	 the	 mechanism	 underlying	 the	 pain	 observed	 –	 which	 is	 likely	 a	combination	 of	 both	 peripheral	 and	 central	 sensitization.	 Reports	 of	mechanical	 hypersensitivity	 in	the	 paw	 however	 provide	 confirmation	 of	 a	 secondary	 hyperalgesia,	 or	 referred	 pain,	 which	 are	suggested	to	characterize	the	presence	of	central	sensitization,	something	commonly	observed	in	the	clinic	 (See	 Section	 1.4.4)	 .	 	 While	 well	 described	 in	 the	 2mg	 model	 of	 MIA,	 fewer	 studies	 have	described	this	in	the	1mg	model(Sagar,	Staniaszek	et	al.	2010,	Thakur,	Rahman	et	al.	2012).	Here	we	demonstrate	that	at	both	days	3	and	10	following	the	injection	of	1mg	MIA	animals	exhibit	increased	sensitivity	to	vF8g	punctate	stimulation	to	the	ipsilateral	hind	paw	compared	to	time	matched	sham	controls.	However,	no	differences	were	observed	at	vF1g,	vF6g	or	to	Acetone.	
While	 these	 behavioural	 changes	 are	 broadly	 in	 line	 with	 expectations,	 based	 on	 previous	 studies	demonstrating	 secondary	 mechanical	 hypersensitivity	 in	 MIA	 animals	 (Bove	 2003,	 Fernihough,	Gentry	et	al.	2004),	this	observed	hypersensitivity	did	not	extend	to	vF6g	or	vF1g	as	observed	in	both	1mg	 and	 2mg	 MIA	 models	 previously(Rahman,	 Bauer	 et	 al.	 2009,	 Vonsy,	 Ghandehari	 et	 al.	 2009,	Burnham	2012,	Thakur,	Rahman	et	al.	2012).	The	overall	mean	difference	in	number	of	withdrawals	are	also	slightly	low	compared	to	past	literature	for	1mg	MIA(Thakur,	Rahman	et	al.	2012),	where	it	is	hard	 to	 draw	 comparisons	with	data	which	use	PWTs	 (e.g.	 Fernihough	 et	 al	 2004).	 Similarly,	 these	animals	 did	 not	 exhibit	 cooling	 hypersensitivity,	 denoted	 by	withdrawals	 from	 acetone	 application,	which	are	reported	in	past	literature(Rahman,	Bauer	et	al.	2009,	Burnham	2012,	Thakur,	Rahman	et	al.	2012).	Once	again,	as	with	punctate	hypersensitivity,	Thakur	et	al	demonstrated	a	strong	cooling	hypersensitivity	in	a	1mg	model,	so	these	differences	cannot	simply	be	dismissed	as	an	effect	of	dose.		
These	contradictions	in	behavioural	findings	are	difficult	to	explain,	especially	when	differences	arise	within	the	1mg	model.	In	part,	the	dose	and	time	point	investigated	can	explain	differences,	since	the	smaller	dose	vs.	2mg	studies	and	day	10	assessments	may	mean	 that	 joint	pathology	at	day	10	and	
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extent	 of	 inflammation	 at	 day	 3	 are	 less	 severe,	 producing	 a	 milder	 pain	 profile	 in	 these	animals(Guingamp,	 Gegout-Pottie	 et	 al.	 1997,	 Sagar,	 Staniaszek	 et	 al.	 2010,	 Thakur,	 Rahman	 et	 al.	2012).	However,	 this	 does	not	 explain	differences	 between	 the	 results	 here	 and	Thakur	 et	 al	 2012,	which	 used	 the	 same	 dose	 and	 similar	 time	 points.	 Consider	 specifically	 cooling	 hypersensitivity.	While	many	 studies	 demonstrate	 increased	withdrawals	 from	 acetone	 this	 is	 not	 universal	 –	 since	Vonsy	 et	 al	 2009	 failed	 to	 define	 a	 cooling	 hypersensitivity	 at	 day	 3,	 day	 11	 or	 day	 14(Vonsy,	Ghandehari	 et	 al.	 2009).	 It	 is	 possible	 that	 these	 discrepancies	 are	 explained	 by	 individual	experimenter	differences,	ranging	from	exact	criteria	for	a	response;	method	and	location	of	acetone	or	vF	application;	acclimatization	time;	MIA	injection	technique	and	the	subsequent	extent	of	leakage	from	 the	 joint	 or	 other	 factors.	 All	 of	 these	 may	 differentially	 impact	 upon	 behavioural	 outcomes.	Additionally,	it	is	possible	that	repeated	pain	testing	over	numerous	days	could	act	as	a	conditioning	stressor	that	enhanced	pain	like	behaviour,	given	Thakur	et	al	tested	multiple	days	-	where	as	each	rat	only	experienced	one	round	of	behaviour	in	this	protocol.	As	such,	experimental	design	and	execution	could	explain	these	differences.	
At	a	more	basic	level,	the	gender	of	the	experimenter	has	previously	been	shown	to	adversely	affect	the	accuracy	of	behavioural	protocols	and	exhibition	of	pain	behaviour	in	mice,	where	the	scent	of	a	male	caused	stress	related	reductions	in	pain	behaviour(Sorge,	Martin	et	al.	2014).	Though,	in	direct	contradiction,	stress	has	also	been	linked	to	hyperalgesia	in	rodents(Imbe,	Iwai-Liao	et	al.	2005),	so	it	is	 possible	male	 experimenters	 could	 themselves	 induced	 increased	 behavioural	 responses	 if	 their	presence	 was	 an	 environmental	 stressor.	 As	 such,	 differences	 in	 behaviour	 may	 occur	 due	 to	individual	experimenter	factors	as	simple	as	gender	and	olfactory	signals.		
It	is	also	worth	considering	the	limitations	of	the	use	of	mean	differences	to	measure	of	the	number	of	withdrawals	to	assess	changes	in	mechanical	sensitivity	in	the	paw.	As	discussed	previously,	it	is	not	unknown	 for	 OA	 to	 induces	 changes	 in	 contralateral	 somatosensation(Creamer,	 Hunt	 et	 al.	 1996),	likely	driven	by	 central	 sensitization	derived	 changes	 in	descending	 controls.	As	 such,	 this	measure	may	 overlook	 contralateral	 changes	 that	 in	 themselves	 are	 informative	 to	 elucidating	 mechanistic	contribution	to	OA	pain,	but	may	similarly	mask	the	extent	of	change	 in	 the	 ipsilateral	paw.	 It	 is	 for	this	 reason	 that	 in	 later	 projects,	 a	 paw	 withdrawal	 threshold	 was	 instead	 calculated	 using	methodology	described	by	Chaplan	et	al	1994	
Though	the	above	highlight	disparities	 in	 the	extent	of	 the	behavioural	profile	of	1mg	MIA	model	of	OA,	 there	 is	a	consistent	suggestion	of	secondary	mechanical	hypersensitivity	 in	 the	 ipsilateral	paw,	consistent	with	the	characterization	of	both	this	model	and	the	clinical	OA	profile.	
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The	importance	of	time	point?	
Past	work	 has	 characterized	 the	 pain	 behaviour	 in	 the	MIA	model	 as	 biphasic	 based	 on	 studies	 of	weight	bearing(Bove	2003,	Fernihough,	Gentry	et	al.	2004,	Pomonis,	Boulet	et	al.	2005,	Kelly,	Dunham	et	 al.	 2012),	 nocturnal	 activity(Guingamp,	 Gegout-Pottie	 et	 al.	 1997)	 or	 secondary	 mechanical	hypersensitivity	of	the	paw(Vonsy,	Ghandehari	et	al.	2009,	Ferland,	Laverty	et	al.	2011,	Burnham	and	Dickenson	 2013).	 As	 such,	 this	 describes	 behavioural	 hypersensitivities	 at	 both	 the	 joint	 and	secondary	sites	as	having	a	bi	phasic	profile,	broadly	as	showing	an	early	climax	in	the	first	2-3days	following	 iodoacetate	 injection,	 followed	by	 a	 brief	 period	of	 respite	 to	 day	7,	 and	 then	 a	 gradually	climbing	profile	by	Day	10-14	onwards.		
This	profile	 is	attributed	to	the	time	course	of	 joint	pathology	exhibited	in	the	MIA	model	of	OA.	 	As	discussed	 above,	 the	 initials	 days	 following	 injection	 are	 coupled	 to	 reductions	 in	proteoglycan(Guingamp,	 Gegout-Pottie	 et	 al.	 1997,	 Janusz,	 Hookfin	 et	 al.	 2001),	 chondrocyte	 death	and	 cartilage	 thinning	 (Dunham,	 Hoedt-Schmidt	 et	 al.	 1992,	 Janusz,	 Hookfin	 et	 al.	 2001,	 Guzman,	Evans	et	al.	2003),	plus	significant	 inflammation	–	involving	thickening	of	the	synovium	and	fat	pad,	swelling,	 monocyte	 and	 neutrophil	 infiltration(Bove	 2003,	 Guzman,	 Evans	 et	 al.	 2003,	 Fernihough,	Gentry	et	al.	2004,	Clements,	Ball	et	al.	2009),	TNFα	IL-6	and	NGF	are	up-regulation	in	the	joint	and	SP	is	increased	in	the	synovium(Ahmed,	Li	et	al.	2012).	In	line	with	the	timelines	observed	in	behaviour,	this	inflammation	is	largely	resolved	by	day	7,	peaking	during	days	1-3(Bove	2003,	Guzman,	Evans	et	al.	 2003,	 Fernihough,	 Gentry	 et	 al.	 2004,	 Clements,	 Ball	 et	 al.	 2009).	 As	 such,	 this	 first	 wave	 of	hypersensitivity	 is	 attributed	 to	 peripheral	 mechanisms,	 where	 the	 inflammatory	 milieu	 not	 only	directly	 activate	 afferents	 serving	 the	 joint	 but	 also	 serve	 to	 sensitize	 them,	 such	 that	 there	 is	 an	observable	increase	in	their	responses,	decrease	in	their	stimulus	threshold	and	fiber	recruitment	of	previously	 silent	 nociceptors	 (Schaible	 and	 Schmidt	 1985,	 Grigg,	 Schaible	 et	 al.	 1986,	 Schaible	 and	Schmidt	1988).	This	peripheral	sensitization	is	confirmed	both	by	the	fact	MIA	animals	exhibit	marked	hypersensitivity	to	ACh,	BK	and	5HT(Okamoto	and	Atsuta	2010),	but	also	by	the	efficacy	of	NSAIDs	to	quench	 the	pain	associated	with	 these	 initial	days	of	MIA	 induction(Fernihough,	Gentry	et	 al.	 2004,	Vonsy	2008).	This	peripheral	sensitization	similarly	drives	central	changes	 in	sensitivity,	 facilitating	synaptic	transmission	from	neighbouring,	uninjured	tissue	too.	
Beyond	day	7,	studies	report	the	increasing	prevalence	of	joint	pathology	namely	the	involvement	of	subchondral	bone(Guzman,	Evans	et	al.	2003),	cartilage	fibrillation	and	ossification,	osteophytes,	bone	sclerosis	and	bone	exposure	by	days	14-21(Dunham,	Hoedt-Schmidt	et	al.	1992,	Janusz,	Hookfin	et	al.	2001,	Morenko,	Bove	et	al.	2004).	As	such,	beyond	day	7	there	is	a	building	pathology	that	begins	to	activate	 the	 rich	 density	 of	 mechano-receptive	 nerve	 endings	 in	 the	 bone,	 to	 cause	 an	 increased	information	 load	 from	 the	 peripheral	 fibers	 to	 the	 spinal	 cord	 upon	 movement.	 This	 is	 clearly	
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demonstrated	 by	work	 directly	 recording	 from	 peripheral	 afferents	 14days	 after	MIA	 induction,	 at	doses	as	small	as	0.3mg,	where	joint	movements	evoke	significantly	enhanced	firing	profiles(Schuelert	and	McDougall	2009).	There	is	similarly	increasing	spontaneous	activity	in	mechanosensitive	C	fibers	at	these	later	stages	following	MIA(Kelly,	Dunham	et	al.	2012),	which	itself	may	also	help	drive	central	sensitization.	This	bombardment	takes	up	the	space	left	by	the	previous	inflammation	to	maintain	or	reinitiate	central	sensitization	in	these	animals–	though	it	is	likely	both	this	enhanced	nociception	and	the	effects	of	inflammation	overlap.	
As	 such,	 we	 expect	 pain	 behaviour	 at	 both	 these	 time	 points,	 but	 with	 pain	 driven	 by	 different	underlying	 mechanisms	 –	 the	 significance	 of	 which	 may	 become	 more	 apparent	 following	pharmacological	 manipulation	 of	 descending	 controls	 in	 Chapter	 4.	 In	 both	 instances,	 there	 is	 an	expectation	 that	 the	 peripheral	 barrage	 would	 generate	 a	 central	 sensitization	 sufficient	 to	 evoke	hypersensitivity	 in	the	paw,	as	well	as	the	ongoing	discomfort	of	 the	 joint,	as	previous	research	had	lead	us	 to	 expect(Vonsy,	Ghandehari	 et	 al.	 2009,	Burnham	2012,	Thakur,	Rahman	et	 al.	 2012).	This	was	 confirmed	 in	 this	 study,	 where	 no	 difference	 was	 observed	 in	 either	 the	 weight	 bearing	 or	punctate	mechanical	 hypersensitivity	 profiles	 of	 1mg	MIA	 animals	 between	days	 3	 and	10	 –	where	both	time	points	were	significantly	different	from	saline	sham	animal	responses.		
	
Secondary	Hypersensitivity	as	an	Indicator	of	Central	Sensitization	
The	presence	of	 increased	 cutaneous	 sensitivity	 to	 vF8g	 in	 the	 IL	paw	of	MIA	 animals	 at	 both	 time	points	is	taken	to	be	indicative	of	central	sensitization	in	this	model	of	OA.	Put	simply,	in	the	absence	of	damage	or	inflammation	at	the	paw	there	are	no	peripheral	changes	in	the	afferent	activity	that	can	explain	 increased	 sensitivity	 to	 this	 punctate	 stimulation.	 Instead,	 this	 behaviour	 is	 explained	 by	changes	 in	 the	 sensitivity	 of	 the	 neurons	 of	 the	 dorsal	 horn,	 to	 which	 primary	 afferents	 synapse,	notably	 a	 reduced	 threshold	 to	 activation	 and	 increased	 outputs	 once	 activated.	 Traditionally	 a	barrage	 of	 nociceptive	 information	 from	 the	 periphery	 triggers	 this	 state,	 but	 given	 the	 paw	 is	undamaged	the	population	of	dorsal	horn	neurons	which	are	primarily	served	are	not	subject	to	such	a	barrage.	There	are	two	possible	explanations	for	this	–	either	the	expansion	of	receptive	fields	that	characterizes	a	secondary	hyperalgesia,	or	the	referral	of	pain.	
In	the	case	of	receptive	field	expansion,	it	is	postulated	that	ascending	fibers	serving	the	joint	largely	receive	inputs	from	the	deep	tissues	but	also	receive	weak	inputs	from	adjacent	cutaneous	sites	and	muscles	 –	 inputs	 that	 do	 not	 usually	 generate	 responses	 from	 the	 ascending	 fiber.	 Following	sensitization,	the	threshold	of	activation	of	this	fiber	is	lowered	such	that	the	weak	inputs	from	these	neighbouring	regions	become	suprathreshold,	thus	expanding	the	receptive	field	of	the	cell	such	that	
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paw	 inputs	 are	 also	 transmitted	 and	 interpreted	 as	 noxious.	 This	 is	 much	 like	 the	 mechanism	 by	which	capsaicin	generates	mechanical	hyperalgesia	in	adjacent	sites(O'Neill,	Brock	et	al.	2012).	
Alternately,	this	behaviour	could	be	explained	by	the	referral	of	pain.	Competing	theories	suggest	this	may	 either	 result	 from	 convergence,	 where	 co-localization	 of	 fibers	 as	 they	 enter	 the	 spinal	 cords	allows	cross	talk	that	facilitates	peripheral	inputs	from	neighbouring	tissue;	or	a	central	sensitization	spreads	 to	 adjacent	 dorsal	 horn	 segments,	 through	 a	 combination	 of	 interneuronal	 signaling,	 the	release	 of	 inflammatory	 and	 algogenic	 mediators	 in	 the	 spinal	 cord,	 in	 addition	 to	 alterations	 in	descending	controls.		
Joint,	muscle	and	cutaneous	afferents	may	converge	in	the	dorsal	horn(Schaible,	Schmidt	et	al.	1987).	Similarly,	 the	 use	 of	 intra-articular	 tracers	 confirm	 projections	 to	 levels	 L3,	 L4	 and	 L5	DRG/sympathetic	ganglia(Edoff,	Grenegard	et	al.	2000),	where	paw	afferents	project	 to	L5.	As	such,	cutaneous	paw	 inputs	 could	 feasibly	 synapse	 onto	 common	neurons	with	 the	 joint,	 as	 suggested	 in	capsaicin	 studies	 at	 the	 knee(Schaible	 and	 Richter	 2004).	 On	 the	 one	 hand,	 these	 support	 the	contribution	of	 the	expansion	of	 receptive	 fields	 in	 the	observed	hypersensitivity	at	 the	paw	during	the	 MIA	 model.	 However,	 the	 expansion	 of	 receptive	 fields	 following	 capsaicin	 can	 be	 further	enhanced	by	spinalization(Neugebauer	and	Schaible	1990,	Vanegas	and	Schaible	2004),	highlighting	the	important	contribution	of	descending	controls,	and	thus	brain	stem	sensitization,	in	this	process.	It	 has	 similarly	 been	 shown	 that	 in	 models	 of	 kaolin	 and	 carrageenan	 induced	 acute	 OA	 that	 the	release	 of	 PGE2	 is	 increased	 and	 COX-2	 up-regulated	 in	 the	 spinal	 cord(Ebersberger,	 Grubb	 et	 al.	1999),	which	would	serve	to	assist	the	spread	of	central	sensitization.	Similarly,	the	enhancement	of	Lamina	 V	 WDR	 cell	 responses	 during	 the	 MIA	 model	 contribute	 to	 a	 picture	 of	 spreading	 central	sensitization	across	dorsal	segments	in	this	model.		
Regardless	 of	 the	 exact	mechanism,	 the	 contribution	 of	 a	 central	 sensitization	 to	 the	 observed	paw	hypersensitivity	 is	 clear.	 That	 the	 hypersensitivity	 observed	 in	 the	 above	 experiments	 is	 perhaps	weaker	 than	 that	 observed	 previously	may	 be	 accounted	 for	 by	 the	 activity	 dependence	 of	 central	plasticity.	 This	 is	 the	 concept	 that	 the	 magnitude	 of	 the	 peripheral	 drive	 goes	 some	 way	 to	determining	the	extent	of	change	in	the	balance	of	central	processes,	best	observed	in	the	adaptations	in	descending	controls	discussed	in	Chapter	4.		
Central	 Sensitization	 is	 a	key	 feature	of	 the	 clinical	profile	of	OA,	 in	which	patients	 exhibit	 referred	pains,	increased	responses	to	hypertonic	saline	injections	to	adjacent	muscle	and	altered	contralateral	VAS	 scores	 in	 response	 to	 local	 anaesthesia	 at	 the	 ipsilateral	 site(Creamer,	 Hunt	 et	 al.	 1996,	 Bajaj,	Graven-Nielsen	et	al.	2001,	Kean,	Kean	et	al.	2004).	This	behaviour,	by	confirming	central	sensitization	in	the	1mg	model,	confirms	the	use	of	this	dose	to	model	OA	pain.	
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3.4.2	 		 Sensitization	Observed	in	Spinal	Electrophysiology	
In	 assessing	 the	 evoked	 responses	 of	 lamina	 V	 WDR	 cells	 serving	 the	 ipsilateral	 hind	 paw,	 these	electrophysiology	measurements	aim	to	ascertain	 the	presence	of	a	central	 sensitization	 in	 the	1mg	MIA	 model.	 As	 discussed	 above	 in	 regards	 to	 the	 mechanical	 hypersensitivity	 to	 vF8g,	 changes	 in	behaviour	 and	 baseline	 electrophysiology	 from	 the	 paw	must	 rely	 upon	 central	 changes	 given	 the	absence	of	a	peripheral	driver.	The	key	advantage	of	this	measure	over	behaviour,	which	it	could	be	argued	had	already	demonstrated	the	presence	of	central	sensitization,	is	the	ability	to	assess	changes	in	 the	 responses	 to	 suprathreshold	 stimuli.	 The	 data	 presented	 here	 has	 demonstrated	 a	 clear	increase	 in	baseline	responses	of	WDR	neurons	to	both	thermal	and	mechanical	stimuli	 in	 the	early	stages	of	 the	MIA	model	compared	to	 their	 time	matched	sham	counterparts.	That	 this	difference	 is	not	 observed	 in	 the	 late	 stage	 MIA	 animals	 may	 be	 the	 result	 of	 either	 the	 increased	 baselines	observed	in	late	stage	sham	animals	to	which	these	Late	MIA	animals	were	compared,	or	the	lack	of	central	sensitization,	or	a	combination	of	both.	These	possibilities	will	be	discussed	further	below.		
	
Enhanced	Responses	to	Mechanical	and	Thermal	Stimulation	at	Days	3-5	Following	MIA	
Rats	 at	 days	 3-5	 following	 the	 intra-articular	 injection	 of	 1mg	 MIA	 exhibited	 heightened	 evoked	responses	to	dynamic	brush,	punctate	and	thermal	stimuli	compared	to	early	shams,	an	effect	which	was	 greatest	 in	 response	 to	 the	 most	 noxious	 stimuli:	 vF26g,	 vF60g	 and	 48°,	 demonstrating	 the	development	of	a	hyperalgesia	 in	these	Early	MIA	animals.	Though	the	response	of	 these	animals	to	vF8g	is	not	considered	significantly	greater	than	shams,	the	p	value	of	0.077	and	trend	observed	here	towards	 heightened	 responses	 compliments	 the	 observations	 made	 in	 behaviour.	 No	 significant	difference	in	the	responses	of	these	animals	to	electrical	stimulation	was	observed	indicating	a	lack	of	changes	in	excitability	of	peripheral	nerves	innervating	the	hindpaw,	which	further	supports	central	changes	as	a	basis	for	the	IL	paw	changes.	
These	observations	are	almost	exactly	aligned	to	those	from	previous	work	in	this	lab	at	days	3-5	of	the	 2mg	MIA	model,	which	 reported	 significantly	 heightened	 responses	 to	mechanical	 and	 thermal	stimulation	at	vF60g	and	48°C(Burnham	2012).	Notably	however,	that	study	also	reported	significant	increases	in	evoked	electrical	responses,	notably	in	the	number	of	action	potentials	attributed	to	each	of	Aβ,	Aδ	and	C	fibers,	increase	input,	but	no	difference	in	dynamic	brush	at	this	time	point	of	the	2mg	MIA	model–	unlike	the	findings	presented	here.	While	electrical	evoked	responses	are	not	considered	significantly	different	in	the	present	study,	it	can	be	observed	that	there	is	a	trend	towards	enhanced	Aδ	 and	 C	 counts	 in	 both	 the	MIA	 groups	 and	 the	 late	 sham	 animals	 compared	 to	 early	 sham.	 This	relationship	is	significant	for	the	comparison	between	Late	MIA	and	Early	Sham	(p=0.037,	unpaired	T-
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test)	and	nears	significance	for	Early	Sham	vs.	Late	Sham	(p=0.074,	unpaired	T-test).	As	such	it	may	be	the	extent	of	change	in	electrically	evoked	responses	are	less	pronounced	here,	but	still	present	in	the	early	(and	late!)	stages	of	the	1mg	MIA	model.		
While	 this	 allows	 clear	 conclusions	 to	 be	 drawn	 about	 the	 presence	 of	 a	 central	 sensitization	 that	facilitates	both	punctate	and	thermal	sensation	in	the	early	stages	of	the	MIA	model	in	both	1mg	and	2mg	doses,	conclusions	explaining	the	observed	differences	in	brush	responses	are	more	complicated.		
Dynamic	 brush	 allodynia	 is	 considered	 a	 strong	 marker	 of	 central	 sensitization(Latremoliere	 and	Woolf	2009).	The	presence	of	heightened	evoked	 responses	 to	dynamic	brush	 in	Early	MIA	but	not	Late	MIA	or	sham	animals	in	this	work	would	normally	suggest	the	presence	of	a	strong	initial	central	sensitization	 that	weakens	 at	 later	 stages	 in	 the	model	with	 the	decline	on	 inflammation.	However,	enhanced	 brush	 responses	 are	 not	 observed	 in	 the	 early	 days	 of	 the	 2mg	 model	 contradicts	 this	theory(Burnham	2012),	given	that	it	is	known	the	behavioural	profile	is	much	greater	with	increasing	doses,	 even	 in	 the	 early	 days(Guingamp,	 Gegout-Pottie	 et	 al.	 1997,	 Sagar,	 Staniaszek	 et	 al.	 2010,	Thakur,	Rahman	et	al.	2012).	The	challenge	is	that	very	few	studies	characterize	dynamic	allodynia	in	behaviour	 or	 at	 this	 early	 stage	 of	 the	 MIA	 model	 with	 electrophysiology.	 While	 not	 considered	significant,	 in	a	behavioural	study	of	the	2mg	model	a	temporary	decrease	in	the	PWL	to	cotton	bud	stroke	was	observed	at	day	7	of	 the	model,	but	not	 later	 time	points(Combe,	Bramwell	et	al.	2004).	Unfortunately,	 this	was	 the	earliest	 time	point	 investigated	but	does	suggest	 that	behaviorally	 there	could	be	a	very	short	term	dynamic	allodynia	in	MIA	animals	as	a	result	of	the	induction	of	the	model.		
Inferences	can	be	made	 from	other	pain	models,	where	a	brush	allodynia	has	been	characterized	 in	secondary	 areas	 following	 capsaicin(Andersen,	 Gracely	 et	 al.	 1995).	 Because	 brush	 sensations	 are	reliant	 upon	Aβ	 inputs	which	 do	 not	 express	 the	 capsaicin	 receptor	 TRPV1	 and	 nor	 can	 this	 brush	allodynia	 be	 relieved	 by	 topical	 NSAIDs,	 this	 dynamic	 allodynia	 are	 attributed	 to	 the	 presence	 of	central	changes	in	the	spinal	cord	that	allow	Aβ	inputs	to	be	transmitted	as	nociceptive	signals	(for	a	full	 review	 and	 discussion	 of	 this	 effect	 see	 (O'Neill,	 Brock	 et	 al.	 2012)).	 These	 observations	 are	similarly	made	for	evoked	brush	in	WDR	recordings	in	a	UVB	rekindling	model	(Jessica	O’Neill*	2015).	In	each	of	these	instances,	changes	to	responses	to	dynamic	brush	are	driven	by	a	strong	peripheral	drive.	 It	 is	possible	that	that	the	 initial	 inflammatory	phase	of	 this	1mg	MIA	models	could	provide	a	similar	 drive,	 and	 thus	 the	 observed	 changes.	 This	 matches	 well	 to	 observed	 enhancements	 to	punctate	 and	 thermal	 stimuli	 too.	However,	 it	 is	 important	 to	 consider	 the	 inconsistency	 in	 evoked	brush	 responses	 between	 pharmacology	 cohorts,	 discussion	 in	 Section	 3.4.3.	 While	 this	 might	 be	taken	 to	 suggest	 inconsistencies	 in	 success	 of	 induction	 of	 the	 MIA	 model	 in	 some	 animals,	 	 the	differences	may	best	be	explained	by	considering	differences	in	sham	responses	(Figure	3.7)	masking	a	potential	significant	brush	allodynia	in	the	ondansetron	cohort	MIA	rats.		
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The	suggestion	that	these	heightened	responses	from	the	paw	in	electrophysiology	may	be	driven	by	inflammation	at	 the	knee	at	days	3-5	 is	hard	to	validate,	given	the	relative	 lack	of	electrophysiology	focusing	on	this	time	point	 in	the	model.	That	both	this	study	and	Burnham	et	al	2012	exhibit	these	mechanical	 and	 thermal	 enhancements	 in	 these	 early	 days	 of	MIA	model	 confirms	 the	 presence	 of	central	sensitization	at	this	stage	of	the	model(Burnham	2012),	where	validation	of	the	contribution	of	inflammation	to	this	must	instead	be	provided	by	behavioural	studies	focusing	on	paw	sensitivities.	One	clear	example	is	given	by	Vonsy	et	al	2008,	where	the	administration	of	methylprednisolone	on	day	 0	 of	 the	 induction	 of	 the	MIA	model	 significantly	 attenuated	 the	 hypersensitivity	 expressed	 on	days	 3	 through	 to	 7(Vonsy	 2008).	 Beyond	 this	 point,	 the	 paw	 hypersensitivity	 regained	 to	 a	 point	similar	 to	 untreated	 MIA	 animals.	 This	 clearly	 demonstrates	 the	 importance	 of	 the	 inflammatory	response,	 thus	 supporting	 the	 proposal	 that	 the	 observed	 changed	 at	 days	 3-5	 in	 the	MIA	 animals	relates	to	an	inflammation	driven	central	sensitization.	
	
Evoked	responses	are	unchanged	in	the	later	stages	of	the	MIA	model	of	OA	
At	days	10-14	following	a	1mg	injection	of	MIA,	the	responses	of	Lamina	V	WDR	cells	are	no	different	to	 their	 time	matched	 counterparts,	who	 received	 just	 saline,	 in	 response	 to	 both	 electrical,	 brush,	punctate	mechanical	stimulation	and	water	jet.	In	fact,	the	results	are	practically	identical	(Figure	3.5b	and	 3.6b).	While	 the	 idea	 that	MIA	may	 not	 provoke	 enhancements	 of	 evoked	 responses	 at	 day	 14	onwards	is	nothing	new,	there	is	no	clear-cut	consensus	–	even	within	the	2mg	MIA	studies	in	this	lab.	While	 two	 characterize	 a	 significant	 increase	 in	 evoked	 responses	 to	 punctate	 stimuli	 in	 rats	 at	day14+	 following	 2mg	 MIA,	 in	 agreement	 with	 work	 in	 mice,	 others	 have	 failed	 to	 replicate	 any	significant	 alteration	 in	 baseline	 responses	 at	 day	 14	 of	 this	 2mg	 model(Vonsy	 2008,	 Patel	 2012,	Thakur	2012).	Rahman	additionally	characterized	an	 increased	mechanically	evoked	after	discharge	in	WDRs	at	days14	onwards	 in	 the	2mg	MIA	model(Rahman,	Bauer	 et	 al.	 2009).	As	 such,	 there	 are	clearly	two	distinct	“camps”	–	one	in	which	there	is	no	clear	central	sensitization,	and	one	where	there	is.	
Beyond	this	 lab,	Sagar	et	al	2010	describes	no	alteration	in	the	responses	of	WDRs	in	either	1mg	or	3mg	MIA	 treated	 rats	 at	days	14-17	 to	punctate	 stimulation,	but	outlines	a	 significant	 sensitivity	 to	vF10g	and	vF15g	by	days	28-31(Sagar,	Staniaszek	et	al.	2010)	–	though	a	relatively	small	number	of	neurones	 were	 characterised.	 Crucially,	 at	 days	 28-31	 the	 enhancements	 in	 evoked	 responses	 to	punctate	stimulation	are	strongly	correlated	to	changes	in	cartilage,	synovium	and	subchondral	bone.	This	 brings	 forward	 the	 first	 possible	 explanation	 for	 these	 differences	 –	 the	 extent	 of	 model	progression,	disease	pathology	and	thus	nociceptive	drive	from	the	knee	joint	may	differ.	Perhaps	in	
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those	 studies	 exhibiting	 central	 enhancements,	 namely	 enhanced	 evoked	 responses	 of	 WDRs,	 the	pathology	has	progressed	further.	As	previously	described,	higher	doses	of	MIA	to	the	knee	provoke	faster	 and	more	 severe	 joint	 pathology(Guingamp,	 Gegout-Pottie	 et	 al.	 1997,	 Pomonis,	 Boulet	 et	 al.	2005,	 Thakur,	 Rahman	 et	 al.	 2012),	 where	 there	 is	 a	 concentration	 dependent	 enhancement	 of	peripheral	afferent	responses	to	noxious	movement	of	the	 joint(Schuelert	and	McDougall	2009)	and	ongoing	afferent	drive(Okun,	Liu	et	al.	2012).	In	my	own	study	of	the	1mg	MIA	model	at	days	10-14	we	would	expect	 joint	pathology	to	be	much	less	severe	and	the	extent	of	peripheral	drive	from	the	joint	to	be	reduced,	while	individual	differences	in	injection	techniques	across	different	studies	could	perhaps	affect	the	extent	of	pathological	progression	in	the	2mg	experiments	(e.g.	leakage).	As	such,	it	could	be	argued	that	 the	drive	 from	the	 joint	 is	 insufficient	 to	provoke	central	sensitization	 in	these	animals,	hence	the	lack	of	difference	in	baselines	from	shams.		
However,	 this	 then	 leaves	 the	 question	 as	 to	 why	 we	 observe	 an	 increased	 sensitivity	 to	 vF8g	 in	behaviour	at	this	time	point.	The	picture	is	complicated	–	it	may	be	that	changes	in	paw	withdrawal	behaviour	are	more	reliant	upon	changes	 in	Lamina	I	WDR	cells,	where	Thakur	described	enhanced	Aδ	input	during	electrical	stimulation	and	heightened	evoked	responses	to	vF8g	in	2mg	MIA	Lamina	I	WDRs,	 despite	 describing	 no	 changes	 at	 Lamina	 V.	 These	 Lamina	 I	 WDRs	 additionally	 showed	enhanced	receptive	fields(Thakur,	Rahman	et	al.	2012).	Here	he	argued	that	changes	in	Lamina	I	drive	behavioural	hypersensitivity,	where	changes	at	Lamina	V	excitability	were	not	observed	as	a	result	of	the	 more	 complex	 informational	 integration	 and	 dilution	 –	 including	 interneuron	 modulation	 by	glycine	and	GABA;	descending	modulation,	triggered	by	ascending	signals	form	lamina	I;	and	the	fact	Lamina	 V	 WDRs	 receives	 inputs	 from	 Aβ’s	 that	 Lamina	 I	 does	 not.	 Also,	 it	 is	 worth	 noting	 that	behaviour	observed	 in	my	study	 is	notably	milder	 than	observed	 in	previous	2mg	work	–	as	such	 it	may	be	that	Lamina	I	is	driving	this	milder	sensitivity	but	that	as	model	severity	increases,	Lamina	V	similarly	becomes	sensitized	to	provoke	more	significant	behaviour.		
Alternately,	as	discussed	above,	behavioural	changes	may	be	the	result	of	the	expansion	of	receptive	field,	a	 secondary	hypersensitivity,	 as	opposed	 to	spreading	sensitization	 to	 those	segments	serving	the	paw	 investigated	during	 spinal	 electrophysiology.	 It	may	be	 that	while	 Lamina	V	WDR	neurons	which	predominately	serve	 the	hind	paw	do	not	exhibit	enhancements	during	 this	stage	of	 the	1mg	model	 -	 perhaps	 as	 a	 result	 of	 differential	 changes	 to	 descending	 control	 –	 those	 ascending	 fibers	serving	the	knee	do	become	sensitized,	and	thus	respond	to	the	previously	sub	threshold	inputs	at	the	edges	of	their	receptive	field.	That	these	broad	but	often	silent	fields,	extending	from	the	knee	to	the	paw,	exist	has	been	demonstrated	by	Sagar	et	al	2015.	This	study	examined	the	activity	and	receptive	fields	of	WDR	neurons	serving	the	joint	in	arthritic	animals,	21days	after	they	received	1mg	MIA.	They	demonstrated	that	following	the	intra	articular	injection	of	NGF,	the	Lamina	V	cells	of	MIA	rats,	but	not	shams,	exhibited	both	enhanced	firing	and	>100%	increase	in	the	receptive	field	of	this	cell,	extending	
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down	 to	 include	 the	 paw(Sagar,	 Nwosu	 et	 al.	 2015).	 Critically,	 this	 study	 suggests	 that	 peripheral	changes	in	the	afferents	serving	the	knee,	including	up-regulation	of	TrkA,	drive	spinal	sensitizations	that	facilitate	an	expansion	of	the	area	over	which	sensory	inputs	are	engaged.	In	other	words,	while	late	MIA	 animals	may	not	 exhibit	 evidence	 of	 central	 sensitization	 at	 the	 segment	 serving	 the	 paw,	sensitizations	 are	 likely	 present	 at	 higher	 segments	 serving	 the	 knee	 that	 can	 account	 for	 punctate	hypersensitivity	at	the	paw.		
However,	considering	the	data	presented	in	Figure	3.5c	and	3.6c,	another	distinct	explanation	for	the	lack	of	observed	excitability	in	late	MIA	animals	presents.	It	may	be	that	the	evoked	responses	are	not	considered	heightened	because	of	changes	 in	 the	baseline	responses	of	Late	Sham	animals.	 In	other	words,	 an	 enhancement	 of	 the	 baselines	 on	 Late	 Shams	 (when	 compared	 to	 Early	 Shams)	may	 be	masking	an	effect	when	compared	to	Late	MIA.	Consider	the	evoked	responses	to	punctate	mechanical	stimulation:	 there	 is	 a	 strong	 trend	 suggesting	 Late	 Sham	baselines	 are	 greater	 than	 those	 in	 Early	Sham	 rats	 (p=0.088).	 For	 thermal	 responses,	 this	 difference	 in	 evoked	 response	 is	 significant,	 at	p=0.018.	 The	 overlay	 of	 baselines	 in	 these	 two	 graphs,	 Figure	 3.5c	 and	 3.6c,	 clearly	 demonstrates	enhancements	of	both	MIA	groups	and	Late	Sham	responses	above	those	seen	in	Early	Shams.	In	this	same	 vein,	 where	 we	 have	 considered	 the	 Early	 MIA	 baselines	 to	 be	 more	 excitable	 compared	 to	shams,	 thus	demonstrating	central	sensitization,	 these	responses	are	not	significantly	different	 from	late	MIA	animals,	for	either	punctate	or	thermally	evoked	responses.		
As	such,	it	may	be	that	as	opposed	to	an	absence	of	central	plasticity	in	the	Late	MIA	model,	there	have	additionally	been	changes	observed	in	the	sham	model	as	a	result	of	the	injection	procedure	itself.	It	could	be	hypothesizes	that	the	insertion	of	a	needle	to	the	intra	articular	space	could	cause	physical	damages,	not	least	if	the	needle	passes	through	the	patellar	tendon,	to	weaken	it	and	cause	long	term	destabilization	 of	 the	 joint,	 or	 scratches	 the	 surface	 of	 the	 articular	 cartilage	 to	 leave	 a	 lesion	 that	could	 cause	 friction.	 Similar	 effects	 have	 been	 observed	 in	 sham	 animals	 in	 work	 from	 other	 labs,	where	paw	withdrawal	 thresholds	declined	 in	shams	following	 injection	–	 though	the	declines	were	much	greater	in	MIA	animals	in	this	study,	as	expected(Mapp,	Sagar	et	al.	2013).	It	may	be	in	that	at	day	 10	 of	 a	 1mg	 model,	 joint	 pathology	 changes	 are	 not	 significant	 enough	 drivers	 of	 pain	 to	differentiate	from	changes	occurring	as	a	result	of	the	injection	procedure	itself.	
The	best	way	to	gain	clarity	on	these	changes	in	the	1mg	MIA	model	would	be	further	study.	Collecting	electrophysiology	baselines	 for	naïve	animals,	 and	1mg	21day+	animals,	 could	elucidate	 further	 the	extent	 of	 excitability	 changes	 in	 the	 dorsal	 horn	 and	 the	 role	 of	 extent	 of	 joint	 pathology,	 or	 lack	thereof,	on	evoked	responses	in	this	MIA	model	of	OA.		
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3.4.3	 	 Study	Limitations	
In	 considering	 the	 results	 and	 potential	 conclusions	 of	 this	 chapter,	 it	 is	 important	 to	 consider	 the	limitations	of	the	present	study’s	design	–	both	to	provide	context	that	will	inform	the	conclusions,	but	also	suggest	potential	modifications	to	the	study	that	would	have	allowed	greater	clarity.	
Evidence	of	Structural	Pathology	
A	major	limitation	in	the	discussion	of	the	results	presented	in	this	chapter,	as	in	all	the	chapters	of	this	thesis,	is	the	absence	of	analysis	of	the	structural	pathology	of	these	animals.	While	previous	literature	has	established	the	histopathological	changes	associated	with	both	the	early(Strassle,	Mark	et	al.	2010,	Kelly,	 Dunham	 et	 al.	 2012)	 and	 late	 (Ivanavicius,	 Ball	 et	 al.	 2007,	 Kelly,	 Dunham	 et	 al.	 2012,	 Thakur	2012)	 stages	 of	 a	 1mg	MIA	model,	 it	 would	 be	 a	 fallacy	 to	 assume	 that	 every	 injection	 of	 MIA	 was	successfully	delivered.	Even	in	a	clinical	setting,	IA	therapies	commonly	miss	their	mark	(in	much	larger	knees)	without	ultrasound	guidance(Berkoff,	Miller	et	al.	2012).	There	are	similarly	considerations	of	the	 potential	 off-target	 effects	 of	 MIA,	 such	 as	 leaking	 from	 the	 synovial	 joint	 to	 affect	 surrounding	tissues	 and	 drive	 pain	 independently	 of	 OA-like	 pathology	 –	 including	 potential	 uptake	 by	 local	neuronal	endings	to	trigger	neuropathic	pain.	These	possibilities	undermine	the	assumption	that	a	pain	profile	necessarily	demonstrates	a	successful	injection	and	the	presence	of	OA-like	changes	in	the	knee	joint.		
Such	variability	of	success	of	injections	might	explain	the	 inconsistency	 of	 the	 presence	 of	 a	 significant	enhanced	 evoked	 responses	 to	 dynamic	 brush	observed	 in	 the	 baseline	 responses	 of	 the	ondansetron	 treated	 and	 atipamezole	 treated	cohorts	 of	 early	 1mg	MIA	 and	 sham	 rats	 (Compare	Figure	3.4b,	4.1b	and	4.3b).	).	I	have	summarized	this	is	 Figure	 3.7.	 When	 baselines	 of	 these	 early	 MIA	animals	 are	 merged	 a	 significant	 enhancement	 is	observed	 to	 dynamic	 brush	 versus	 sham	 animal	evoked	 responses.	 While	 this	 significant	 effect	 was	observed	 in	 the	 atipamezole	 treated	 cohort’s	baselines	 the	 effect	 was	 not	 observed	 for	 the	ondansetron	 cohort	 baselines.	 This	 suggests	 a	different	 profile	 between	 the	 two	 sets	 of	 1mg	 MIA	treated	 rats,	 perhaps	 where	 significance	 in	 the	
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Figure	 3.7	 -	 Comparison	 of	 dynamic	 brush	 evoked	
responses	 of	 Lamina	 V	WDR	 cells	 in	 Early	 MIA	 (red)	 and	
Early	 Sham	 (purple)	 animals	 depending	 on	 the	
experimental	cohort.	 	Those	animals	used	in	the	ondansetron	experiments	 (O)	 show	 no	 significant	 difference	 in	 baseline	evoked	 activity	 to	 brush,	 unlike	 the	 atipamezole	 cohort	 (A),	which	 may	 in	 turn	 drive	 the	 significance	 observed	 in	 the	merged	cohort	(*p≤0.05)		
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merged	analysis	is	driven	by	the	dramatic	difference	in	the	atipamezole	treated	cohort’s	baselines.	An	understanding	of	the	differing	structural	pathophysiology,	or	off	target	effects	due	to	failed	injections,	including	 potential	 physical	 damage	 that	 could	 cause	 a	 post-op	 style	 sensitization	 in	 some	 sham	animals,	 could	 provide	 clarity	 of	 potential	 mechanisms	 underlying	 this	 difference	 that	 the	 currently	presented	data	alone	cannot.	However,	it	appears	from	Figure	3.7	that	in	reality	these	between	groups	are	driven	by	differences	 in	the	extent	of	 the	Sham	animal	response	to	dynamic	brush	–	with	relative	consistency	 in	 the	extent	of	evoked	activity	between	the	MIA	Early	groups.	This	might	suggest	 this	 is	not	a	problem	of	failed	injection	at	all,	but	of	insufficient	n	numbers		–	discussed	further	in	the	Chapter	4’s	study	limitations	–	and	a	degree	of	variability	of	WDR	profiles.	
The	conclusions	drawn	in	this	study	(Chapters	3	and	4)	are	based	upon	potential	considerations	of	the	extent	 of	 histopathological	 changes	 –	 inflammatory	 in	 the	 early	 animals,	 and	 structural	 in	 the	 late	animals.	These	conclusions	would	be	 far	stronger	with	a)	evidence	of	such	changes,	on	which	to	base	these	conclusions	and	b)	a	correlation	analysis,	to	detect	any	potential	relationship	between	the	extent	of	 structural	 pathology,	 behaviour	 and	 electrophysiology.	 Of	 note,	 previous	 analysis	 of	 this	 kind	 has	failed	 to	 characterize	 a	 relationship	 between	 structural	 pathology	 and	 nociceptive	 behaviour	 or	electrophysiology	 (McDougall,	 Andruski	 et	 al.	 2009,	 Kelly,	 Dunham	 et	 al.	 2012),	 suggesting	 alternate	explanations	for	the	differences	observed	between	this	work	and	earlier	studies	in	the	2mg	MIA	could	be	required.	
Such	 analysis	 could	 also	 allow	 the	 exclusion	 from	 analysis	 of	 animals	 in	 which	 OA	 had	 not	 been	successfully	 induced	 by	 the	 MIA	 model.	 It	 is	 possible	 that	 in	 so	 doing,	 more	 significant	 differences	between	groups	and	after	pharmacology	might	be	detected.	Conversely,	 in	a	meta	analysis	of	 studies	that	measured	behavioural	pain	outcomes	in	small	animal	models	of	OA,	Suokas	et	al	2014	demonstrate	that	 	 “Lack	 of	 reported	 evidence	 that	 OA	 structural	 change	was	 successfully	 induced	 in	 the	model	 was	
strongly	 associated	 with	 larger	 effect	 sizes”,	 where	 effect	 size	 refers	 to	 reported	 analgesic	efficacy(Suokas,	 Sagar	 et	 al.	 2014).	 This	 analysis	 suggests	 that	 incomplete	 phenotyping	 of	 animals,	including	the	failure	to	confirm	structural	pathology,	prior	to	pharmacological	 interventions	may	lead	to	 false	 conclusions.	 In	 this	 instance,	 the	 false	 conclusion	 would	 be	 to	 attribute	 differences	 in	 the	response	 to	ondansetron	or	atipamezole	 in	 these	1mg	animals	vs.	previous	2mg	studies	 to	 structural	pathological	 differences,	 when	 these	 differences	 may	 instead	 related	 to	 off	 target	 effects	 of	 MIA	 in	tissues	surrounding	the	joint	capsule	
Direct	Comparisons	Between	1mg	and	2mg	Animals	
In	 opting	 not	 to	 include	 a	 2mg	MIA	 cohort	 within	 these	 studies,	 I	 had	 sought	 not	 to	 replicate	work	already	published	and	to	instead	use	it	as	a	comparator	reference(Rahman,	Bauer	et	al.	2009,	Burnham	
		 142	
and	Dickenson	2013).	However,	this	approach	may	be	flawed	given	the	previously	discussed	variability	and	lack	of	consensus	on	whether	the	MIA	model	results	in	increased	evoked	responses	to	mechanical	and	 thermal	 stimulation,	 and	 the	 absence	 of	 structural	 pathology	 analysis	 in	 these	 reference	studies(Rahman,	Bauer	et	al.	2009,	Burnham	and	Dickenson	2013).	Though	the	use	of	2mg	MIA	cohort	for	direct	comparison	would	have	required	the	repetition	of	previous	studies,	it	would	have	facilitated	direct	 comparison	 between	 sham,	 1mg	 and	 2mg	 MIA	 animals	 without	 accounting	 for	 inter-experimenter	 variability.	 In	 conjunction	 with	 joint	 histopathology,	 such	 work	 could	 have	 allowed	analysis	of	any	potential	relationship	between	dose,	joint	pathology	and	evoked	electrophysiology	and	pharmacology.	
	
3.4.4			 Overall	Implications	
In	conclusion,	herein	I	have	demonstrated	a	significant	behavioural	profile	 in	the	1mg	model	of	MIA	that	 involves	 both	 ongoing	 pain	 from	 the	 joint,	 as	 observed	 by	 incapacitance,	 and	 a	 secondary	hypersensitivity	in	the	paw,	demonstrated	by	increased	withdrawal	from	vF8g,	at	both	the	early	and	late	 stages.	The	combination	of	 this	behavioural	profile	with	 the	 changes	 in	excitability	observed	 in	Lamina	V	dorsal	horn	WDRs	at	early	but	not	 late	 time	points	 in	MIA	animals	may	 indicate	 that	 this	pain	is	driven	differentially	at	the	two	stages.	During	the	initial	days	of	the	model,	inflammation	at	the	joint	may	 cause	 the	 spreading	of	pain	 to	 the	paw,	 likely	 through	a	 combination	of	 the	 expansion	of	receptive	 fields,	 convergence	 and	 spreading	 central	 sensitization,	 possibly	 due	 to	 changes	 in	descending	controls.	During	the	later	stages	of	the	1mg	model,	the	mildly	enhanced	sensitivities	at	the	paw	appear	to	be	driven	by	the	expansion	of	receptive	fields.	It	is	likely	that	over	time	the	pathology	in	this	1mg	model	would	increase,	eventually	driving	changes	observed	in	these	late	stages	in	the	2mg	model	 –	 notably	more	 emphasized	 behavioural	 pain	 profiles	 and	more	 excitable	 electrophysiology	baselines.	However,	all	things	considered,	this	may	allow	the	1mg	model	at	day	10	to	effectively	model	the	 early	 years	 of	 clinically	 developing	 OA	 pain,	 and	 day	 3	 the	 periodic	 flares	 of	 painful	 synovitis	experienced	by	patients.	
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Chapter	4	–	Descending	Monoaminergic	Controls	in	the	MIA	Model	
The	 ultimate	 goal	 of	 modeling	 OA	 pain	 in	 the	 MIA	 model	 is	 to	 better	 elucidate	 the	 mechanisms	underlying	this	chronic	pain	condition	and	validate	new	avenues	of	therapy.	Mirroring	the	established	effects	 clinically,	 numerous	 trials	 have	 confirmed	 and	 compared	 the	 efficacy	 of	 NSAIDs,	 COX-2	inhibitors,	capsaicin,	opiates	and	mAbs	for	NGF	in	the	MIA	model(Bove	2003,	Combe,	Bramwell	et	al.	2004,	 Pomonis,	 Boulet	 et	 al.	 2005,	 Ivanavicius,	 Ball	 et	 al.	 2007,	 Kalff,	 El	 Mouedden	 et	 al.	 2010,	Ishikawa,	 Koya	 et	 al.	 2015).	 With	 the	 clinical	 efficacy	 of	 antidepressants	 in	 OA	 pain	 becoming	increasingly	 established	 (see	 Section	1.3.1),	 attention	has	 turned	 to	 the	 possible	 role	 of	 descending	controls	 in	development	and	maintenance	of	pain	 in	 the	MIA	model	of	OA.	By	better	understanding	the	role	 this	descending	system	plays,	 it	 is	possible	 that	pharmacological	 intervention	can	be	better	tailored	to	exploit	or	block	these	changes	and	thus	provide	superior	analgesia	to	the	current	standard	of	care.			
	
4.1.1			 Serotonin	
As	discussed	in	Section	1.4.6,	serotonin	is	a	pivotal	transmitter	in	the	modulation	of	spinal	signaling	and	is	released	from	fibers	descending	from	the	brainstem.	Serotonin	exerts	a	bidirectional	control	on	transmission	in	the	spinal	cord,	by	virtue	of	an	interaction	with	different	receptor	subtypes.	Serotonin	at	 5HT7	 will	 inhibit	 transmission	 and	 provide	 analgesia	 while	 5HT3	 enhances	 transmission	 to	induce/sustain	 hyperalgesia(Dogrul,	 Ossipov	 et	 al.	 2009)	 –	 where	 the	 balance	 of	 controls	 may	 be	altered	during	disease	states(Suzuki,	Rahman	et	al.	2004,	Suzuki,	Rygh	et	al.	2004,	Suzuki,	Rahman	et	al.	2005).	
Previous	work	has	utilized	the	5HT3	antagonist	ondansetron	in	a	2mg	MIA	model	of	OA,	highlighting	an	 adaptive	 change	 in	 the	 excitatory	 serotonergic	 drive	modulating	 low	 threshold	 evoked	neuronal	responses	 in	 MIA-induced	 OA	 pain(Rahman,	 Bauer	 et	 al.	 2009).	 Specifically,	 it	 was	 shown	 that	ondansetron	produced	marked	inhibition	of	dynamic	brush,	punctate	and	thermally	evoked	responses	applied	 to	 the	paw,	where	 this	brush	and	non-noxious	punctate	 inhibition	was	not	observed	or	 less	robust	in	animals	given	a	sham	injection	into	the	joint	(saline)(Rahman,	Bauer	et	al.	2009).	
Similarly	it	has	been	demonstrated	that	the	inhibitory	serotonergic	drive	may	also	have	a	role	to	play	in	 OA	 pain.	 The	 5HT7	 antagonist,	 SB-269970,	 significantly	 enhanced	 both	 the	 noxious	 thermal	 and	electrically	evoked	responses	in	late	phase	MIA	animals,	an	effect	not	observed	in	naïve	or	early	phase	MIA	animals.	 	This	suggests	that	MIA	and	the	joint	destruction	that	develops	as	a	consequence	of	 its	injections	 may	 induce	 an	 increased	 5HT7	 mediated	 serotonergic	 inhibition	 as	 joint	 destruction	
		 144	
becomes	chronic	and	nociceptive	drivers	ongoing,	perhaps	as	a	counterbalance	to	the	development	of	central	sensitization	in	this	model.			
Milnacipran,	 the	 serotonin	and	noradrenaline	 reuptake	 inhibitor	 (SNRI)	utilized	 in	 the	 treatment	of	major	depressive	disorders,	successfully	attenuates	both	mechanical,	thermal	and	electrically	evoked	responses	 in	 MIA	 animals(Burnham	 and	 Dickenson	 2013).	 Crucially,	 this	 study	 found	 the	 effect	 of	milnacipran	was	reversed	significantly	by	spinal	SB-269970,	indicating	that	the	analgesic	effect	of	this	SNRI	 in	 the	OA	 pain	model	 is	 in	 part	mediated	 by	 an	 interaction	 between	 descending	 serotonergic	controls	and	spinal	5HT7	receptors.		
Similarly	Tramadol,	a	µ-opioid	receptor	agonist	and	SNRI,	has	been	shown	to	be	highly	effective	in	the	treatment	of	punctate	allodynia	and	weight	bearing	deficits	in	the	MIA	model(Combe,	Bramwell	et	al.	2004),	 where	 the	 efficacy	 of	 Tramadol	 is	 attributed	 in	 large	 part	 to	 the	 activation	 of	 the	 5HT7	receptor(Yanarates,	Dogrul	et	al.	2010).	
	
4.1.2			 Noradrenaline	
As	with	Serotonin,	Noradrenaline	also	has	a	crucial	role	to	play	in	the	modulation	of	pain	signaling	in	the	MIA	model	–the	role	of	NA	in	pain	is	discussed	more	fully	in	Section	1.4.6.	NA	descending	from	the	dorsolateral	pontine	nuclei	binds	at	spinal	α2	adrenoceptors	to	hyperpolarize	cells,	reducing	both	the	 likelihood	 of	 action	 potential	 generation	 but	 also	 the	 release	 of	 transmitters	 at	 pre-synaptic	terminals.	 Work	 in	 both	 acute	 and	 chronic	 inflammation,	 and	 neuropathy,	 has	 pointed	 to	 a	 time-sensitive	role	in	the	extent	of	the	noradrenergic	modulation	in	pain	transmission(Green,	Lyons	et	al.	1998,	Pertovaara	2006,	Hughes,	Hickey	et	al.	2013).	
Relatively	little	work	has	been	performed	on	the	role	of	NA	in	models	of	OA	pain,	despite	the	efficacy	of	SNRIs	like	duloxetine	to	treat	OA	in	the	clinic(Chappell,	Ossanna	et	al.	2009,	Sullivan,	Bentley	et	al.	2009,	 Hochberg,	 Wohlreich	 et	 al.	 2012,	 Pergolizzi,	 Raffa	 et	 al.	 2013).	 Work	 from	 this	 lab	 has	investigated	 the	 effect	 of	 atipamezole,	 an	α2	antagonist,	 in	 a	 2mg	model	 of	MIA,	 demonstrating	 that	this	drug	significantly	enhanced	the	response	of	WDRs	in	early	phase	MIA	animals	to	punctate	stimuli,	but	had	no	effect	in	either	late	phase	or	naïve	animals(Burnham	and	Dickenson	2013).	Interestingly,	the	administration	of	spinal	atipamezole	following	systemic	milnacipran	reversed	the	inhibitory	effect	of	the	latter	on	responses	of	deep	WDR	neurones	to	both	mechanical	and	thermal	stimuli	back	to	pre-milnacipran	baselines	 in	 the	early	phase	of	 the	MIA	model	 (3	days).	However,	a	 full	 reversal	of	 this	inhibitory	effect	was	not	seen	with	spinal	administration	of	atipamezole	in	the	late-phase	of	the	model	(Burnham	and	Dickenson	2013),	suggesting	a	declining	role	for	noradrenergic	descending	modulation	
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in	the	 latter	stages	of	 this	model	and	thus	a	role	 for	agents	acting	upon	this	descending	system	that	may	depend	on	the	state	of	the	OA	and/or	OA	pain.	
The	 combined	 conclusion	 from	 this	 and	 the	 results	with	 SB-269970	 above	would	 indicate	 that	 the	mechanism	underlying	the	analgesia	produced	by	the	SNRI	milnacipran	changes	over	time	during	the	MIA	 model	 –	 whereby	 NA	 at	 the	 spinal	 α2	 adrenoceptor	 drives	 the	 inhibitory	 effect	 in	 the	 early,	inflammatory	 stages	 of	MIA,	while	 5HT	 at	 the	 spinal	 5HT7	 receptor	mediates	 this	 inhibition	 in	 the	latter	stages	of	the	model,	where	pain	is	driven	by	advanced	pathology	and	not	inflammation.		
These	 spinal	 electrophysiology	 studies	 indicate	 time-dependent	 alterations	 in	 monoaminergic	regulation	 of	 the	 2mg	 MIA	 model.	 During	 the	 early	 inflammatory	 stages	 of	 the	 model,	 there	 is	 a	descending	 noradrenergic	 drive	 limiting	 transmission	 to	 punctate	 stimuli	 in	 the	 dorsal	 horn	 via	 α2.	During	the	latter	stages,	there	appears	to	be	a	5HT-driven	inhibition	of	thermal	evoked	responses	via	spinal	5HT7	receptors,	while	an	excitatory	serotonergic	drive	enhances	low-threshold	and	thermally-evoked	 neuronal	 responses	 via	 spinal	 5HT3	 receptors.	 This	 demonstrates	 the	 importance	 of	 the	balance	 between	 these	 antagonistic	 controls.	 It	 is	 not	 yet	 known	 if	 or	 how	 the	 role	 of	 spinal	 5HT3	receptor	activation	changes	during	the	early	phase	of	MIA.		
One	interesting	comparison	that	can	also	be	made	throughout	these	studies	is	the	relative	inhibitory	contribution	of	5HT	or	NA	to	differing	peripheral	stimuli,	perhaps	clearest	in	the	work	of	Burnham	et	al.	The	relative	extent	of	reversal	of	the	effect	of	milnacipran	by	spinal	SB-269970	was	much	greater	for	 thermally-evoked	 than	mechanically-evoked	 responses,	while	 spinal	 atipamezole	 only	 enhanced	responses	 of	 mechanically-evoked	 activity	 and	 not	 thermally-evoked	 activity.	 In	 other	 words,	descending	 inhibition	 from	 the	 serotonergic	 system	 has	 a	 greater	 effect	 on	 thermally-evoked	responses,	while	descending	noradrenergic	 inhibition	 is	more	effective	 in	modulating	mechanically-evoked	responses.	This	is	not	a	new	concept	-	it	has	been	shown	that	intrathecal	NA	is	180	times	more	potent	than	5HT	at	 inhibiting	mechanical	nociception(Kuraishi,	Harada	et	al.	1979).	 It	has	also	been	shown	that	the	analgesic	effect	of	morphine	on	different	forms	of	nociception	can	be	similarly	divided	–	descending	NA	playing	a	greater	role	in	inhibiting	mechanical	nociception	(e.g.	to	tail	pinch),	while	descending	5HT	played	a	greater	role	in	inhibition	of	thermal	nociception	(e.g.	to	hot	plate),	though	it	was	 noted	 that	 both	 transmitters	 had	 a	 role	 in	 morphine-induced	 analgesia	 to	 both	 forms	 of	stimulation(Kuraishi,	 Harada	 et	 al.	 1983).	 The	 consequence	 of	 this	 for	 OA	 is	 that	we	would	 expect	noradrenergic	systems	to	provide	more	potent	relief	of	 this	predominantly	mechanical	hyperalgesia	and	 allodynia–	 such	 that	 an	 SNRI	 would	 be	 preferable	 to	 an	 SSRI,	 although	 this	 remains	 to	 be	empirically	tested.	
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It	 is	worth	noting	 that	 these	aforementioned	preclinical	 studies	all	 focus	on	stimulation	of	 the	paw.	Work	by	Kelly	et	al	2013	assessed	the	effect	of	spinalization	on	the	thresholds	and	reflex	responses	of	the	 tibialis	anterior	(TA)	or	biceps	 femoris	 (BF)	 in	animals	given	an	1mg	 intra-articular	dose	of	MIA	 to	 the	 knee	 joint	 and	 those	 given	 a	 similar	 sham	 injection	 at	 days	 14	 and	 28.	While	 the	injection	 of	 MIA	 resulted	 in	 reduced	 mechanical	 thresholds	 in	 the	 BF,	 which	 were	 unaltered	 by	spinalization	 at	 day	 28,	 the	 effect	 of	 MIA	 injection	 on	 mechanical	 sensitivity	 in	 the	 TA	 was	 only	unmasked	 by	 spinalization	 –	 which	 revealed	 a	 hyperexcitability(Kelly,	 Dobson	 et	 al.	 2013).	 This	suggests	 that	 secondary	hyperalgesia	 at	 the	BF	 is	maintained	 at	 the	 spinal	 level,	 not	 by	descending	facilitations,	 while	 at	 the	 TA	 spinal	 hypersensitivities	 are	 moderated	 by	 descending	 inhibitions.	Interestingly,	these	reflexes	were	unaltered	at	day	14,	suggesting	that	central	sensitization	in	this	1mg	model	 manifests	 at	 later	 time	 points.	 The	 implications	 of	 this	 for	 the	 investigation	 of	 changes	 in	descending	control	at	the	paw	in	a	1mg	model	is	the	expectation	of	enhanced	descending	inhibitions	at	a	later	stage	of	the	model	(as	seen	in	the	TA),	driven	by	enhanced	pathology	at	the	knee,	that	may	not	be	visible	at	day	14	but	could	be	evident	by	day	28.	Given	 the	 findings	by	Burnham	 in	 the	2mg	model	 discussed	 above,	 it	 could	 be	 hypothesized	 that	 these	 descending	 controls	 that	 mask	hypersensitivities	are	serotonergic	inhibitions.		
Previous	 work	 from	 this	 lab	 has	 identified	 time-dependent	 changes	 in	 the	 noradrenergic	 and	serotonergic	 descending	 controls	 mediating	 spinal	 excitability,	 and	 thus	 pain	 perception,	 in	 a	 2mg	model	of	OA	pain	compared	to	sham	and	naïve	controls.	Given	this	dose	of	MIA	has	been	identified	as	driving	 neuropathy(Ivanavicius,	 Ball	 et	 al.	 2007,	 Thakur,	 Rahman	 et	 al.	 2012),	 and	 the	 extent	 of	change	 of	 descending	 controls	 has	 been	 shown	 to	 be	 variable	 between	 different	 pain	conditions(Green,	Scarth	et	al.	2000,	Rahman,	Suzuki	et	al.	2004),	it	is	hypothesized	that,	at	this	lower,	non-neuropathic	dose	of	MIA,	modifications	in	the	descending	control	on	spinal	excitability	by	NA	and	5HT,	as	revealed	by	the	spinal	application	of	various	antagonists,	may	also	differ.	
	
4.1.3			 Chapter	Aims	
For	 patients	 with	 symptomatic	 OA	 the	 unmet	 needs	 are	 still	 clear	 –	 efficacious,	 safe	 and	 tolerable	analgesia.	 However,	 many	 drugs	 still	 struggle	 to	 translate	 from	 laboratory	 success	 to	 marketing	approval	for	OA	pain.		
While	this	problem	in	part	stems	from	the	difficulties	in	translating	pharmacological	observations	in	animal	models	due	to	poor	study	quality	(Suokas,	Sagar	et	al.	2014),		it	could	also	stem	from	an	over	generalization	 that	 results	 in	 one	 model	 of	 OA	 pain	 relate	 to	 a	 broad	 and	 diverse	 patient	 cohort.	Previous	work	has	suggested	that	the	MIA	model	of	OA	pain	may	model	a	more	neuropathic	driven	OA	
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pain	 condition	 at	 doses	 of	 ≥2mg	 at	 14days,	 but	 not	 the	 1mg	 model(Ivanavicius,	 Ball	 et	 al.	 2007,	Thakur,	Rahman	et	al.	2012).	Thus	pharmacological	observations	identifying	dynamic	contributions	of	descending	 controls	 in	 the	 2mg	model	 (Rahman,	 Bauer	 et	 al.	 2009,	 Burnham	and	Dickenson	 2013)	may	 relate	 to	 a	 patient	 segment	 with	 neuropathic	 like	 pain,	 and	 not	 the	 larger	 cohort	 with	 non-neuropathic	pain.	
This	study	aims	to	characterize	differences	in	the	extent	of	descending	control,	both	serotonergic	and	noradrenergic,	 in	 the	early	and	 later	stages	of	a	1mg	MIA	model	of	OA	pain	versus	those	previously	characterized	and	published	in	the	2mg	model	(Rahman,	Bauer	et	al.	2009,	Burnham	and	Dickenson	2013)	–	now	understood	to	be	neuropathic	in	nature(Ivanavicius,	Ball	et	al.	2007,	Thakur,	Rahman	et	al.	 2012).	 This	 will	 be	 studied	 using	 spinal	 cord	 electrophysiology	 and	 the	 selective	 antagonists	ondansetron	and	atipamezole.	
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4.2	 		 Methods	
4.2.1			 Animals	
All	 work	 was	 conducted	 in	 Male	 Sprague	 Dawley	 rats,	 bred	 and	 housed	 in	 the	 Central	 Biological	Services	 Unit	 at	 University	 College	 London.	 As	 described	 in	 Chapter	 2,	 behavioural	 and	electrophysiological	 studies	were	 conducted	 either	 at	 the	 early	 stages	 of	 OA	 pain	 development,	 on	days	3-5	after	injection	of	either	MIA	(1mg,	25μl,)	or	Saline	(25	μl);	or	late	stages,	on	days	10-14	after	injection	in	animals	weighing	in	the	range	of	220-250g.	At	the	time	of	experimentation	As	such,	results	for	 four	 populations	 of	 experimental	 animals	 are	 described	 in	 this	 chapter:	 Early	MIA,	 Early	 Sham,	Late	MIA	and	Late	Sham.	
	
4.2.2	 		 Induction	of	the	model	
As	detailed	in	Section	2.2,	rats	were	injected	with	either	25μl	l	of	1mg	MIA	(Sigma,	UK)	or	Saline	to	the	left	knee.	
	
4.2.3	 		 Behavioural	Assessment		
Methods	and	results	presented	in	Chapter	3	(Section	3.2.3	and	3.3.1)	
	
4.2.4	 		 Electrophysiological	Assessment	
Spinal	electrophysiology	was	carried	out	in	rats	weighing	220-250g	at	either	days	3-5	(Early)	or	days	10-14	(late)	after	injection	of	either	1mg	MIA	or	Saline,	as	described	in	detail	in	Section	2.4.		
Once	 a	 single	WDR	 neuron	 had	 been	 isolated,	 rounds	 of	 20minute	 recordings	 of	 evoked	 neuronal	responses	 to	 electrical,	 mechanical	 and	 thermal	 stimuli	 were	 performed.	 Once	 each	 neuron	 had	produced	 stable	 responses	 to	 three	 consecutive	 rounds	 of	 stimulation	 by	 the	 same	 stimuli	 set,	pharmacology	was	then	performed.	Note	that	these	three	readings	in	a	row	are	averaged	to	provide	a	baseline	 from	which	 to	 judge	 any	 changes	 following	pharmacology.	These	baseline	 recordings	have	been	collated	and	analysed	in	Chapter	3.	
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The	effect	of	two	antagonists	on	evoked	responses	of	WDR	neurons	were	assessed:	
• Ondansetron:	A	selective	antagonist	for	the	5HT3	receptor,	with	a	selectivity	ratio	of	over	1000	for	this	site	compared	to	the	other	receptors.	
• Atipamezole:	A	selective	antagonist	of	the	α2	noradrenergic	receptor,	which	shows	a	roughly	>8000	fold	selectivity	for	α2	over	α1,	and	greater	potency	than	yohimbine.		
where	each	animal	only	received	one	of	these	drugs.	As	such,	of	the	four	experimental	groups	of	animals	 (Early	 MIA,	 Early	 Sham,	 Late	 MIA	 and	 Late	 Sham)	 half	 from	 each	 group	 received	ondansetron,	and	half	received	atipamezole.	
1)	Ondansetron:		
• Ondansetron	(PLIVA	Pharma	Ltd)	was	purchased	in	vials	of	2mg/ml	solution.		
• 50μl	 was	 administered	 directly	 to	 the	 spinal	 cord,	 using	 a	 Hamilton	 syringe,	 to	 provide	 a	100μg	dose;	 this	dose	was	selected	based	on	previous	work	 in	 the	2mg	MIA	model	 in	which	100	μg	had	provided	successful	modulation	of	evoked	activity	of	single	neurons	 in	Lamina	V	(Rahman,	Bauer	et	al.	2009).	
• The	effect	of	 this	dose	was	 followed	 for	an	hour	at	10,	30	and	50	minute	 intervals	 following	administration,	 where	 the	 electrical,	 mechanical	 and	 thermal	 stimulation	 protocol	 used	 to	characterize	the	cell	was	repeated	at	each	of	these	time	points.	
2)	Atipamezole:	
• Atipamezole	(Sigma,	UK)	was	dissolved	in	95:5	saline:DMSO	to	create	solutions	of	2mg/ml	and	0.2mg/ml	atipamezole.		
• Doses	were	 administered	 in	 a	 volume	 of	 50μl,	 directly	 to	 the	 spinal	 cord,	 using	 a	Hamilton	syringe.	
• The	effect	of	 two	doses	were	 followed	 in	each	animal,	administered	sequentially	and	spread	over	time	such	that:	
o Dose	1:	10μg	applied	directly	after	baseline	characterization	of	each	neuron	(t=0).	
o Dose	 2:	 100μg	 applied	 at	 t=70	mins,	 such	 that	 the	 drug	 was	 being	 applied	 once	 all	three	 rounds	 of	 characterization	 had	 been	 performed	 to	 assess	 the	 effect	 of	 dose	 1,	plus	an	additional	10minute	buffer.	
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These	 doses	 were	 selected	 based	 on	 previous	 work	 in	 the	 lab	 where	 10	 and	 100μg	 had	provided	 successful	 modulation	 of	 evoked	 activity	 in	 Lamina	 V,	 including	 in	 a	 2mg	 MIA	model(Green,	Lyons	et	al.	1998,	Burnham	2012).	
• The	effect	of	each	dose	was	followed	for	an	hour	after	administration,	at	10,	30	and	50minutes,	where	the	electrical,	mechanical	and	thermal	protocol	used	to	characterize	the	cell’s	responses	were	repeated	at	each	of	these	time	points	
	
4.2.5	 Data	Analysis	 	
The	 effect	 of	 each	drug	 is	 expressed	 as	 the	maximum	change	 	 in	 absolute	 terms	 from	 the	 	 baseline	value	 per	 individual	 drug	 dose	 across	 all	 time	 points.	 All	 data	 is	 expressed	 as	 number	 of	 action	potentials,	presented	as	the	mean	±	SEM.	
Effect	of	ondansetron	
• Naturally	evoked	(mechanical	and	thermal)	responses:	Difference	between	baseline	and	post-drug	 groups	 analysed	 using	 a	 two-way	 ANOVA	 followed	 by	 Bonferroni	 corrected	 post-hoc	tests.	
• Electrically	evoked	and	dynamic	brush	responses:	Difference	between	groups	analysed	using	paired	student’s	T	test.	
Effect	of	atipamezole	
• Naturally-evoked	 (mechanical	 and	 thermal)	 responses:	 Difference	 between	 groups	 analysed	using	a	two-way	ANOVA	followed	by	Bonferroni-corrected	post-hoc	tests.	
• Electrically-evoked	and	dynamic	brush	responses:	Difference	between	group	(Baseline,	10	and	100	μg)	analysed	using	one-way	ANOVA	with	Dunnett’s	correction	for	multiple	comparisons.	
Values	were	deemed	significant	at	p<0.05.	
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4.3	 Results	
4.3.1	Effect	of	ondansetron	in	Early	MIA	animals	
The	 effect	 of	 100μg	 ondansetron	 on	 evoked	 responses	 of	 Lamina	 V	WDR	 neurons	was	 assessed	 in	Arthritic	and	Sham	rats	3-5days	after	injection	of	MIA	or	Saline	respectively.	No	significant	effect	was	observed	in	either	group	of	animals,	across	electrical,	mechanical	and	thermal	stimulation.		
No	significant	change	in	electrically	evoked	activity	was	observed	in	either	Early	MIA	or	Sham	animals	following	 application	 of	 ondansetron	 (Figure	 4.1a).	 However,	 Early	MIA	 animals	 exhibited	 a	 strong	trend	 towards	 reduction	 in	 electrically	 evoked	 responses,	 notably	 Aδ	 (p=0.051)	 and	 windup	(p=0.054).	
No	 significant	 effect	 of	 ondansetron	 was	 observed	 in	 mechanically	 evoked	 responses,	 to	 either	dynamic	brush	or	punctate	stimuli,	in	either	group	(2	way	ANOVA)(Figure	4.1b,	c	&	d).	However,	there	is	an	observable	trend	towards	inhibition	of	evoked	mechanical	responses,	to	both	brush	and	punctate	stimuli	 in	 the	Early	MIA	animals	 that	 is	not	 seen	 in	 the	Sham	groups.	Similarly,	 though	 the	effect	of	ondansetron	was	not	significant	for	evoked	responses	to	thermal	stimulation	in	either	group	(2	way	ANOVA)	 (Figure	 4.1e	 &	 f),	 there	 is	 a	 sizable	 inhibition	 at	 45°C	 in	 Early	 MIA	 animals,	 which	 if	Bonferroni	post	tests	were	legitimate	give	a	p=0.081,	and	at	40°C	in	Early	Sham	animals	p=0.020.	AUC	analysis	(data	not	shown)	did	not	reveal	any	significant	difference.		Note	also,	in	Figure	4.1b,	that	no	difference	of	brush-evoked	responses	in	early	MIA	animals	vs.	shams	are	observed,	contrary	to	Figure	3.4b,	and	discussed	in	Section	3.4.3.	
4.3.2	Effect	of	ondansetron	in	Late	MIA	animals	
Ondansetron	had	no	significant	effect	on	Lamina	V	WDR	neuron	electrically	evoked	responses	in	Late	MIA	animals,	but	caused	a	significant	inhibition	of	both	the	Aβ	and	Aδ	counts	in	Late	Shams	animals	(Paired	 T	 Test,	 *	 p≤0.05)(Figure	 4.2a).	 This	 is	 a	 trend	 carried	 across	 the	 sham	 electrically	 evoked	responses,	 with	 a	 reduction	 in	 post	 discharge	 nearing	 significance	 at	 p=0.064.	 This	 is	 similarly	reflected	in	MIA	Aδ	counts	in	MIA	animals	following	ondansetron.	
No	 significant	 change	 in	 mechanically	 or	 thermally	 evoked	 responses	 following	 application	 of	ondansetron	was	 observed	 in	 either	 Late	MIA	 or	 Late	 Sham	 animals	 (2way	 ANOVA,	 Figure	 4.2c-f),	though	 both	 groups	 exhibited	 a	 trend	 towards	 reduced	 punctate	 mechanically	 evoked	 activity.	 A	similar	 trend	was	observed	 in	 thermally	evoked	responses	 in	Late	Shams,	whereby	Bonferroni	post	hoc	tests	indicated	a	significant	reduction	to	45°C	water	jet	(p=0.033).	AUC	analysis	(data	not	shown)	did	not	reveal	any	significant	difference.	
		 154	
	
Figure	4.1	 –100μg	of	spinally	 administered	ondansetron	has	no	significant	 effect	on	 the	evoked	responses	of	
Lamina	 V	 WDR	 neurons	 in	 Early	 MIA	 (n=7)	 or	 Early	 Sham	 (n=6)	 rats	 (Days	 3-5	 following	 injection).	 A)	Electrically	 evoked	 responses	 are	unaltered	 following	ondansetron	 in	both	MIA	 and	 Sham	B)	Dynamic	brush	 evoked	responses	 are	 unaltered	 following	 ondansetron,	 though	 there	 is	 a	 trend	 indicating	 inhibition.	 Paired	T-test	 assessed	effect	of	ondansetron.		
Second	 row:	 Punctate	 mechanical	 evoked	 responses	 in	 MIA	 (C)	 and	 Sham	 (D)	 are	 not	 significantly	 altered	 by	 the	application	of	ondansetron,	though	a	trend	indicating	inhibition	of	evoked	responses	is	apparent	to	noxious	mechanical	stimulation	in	MIA	animals.	Bottom	Row:	 	Thermally	evoked	responses	in	MIA	(E)	and	Sham	(F)	are	not	significantly	altered	 by	 the	 application	 of	 ondansetron,	 however	 a	 notable	 trend	 towards	 inhibition	 of	 45°C	 evoked	 responses	 is	apparent	in	MIA	animals	to	40°C	evoked	responses	in	Sham	animals.	2-way	ANOVA	assessed	effect	of	ondansetron.	
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Figure	4.2	 -100μg	of	spinally	administered	ondansetron	has	no	significant	effect	on	the	mechanically	or	 thermally	
evoked	 responses	 of	 Lamina	 V	WDR	 neurons	 in	 Late	 MIA	 (n=6)	 or	 Late	 Sham	 (n=7)	 rats	 (Days	 10-14	 following	
injection),	but	significantly	inhibited	the	electrically	evoked	Aβ	and	Aδ	counts	in	sham	animals.	A)	Electrically	evoked	responses	are	unaltered	following	ondansetron	in	MIA	animals,	but	significant	inhibition	of	Aβ	and	Aδ	counts	are	observed	in	Shams.	Paired	T-test	assessed	effect	of	ondansetron	(*	p≤0.05)	B)	Dynamic	brush	evoked	responses	are	unaltered	following	ondansetron	in	MIA	and	sham	animals.		
Second	row:	Punctate	mechanical	evoked	responses	in	MIA	(C)	and	Sham	(D)	are	not	significantly	altered	by	the	application	of	 ondansetron.	Bottom	 Row:	 	 Thermally	 evoked	 responses	 in	MIA	 (E)	 and	 Sham	 (F)	 are	not	 significantly	 altered	by	 the	application	of	 ondansetron,	 however	a	 notable	 trend	 towards	 inhibition	of	 45°C	 evoked	 responses	 is	 apparent	 in	 in	 Sham	animals.	2	way	ANOVA	assessed	effect	of	ondansetron.	
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4.3.3	Effect	of	atipamezole	in	Early	MIA	animals	
The	effect	of	sequential	doses	of	10μg	and	100μg	of	atipamezole,	when	applied	spinally,	on	the	evoked	responses	of	Lamina	V	WDR	neurons	was	 investigated	 in	arthritic	and	sham	animals,	3-5	days	after	the	 injection	 of	 either	 MIA	 or	 Saline	 respectively.	 Unlike	 previous	 work	 in	 the	 2mg	 model,	 no	significant	 effect	 was	 observed	 at	 either	 dose	 in	 either	 group	 for	 mechanical	 or	 thermally	 evoked	activity	(Figure	4.3).	
One	way	ANOVA	identified	a	significant	effect	of	atipamezole	on	electrically	evoked	windup	in	Early	MIA	animals,	in	which	Dunnets’	multiple	comparisons	identified	a	significant	reduction	from	100μg	of	atipamezole	(**p≤0.01).	No	significant	effect	was	observed	to	any	other	electrically	evoked	measure	in	Early	MIA	animals,	nor	in	Early	Shams,	as	a	result	of	atipamezole.	
While	One	Way	ANOVA	and	Two	Way	ANOVA	failed	to	 identify	a	significant	effect	of	atipamezole	 in	either	dynamic	brush	or	punctate	mechanically	evoked	responses	respectively	in	Early	MIA	animals,	there	is	an	unexpected	trend	towards	an	inhibitory	effect	of	atipamezole.	This	effect	nears	significance	for	 punctate	mechanical	 evoked	 responses,	 at	 p=0.082,	where	 the	 effects	 at	 vF26g	 following	100μg	atipamezole	or	at	vF60	following	10μg	are	clear.	In	contrast,	no	significant	effect	or	trend	is	observed	in	 the	Early	Sham	animals,	where	responses	closely	aligned	at	all	doses	of	atipamezole	 for	dynamic	brush	 and	 punctate	mechanical	 stimulation.	 Note	 also,	 in	 Figure	 4.3b	 that	 unpaired	 student’s	 t	 test	confirms	 the	 significant	 enhancement	 of	 brush-evoked	 responses	 in	 early	 MIA	 animals	 vs.	 shams	(*p≤0.05),	as	observed	in	Figure	3.4b.	
Atipamezole	 had	 no	 observable	 or	 significant	 effect	 on	 thermally	 evoked	 responses	 in	 either	 Early	MIA	or	Early	Sham	animals.	
	
4.3.4	Effect	of	atipamezole	in	Late	MIA	animals	
Neither	dose	of	10μg	nor	100μg	of	spinally	applied	atipamezole	has	a	significant	or	observable	effect	on	the	evoked	responses	of	Lamina	V	WDRs	in	arthritic	or	sham	animals	10-14	days	after	the	injection	of	 MIA	 or	 saline	 respectively,	 across	 all	 three	 stimulus	 modalities.	 Evoked	 responses	 were	 highly	consistent	across	the	two	doses	in	both	animals	groups	to	both	mechanical	and	thermal	stimulation.		As	 in	Early	animals,	 there	 is	arguably	a	 trend	 towards	reduced	electrically	evoked	responses	 in	 late	MIA	animals,	notably	wind	up.	
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Figure	4.3	-	Spinally	administered	atipamezole	has	no	significant	effect	on	the	mechanically	or	thermally	evoked	
responses	of	Lamina	V	WDR	neurons	in	Early	MIA	(n=7)	or	Early	Sham	(n=7)	rats	(Days	3-5	following	injection),	
but	 significantly	 inhibited	 the	 electrically	 evoked	 wind	 up	 in	 MIA	 animals.	 A)	 Electrically	 evoked	 responses	 are	unaltered	following	atipamezole	in	Sham	animals,	but	significant	inhibition	wind	up	is	observed	in	MIA	animals.	A	trend	towards	 increased	 C	 fiber,	 PD,	 input	 and	 wind-up	 is	 apparent	 in	 the	 Sham	 animals.	 One-way	 ANOVA	 with	 Dunnetts	multiple	comparisons	assessed	effect	of	atipamezole	(**	p≤0.01)	B)	Dynamic	brush	evoked	responses	are	not	significantly	altered	 by	 atipamezole	 in	 MIA	 and	 sham	 animals,	 though	 a	 trend	 towards	 inhibition	 is	 apparent	 in	 MIA	 animals.		Responses	are	significantly	enhanced	in	Early	MIA	vs.	Sham	(*	p≤0.05,	unpaired	student’s	T	test)	
Second	 row:	 Punctate	 mechanical	 evoked	 responses	 in	 MIA	 (C)	 and	 Sham	 (D)	 are	 not	 significantly	 altered	 by	 the	application	 of	 atipamezole.	Bottom	 Row:	 	 Thermally	 evoked	 responses	 in	MIA	 (E)	 and	 Sham	 (F)	 are	 not	 significantly	altered	by	the	application	of	atipamezole.	2	way	ANOVA	assessed	effect	of	atipamezole.	
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Figure	4.4	-	Spinally	administered	atipamezole	has	no	significant	effect	on	evoked	responses	of	Lamina	V	WDR	
neurons	 in	 Late	 MIA	 (n=7)	 or	 Late	 Sham	 (n=7)	 rats	 (Days	 10-14	 following	 injection)	 A)	 Electrically	 evoked	responses	are	unaltered	following	atipamezole	in	both	MIA	and	Sham.	A	trend	towards	increased	C	fiber,	PD	and	input	is	apparent	in	the	Sham	animals,	while	a	trend	towards	increasing	wind-up	is	seen	in	MIA	animals.	 	B)	Dynamic	brush	evoked	 responses	 are	 unaltered	 following	 atipamezole	 in	 both	 MIA	 and	 Sham.	 One-way	 ANOVA	 assessed	 effect	 of	atipamezole.		
Second	 row:	 Punctate	 mechanical	 evoked	 responses	 in	 MIA	 (C)	 and	 Sham	 (D)	 are	 unaltered	 by	 the	 application	 of	atipamezole	 in	 both	 MIA	 and	 Sham.	 Bottom	 Row:	 	 Thermally	 evoked	 responses	 in	 MIA	 (E)	 and	 Sham	 (F)	 are	 not	unaltered	 by	 the	 application	 of	 atipamezole	 in	 both	 MIA	 and	 Sham	 animals.	 2	 way	 ANOVA	 assessed	 effect	 of	ondansetron.	
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4.4	 Discussion	
A	 role	 for	 adaptations	 in	 tonic	descending	 controls	 in	OA	pain	were	 first	 suggested	by	 finding	 that,	following	 spinalization	 in	 cats	 with	 acute	 inflammatory	 monoarthritis,	 deep	 dorsal	 horn	 neurons	exhibited	greater	excitability	 and	enhanced	 receptive	 fields,	both	at	 the	knee	and	 the	paw(Schaible,	Neugebauer	et	al.	1991).Subsequently,	OA	has	been	modeled	using	MIA	injected	into	the	joint,	where	selective	antagonists	have	allowed	the	roles	of	individual	transmitters	and	receptors	to	be	teased	out.	These	 have	 pointed	 to	 time-sensitive	 adaptations	 in	 both	 the	 descending	 facilitatory	 and	 inhibitory	systems	on	deep	dorsal	horn	excitability	in	WDRs	receiving	inputs	from	the	hindpaw(Rahman,	Bauer	et	al.	2009,	Burnham	and	Dickenson	2013).	Herein	I	set	out	to	establish	if	these	adaptive	changes	are	consistent	in	at	a	milder,	non-neuropathic	dose	of	MIA	to	model	of	OA	pain.	Findings	here	suggest	they	are	not,	adding	 further	 to	our	understanding	 that	OA	 is	a	complex	and	highly	plastic	pain	condition	whose	mechanisms	and	manifestations	depend	both	on	time	point	and	extent	of	pathophysiology.		
Herein	 I	 have	 demonstrated	 that	 at	 neither	 time	 point	 investigated	 in	 this	 1mg	 MIA	 model	 is	 a	significant	effect	of	antagonism	of	either	5HT3	or	α2	observed	on	the	mechanically	or	thermally	evoked	responses	of	 lamina	V	WDR	cells,	 as	 in	 the	sham	groups,	 though	 trends	may	be	apparent.	This	 is	 in	direct	contradiction	to	findings	in	the	2mg	MIA	model,	which	have	demonstrated	significantly	greater	attenuation	 by	 ondansetron	 of	 thermal	 and	 non-noxious	 punctate	 and	 brush-evoked	 responses	 at	days	 14(Rahman,	 Bauer	 et	 al.	 2009),	 and	 significant	 facilitation	 by	 atipamezole	 of	 mechanically-evoked	 responses	at	days	3-5(Burnham	and	Dickenson	2013),	 effects	not	observed	 in	 sham	control	animals.			
4.4.1	The	1mg	MIA	model	of	OA	fails	to	recruit	descending	serotonergic	facilitatory	systems	
While	 plasticity	 of	 peripheral	 and	 spinal	 processes	 are	 crucial	 determinants	 of	 the	 pain	 experience,	especially	 in	 chronic	 conditions,	 the	 contribution	 of	 descending	 serotonergic	 influences	 from	 the	brainstem,	which	either	facilitate,	maintain	or	attenuate	spinal	excitability,	have	been	demonstrated	in	inflammatory,	neuropathic	and	visceral	pain	models(Urban,	Zahn	et	al.	1999,	Wei,	Dubner	et	al.	1999,	Green,	Scarth	et	al.	2000,	Terayama,	Guan	et	al.	2000,	Suzuki,	Rahman	et	al.	2004,	Bee	and	Dickenson	2007,	 Wei,	 Dubner	 et	 al.	 2010,	 Sikandar,	 Bannister	 et	 al.	 2012).	 While	 both	 these	 inhibitory	 and	facilitatory	systems	may	be	active	at	once,	it	is	postulated	that	it	is	the	discreet	balance	between	the	two	that	 may	 determine	 the	 profile	 of	 the	 pain	 experienced(Porreca,	 Ossipov	 et	 al.	 2002,	 Vanegas	 and	Schaible	2004).		
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Crucially,	 the	 net	 balance	 of	 inhibitory	 and	 facilitatory	 controls	may	 differ	 between	 the	 primary	 and	secondary	 pain	 sites,	 helping	 to	 explain	 the	 presence	 of	 referred	 pains	 –	 both	 in	 the	 clinic,	 where	referred	pain	is	correlated	with	the	presence	of	brain	stem	sensitization(Gwilym,	Keltner	et	al.	2009),	but	also	in	the	MIA	model,	where	changes	in	sensitivity	are	observed	beyond	the	knee,	in	the	paw.	It	has	previously	 been	 demonstrated	 that	 local	 administration	 of	 lidocaine,	 or	 antagonists	 for	 NMDA	 or	neurotensin	 receptors	 in	 the	 RVM	 attenuates	 the	 development	 of	 secondary	 thermal	 hyperalgesia	during	paw	inflammation(Ren	and	Dubner	1996,	Urban,	Coutinho	et	al.	1999,	Wei,	Dubner	et	al.	1999).	This	 points	 to	 a	 possible	 role	 for	 descending	 facilitations	 in	 driving,	 or	 at	 least	 maintaining,	 these	secondary	or	referred	pains.	However,	these	studies	focus	on	relatively	acute	periods	of	time,	largely	3-5days	after	the	 inflammatory	 insult.	 In	the	absence	of	work	on	descending	serotonergic	 facilitation	in	the	 early	 days	 of	 the	 MIA	 model,	 these	 results	 predict	 a	 serotonergic	 drive	 of	 excitability	 of	 WDRs	serving	 the	 paw	 in	 the	 early	 stages	 of	 the	 MIA	 model.	 Work	 from	 this	 lab	 has	 already	 pointed	 to	increased	drive	acting	at	5HT3	at	day	14+	of	the	2mg	MIA	model,	though	it	is	of	note	that	this	does	not	necessarily	 mean	 that	 facilitation	 predominates,	 as	 descending	 inhibitory	 controls	 have	 also	 been	shown	 to	be	 increased	or	even	dominant	over	 facilitations	at	 later	 stages	of	 the	model(Burnham	and	Dickenson	2013,	Kelly,	Dobson	et	al.	2013).		
	
Electrically-evoked	Responses	
Previous	work	 in	 this	 lab,	 across	naïve,	 shams,	 SNL,	2mg	MIA	and	 carrageenan	 inflammatory	models	have	 failed	 to	 identify	 any	 effect	 of	 spinal	 application	 of	 ondansetron	 on	 the	 electrically	 evoked	measures	of	spinal	excitability	in	deep	dorsal	horn	neurons(Green,	Scarth	et	al.	2000,	Suzuki,	Rahman	et	al.	2004,	Rahman,	Bauer	et	al.	2009).	This	is	broadly	in	line	with	findings	reported	here,	in	which	no	significant	effect	of	ondansetron	is	observed	in	either	early-	or	late-phase	MIA	animals,	or	early-phase	sham	animals.	However,	there	are	two	notable	exceptions	–	the	evoked	Aβ	and	Aδ	counts	in	late	shams	are	 significantly	 reduced	 following	 ondansetron,	 where	 Aδ	 counts	 similarly	 show	 a	 strong	 trend	towards	reduction	in	early-phase	and	late-phase	MIA	animals	(p=0.051	in	early	MIA).		
If	we	 first	consider	results	presented	 in	Chapter	3	(Figure	3.2),	 it	can	be	observed	that	 the	Aδ	counts	were	enhanced	in	all	MIA	and	the	late-phase	sham	animals	compared	to	early-phase	sham	animals.	This	relationship	is	significant	for	the	comparison	between	Late	MIA	and	Early	Sham	(p=0.037,	unpaired	T-test)	and	nears	significance	for	Early	Sham	vs.	Late	Sham	(p=0.074,	unpaired	T-test).	Given	conclusions	from	Chapter	3,	that	Late	Sham	animals	may	be	exhibiting	enhancements	relating	to	long-term	damage	by	 injection	 process	 such	 that	 only	 early	 Shams	 represent	 the	 true	 control	 baseline,	 it	 could	 be	postulated	that	in	these	three	animal	groups	(Both	MIA	groups	and	Late	Sham)	there	is	a	potentiation	in	
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the	range	of	the	Aδ	fibers	to	electrical	stimulation.	Such	changes	have	previously	been	observed	in	the	2mg	MIA	model(Vonsy	2008,	Harvey	and	Dickenson	2009,	Burnham	and	Dickenson	2013),	as	well	as	in	studies	considering	 the	effects	of	capsaicin(O'Neill,	Brock	et	al.	2012,	O'Neill	2014).	Such	changes	are	broadly	considered	to	be	indicative	of	central	sensitization,	indicating	the	recruitment	of	Aδ	fibre	input	to	WDRs,	supporting	the	idea	of	central	sensitization	in	both	the	early	and	late	stages	of	the	1mg	MIA	model,	and	perhaps	even	the	late	sham	animals.		
If	we	then	consider	the	effect	of	ondansetron,	which	reduces	these	Aδ	counts	from	electrically-evoked	responses,	 it	 could	 be	 postulated	 that	 descending	 serotonergic	 systems	 may	 be	 facilitating	 the	recruitment	of	these	Aδ	fibers	during	MIA	model.	Because,	with	the	exception	of	Aβ	counts	in	late	sham,	no	similar	effect	or	trend	is	observed	to	the	counts	attributed	to	other	fiber	types	or	post	discharge,	it	seems	likely	this	could	be	a	pre-synaptic	effect	which	is	predominantly	restricted	to	Aδ	fibers,	assisting	in	 their	 recruitment	 and	 potentiation	 of	 electrically-evoked	 responses.	 This	 is	 in	 line	 with	 previous	work	 characterizing	 the	 expression	 of	 5HT3	 receptors	 in	 primary	 afferents,	 which	 identifies	 the	predominant	expression	of	 these	receptors	 to	be	on	Aδ	 fibers(Zeitz,	Guy	et	al.	2002),	as	well	as	work	identifying	that	PAG	activation	either	facilitated	or	suppressed	responses	of	dorsal	horn	neurons	with	A	fiber	or	C	 fiber	driven	 input	 respectively(Waters	 and	Lumb	2008).	 (For	 an	overview	of	 the	plasticity	and	functional	significance	of	this	see	Heinricher	et	al	2009(Heinricher,	Tavares	et	al.	2009)).	It	could	be	 hypothesized	 that	 descending	 serotonin	 acts	 at	 5HT3	 receptors	 on	 pre-synaptic	 terminals	 of	 Aδ	fibers	to	augment	transmitter	release	and	thus	the	likelihood	of	activating	the	secondary	fiber.	This	sub-population	of	non-peptidergic	and	non-IB4	containing	afferents	with	pre-synaptic	5HT3	receptors	are	predominantly	 found	 in	 the	 superficial	 lamina(Kidd,	 Laporte	 et	 al.	 1993,	 Miquel,	 Emerit	 et	 al.	 2002,	Zeitz,	Guy	et	al.	2002),	making	 it	most	 likely	that	ondansetron	restricts	the	passage	of	 information	by	interneurons	from	Aδ	to	WDR	neurons	in	the	deep	dorsal	horn.	
As	such,	the	apparent	potentiation	in	the	range	of	the	Aδ	fibers	to	electrical	stimulation	in	these	groups	following	 MIA	 and	 at	 days	 10-14	 following	 sham	 injection,	 plus	 the	 reduction	 apparent	 following	ondansetron	 may	 indicate	 that	 the	 peripheral	 driver	 from	 the	 knee	 are	 activating	 descending	serotonergic	controls	from	the	brainstem	which	facilitate	the	recruitment	of	Aδ	fibers	during	this	state	of	 central	 sensitization.	 However,	 this	 effect	 is	 only	 significant	 in	 late-phase	 shams	 and	 nears	significance	in	early-stage	MIA	animals.	It	could	be	postulated	that	the	contribution	of	serotonin	to	this	process	 is	relatively	minor,	 thus	explaining	why	this	effect	was	not	reported	 in	previous	studies	–	 for	example,	in	Green	et	al	2000	the	application	of	ondansetron	produced	an	average	19%	reduction	in	Aδ	response(Green,	Scarth	et	al.	2000);	as	all	other	electrically-evoked	measures	in	this	study	remained	at	99%	 of	 baseline	 values	 or	 above,	 this	 may	 represent	 a	 small	 but	 meaningful	 reduction	 in	 Aδ	 fiber	activity.		
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Mechanically-evoked	responses	
This	 study	 failed	 to	 identify	 any	 significant	 effect	 of	 the	 spinal	 application	 of	 100μg	 ondansetron	 on	either	the	dynamic	brush-	or	punctate	mechanically-evoked	responses	in	either	MIA	or	sham	animals,	at	 either	 time	 point.	 While	 a	 trend	 towards	 reduced	 evoked	 responses	 was	 observed,	 this	 lacks	significance.	 As	 such,	 these	 results	 are	 far	 more	 in	 line	 with	 observations	 of	 the	 effect	 of	 spinal	ondansetron	 in	 naïve	 and	 sham	 animals	 that	 do	 not	 show	 evidence	 of	 significant,	 active	 descending	serotonergic	facilitation	of	mechanically-evoked	responses(Suzuki,	Rahman	et	al.	2004,	Rahman,	Bauer	et	al.	2009).	This	is	in	direct	contrast	to	findings	in	the	2mg	MIA	model,	in	which	evoked	responses	to	dynamic	 brush,	 vF2g	 and	 vF8g	were	 reduced	by	more	 than	50%	at	 this	 dose	 of	 ondansetron	 in	MIA	animals,	but	not	 shams(Rahman,	Bauer	et	al.	2009).	This	work	similarly	 showed	no	 increase	 in	5HT3	receptor	mRNA	in	 the	DRG	of	MIA	animals,	which	suggests	 these	changes	are	 the	result	of	 increasing	transmitter	as	opposed	to	increased	receptor	expression	driving	facilitation.		
Many	reports	describe	how	the	facilitatory	effects	of	descending	serotonin	contribute	to	excitability	in	the	dorsal	horn,	as	is	also	reflected	in	behaviour.,	including	time	spent	licking	or	biting.	The	effects	are	seen	in	the	second	phase	of	the	formalin	response(Green,	Scarth	et	al.	2000,	Zeitz,	Guy	et	al.	2002);	in	SNL	and	SCI	models	of	neuropathic	pain(Oatway,	Chen	et	al.	2004,	Suzuki,	Rahman	et	al.	2004,	Bee	and	Dickenson	2008);	in	models	of	visceral	pain(Vera–Portocarrero,	Yie	et	al.	2006,	Sikandar,	Bannister	et	al.	2012);	and	in	carrageenan	and	CFA	models	of	 inflammatory	pain(Rahman,	Suzuki	et	al.	2004,	Wei,	Dubner	 et	 al.	 2010).	 In	 contrast,	 blocking	 descending	 facilitatory	 pathways	 leaves	 baseline	 (naïve	animal)	electrophysiological	and	behavioural	responses	to	mechanical	stimuli	unaltered	–	in	line	with	this,	5HT3	receptor	knock	out	mice	or	mice	with	genetic	deletion	of	5HT3	receptors	show	a	normal	acute	pain	profile(Zeitz,	Guy	et	al.	2002,	Kayser,	Elfassi	et	al.	2007),	similar	to	wild	type	mice,	but	the	second	phase	of	 the	 formalin	test	 is	significantly	reduced.	This	 is	 in	agreement	with	work	utilizing	molecular	depletion	 of	 serotonin(Wei,	 Dubner	 et	 al.	 2010),	 which	 showed	 unaltered	 acute	 pain	 profiles	 but	reduced	 second	 phase	 formalin	 and	 WDR	 electrophysiology,	 which	 is	 unaltered	 by	 ondansetron	 in	naïve	and	shams(Suzuki,	Rahman	et	al.	2004,	Rahman,	Bauer	et	al.	2009).		
As	such,	 it	 is	proposed	that	serotonergic	 facilitation	 is	only	activated	by	stimuli	and	conditions	which	generate	 a	 sufficient	 drive	 from	 the	 periphery,	 where	 descending	 facilitations	 contribute	 to	 the	enhanced	 excitability	 of	 spinal	 cord	 neurons	 and	 the	 maintenance	 of	 a	 state	 of	 central	sensitization(Bardin	 2011).	 This	 barrage	 of	 nocifensive	 information	 thus	 triggers	 descending	serotonergic	 facilitation,	 as	 shown	 by	 replication	 of	 the	 analgesic	 effect	 of	 selective	 ablation	 of	NK1-containing	 ascending	neurons	 in	 the	 superficial	 lamina	 on	 the	 second	phase	 of	 formalin	 response	by	ondansetron(Suzuki,	 Morcuende	 et	 al.	 2002).	 This	 is	 similarly	 suggested	 by	 Green	 et	 al	 2000,	 who	suggest	a	“state	dependent	action”	of	descending	facilitation,	and	Peters	et	al	2010,	who	demonstrated	
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the	failure	of	ondansetron	to	provide	analgesic	efficacy	on	PWT	in	SNL	animals	because	of	the	failure	of	sub-	 or	 at-threshold	 stimuli	 to	 recruit	 descending	 serotonergic	 controls(Green,	 Scarth	 et	 al.	 2000,	Peters,	Hayashida	et	al.	2010).	
As	such,	the	failure	of	ondansetron	to	significantly	reduce	the	mechanically-evoked	responses	of	either	MIA	or	Sham	rats,	regardless	of	time	point,	in	this	1mg	model	of	MIA	can	be	attributed	to	the	severity,	or	lack	thereof,	of	joint	damage	in	this	model.	As	discussed	in	Chapter	3,	the	1mg	model	is	established	as	a	much	milder	OA	model,	 both	 in	 terms	 of	 extent	 of	 inflammation,	 extent	 of	 pathological	 changes	 at	earlier	 time	 points	 and	 lacking	 in	 neuropathic	 contributions.	 It	 could	 be	 interesting,	 given	 work	 of	others	in	the	1mg	model,	which	reveal	a	lack	of	behavioural	sensitivity	at	day	14	but	not	day	28(Kelly,	Dobson	 et	 al.	 2013),	 to	 investigate	 whether	 this	 remains	 the	 case	 at	 later	 days	 within	 this	 model	 –	where	 it	 could	 be	 hypothesized	 that	 at	 later	 points,	 where	 bone	 pathology	 becomes	 far	 more	pronounce,	that	descending	facilitations	could	finally	become	engaged.		
	
Thermally-evoked	responses	
In	 line	with	 observations	 of	 the	mechanically-evoked	 responses,	 no	 significant	 effect	 of	 ondansetron	was	observed	in	either	MIA	or	sham	animals,	at	either	time	point,	on	the	responses	of	deep	dorsal	horn	neurons	 following	 thermal	 water	 jet	 to	 the	 paw.	 As	 discussed	 above,	 this	 can	 be	 attributed	 to	 the	inability	of	this	milder	model	of	OA	to	recruit	descending	facilitatory	controls.		
That	 serotonin	 contributes	 to	 secondary	 thermal	 hyperalgesia	 has	 been	 established	 in	 certain	 pain	conditions.	The	molecular	depletion	of	5HT	using	shRNA	for	Tph-2	produced	significant	reductions	in	thermal	hyperalgesia	in	both	SNL	and	CFA	treated	animals,	but	failed	to	affect	thermal	paw	withdrawal	latencies	 in	control	animals.	 It	 is	notable	 that	 these	effects	were	 time-dependent	 in	 the	 inflammatory	model	–	indicating	the	plasticity	of	this	descending	facilitation	during	inflammatory	pain(Wei,	Dubner	et	 al.	 2010).	 Similarly	RVM	 lesioning	and	spinalizations	blocked	 the	development	of	 reduced	 thermal	withdrawal	thresholds	at	secondary	sites(Urban,	Jiang	et	al.	1996,	Urban,	Zahn	et	al.	1999,	Urban	and	Gebhart	1999),	supporting	the	importance	of	these	controls	in	the	development	of	thermal	sensitivities.	
Additionally,	 certain	 thermal	 stimuli	may	be	 considered	 sufficient	 to	 engage	 descending	 serotonin	 in	naïve	or	sham	animals,	where	strong	engagement	of	A	and	C	fibers	may	presents	a	sufficient	peripheral	drive	 even	 in	 healthy	 animals.	 This	 goes	 some	way	 to	 explain	 how	ondansetron	produces	 significant	inhibition	of	 thermally-evoked	responses	between	42-48°C	 in	shams,	SNLs	and	2mg	MIA	animals	but	that	 the	extent	of	 inhibition	 is	not	 significantly	different	between	 the	 control,	 acute	and	chronic	pain	groups(Rahman,	Suzuki	et	al.	2004,	Suzuki,	Rahman	et	al.	2004,	Rahman,	Bauer	et	al.	2009).	It	similarly	
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explains	 how	 SP-SAP	 treated	 animals,	 which	 have	 NK-1	 containing	 superficial	 neurons	 in	 the	 dorsal	horn	ablated,	exhibit	significantly	reduced	evoked	responses	to	42-48°C	stimulation(Suzuki,	Morcuende	et	al.	2002).	This	could	account	for	the	differences	observed	at	45°C	in	early-phase	MIA	and	late-phase	sham	 animals	 following	 ondansetron	 and	 40°C	 in	 early-phase	 sham,	 which	 show	 near	 or	 significant	reductions,	when	considering	these	temperature	in	isolation.		
However,	as	previously	mentioned,	the	5HT3	receptor	has	been	shown	to	be	unnecessary	for	acute	pain	responses	 to	 both	 52.5°C	 hot	 plate,	Hargreaves	 test	 and	 tail	 flick(Zeitz,	 Guy	 et	 al.	 2002).	 	 This	 is	 not	necessarily	 contradictory	 however.	 It	 may	 be	 that	 beyond	 certain	 highly	 noxious	 temperatures,	certainly	 >50°C,	 the	 peripheral	 input	 from	 thermosensitive	 nociceptors	 is	 sufficient	 to	 maximally	activate	 WDRs	 such	 that	 facilitation	 from	 5HT3	 is	 no	 longer	 necessary	 nor	 relevant,	 such	 that	 this	neuron	cannot	be	further	activated.	This	is	not	to	say	that	serotonin	is	not	still	released	in	response	to	this	stimulus,	only	that	spinal	WDRs	are	already	responding	maximally	to	a	large	peripheral	input	,	so	the	impact	of	serotonin	release	is	less	relevant	versus	responses	to	lower	temperatures.	
Herein	 I	 have	 demonstrated	 that	 ondansetron	 has	 no	 significant	 effect	 on	 the	 thermally	 evoked	responses	of	WDR	neurones	in	a	1mg	model	of	MIA,	in	direct	contrast	to	previous	results	from	a	2mg	model.	 These	 results	 suggest	 that	 the	 1mg	 MIA	 model	 is	 not	 severe	 enough	 to	 recruit	 descending	facilitation,	as	is	seen	on	other	pain	models.	That	some	significant	or	near	significant	effect	is	observed	in	 early	MIA	 and	 sham	animals	 in	 the	middle	 of	 the	 thermal	 range	may	be	 attributed	 to	 the	noxious	drive	 of	 the	 temperature	 itself	 recruiting	 descending	 serotonin,	 an	 effect	 that	 looses	 physiological	relevance	at	the	upper	end	of	the	thermal	test	battery	as	the	WDR	approaches	maximal	rate	of	firing.	
Overall,	 these	 results	 suggest	 that	 the	1mg	MIA	model	 of	OA	 fails	 to	 recruit	 descending	 serotonergic	facilitations	of	mechanical	or	thermally	evoked	responses	at	either	days	3-5	or	days	10-14,	 likely	as	a	result	 of	 the	 milder	 profile	 of	 this	 smaller	 dose	 MIA	 model.	 This	 points	 to	 a	 mechanism	 in	 which	descending	 serotonergic	 facilitating	 plays	 no	 part	 in	 the	 hypersensitivities	 observed	 at	 the	 paw	 in	behavioural	 studies	 (Chapter	 3,	 Figure	 3.1).	 Given	 that	 it	 is	 believed	 by	 some	 that	 descending	facilitations	drive	secondary	but	not	primary	hyperalgesia(Urban	and	Gebhart	1999),	this	also	suggests	that	at	these	time	points	in	a	1mg	model	of	MIA	that	spinal	neurons	receiving	inputs	from	the	knee	will	similarly	lack	such	controls.		
While	 the	 wider	 implications	 of	 these	 findings	 to	 OA	 will	 be	 discussed	 alongside	 results	 of	noradrenergic	controls	in	Section	4.3.1,	there	are	some	issues	specific	to	serotonergic	regulation	of	the	1mg	 model	 that	 remain	 unanswered	 which	 could	 be	 addressed	 by	 future	 work.	 Namely	 –	 1)	 Are	facilitatory	 controls	 recruited	 at	 later	 time	 points	 in	 this	 1mg	 model?	 2)	 What	 role,	 if	 any,	 does	serotonergic	 facilitation	 or	 inhibition	 have	 at	 the	 knee	 joint?	 3)	 What	 role,	 if	 any,	 does	 descending	
		 165	
serotonin	 acting	 at	 5HT7	 have	 in	 this	 1mg	 model?	 The	 answers	 to	 these	 questions	 would	 perhaps	provide	a	more	complete	picture	of	the	role	of	the	brainstem	in	enabling	pain	in	OA.	
	
4.4.2	The	1mg	MIA	model	of	OA	fails	to	recruit	descending	noradrenergic	inhibitory	systems	
Descending	projections	from	the	dorsolateral	pontine	(DLP)	noradrenergic	cell	groups	(most	especially	from	the	locus	coeruleus	[A6],	A5	and	A7	nuclei)	provide	a	rich	source	of	NA	in	the	deeper	laminae	of	the	 dorsal	 horn	 spinal	 cord(Westlund,	 Bowker	 et	 al.	 1983,	Westlund,	 Bowker	 et	 al.	 1984,	 Clark	 and	Proudfit	 1991,	 Kwiat	 and	 Basbaum	 1992).	 When	 these	 nuclei	 are	 activated	 they	 trigger	 the	 spinal	release	of	NA	which,	through	action	at	the	α2	receptor,	provides	an	inhibition	that	curbs		the	excitability	of	spinal	neurons	and	inhibits	reflex	responses	in	behavioural	studies(Jones	and	Gebhart	1986).	During	states	 of	 central	 sensitization,	 especially	 in	 diseased	 states	 where	 inflammation	 drives	 a	 robust	peripheral	sensitization,	these	descending	controls	become	enhanced	to	provide	protection	from	both	primary	and	secondary	hyperalgesia(Tsuruoka	and	Willis	1996,	Green,	Lyons	et	al.	1998,	Wei,	Dubner	et	 al.	 1999,	 Tsuruoka,	 Maeda	 et	 al.	 2004,	 Hughes,	 Hickey	 et	 al.	 2013).	 It	 is	 suggested	 that	 these	descending	 inhibitions	 prevent	 “response	 saturation”	 at	 the	 top	 end	 of	 the	 noxious	 stimulation	 scale	and	 thus	maintain	accuracy	of	coding	 in	 the	WDR	neurons	during	periods	of	 inflammation(Tsuruoka,	Tamaki	 et	 al.	 2012).	 As	 is	 the	 case	 for	 descending	 serotonergic	 facilitations,	 much	 of	 the	 evidence	suggests	that	this	pathway	is	not	active	during	healthy,	acute	nociception(Hylden,	Thomas	et	al.	1991,	Tsuruoka	and	Willis	1996,	Gutierrez,	Nackley	et	al.	2003,	Hayashida,	Peters	et	al.	2012),	but	is	instead	activated	 by	 injury	 and	 inflammation.	 	 The	 contribution	 of	 this	 descending	 system	 in	 the	 2mg	 MIA	model	 of	 OA	 has	 previously	 been	 investigated	 in	 this	 lab,	 as	 outlined	 above,	 at	 both	 the	 early	inflammatory	and	later	nociceptive	driven	stage.	This	work	revealed	a	α2	driven	inhibition	of	response	of	WDRs	in	early	phase	MIA	animals	to	punctate	stimuli,	but	had	no	effect	in	either	late	phase	or	naïve	animals(Burnham	 and	 Dickenson	 2013).	 Interestingly,	 the	 administration	 of	 atipamezole	 following	milnacipran	reversed	deep	WDR	responses	to	both	mechanical	and	thermal	stimuli	to	pre-milnacipran	baselines	in	early	phase	2mg	MIA	and	naïve	animals,	but	failed	to	fully	reverse	this	effect	in	late	phase	animals(Burnham	 and	 Dickenson	 2013),	 suggesting	 a	 declining	 role	 for	 noradrenergic	 descending	inhibition	in	the	latter	stages	of	this	model	–	which	may	allow	for	a	shift	 in	the	balance	of	descending	controls	to	favour	the	facilitation	observed	at	days	14	of	the	2mg	model(Rahman,	Bauer	et	al.	2009).	
In	 contrast	 to	 the	 results	 observed	 in	 this	 2mg	 MIA	 model,	 no	 significant	 effect	 of	 10	 and	 100μg	atipamezole	on	the	evoked	responses	of	WDR	neurons	was	observed	at	either	the	early	or	late	stages	of	the	1mg	MIA	model,	much	as	has	previously	been	observed	 in	 sham	and	naïve	 animals.	 Importantly,	given	these	doses	of	atipamezole	have	previously	demonstrated	efficacy,	it	seems	less	likely	the	absence	
		 166	
of	 effect	 observed	 here	 is	 dose	 related(Green,	 Lyons	 et	 al.	 1998,	 Burnham	 and	Dickenson	 2013).	 An	inference	 from	 these	 results	 may	 be	 that	 this	 1mg	 MIA	 model	 is	 of	 insufficient	 severity	 to	 activate	descending	noradrenergic	controls	during	these	early	stages	of	OA.	
	
Absence	of	activation	of	descending	noradrenergic	controls		
As	 previously	 mentioned,	 animals	 that	 do	 not	 exhibit	 pain	 states	 do	 not	 exhibit	 descending	noradrenergic	 inhibition(Hylden,	Thomas	et	al.	1991,	Tsuruoka	and	Willis	1996,	Gutierrez,	Nackley	et	al.	 2003,	 Hayashida,	 Peters	 et	 al.	 2012).	 Put	 another	 way,	 naïve	 animals	 do	 not	 experience	 tonic	noradrenergic	 regulation	of	 spinal	excitability.	The	results	observed	at	both	 time	points	 for	 the	sham	animals	are	in	agreement	with	this,	if	we	accept	(contrary	to	some	observed	enhancements	of	baseline	neuronal	 responses	 to	 stimuli	 in	 late	 stage	 sham	 animals)	 that	 these	 animals	 accurately	 model	 the	absence	of	a	pain	state	–	as	observed	in	behaviour	in	Chapter	3.	While	there	is	some	evidence	of	tonic	NA	 in	 the	 spinal	 cord,	 this	 is	 attributed	 to	 the	 role	 of	NA	 in	modulating	 ventral	 horn	motor	 activity,	where	 dorsal	 horn	 NA	 levels	 remain	 unchanged	 over	 time	 in	 naïve	 animals	 but	 show	 considerable	increases	during	inflammation(Tsuruoka,	Hitoto	et	al.	1999).	
However,	 this	 does	 not	 necessarily	mean	 that	 animals	 exhibiting	 a	 lack	 of	 noradrenergic	 descending	inhibition	 do	 not	 have	 a	 pain	 condition.	 While	 activation	 of	 noradrenergic	 inhibition	 is	 intensity	dependent,	explaining	much	in	the	same	way	as	with	serotonergic	controls	how	such	inhibition	could	be	absent	in	this	low	dose	MIA,	the	changes	are	also	dynamic	over	the	time	course	of	injury.	Hughes	et	al	2013	suggest	that	this	descending	noradrenergic	system	spatially	restricts	and	temporally	delays	the	expression	of	neuropathic	pain(Hughes,	Hickey	et	al.	2013),	but	loses	influence	once	neuropathic	pain	is	established	–	as	seen	by	the	 lack	of	an	effect	of	α2	adrenoceptor	antagonism	in	neuropathic	animals	 -	using	this	argument	to	explain	the	lack	of	efficacy	of	NA-based	therapies	in	neuropathic	pain	(Hughes,	Hickey	et	al.	2013).	The	lack	of	α2	adrenoceptor	inhibition	is	similarly	observed	in	electrophysiological	studies	 with	 SNL	 animals,	 which	 exhibit	 clear	 behavioural	 hypersensitivity(Rahman,	 D’Mello	 et	 al.	2008).	It	can	similarly	be	observed	that	antagonism	at	α2	adrenoceptors	in	HZ	rats	that	fail	to	develop	neuropathic	pain	 can	 “unveil’	 the	pain	 state(De	Felice,	 Sanoja	et	 al.	 2011),	 suggesting	 that	 the	higher	proportion	(~85%	vs.	50%)	of	SD	rats	which	go	on	to	develop	allodynia	in	this	model	may	experience	the	development	of	this	chronic	pain	state	due	to	the	loss	of	noradrenergic	protections.	As	such,	there	is	clear	 evidence	 that	 not	 only	 can	 pain	 exist	 without	 the	 apparent	 engagement	 of	 descending	noradrenergic	systems,	but	seemingly	it	is	the	loss	of	these	systems	that	may	underlie	the	development	of	the	chronic	pain	condition.	
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However,	these	examples	relate	to	neuropathic	pain	while	in	the	current	work	this	1mg	dose	of	MIA	has	been	explicitly	chosen	to	avoid	neuropathic	contributions	to	pain,	at	both	time	points	investigated.	Such	changes	to	NA	controls	have	also	been	seen	in	inflammation:	Danziger	et	al	2001	have	shown	in	a	CFA	model	of	ankle	arthritis	 that	 tonic	descending	 inhibitions	were	enhanced	during	 the	acute	stages	 (24	hours)	and	decreased	over	the	chronic	stages	(3-4	weeks)(Danziger,	Weil‐Fugazza	et	al.	2001).	They	also	argue	that	regardless	of	descending	inhibition,	spinal	nociceptive	outputs	remain	increased	in	both	stages	of	inflammation	due	to	increased	peripheral	input	into	the	spinal	cord.	
Recent	work	from	this	lab	has	established	that	DNIC,	the	process	by	which	noxious	stimuli	to	one	part	of	the	body	inhibits	pain	perception	in	another,	has	identified	a	clear	role	for	descending	NA	at	α2	in	the	observed	effects	of	DNIC,	 through	both	 the	use	of	 atipamezole	and	Yohimbine	 (Bannister,	Patel	 et	 al.	2015)).	Given	that	a	loss	of	DNIC	is	described	in	patients	with	OA(Arendt-Nielsen,	Nie	et	al.	2010),	the	application	of	conclusions	on	the	absence	or	loss	of	a	NA	pain	protection	system	in	these	MIA	animals	may	reflect	the	loss	of	DNIC	in	patients,	where	such	changes	may	leave	increases	in	spinal	excitability	and	high	outputs	from	peripheral	barrage	to	the	spinal	cord	unchecked,	allowing	for	the	development	of	referred	pains	observed	in	patients	and	rats.	
In	the	above-discussed	experimental	protocols	however,	a	descending	NA	‘protection’	system	has	been	engaged	 and	 then	 lost,	 for	 which	 there	 is	 no	 evidence	 in	 this	 investigation	 present	 work,	 since	 no	atipamezole	related	enhancements	in	evoked	activity	are	observed	across	either	time	point.	In	this	1mg	MIA	model,	 in	contrast	 to	 findings	 in	 the	2mg	model,	atipamezole	has	no	significant	effect	on	evoked	responses	 of	WDR	neurons	 at	 days	 3-5	 post-injection.	 This	 could	 be	 the	 consequence	 of	 one	 of,	 or	 a	combination	of,	 two	possible	 factors.	First,	 that	 in	 the	1mg	model	 the	size	of	 the	 inflammatory	 insult,	and	thus	 the	peripheral	drive	 from	the	knee,	 is	 insufficient	 to	engage	 tonic	descending	noradrenergic	controls	 to	 this	 secondary	 site.	 Second,	 that	 this	 may	 relate	 to	 the	 differential	 regulation	 between	primary	and	secondary	sites.		
Ren	 and	 Dubner,	 in	 their	 review	 of	 descending	 modulation	 in	 persistent	 pain,	 state	 that	 “This	enhancement	of	descending	inhibition	appears	to	be	present	when	the	animal	is	subject	to	continuous,	persistent	 noxious	 stimulation”,	 where	 the	 primary	 afferent	 input	 is	 attributed	 to	 triggering	 this	ascending-descending	 feedback	 circuit.	 However,	 unlike	 the	 serotonergic	 system	 which	 appears	 to	require	 “sufficient”	 input	 above	 a	 certain	 threshold	 of	 nociceptive	 activity	 –	 given	 effects	 of	 5HT3	receptor	antagonism	are	not	seen	 in	 the	carrageenan	model	(Green,	Scarth	et	al.	2000)-	 the	effects	of	descending	 NA	 are	 observed	 as	 early	 as	 2	 hours	 and	 as	 late	 as	 5	 days	 after	 insult	 across	 various	“strengths”	of	inflammatory	pain	modeling(Tsuruoka	and	Willis	1996,	Tsuruoka	and	Willis	1996,	Green,	Lyons	et	al.	1998,	Tsuruoka,	Hitoto	et	al.	1999,	Gjerstad,	Tjølsen	et	al.	2000).	Such	 inflammatory	pain	models	are	likely	to	provide	a	rough	equivalent	to	this	early	phase	of	the	MIA	model.	As	such,	it	seems	
		 168	
that	pain	sufficient	to	be	observed	in	behavioural	studies	should	be	sufficient	to	activate	descending	NA	controls.		
We	 know	 from	 both	 the	 results	 presented	 in	 Chapter	 3,	 of	 both	 changes	 in	 weight	 distribution	 and	withdrawals	from	vF8g,	and	the	characterization	of	behaviour	in	this	model	that	animals	exhibit	pain-like	 behaviour	 at	 this	 time,	 at	 this	 dose(Thakur,	 Rahman	 et	 al.	 2012).	 Perhaps	 then,	 during	 the	electrophysiological	 recordings	 presented	 here,	 the	 lack	 of	movement	 or	weight	 bearing	 in	 the	 joint	allowed	 a	 break	 from	 high-level	 activity	 from	 the	 knee,	 and	 thus	 immobility-related	 quieting	 of	descending	 NA	 controls,	 while	 in	 the	 2mg	 animal	 the	 insult	 to	 the	 knee	 is	 sufficient	 that	 without	movement	 or	weight	 bearing	 pressure	 there	 is	 still	 ongoing	 input	 to	 the	 spinal	 cord	 and	DLP.	While	work	from	Kelly	et	al	2012	have	demonstrated	the	presence	of	a	significant	spontaneous	C-fiber	drive	form	the	periphery	in	immobile,	anaesthetized	1mg	MIA	animals(Kelly,	Dunham	et	al.	2012),	this	study	used	sodium	pentobarbital.	It	has	been	shown	previously	that	recordings	from	cortical	neurons	in	the	auditory	 center	 exhibit	 significantly	 reduced	 spontaneous	 activity	 under	 isoflurane	 vs.	 pentobarbital	(Cheung,	Nagarajan	et	al.	2001),	and	significant	differences	have	previously	been	observed	in	the	effects	of	 isoflurane	 and	 pentobarbital	 anaesthesia	 in	 animals	with	 inflammatory	 pains(Boegel,	 Gyulai	 et	 al.	2011)	 –	 though	 these	 are	 largely	 attributed	 to	 spinal	 GABAA	 differences	 and	may	 not	 be	 relevant	 to	these	peripheral	recordings.	To	test	this	theory,	it	would	be	interesting	to	investigate	the	effect	of	joint	movement	upon	noradrenergic	control	of	spinal	excitability	–	since	previous	work	has	shown	that	joint	manipulation	 following	 capsaicin	 injection	 to	 the	 knee	 induces	 an	 α2	 driven	 antinociception(Skyba,	Radhakrishnan	et	al.	2003).	
As	such,	it	is	possible	that	the	milder,	1mg	model	does	not	induce	sufficient	ongoing	activity	during	rest	to	 provide	 tonic,	 ongoing	 inhibition	 from	 descending	 noradrenaline	 –	 and	 instead	 this	 system	 may	simply	be	recruited	during	noxious	movement.	The	implication	of	this	is	two-fold.	First,	that	in	milder	1mg	 there	 is	 less	 ongoing	 pain	 and	 instead	 pain	 is	movement	 evoked.	 Conditioned	 place	 preference	(CPP)	work	across	multiple	MIA	doses	provides	support	for	this	hypothesis,	as	CPP	following	lidocaine	to	the	affected	knee	is	only	observed	in	3mg	animals(Okun,	Liu	et	al.	2012).	Second,	that	SNRI	therapies	would	only	provide	relief	 to	movement	evoked	pains.	 It	would	be	 interesting	to	consider	the	effect	of	SNRI	 therapy	 on	 behavioural	 measures	 including	 Rota	 rod,	 night	 time	 movement	 and	 burrowing	activities	in	the	1mg	model	to	see	if	this	is	indeed	the	case.	
How	else	can	the	lack	of	NA	modulation	be	explained?	It	could	be	that	these	results	can	be	attributed	to	the	areas	of	stimulation	on	the	animal.	By	testing	evoked	responses	from	paw	stimulation,	this	study	is	exclusively	considering	a	referred,	secondary	pain.	 It	 is	suggested	 that	during	 inflammatory	pain	 that	descending	 control	 systems	 discriminate	 between	 the	 sites	 of	 primary	 and	 secondary	 hyperalgesia,	such	 that	 inhibitions	 predominate	 to	 the	 primary	 sites	 and	 facilitations	 predominate	 to	 the	
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secondary(Vanegas	 2004).	 Indeed,	 many	 of	 the	 studies	 outlined	 above	 in	 which	 descending	 NA	 is	engaged	 to	 limit	 spinal	 excitability	 and	 behaviour	 investigate	 the	 primary	 injury	 sites.	 	 Though,	 of	course,	 the	 adaptations	 identified	 from	 previous	 work	 on	 2mg	 MIA	 from	 this	 lab	 is	 focusing	 on	 a	secondary	areas(Burnham	and	Dickenson	2013).	Perhaps,	 if	work	were	 to	 investigate	NA	controls	 to	the	knee	in	a	1mg	model	such	controls	would	be	evident,	and	may	be	an	avenue	for	future	investigation.	
Ultimately,	 with	 the	 clear	 presence	 of	 hypersensitivity	 at	 this	 time	 point	 in	 these	 early-phase	 MIA	animals,	alongside	work	that	well	characterizes	inflammation	and	pain	in	these	animals,	the	absence	of	recruited	descending	noradrenergic	inhibition	from	the	LC	is	hard	to	explain.	It	is	possible	to	attribute	this	to	a	bad	batch	of	drug,	however	when	this	lack	of	effect	was	first	observed	a	second,	new	batch	of	atipamezole	was	additionally	dissolved	and	tested.	This	similarly	failed	to	produce	any	effect.	
The	final	(but	very	unlikely!)	possibility,	when	considering	the	effect	of	atipamezole	in	these	early	MIA	animals	is	that	NA	is	in	fact	present	in	the	dorsal	horn,	but	instead	facilitating	excitability	–	given	there	appears	 to	 be	 a	 possible	 inhibition	 of	 evoked	 responses	 by	 atipamezole	 in	 the	 Early	 MIA	 animals,	instead	of	the	expected	enhancements.	While	the	lack	of	effect	of	atipamezole	on	evoked	responses	of	WDRs	in	both	MIA	and	Sham	animals	was	relatively	robust	–	with	virtually	indistinguishable	response	curves	to	vF	and	temperature	in	 late	MIA	and	Sham	animals	-	 there	are	two	curious	exceptions.	First,	the	 significant	 reduction	 in	 windup	 observed	 following	 atipamezole,	 and	 secondly,	 a	 trend	 towards	
reduction	 in	mechanically	 evoked	 responses	 in	 the	 early	MIA	 animals,	 though	 this	 is	 not	 statistically	significant	
	
How	could	atipamezole	significantly	inhibit	windup	in	the	early	1mg	MIA	model?	
As	can	be	seen	in	Figure	4.3a,	increasing	doses	of	atipamezole	result	in	increasing	reduction	in	wind	up	to	evoked	electrical	responses	 in	Early	MIA	animals,	where	the	effect	of	100μg	was	highly	significant.	The	indication	of	such	an	effect	is	that,	by	some	unclear	mechanism,	descending	noradrenaline	at	days	3-5	 is	 facilitating	wind	up	 such	 that	 its	 blockade	 results	 in	 a	 reduction	 to	 levels	 below	 those	 seen	 in	sham	 animals.	 Traditionally	 the	 analgesic	 action	 of	 α2	 adrenoceptor	 activation	 is	 driven	 by	 the	presynaptic	 inhibition	 of	 excitatory	 glutamatergic	 inputs	 from	 afferents,	 especially	 C	 fiber,	 and	interneuron	input(Sullivan,	Dashwood	et	al.	1987,	Kamisaki,	Hamada	et	al.	1993,	Pan,	Li	et	al.	2002),	as	well	 as	 enhancing	 GABA	 release(Gassner,	 Ruscheweyh	 et	 al.	 2009).	 Logically,	 for	 atipamezole	 to	 be	inhibiting	windup,	NA	would	have	to	be	enabling	windup	–	perhaps	by	enhancing	excitatory	transmitter	release	 from	 presynaptic	 button,	 possibly	 by	 reducing	 inhibitory	 transmitter	 release	 from	 inhibitory	interneurons.	In	other	words,	the	complete	opposite	to	the	actions	previously	characterized.		
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Other	 possibilities,	 that	 NA	 could	 be	 exerting	 an	 excitatory	 role	 through	 the	 inhibition	 of	 inhibitory	systems	or	 activation	of	 excitatory	 systems	are	 already	established	not	 to	be	 the	 case	by	a	wealth	of	previous	 study,	 reviewed	 by	 Pertovaara	 et	 al	 2013(Pertovaara	 2013),	 leaving	 these	 results	 as	 some	what	of	an	anomaly	that	I	am	unable	to	explain.	
	
Does	noradrenaline	at	the	α2	receptor	facilitate	mechanically	evoked	responses?	
Similarly	to	the	above,	the	spinal	application	of	atipamezole	in	early	MIA	animals	led	to	a	trend	towards	inhibition	of	mechanically	evoked	responses.	In	Figure	4.3b	there	is	a	sizeable	reduction	in	the	evoked	responses	 to	 brush	 observed	 in	 the	 100	 μg	 of	 atipamezole	 test.	 Similarly,	 in	 Figure	 4.3c	 the	 trend	towards	 significant	 reduction	 to	 punctate	mechanical	 evoked	 responses	 following	 atipamezole	 nears	significance	at	p=0.082	and	such	that,	if	considered	in	isolation,	the	reduction	observed	to	vF26g	after	100μg	atipamezole	and	the	reduction	at	vF60g	after	10μg	would	be	significant.		
This	 again	presents	 the	 same	 issue	discussed	 for	wind-up	 –	 for	 atipamezole	 to	 provoke	 inhibition	 of	evoked	responses,	NA	must	be	facilitating	mechanically	evoked	responses.	As	previously,	control+saline	responses	 exhibited	 in	 the	 appendix	 exclude	 flaws	 to	 technique	 underlying	 this	 decline	 in	 evoked	activity.	Similarly,	the	hitherto	understood	mechanisms	of	NA	at	α2	in	the	spinal	cord,	and	the	effect	of	α2	antagonism	across	a	range	of	pain	models,	go	against	the	observations	in	these	early	MIA	animals.	
	
4.4.3		Question	of	Central	Sensitization	in	the	MIA	Model	
In	this	chapter	I	have	presented	results	that	suggest	that	in	this	1mg	MIA	model,	at	both	the	early	and	later	 stages,	 there	 is	 an	 apparent	 absence	 of	 a	 descending	 serotonergic	 drive	 or	 noradrenergic	inhibition	of	spinal	excitability	in	response	to	both	mechanical	and	thermal	stimulation.	This	aligns	to	results	of	Chapter	3,	in	which	little	to	no	significant	enhancement	of	baseline	evoked	responses	of	WDR	neurons	 in	MIA	animals	are	observed.	This	 leads	me	to	question	the	presence	of	central	sensitization	(CS),	 at	 least	 at	 the	 L5	 segment	 serving	 the	 paw,	 during	 this	 1mg	 model	 of	 OA	 at	 the	 time	 points	considered,	 since	 WDRs	 are	 exhibiting	 neither	 enhanced	 evoked	 responses	 nor	 recruitment	 of	descending	 controls.	 This	 instead	 suggests	 that,	 prior	 to	 day	 14	 of	 the	 1mg	 MIA	 model,	 the	 pain	observed	in	this	model	is	likely	driven	by	peripheral	changes	and	strong	nociceptive	signals	from	knee	pathology.		
Though	 investigation	of	measures	 that	may	 indicate	CS	 in	 the	1mg	model	are	 less	common,	 there	are	studies	that	refute	my	conclusion	and	point	to	a	potential	CS	at	these	time	points	(See	Table	4.1).	Of	22	
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studies	investigating	pain	in	the	1mg	MIA	model	of	OA,	8	extend	results	indicative	of	a	potential	central	sensitization	in	one	of	the	time	periods	of	 interest.	Notably	however	only	one	study,	Sagar	et	al	2011,	present	data	in	which	central	sensitization	at	one	of	these	time	points	is	supported	by	multiple,	diverse	measures.	Within	this	specific	study	treatment	with	1mg	MIA	significantly	decreased	ipsilateral	WB	and	PWTs	 of	 the	 hindpaw	 (distal	 allodynia),	 compared	 to	 saline-treated	 rats,	 from	 post-injection	 day	 7	onwards.	 The	 numbers	 of	 Iba-1	 positive,	 morphologically	 identified,	 activated	 microglia	 were	 also	significantly	increased	in	the	ipsilateral	spinal	cord	at	days	7,	14	and	28	in	MIA-treated	rats	vs.	CL,	and	vs.	Saline	treated	rats(Sagar,	Burston	et	al.	2011).		Additionally,	oral	administration	of	nimesulide	(days	14-20)	 significantly	 attenuated	 MIA-induced	 decreases	 in	 weight	 bearing	 and	 distal	 allodynia.	 Such	changes	in	the	activation	of	microglia,	combined	with	changes	in	distal	allodynia,	point	to	a	CS	from	day	7	onwards	(For	discussion	of	microglia	contributions	to	CS	see(Woolf	and	Salter	2006)).		However	this	study	only	found	a	significant	correlation	between	the	numbers	of	activated	microglia	in	the	ipsilateral	spinal	 cord	 and	 distal	 allodynia	 at	 Day	 28.	While	 this	 advocates	 strongly	 for	 contribution	 of	 central	sensitization	 to	 aberrant	 pain	 responses	 at	 these	 later	 stages,	 the	 failure	 to	 correlate	 the	 significant	changes	 observed	 from	day	 7	 onwards	 provides	weaker	 support	 of	 an	 active	 contribution	 of	 central	sensitization	to	the	pain	observed	in	the	MIA	model	during	days	10-14.			
Of	the	remaining	7	studies	whose	results	are	suggestive	of	CS	in	either	the	early	(3-5day)	or	late	(10-14day)	stages	of	the	1mg	MIA	model,	all	fail	to	conclusively	refute	my	conclusions	of	the	absence	of	CS	in	L5	lamina	V	at	the	time	points	studied	(Table	4.1).	In	the	case	of	Ivanavicus	et	al	2007(Ivanavicius,	Ball	 et	 al.	 2007)	 the	 observed	 efficacy	 of	 gabapentin	 at	 day	 14	 (the	 earliest	 time-point	 used	 for	pharmacological	 assessment)	 may	 only	 be	 used	 confidently	 as	 surrogate	 indicator	 of	 central	sensitization	 if	 the	 potential	 contributions	 of	 peripheral	 action	 are	 dismissed(Chapman,	 Suzuki	 et	 al.	1998,	Hanesch,	Pawlak	et	al.	2003).	In	the	remaining	6	studies,	evidence	of	CS	relies	upon	the	observed	changes	 in	 PWT	 at	 these	 time	 points.	 As	 already	 discussed	 in	 Chapter	 3	 and	 this	 chapter,	 these	behavioural	hypersensitivities	were	observed	 in	 this	work’s	own	1mg	MIA	rats	at	 the	early	and	 later	stages	 in	 behavioural	 studies	 without	 significant	 observable	 change	 to	 the	 evoked	 spinal	 cord	electrophysiology	 of	 lamina	 V	 WDRs	 in	 late	 stage	 animals,	 or	 descending	 controls,	 suggesting	 such	measures	may	be	poor	stand	alone	measure	of	CS.	This	is	observed	in	Sagar	et	al	2010,	one	of	these	6	studies,	where	hind	paw	withdrawal	thresholds	to	mechanical	punctuate	stimulation	were	significantly	decreased	 compared	 with	 those	 in	 rats	 receiving	 saline	 treatment,	 on	 days	 3,	 10,	 14-28	 -	 but	 no	difference	was	observed	between	mechanically	evoked	WDR	responses	of	MIA	treated	and	sham	rats	on	days	14-17(Sagar,	 Staniaszek	 et	 al.	 2010).	Meanwhile	 the	 study	observed	a	 significant	 increase	 in	mechanically	 evoked	 responses	 at	 days	 28-	 31	 in	 responses	 to	 10	 &	 15g	 vF.	 Much	 like	 the	 studies	presented	in	Chapter	3,	this	study	failure	to	characterize	evoked	spinal	responses	at	days	14-17	while	demonstrating	such	changes	at	4weeks	post	MIA.	
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Table	4.5:	Evidence	for	central	sensitization	in	22	published	studies	using	the	1mg	MIA	model	to	investigate	pain	in	
OA.	Those	papers	that	did	not	involve	the	assessment	of	pain	or	related	measures,	such	as	electrophysiology,	were	excluded	from	the	summary.		The	first	8	studies	listed	specifically	noted	changes	consistent	with	or	suggestive	of	central	sensitization	at	the	 time	 points	 of	 interest,	 including	 mechanical	 hypersensitivity	 at	 the	 paw	 or	 changes	 in	 immune-fluorescence	 or	pharmacological	parameters,	where	*	indicated	those	studies	observing	a	change	in	PWT	without	investigation	of	or	significant	change	in	additional	parameters	at	the	time	points	of	interest.	The	remaining	14	studies	either	characterized	later	time	points,	engaged	measures	unable	to	characterize	central	sensitization,	most	commonly	WB,	or	the	resource	was	unavailable	online	to	read	 in	 full.	 (WB	 =	 weight	 bearing	 asymmetry,	 PWT	 =	 hindpaw	 mechanical	 withdrawal	 thresholds,	 IHC	 =	Immunohistochemistry,	 IF	 =	 immunofluorescence,	 SpEphys	 =	 Spinal	 Electrophysiology,	 PEphys	 =	 Peripheral	Electrophysiology)	 (Bove	2003,	 Pomonis,	 Boulet	 et	 al.	 2005,	Bley,	 Bhattacharya	 et	 al.	 2006,	 Pulichino,	Rowland	 et	 al.	 2006,	Ivanavicius,	Ball	et	al.	2007,	Baragi,	Becher	et	al.	2009,	Cialdai,	Giuliani	et	al.	2009,	Clements,	Ball	et	al.	2009,	Sagar,	Staniaszek	et	al.	2010,	Strassle,	Mark	et	al.	2010,	Yoshimi,	Yamamoto	et	al.	2010,	Sagar,	Burston	et	al.	2011,	Kelly,	Dunham	et	al.	2012,	Nagase,	 Kumakura	 et	 al.	 2012,	 Rashid,	 Theberge	 et	 al.	 2012,	 Thakur,	 Rahman	 et	 al.	 2012,	 Burston,	 Sagar	 et	 al.	 2013,	 Kelly,	Dobson	et	al.	2013,	Mapp,	Sagar	et	al.	2013,	Rashid,	Theberge	et	al.	2013,	Sagar,	Nwosu	et	al.	2015,	Abaei,	Sagar	et	al.	2016,	Burston,	Xu	et	al.	2016)	
Study	 Time	point	 Measure		(Pain	specific)	
Support	CS	in	
early?	
Support	CS	
in	late?	
Suggest	CS	at	Both	Time	points	
Abaei	et	al	2016	 5-32	days	 WB,	PWT,	fMRI	during	IA	Capsaicin	(@28days	+)	 Yes*	 Yes*	
Sagar	et	al	2010	 	0-28	days	 WB,	PWT,	SpEphys	+	CB1	or	CB2	receptor	antagonist	/	FAAH	inhibitor	 Yes*	 Yes*	
Suggest	CS	at	Early	(3-5	day)	Time	points	Only	
Thakur	et	al	2012	 3-19	days	 Cooling,	mechanical	hypersensitivity,	WB,	IF,	SpEphys	+	PGB	 Yes*	 No	
Suggest	CS	at	Late	(10-14	day)	Time	points	Only	
Burston	et	al	2013	 0-28	days	 WB,	PWT,	SpEphys,	PCR,	ELISA	+	CB2	receptor	agonist	 No		 Yes*	
Sagar	et	al	2011	 7-28	days	 WB,	PWT,	IF,	IHC	+	nimesulide	 No		 Yes	
Sagar	et	al	2015	 0-24	days	 WB,	PWT,	SpEphys	+	intra-articular	NGF	 No	 Yes*	
Ivanavicus	et	al	2007	 8-35	days	 WB,	IF	+	GBP	 No	 Possibly	
Mapp	et	al	2013	 0-21	days	 WB,	PWT	+	Triamcinalone	acetonide	 No	 Yes*	
1mg	Studies	That	Do	Not	Support	CS	at	These	Time	points	
Kelly	et	al	2012	 3&14	days	 WB,	pEphys	 No	 No	
Kelly	et	al	2013	 3-28	days	 WB,	pEphys	 No	 No	
Nagase	et	al	2012	 0-28	days	 Spontaneous	night-time	activity	+	NSAID	/Gabapentin	/Amitriptyline/	Opiates	 No	 No	
Pomonis	et	al	2005	 0-28	days	 WB	+	morphine/	indomethacin/	celecoxib	 No	 No	
Pulichino	et	al	2006	 0-7	days	 WB	+	IP	antagonist	 No	 No	
Rashid	et	al	2013	 0	-	28	days	
Tekscan®	WB	or	pEphys+	dexamethasone	
/celecoxib	/	duloxetine	/naproxen	
/morphine	/pregabalin	
No	 No	
Strassle	et	al	2010	 1-21	days	 WB	+	zoledronate	 No		 No		
Yoshimi	et	al	2010	 21+28	days		 WB	+	AS1892802/	fasudil/	diclofenac/		tramadol	 No		 No	
Burston	et	al	2016	 0-27	days		 	WB,	PWT	+	L-006235	 Unclear	from	abstract	alone	(OARSI	poster)	
Bley	et	al	2006	 Day	14	 WB	+	rofecoxib/	RO1138452/	RO3244794	 No	 No	
Bove	et	al	2003	 1-14	days	 WB	+	Paracetamol/	naproxen/		rofecoxib	 No	 No	
Clements	et	al	2009	 0-21	days	 WB,	IHC	 No	 No	
Baragi	et	al	2009	 0-14	days	 WB,	ELISA	+	MMP-13i	 No	 No	
Cialdai	et	al	2009	 0-14	days	 WB,	ELISA	+	MEN16132/	icatibant/	indomethacin	 No	 No	
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In	the	remaining	14	1mg	MIA	studies,	many	presented	evidence	supporting	CS	at	later	time	points	but	the	study	methodology	had	not	allowed	for	assessment	during	the	earlier	stages,	while	others	had	used	WB	as	 the	 sole	 behavioural	measure	of	 pain	 and	 thus	 failed	 to	 capture	 any	potential	 sensitization	 in	uninjured	tissue	such	as	the	paw.	 	One	study	could	not	provide	evidence	as	the	abstract	refereed	to	a	poster	unavailable	for	review	online.	
As	 such,	 it	 seems	 apparent	 that	 evidence	 supporting	 potential	 CS	 in	 these	 earlier	 stages	 of	 the	 1mg	model	is	inconclusive.	It	may	be	that	at	later	stages,	perhaps	days	21-28,	central	changes	in	this	smaller	dose	model	 of	 OA	 pain	may	 become	 apparent	 or	 dominant,	 including	 the	 recruitment	 of	 descending	controls,	 given	 the	 “unmasking”	 effect	 spinalization	 has	 been	 shown	 to	 have	 at	 28th	 day	 of	 this	model(Kelly,	Dobson	et	al.	2013),	the	role	of	activated	microglia	in	distal	allodynia(Sagar,	Burston	et	al.	2011),	 and	 the	efficacy	of	 selective	NA	re-uptake	 inhibition	 to	 resolve	 incapacitance	at	week	3	of	 the	1mg	MIA	model(Whiteside,	Dwyer	et	al.	2010).	
It	would	be	interesting	to	consider	what	evidence	of	CS	spinal	recordings	at	higher	lumbar	levels	might	detect,	 notably	 in	 spinal	 segments	 with	 greater	 knee	 input	 versus	 L5,	 where	 this	 work	 records.	Conclusions	about	the	presence	of	central	sensitization	at	those	higher	levels,	largely	levels	L3	and	L4	(with	overlapping	input	with	the	paw	into	L5(Edoff,	Grenegard	et	al.	2000))	cannot	be	drawn	from	this	thesis’	data.	To	gain	a	more	complete	picture	of	the	dynamic	and	seemingly	knee	pathology	dependent	changes	 in	 the	 descending	 controls	 it	 would	 be	 beneficial	 to	 characterize	 the	 effect	 of	 monoamine	antagonism	on	WDR	evoked	responses	serving	the	knee	joint	itself.		
Clearly,	 the	 conclusions	 drawn	 here,	 pointing	 to	 the	 absence	 of	 descending	 control,	 also	 have	implications	upon	 the	mechanisms	by	which	pain	might	be	 referred	 to	 the	paw,	 given	 the	behaviour	observed	in	Chapter	3.	This	favours	the	theory	of	receptive	field	expansion	of	secondary	hyperalgesia,	in	which	sensitization	of	ascending	fibers	serving	the	knee	lower	the	threshold	of	activation	such	that	previously	weak	or	silent	inputs	from	neighbouring	regions	(like	the	paw)	become	sufficient	to	activate	ascending	 neurons,	 as	 discussed	 by	 Schiable	 and	 Richter	 2004.	 Interestingly,	 we	 could	 consider	whether	these	changed	are	occurring	at	a	higher	spinal	segments,	or	in	a	different	lamina.	Such	changes	in	 ascending	 lamina	 I	 NK1	 positive	 neurons	 have	 been	 characterized	 in	 rats	 following	 CFA	inflammation,	 seen	 as	 both	 the	 increase	 in	 receptive	 filed(Hylden,	 Nahin	 et	 al.	 1989)	 and	 shift	 	 to	 a	greater	 proportion	 of	 monosynaptic	 Aδ	 inputs(Torsney	 2011).	 Most	 interestingly,	 receptive	 field	expansions	 have	 previously	 been	 characterized	 in	 a	 2mg	model	 of	MIA	 in	 lamina	 I	 but	 not	 lamina	V	ascending	 neurones	 during	 evoked	 spinal	 cord	 electrophysiology(Thakur	 2012)	 –	 a	 study	 which	similarly	 demonstrating	 that	 lamina	 I	 but	 not	 Lamina	 V	 neurones	 at	 day	 14	 post	 2mg	 MIA	 had	potentiated	responses	from	fibers	 in	the	Aδ	range.	Such	changes	could	not	have	been	observed	in	the	present	 lamina	 V	 study.	 As	 such,	 the	 potential	 expansion	 the	 receptive	 field	 of	 lamina	 I	 ascending	
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neurons,	 such	 that	 paw	 inputs	 are	 also	 transmitted	 and	 interpreted	 as	 noxious,	 might	 explain	 the	observed	changes	in	behaviour	in	this	1mg	MIA	model.	
	
4.4.4	Study	Limitations	
In	 considering	 the	 results	 and	 potential	 conclusions	 of	 this	 chapter,	 it	 is	 important	 to	 consider	 the	limitations	of	the	present	study’s	design	–	both	to	provide	context	that	will	inform	the	conclusions,	but	also	suggest	potential	modifications	to	the	study	that	would	have	allowed	greater	clarity.	
	
Dose	Selection	and	Pharmacology	
Within	 this	 study,	 single	 or	 two-dose	 pharmacology	 was	 performed	 using	 doses	 of	 the	 selected	antagonist	previously	characterized	as	exerting	an	effect	in	the	2mg	MIA	model	by	Rahman	et	al	2009	or	 Burnham	 et	 al	 2013	 for	 Ondansetron	 and	 Atipamezole	 respectively(Rahman,	 Bauer	 et	 al.	 2009,	Burnham	 and	 Dickenson	 2013).	 However,	 the	 assumption	 that	 a	 dose	 sufficient	 to	 alter	electrophysiology	in	the	2mg	model	cannot	be	made	with	the	same	confidence	that	multiple	ascending	doses	could	provide.	
As	already	discussed,	it	has	previously	been	observed	that	spinal	application	of	either	ondansetron	or	atipamezole	has	no	significant	effect	in	naïve	or	sham	animals	at	doses	that	affected	MIA	or	peripheral	nerve	injury	(Suzuki,	Rahman	et	al.	2004,	Rahman,	Bauer	et	al.	2009,	Burnham	2012).		This	is	similarly	the	 case	 in	Sham	animals	 in	Figures	4.1-4.4.	While	 this	 supports	 the	 concept	of	 recruited	descending	control	in	OA	and	neuropathic	pain	models,	it	does	not	exclude	the	possibility	of	descending	serotonin	or	 noradrenaline	 completely.	 The	 sensitivities	 of	 the	 animals	 to	 antagonism	may	 simply	 differ,	 for	 a	variety	of	reasons	–	including	receptor	population,	transmitter	release	etc.		
In	 this	 instance,	 the	 use	 of	multiple	 ascending	 doses	would	 have	 allowed	 the	 construction	 of	 a	 dose	response	 curve	 for	both	MIA	and	 sham	animals.	This	would	have	provided	greater	 confidence	 in	 the	ultimate	 absence	 of	 descending	 serotonergic	 or	 noradrenergic	 modulation,	 and	 potentially	 greater	clarity	 on	 the	 differing	 extent	 of	 descending	 modulation	 of	 variously	 evoked	 neuronal	 responses	between	the	1mg	and	sham	animals.	
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n	Number	and	Power	Equations	
Conscientious	 animal	 research	 requires	 experimenters	 to	 find	 the	 balance	 between	 sufficiently	powered	experiments	that	do	not	miss	significant	differences	and	the	use	of	 the	minimum	number	of	animals	required,	to	avoid	unnecessary	wastage	of	animal	lives.	In	the	execution	of	these	experiments,	I	chose	to	finish	with	an	n=7	per	group	as	it	was	becoming	clear	that	ondansetron	and	atipamezole	were	having	 no	 observable	 separation	 from	 baseline	 electrophysiological	 profiles.	 This	 was	 driven	 by	 a	desire	to	limit	the	number	of	animals	used,	which	totaled	54	rats	without	consideration	of	those	rats	in	which	 experiments	 failed	 (e.g.	 premature	 death,	 inability	 to	 find	 and	 characterize	 a	 cell),	 and	 an	awareness	 that	n	numbers	of	7	or	8	had	successfully	characterized	significant	effects	 in	 the	2mg	MIA	studies	from	which	my	work	followed(Rahman,	Bauer	et	al.	2009,	Burnham	and	Dickenson	2013).	
With	hindsight,	I	should	have	performed	power	calculations	to	define	the	minimum	number	of	animals,	in	line	with	ARRIVE	guidelines(Kilkenny,	Browne	et	al.	2010,	Charan	and	Kantharia	2013).	This	would	have	defined	an	objective,	 as	opposed	 to	 subjective,	 cut	off.	That	 said,	performing	power	calculations	using	the	data	from	Rahman	et	al	2013	suggests	a	sample	size	between	6-10.	All	data	used	was	from	the	same	 dose	 of	 ondansetron	 used	 in	 this	 study,	 where	 the	 sample	 size	 suggestion	 depending	 on	 the	evoked	response	selected	to	estimated	group	means	and	standard	deviation.	It	is	possible	that	if	I	had	continued	with	the	experiments	to	the	upper	bracket	of	this	range,	using	a	total	of	80	rats,	I	might	have	seen	a	significant	effect	of	ondansetron	or	atipamezole	not	detected	at	the	current	study	power.	
	
Evidence	of	Structural	Pathology	
Another	major	limitation	in	the	discussion	of	the	results	presented	in	this	chapter,	as	in	all	the	chapters	of	 this	 thesis,	 is	 the	 absence	 of	 analysis	 of	 the	 structural	 pathology	 of	 these	 animals.	While	 previous	literature	has	established	the	histopathological	changes	associated	with	both	the	early(Strassle,	Mark	et	al.	2010,	Kelly,	Dunham	et	al.	2012)	and	late	(Kelly,	Dunham	et	al.	2012,	Thakur	2012)	stages	of	a	1mg	MIA	model,	it	would	be	a	fallacy	to	assume	that	every	injection	of	MIA	was	successfully	delivered.	Even	in	a	clinical	setting,	IA	therapies	commonly	miss	their	mark	(in	much	larger	knees)	without	ultrasound	guidance(Berkoff,	 Miller	 et	 al.	 2012).	 There	 are	 similarly	 considerations	 of	 the	 potential	 off-target	effects	 of	 MIA,	 such	 as	 leaking	 from	 the	 synovial	 joint	 to	 affect	 surrounding	 tissues	 and	 drive	 pain	independently	 of	OA-like	pathology	 –	 including	potential	 uptake	by	 local	 neuronal	 endings	 to	 trigger	neuropathic	 pain.	 These	 possibilities	 undermine	 the	 assumption	 that	 a	 pain	 profile	 necessarily	demonstrates	a	successful	injection	and	the	presence	of	OA-like	changes	in	the	knee	joint.		
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Such	 variability	 of	 success	 of	 injections	 might	 also	 explain	 the	 inconsistency	 of	 the	 presence	 of	enhanced	evoked	responses	to	dynamic	brush	observed	in	the	baseline	responses	of	the	ondansetron	treated	 and	 atipamezole	 treated	 cohorts	 of	 early	 1mg	 MIA	 and	 sham	 rats	 (See	 section	 3.4.3).	 An	understanding	of	 the	differing	 structural	pathophysiology	or	off	 target	effects	due	 to	 failed	 injections	could	provide	clarity	of	potential	mechanisms	underlying	 this	difference	 that	 the	currently	presented	data	alone	cannot.	
The	conclusions	drawn	in	this	study	(Chapters	3	and	4)	are	based	upon	potential	considerations	of	the	extent	 of	 histopathological	 changes	 –	 inflammatory	 in	 the	 early	 animals,	 and	 structural	 in	 the	 late	animals.	These	conclusions	would	be	 far	stronger	with	a)	evidence	of	such	changes,	on	which	to	base	these	conclusions	and	b)	a	correlation	analysis,	to	detect	any	potential	relationship	between	the	extent	of	 structural	 pathology	 and	 behaviour,	 electrophysiology,	 or	 pharmacological	 outcomes.	 Of	 note,	previous	analysis	of	this	kind	has	failed	to	characterize	a	relationship	between	structural	pathology	and	nociceptive	 behaviour	 or	 electrophysiology	 (McDougall,	 Andruski	 et	 al.	 2009,	 Kelly,	 Dunham	 et	 al.	2012),	 suggesting	 alternate	 explanations	 for	 the	 differences	 observed	 between	 this	work	 and	 earlier	studies	in	the	2mg	MIA	would	be	required.	
Such	 analysis	 could	 also	 allow	 the	 exclusion	 from	 analysis	 of	 animals	 in	 which	 OA	 had	 not	 been	successfully	 induced	 by	 the	 MIA	 model.	 It	 is	 possible	 that	 in	 so	 doing,	 more	 significant	 differences	between	groups	and	after	pharmacology	might	be	detected.	Conversely,	 in	a	meta	analysis	of	 studies	that	measured	behavioural	pain	outcomes	in	small	animal	models	of	OA,	Suokas	et	al	2014	demonstrate	that	 	 “Lack	 of	 reported	 evidence	 that	 OA	 structural	 change	was	 successfully	 induced	 in	 the	model	 was	
strongly	 associated	 with	 larger	 effect	 sizes”,	 where	 effect	 size	 refers	 to	 reported	 analgesic	efficacy(Suokas,	 Sagar	 et	 al.	 2014).	 This	 analysis	 suggests	 that	 incomplete	 phenotyping	 of	 animals,	including	the	failure	to	confirm	structural	pathology,	prior	to	pharmacological	 interventions	may	lead	to	 false	 conclusions.	 In	 this	 instance,	 the	 false	 conclusion	 would	 be	 to	 attribute	 differences	 in	 the	response	 to	ondansetron	or	atipamezole	 in	 these	1mg	animals	vs.	previous	2mg	studies	 to	 structural	pathological	 differences,	 when	 these	 differences	 may	 instead	 related	 to	 off	 target	 effects	 of	 MIA	 in	tissues	surrounding	the	joint	capsule.	
	
Direct	Comparisons	Between	1mg	and	2mg	Animals	
As	 discussed	 with	 n	 number	 limitations,	 the	 desire	 not	 to	 waste	 animal	 life	 must	 be	 balanced	 by	gathering	sufficient	 information	 for	confident	conclusions.	 In	opting	not	 to	 include	a	2mg	MIA	cohort	within	 these	 studies,	 I	 had	 sought	 not	 to	 replicate	work	 already	published	 and	 to	 instead	 use	 it	 as	 a	comparator	reference(Rahman,	Bauer	et	al.	2009,	Burnham	and	Dickenson	2013).	However,	given	the	
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previously	discussed	variability	and	lack	of	consensus	on	whether	the	MIA	model	results	in	increased	evoked	 responses	 to	 mechanical	 and	 thermal	 stimulation,	 and	 the	 absence	 of	 structural	 pathology	analysis	 in	 these	 reference	 studies(Rahman,	 Bauer	 et	 al.	 2009,	 Burnham	 and	 Dickenson	 2013).,	 the	analysis	 of	 results	 in	 this	 study	 are	 similarly	 limited	 by	 the	 absence	 of	 a	 2mg	 MIA	 cohort	 for	comparison.	 Though	 this	 would	 have	 required	 the	 repetition	 of	 previous	 studies,	 it	 would	 have	facilitated	direct	comparison	between	sham,	1mg	and	2mg	MIA	animals	without	accounting	 for	 inter-experimenter	 variability	 and	 in	 conjunction	with	 joint	 histopathology	 could	 have	 allowed	 analysis	 of	any	potential	relationship	between	joint	pathology	and	evoked	electrophysiology	and	pharmacology.	
	
4.4.5	Overall	Implications	
Overall,	these	results	might	suggest	additional	considerations	during	the	selection	of	pharmacotherapy	for	 the	management	 of	 OA	 pain.	 These	 results	 suggest	 that	 in	mild,	 non-neuropathic	 OA,	 where	 the	extent	of	pathological	changes	are	still	 relatively	 limited	and	 the	pain	 less	severe,	 that	patients	might	not	benefit	from	tricyclic’s	or	SNRIs	which	manipulate	these	descending	control	systems.	As	is	already	the	case	in	patient	treatment	pathways,	and	as	has	been	validated	in	the	MIA	model,	these	patients	may	best	 benefit	 from	 therapies	 which	 focus	 on	 the	 peripheral	 origins	 of	 pain	 –	 notably	 NSIADs	 and	paracetamol,	where	patients	may	only	benefit	from	progression	to	antidepressant	therapies	once	their	pain	becomes	more	pronounced	and	engages	brainstem	controls.	
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Chapter	5	–	Brainstem	Sensitization	in	Osteoarthritis	Pain	
5.1	 	 Introduction	
The	 state	 of	 central	 sensitization	 (CS),	 characterized	 by	 reduced	 threshold,	 increased	responsiveness	and	enlargement	of	the	receptive	fields,	is	a	term	that	describes	changes	in	the	spinal	cord	during	pain(Cook,	Woolf	et	al.	1987,	Hylden,	Nahin	et	al.	1989,	Woolf	2011).	Such	changes	 are	 held	 to	 underlie	 hyperalgesia	 and	 allodynia	 during	 chronic	 pain	 states,	 and	crucially	 to	 the	 OA	 pain	 experience	 –	 the	 referral	 of	 pain	 to	 healthy,	 unaffected	tissue(Skagerberg	 and	 Björklund	 1985,	 Giamberardino	 2003).	 However,	 what	 is	 becoming	increasingly	 clear	 is	 a	picture	 in	which	CS	 is	 either	maintained	or	 limited	by	 the	presence	of	descending	controls(Suzuki,	Rygh	et	al.	2004).	Similarly,	chronic	pain	not	only	causes	adaptive	changes	 in	 spinal	 processing	 but	 drives	 plasticity	 of	 synaptic	 efficacy	 and	 patterns	 of	 cell	activity	in	the	RVM(Vasko,	Pang	et	al.	1984,	Fields,	Heinricher	et	al.	1991,	Potrebic,	Fields	et	al.	1994,	Gao	and	Mason	2000,	Terayama,	Guan	et	al.	2000,	Cleary	and	Heinricher	2013),	part	of	a	process	 which	 has	 previously	 be	 coined	 as	 brainstem	 sensitization.	 By	 better	 characterizing	these	adaptations	we	may	better	understand	the	drivers	underlying	OA	pain.	
	
5.1.1	 		 Heterogeneity	of	RVM	Neurones	
The	RVM	comprises	one	half	of	a	critical	pain	control	axis	in	the	brainstem.	In	communication	with	the	PAG,	and	integrating	inputs	both	from	the	spinal	cord	and	surrounding	nuclei,	the	RVM	exerts	 a	 bilateral	 descending	 facilitatory	 and	 inhibitory	 control	 over	 synaptic	 strength	 in	 the	spinal	cord	such	that	it	modulates	nociceptive	processing.	It	has	become	apparent	that	the	RVM	may	both	 enhance	 and	diminish	nociceptive	processing,	 ultimately	determining	 the	 extent	 of	pain	perception.	This	is	based	in	large	part	on	the	distinct	populations	of	cells	in	the	RVM	which	are	recruited,	where	the	distinct	roles	of	ON-,	OFF-	and	Neutral	cells,	defined	by	their	distinct	firing	 patterns,	 has	 become	 increasingly	 apparent.	 Early	 studies	 defined	 the	ON	 cell	 as	 those	which	increase	their	firing	just	prior	to	the	initiation	of	nociceptive	reflex	(such	as	tail	flick	in	the	 rat)	while	OFF	 cells	 are	 tonically	 active	 and	decrease	 firing	 prior	 to	 nociceptive	 reflexes.	Neutral	cells	show	no	real	change	in	activity	prior	to	or	during	the	nociceptive	reflex(Fields,	Bry	et	al.	1983,	Heinricher,	Barbaro	et	al.	1989).			
The	 roles	 of	 these	 sub	 populations,	 most	 especially	 their	 patterns	 of	 firing,	 in	 relation	 to	nociception	and	analgesia	has	become	increasingly	apparent.	During	periods	of	increased	OFF	cell	activity	there	is	an	observable	increase	in	latency	to	tail	flick	and	conversely	increased	ON	
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cell	 activity	 shortens	 this	 latency	 (Barbaro,	 Heinricher	 et	 al.	 1989,	 Heinricher,	 Barbaro	 et	 al.	1989).	As	such,	it	makes	sense	that	a	pharmacological	agent	that	increase	OFF	cell	activity	and	decrease	ON	cell	activity	would	prove	successful	analgesics	–	exactly	the	mechanism	underlying	opiate	 analgesia.	The	administration	of	morphine	 causes	 significant	 reduction	 in	 the	 firing	of	ON	cells	while	enhancing	the	activity	of	OFF	cells(Heinricher,	Morgan	et	al.	1994).	It	has	been	shown	 that	 the	 systemic	 or	 iontophoretic	 administration	 of	 morphine	 reduces	 both	 the	spontaneous	 and	 nocifensive	 reflex	 related	 firing	 of	 ON-cells	 at	 doses	 which	 inhibit	 noxious	heat	 related	 tail	 flick(Barbaro,	 Heinricher	 et	 al.	 1986,	 Heinricher,	 Morgan	 et	 al.	 1992).	Conversely,	 systemic	 administration	 results	 in	 ongoing	 activity	 from	 OFF-cells	 following	morphine(Fields,	 Vanegas	 et	 al.	 1983,	 Heinricher,	Morgan	 et	 al.	 1992).	 During	 normal/acute	pain	 states	 this	 activation	 of	 OFF	 cells	 is	 both	 necessary	 and	 sufficient	 for	 opiate	 analgesia,	while	 inhibition	 of	 ON-cells	 alone	 is	 insufficient	 (Fields;,	 Basbaum;	 et	 al.	 2006).	 However,	during	chronic	pain	states	such	as	 inflammation	 the	direct	opioid	 inhibition	of	ON-cells	has	a	much	greater	 impact	on	hyperalgesia	 (Porreca,	Ossipov	et	al.	2002),	a	 result	of	 the	 increased	activity	of	ON-cells	during	 inflammatory	pain.	While	opiates	produce	direct	 inhibition	of	ON-cells,	 through	 μ-opioid	 receptors(Heinricher,	 Morgan	 et	 al.	 1994,	 Marinelli,	 Vaughan	 et	 al.	2002),	 the	 action	 on	OFF-cells	 is	 the	 result	 of	 dis-inhibition(Heinricher,	Morgan	 et	 al.	 1994),	where	 the	 inputs	of	 the	opioids	 targeted	 inhibitory	GABAergic	neurones	 likely	originate	 from	beyond	the	RVM.	This	allows	independent	functional	changes	in	these	two	populations(Cleary,	Neubert	et	al.	2008).	
The	heterogeneity	in	function	similarly	extends	to	the	effects	of	excitatory	neurotransmitters	-	where	small	doses	of	Glutamate	produces	descending	facilitation	to	the	dorsal	horn,	while	high	dose	Glutamate	inhibits	transmission	(Zhuo	and	Gebhart	1992,	Zhuo	and	Gebhart	1997).		These	differences	 seemingly	 result	 from	 the	 differing	 roles	 of	 different	 Glutamate	 receptors	 on	 ON	and	 OFF	 cells.	 NMDA	 receptor	 antagonism	 by	 AP5	 attenuates	 or	 blocks	 OFF	 cell	activation/disinhibition,	but	had	no	effect	on	ON	cell	dischargers,	while	the	AMPA	and	Kainate	receptor	 antagonist	 CNQX	 significantly	 attenuated	 this	 ON	 cell	 nociceptive	 reflex	 related	discharge(Heinricher,	Schouten	et	al.	2001).		This	study	similarly	highlighted	the	role	of	NMDA	recruitment	 to	 the	 analgesic	 effect	 of	 Morphine,	 through	 the	 NMDA	 mediated	activation/disinhibition	of	OFF	cells.	
Their	 transmitter	 content	 can	 similarly	 distinguish	 these	 neurons.	 It	 is	 postulated	 that	 some	40%	of	RVM	neurones	projecting	to	the	spinal	cord	contain	serotonin	(Marinelli,	Vaughan	et	al.	2002).	 As	 such,	 these	 serotonergic	 cells	 may	 themselves	 be	 in	 the	 minority	 within	 the	RVM(Skagerberg	and	Björklund	1985),	of	which	some,	but	not	all,	are	responsive	to	opiates	-	roughly	 33%	 to	 μ	 and	 25%	 to	 κ	 agonists.	 The	 remaining	 60%	 of	 spinally	 projecting	 RVM	
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neurones	may	be	GABAergic,	of	which	67%	were	μ	responsive(Marinelli,	Vaughan	et	al.	2002).	In	other	words,	those	neurones	projecting	to	the	dorsal	horn	can	be	subdivided	by	serotonergic	and	GABAergic	content.		
It	 had	 been	 suggested	 that	 serotonergic	 neurones	 represent	 an	 independent	 population,	composed	of	neither	ON	nor	OFF	cells(Potrebic,	Fields	et	al.	1994,	Gao	and	Mason	2000).	This	is	contradicted	however	by	both	the	identification	of	5HT	containing	ON	cells,	designated	by	the	expression	of	the	μ	opioid	receptor	(so	called	MOR+)(Marinelli,	Vaughan	et	al.	2002),	and	the	ability	 of	 5HT	 depletion	 by	 the	 neurotoxin	 5,7-dihydroxytryptamine	 to	 block	 the	 analgesic	effect	of	morphine	microinjection	into	the	RVM,	believed	to	rely	on	OFF	cells(Vasko,	Pang	et	al.	1984,	Fields,	Heinricher	et	al.	1991).	Crucially	ON	and	OFF	cells	are	not	believed	 to	have	one	single	neurochemical	designation,	though	both	may	have	subsets	of	5HT	containing	neurones.	It	has	additionally	been	proposed	that	perhaps	those	serotonergic	cells,	which	are	neither	ON	nor	 OFF	 cells,	 are	 in	 fact	 neutral	 cells	whose	 characteristics	 adapt	 during	 pain	 conditions	 to	underlie	the	plasticity	of	descending	controls	during	pain	conditions(Ellrich,	Ulucan	et	al.	2000,	Miki,	Zhou	et	al.	2002).		
In	addition	to	5HT,	OFF	cells	drive	direct	inhibition	through	GABA	–	as	evidenced	by	most	OFF	cells	staining	for	GAD,	the	GABA	synthesizing	enzyme(Winkler,	Hermes	et	al.	2006).	However,	ON	 cells	 similarly	 stain	 for	 GAD	 –	 an	 observation	which	may	 seem	 hard	 to	 resolve	with	 the	nociceptive	facilitatory	role	of	this	cell	population(Mason	2012).	This	could	be	attributed	to	a	possible	inhibitory	effect	of	ON	cells	on	OFF	cells(Fields,	Heinricher	et	al.	1991).		
Meanwhile	the	picture	for	descending	facilitation	is	not	yet	fully	understood.	Lesioning	studies	suggest	that	descending	facilitation	is	driven	by	two	distinguishable	groups	of	neurones,	those	defined	 by	 5HT	 content	 and	 those	 defined	 by	 μ	 opioid	 receptor	 expression,	 considered	 to	represent	 the	ON	cell	population.	Crucially,	when	comparing	 the	effects	of	5HT	or	MOR+	cell	depletion,	 it	 is	observed	 that	while	both	attenuate	 the	development	of	 inflammatory	pain	 the	effect	of	MOR+	depletion	 is	more	prolonged,	 likely	due	to	 the	overlap	between	these	 two	cell	populations(Carr,	 Géranton	 et	 al.	 2014).	 This	 study	 similarly	 went	 on	 to	 suggest	 a	 possible	mechanism	 of	 non-serotonergic	 facilitations,	 likely	 through	 the	 positive	 modulation	 of	 the	immune	 cell	 process	 in	 the	 dorsal	 horn	 by	 MOR+	 cells,	 identifying	 a	 role	 for	 iNOS	 and	chemokines	including	CXCl9	and	CXCl10	in	dorsal	horn	excitability(Carr,	Géranton	et	al.	2014).	
As	such	it	is	clear	that	subdivisions	of	cells	in	the	RVM	is	far	from	simple,	though	I	have	tried	to	simplify	this	in	Figure	5.1.	
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5.1.2	 		 Evidence	of	Brainstem	Plasticity	During	Pain	
It	has	been	observed,	 through	various	combinations	of	 lesioning,	neurotransmitter	depletion,	pharmacology	studies,	 electrical	 stimulation	 (ES)	and	PCR,	 that	 the	RVM	 is	highly	plastic	and	changeable	during	the	time	course	of	a	pain	condition,	be	it	inflammatory	or	neuropathic.	Here	I	will	specifically	consider	inflammation.	
During	the	initiation	period,	namely	the	first	3	hours,	RVM	controls	shift	to	favour	descending	facilitation	of	dorsal	horn	processing	(Terayama,	Guan	et	al.	2000),	driven	by	plasticity	of	the	NMDA	 receptor	 population(Terayama,	 Dubner	 et	 al.	 2002).	 It	 was	 similarly	 shown	 that	molecular	depletion	of	5HT	from	the	NGCα	neurons	attenuates	the	development	of	mechanical	hyperalgesia	 and	 allodynia	 after	 CFA	 injection,	 suggesting	 serotonergic	 neurons	 have	 a	significant	 role	 in	 facilitating	 the	 development	 of	 hyperalgesia	 following	 inflammation(Wei,	Dubner	et	 al.	 2010).	 	This	differs	 considerably	 from	neuropathy,	where	 it	 has	been	observed	that	descending	facilitation	is	not	a	requirement	for	the	initiation	of	pain	in	neuropathy,	as	it	is	for	inflammatory	pain,	but	is	a	requirement	for	it’s	maintenance(Burgess,	Gardell	et	al.	2002).	
Figure	5.1	–	Pictorial	summary	of	a	simplified	possible	sub-classifications	of	neurons	descending	 from	the	
RVM,	based	upon	Barbaro	1986.;	Heinricher	1992;	Fields,	H.,	 et	 al	1983;	Porreca	2002;	Cleary	2008;	Zhuo	
and	Gebhart	1997;	Zhuo	and	Gebhart	1992;	Heinricher	2001;	Winkler	et	al.2006.	
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Given	 this	 information,	 it	 seems	 feasible	 that	 in	 the	 initial	hours	of	 inflammation	 the	sensory	barrage	 ascending	 to	 the	 brain	 stem	 activates	 facilitatory	 descending	 controls.	 As	 with	peripheral	sensitization,	this	early	facilitation	is	beneficial	as	a	mechanism	for	limiting	the	use	of	injured	tissue.		
	
Modulation	of	Established	Inflammatory	Pain	
It	is	now	established	that	during	inflammation,	beyond	this	initial	facilitation	on	day	1,	there	is	a	 superseding	 shift	 towards	 descending	 inhibition	 of	 the	 site	 of	 primary	 hyperalgesia,	which	acts	to	limit	the	impact	of	accumulating	peripheral	and	central	sensitization.	First	suggested	by	Schiable	and	colleagues,	who	reversibly	spinalized	cats	using	cooling	of	the	spinal	cord,	it	was	shown	 that	 inflammation	 induced	 a	 progressive	 enhancement	 of	 descending	inhibition(Schaible,	Neugebauer	et	al.	1991).	This	effect	was	similarly	replicated	using	lidocaine	to	block	descending	controls	during	CFA	induced	paw	inflammation	(Ren	and	Dubner	1996).	
Terayama	 and	 colleagues	 showed	 that	 this	 predominance	 of	 inhibition	 does	 not	 occur	immediately,	rather	developing	after	an	initial	period	of	facilitation.	After	the	initial	increase	in	current	 intensity	 required	 for	 complete	 inhibition	 of	 PW	 observed	 at	 the	 3rd	 hour	 of	 CFA	inflammation	there	is	a	decrease	over	the	next	21hours,	shifting	the	stimulus	response	curve	to	the	 left,	 indicating	 the	 switch	 to	 a	 net	 descending	 inhibition	 (Terayama,	 Guan	 et	 al.	 2000,	Terayama,	Dubner	et	al.	2002).	This	 leftward	shift	 is	similarly	replicated	 in	NMDA	and	AMPA	dose-response	curves	24hrs	post	inflammation	(Guan,	Terayama	et	al.	2002).	This	is	indicative	of	 a	 switch	 in	 the	 RVM	 to	 descending	 inhibition,	 originating	 from	 plasticity	 at	 glutamatergic	synapses(Vanegas	 2004).	 This	 plasticity	 similarly	 increases	 the	 sensitivity	 of	 the	 RVM	 to	opiates(Zhang	and	Hammond	2010).	
Single	 unit	 recordings	 from	 the	 RVM	 similarly	 support	 the	 idea	 of	 a	 shift	 towards	 inhibition	from	 the	 RVM(Miki,	 Zhou	 et	 al.	 2002).	 Continuous	 recordings	 over	 the	 3-6	 hours	 after	 CFA	identified	a	phenotypic	switch	of	neutral	cells	to	pain	modulating	ON-like	or	OFF-like	cells,	as	was	not	seen	in	naïve	animals.	This	was	confirmed	with	a	population	study.	There	was	similarly	a	 reduction	 in	 the	 number	 of	 OFF-like	 cells	 showing	 a	 pause	 of	 activity	 after	 noxious	stimulation	 after	 inflammation,	 which	 together	 lead	 to	 a	 suggestion	 that	 RVM	 neurons	 may	switch	to	favour	descending	inhibition(Miki,	Zhou	et	al.	2002).	
This	enhancement	of	descending	inhibition	is	not	limited	to	the	RVM	however	but	involves	the	noradrenergic	system	too.	Using	lesioning,	Tsuruoka	et	al	suggests	that	inflammation	activates	
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inhibitory	controls	originating	from	the	LC	to	restrict	the	development	of	hyperalgesia	during	inflammation(Tsuruoka	and	Willis	1996).	However,	the	effect	of	lesioning	are	lost	by	the	7th	day	of	 inflammation,	 whereby	 no	 difference	 is	 observed	 between	 the	 hyperalgesia	 between	 the	sham	and	lesion	groups(Tsuruoka	and	Willis	1996).	This	suggests	that	the	LC	and	NA	are	only	involved	in	descending	inhibition	during	a	short	initial	window	of	inflammation,	as	is	observed	in	both	the	MIA	model	of	OA	and	tibial	nerve	injury	neuropathic	pain	model(Hughes,	Hickey	et	al.	2013).		
In	considering	the	plasticity	of	these	systems	other	experiments	have	shown	that,	much	like	in	the	dorsal	horn,	 there	are	significant	alterations	 in	gene	expression	and	receptor	populations	over	 the	 course	 of	 inflammation.	Miki	 and	 colleagues,	 in	 proposing	 the	 concept	 of	 brainstem	sensitization,	 identified	 peripheral	 inflammation	 induced	 changes	 in	 NMDA	 receptor	 gene	expression	in	the	RVM	(Miki,	Zhou	et	al.	2002).		They	identified	a	significant	increase	in	NMDA	subunit	mRNA	over	 the	proceeding	1-7days	after	CFA	 injection,	with	 the	greatest	 increase	 in	NR2A	unit	mRNA	and	protein.	Similarly,	 inflammation	 induces	a	significant	 increase	 in	AMPA	receptor	 subunit	mRNA,	with	 significant	up-regulation	of	GluR1-flip	protein	over	24hr-3days	after	CFA(Guan,	Guo	et	al.	2003).		It	is	well	established	that	Glutamate	plays	a	prominent	part	in	excitatory	 transmission	 in	 the	 RVM	 and	 activation	 of	 descending	 control	 from	 brainstem	sites(Aimone	 and	 Gebhart	 1986,	 Beitz	 1990,	 Spinella,	 Cooper	 et	 al.	 1996),	 where	 we	 have	discussed	 above	 the	 shift	 in	 the	 dose	 response	 curves	 for	 this	 transmitter	 during	inflammation(Guan,	Terayama	et	al.	2002).	As	such,	these	results	would	suggest	that	part	of	the	increase	 in	descending	control	observed	during	 inflammation	may	originate	 from	an	 increase	in	 NMDA	 and	 AMPA	 receptor	 populations,	 composed	 of	 subunits	 with	 high	 conductance	properties	 (NR2A)	 and	 a	 reduced	 rate	 of	 desensitization	 (GluR1-flip),	 which	 increase	excitability	and	activation	of	RVM	neurons.	Since	the	activation	of	AMPA	receptors	in	the	RVM	mediate	 descending	 inhibition(Urban,	 Coutinho	 et	 al.	 1999),	 the	 growth	 of	 this	 receptor	population	 in	 the	 RVM	 during	 the	 first	 week	 of	 inflammation	 goes	 some	way	 to	 explain	 the	increased	descending	inhibition	observed	to	be	limiting	acute	inflammatory	pain.	However,	the	leftward	 shift	 in	 the	 dose	 response	 curve	 of	 AMPA	 and	 NMDA	 in	 descending	 inhibition	was	significant	as	early	as	5hrs	after	the	induction	of	inflammation	when	these	protein	changes	only	reach	 significance	 after	 24hrs(Guan,	 Guo	 et	 al.	 2003),	 pointing	 to	 additional,	 faster	 acting	mechanisms	of	plasticity	in	the	brain	stem.		
The	 complexity	 of	 the	 overall	 pain	 profile	 during	 inflammation	 is	 added	 to	 by	 evidence	suggesting	 that	 primary	 and	 secondary	 sites	 of	 hyperalgesia	 may	 be	 differentially	controlled(Vanegas	 2004).	 It	 is	 suggested	 that	 there	 is	 an	 inhibitory	 drive	 to	 the	 area	 of	primary	hyperalgesia,	but	a	facilitatory	drive	in	the	surrounding	spinal	segments	that	underlie	
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secondary	 hyperalgesia	 and	 referred	 pain.	 This	 is	 demonstrated	 by	 the	 ability	 of	 lidocaine,	NMDA	receptor	or	neurotensin	receptor	antagonists	in	the	RVM	to	attenuate	the	development	of	 secondary	 thermal	 hyperalgesia	 during	 paw	 inflammation(Ren	 and	 Dubner	 1996,	 Urban,	Coutinho	et	al.	1999,	Wei,	Dubner	et	al.	1999).	On	the	basis	of	this	evidence	we	would	expect	a	descending	 facilitation	 of	 noxious	 transmission	 from	 areas	 of	 secondary	 hyperalgesia,	 for	example	 the	 rat	 paw	 in	 a	model	 of	 knee	OA,	 and	 inhibitory	 controls	 presiding	 over	 the	 joint	itself.	
When	we	consider	OA	specifically,	much	is	yet	to	be	understood	about	the	role	of	supraspinal	controls	in	OA	pain.	While	some	work	has	been	done	to	characterize	how	these	influences	may	change	during	OA,	and	the	consequences	this	may	have	on	OA	pain,	the	picture	is	by	no	means	complete.	Early	work	using	either	cold	block	spinalization	or	transection	to	elucidate	the	role	of	descending	controls	 in	 inflammatory	joint	pain	revealed	the	increase	in	descending	inhibition	which	followed	in	the	initial	24hrs(Schaible,	Neugebauer	et	al.	1991,	Danziger,	Weil-Fugazza	et	al.	1999).	More	recently,	work	from	this	lab	has	characterized	the	chronic	shifts	in	descending	controls	during	the	MIA	model	of	OA.	They	showed	adaptive	changes	in	serotonergic	controls	that	 may	 underlie	 increased	 evoked	 responses	 to	 dynamic	 brush	 and	 innocuous	 punctate	stimuli(Rahman,	 Bauer	 et	 al.	 2009),	 along	 side	 work	 revealing	 a	 time	 sensitive	 effects	 of	atipamezole	or	milnacipran	plus	atipamezole	on	evoked	responses	 in	 the	early	 stages	of	MIA	induced	OA(Burnham	and	Dickenson	2013).	
	
5.1.3	 		 Our	Understanding	of	Brainstem	Sensitization	in	the	OA	Clinic		
The	 large	 part	 of	 our	 understanding	 of	 brainstem	 sensitization	 in	 the	 clinic	 originates	 from	brain	 imaging	processes,	notably	fMRI.	 In	some	of	the	 initial	studies	characterizing	brainstem	activation	during	central	sensitization,	Zambreanu	and	colleagues	demonstrated	that	following	the	heat/capsaicin	sensitisation	model,	to	induce	secondary	hyperalgesia,	significantly	greater	brainstem	activation	was	observed	in	capsaicin	sensitized	subjects	versus	controls,	specifically	in	 the	 nucleus	 cuneiformis	 (NCF)	 and	 PAG,	 areas	with	 substantial	modulatory	 input	 into	 the	RVM(Zambreanu,	 Wise	 et	 al.	 2005).	 In	 another	 study,	 cardiac-gated	 fMRI	 techniques	demonstrated	 changes	 and	 differences	 in	 brainstem	 activity	 during	 primary	 and	 secondary	dynamic	 mechanical	 allodynia	 in	 the	 capsaicin	 model(Mainero,	 Zhang	 et	 al.	 2007).	 During	dynamic	 brush	 stimulation	 of	 either	 the	 primary	 or	 secondary	 area	 of	mechanical	 allodynia,	increased	activity	was	observed	versus	controls	 in	 the	LC	and	PB.	These	enhancements	 in	PB	and	 LC	 processing	 are	 understood	 to	 represent	 increased	 processing	 of	 ascending	 and	
		 186	
descending	 signals	 respectively.	 Similarly,	 significantly	 enhanced	 activity	 of	 dorsal	 reticular	nuclei	and	RVM	were	observed	during	stimulation	of	 the	primary	hyperalgesia	sights,	 though	not	during	stimulation	of	the	secondary	areas.	This	work	suggested	that	brainstem	involvement	in	 pain	 and	 CS	 may	 differ	 between	 primary	 and	 secondary	 sites	 of	 allodynia,	 as	 previously	reported	in	animal	work.	
Later	brain	imaging	studies	have	similarly	suggested	greater	activation	of	the	PAG,	this	time	in	OA	 patients	 receiving	 punctate	 stimulation	 to	 areas	 of	 referred	 pain	 vs.	 controls(Gwilym,	Keltner	et	al.	2009).	These	works	were	used	to	suggest	that	these	spinally	projecting	brain	stem	centers	might	be	highly	relevant	to	the	generation	of	the	overall	OA	pain	profile,	at	least	playing	some	 important	 role	 within	 the	 overall	 CS	 profile.	 	 The	 study	 similarly	 showed	 a	 strong	correlation	 between	 the	 extent	 of	 PAG	 activation	 and	 the	 degree	 of	 CS,	 as	 measured	 by	PainDETECT.	Such	measures	 support	 the	 conclusions	of	 animal	work	 for	a	 crucial	 role	of	 the	brainstem	in	the	overall	pain	profile.	
However,	 discussions	 of	 the	 inferences	 of	 brain	 imaging	 work	 also,	 rightly,	 point	 to	 the	importance	of	the	entire	pain	matrix	feeding	into	and	modulating	the	brain	stem.	For	example,	in	 a	 study	 of	 visceral	 pain	 in	 IBS	 patients	 it	 was	 suggested	 that	 hypersensitivity	 related	 to	deficits	 in	 inhibitory	 systems	 as	 a	 result	 of	 failed	 anticipatory	 down-regulation(Berman,	Naliboff	et	al.	2008)	as	seen	by	the	lost	anticipatory	deactivation	of	areas	such	as	the	amygdala	or	supragenual	anterior	cingulate	cortex	in	IBS	patients	when	anticipating	a	painful	distention.	In	essence,	it	is	possible	that	enhanced	pain,	as	a	result	of	adapted	in	descending	control,	could	be	 the	 complex	 outcome	 of	 negative	 emotional	 outputs	 of	 the	 pain	 matrix,	 not	 least	catastrophising,	hypervigilence	and	anxiety,	the	consequences	of	which	feed	into	areas	like	the	RVM(Bingel	and	Tracey	2008).	
It	is	clear	from	both	pre-clinical	and	clinical	analysis	that	adaptations,	both	short	and	long	term,	occur	 across	 the	 brain	 during	 pain	 conditions.	 Previous	 work	 in	 this	 lab	 and	 others	 has	suggested	adaptations	in	RVM	cell	characteristic	firings	could	be	expected	during	chronic	pain.	This	 work	 sets	 out	 to	 identify	 whether	 in	 this	 milder	 model	 of	 OA	 pain	 adaptations	 in	 the	magnitude	of	 responses	 of	RVM	ON-cells	 are	 observed	 following	 ipsilateral	 and	 contralateral	mechanical	stimulation;	adaptations	which	could	be	 interpreted	as	a	brainstem	manifestation	of	CS.	
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5.1.4	 	 Chapter	Aims	
For	 patients	 with	 symptomatic	 OA	 the	 unmet	 needs	 are	 still	 clear	 –	 efficacious,	 safe	 and	 tolerable	analgesia.	 In	 part,	 this	 is	 a	 consequence	 of	 the	 remaining	 limitations	 to	 our	 understanding	 of	 the	mechanisms	underlying	pain	in	OA.	
This	 study	 aims	 to	 characterize	 potential	 adaptations	 in	 the	 response	 properties	 of	 the	 pain	responsive	cells	in	the	RVM	in	a	1mg	MIA,	non-neuropathic	model	of	OA	using	electrophysiology.		It	is	hoped	this	may	 further	our	understanding	of	 the	supra	spinal	controls	 involved	 in	 this	model	of	OA	pain,	and	consequently	inform	our	understanding	of	viable	targets	for	pharmacological	 intervention.	Many	previous	studies	have	used	shorter-term	models	so	here	the	impact	of	OA	was	examined	in	the	later	stages.		
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5.2	 		 Methods	
5.2.1			 Animals	
All	work	was	conducted	in	Male	Sprague	Dawley	rats,	bred	and	housed	in	the	Central	Biological	Services	 Unit	 at	 University	 College	 London.	 As	 described	 in	 Chapter	 2,	 behaviour	 and	electrophysiology	was	conducted	from	day	14	onwards	in	animals	weighing	250-300g.			
	
5.2.2	 		 Induction	of	the	model	
As	detailed	in	Section	2.2,	rats	were	injected	with	1mg	MIA	(Sigma,	UK)	to	the	left	knee.	
	
5.2.3	 		 Behavioural	Assessment		
As	 described	 in	 Section	 2.3.3,	 paw	 withdrawal	 was	 assessed	 at	 day	 14	 using	 the	 “up-down	method”,	 as	 described	 by	 Chaplan	 et	 al(Chaplan,	 Bach	 et	 al.	 1994).	 In	 brief,	 vF	 hairs	 of	sequential	 increasing	or	decreasing	 force	are	applied,	based	on	 the	 response	 to	 the	previous	stimuli	 (withdrawal	or	 lack	 there	of).	The	statistical	 formula	described	by	Dixon	et	al	 is	 then	utilized	to	calculate	the	50%	withdrawal	threshold(Dixon	1980)	–	which	describes	the	force	at	which	 the	 animal	will	withdraw	 50%	 of	 the	 time.	 Significant	 differences	 in	 paw	withdrawal	thresholds	analysed	using	an	un-paired	students’	t-test.	
	
5.2.4	 		 Electrophysiological	Assessment	
in	vivo	electrophysiology	was	carried	out	in	rats	weighing	250-300g	at	day	14-16	after	injection	of	either	1mg	MIA	or	Saline,	as	described	in	detail	in	Section	2.5.	
Once	a	cell	had	been	identified	and	classified	as	either	ON-,	OFF-	or	neutral,	based	on	changes	in	firing	prior	to	tail	flick,	the	cell	was	characterized	through	three	phases	of	testing,	all	described	in	detail	Section	2.5.2:	
1. Change	in	rate	of	firing	in	response	to	tail	flick.		
2. Mean	resting	activity	over	15minutes.	
		 190	
3. Change	 in	 rate	 of	 firing	 in	 response	 to	 ipsilateral	 and	 contralateral	 stimulation	of	 the	paw	and	knee.	
	
5.2.5	 		 Data	Analysis	
While	recording,	individual	cells	were	isolated	visually	on	the	oscilloscope	and	audibly	through	the	 speakers,	 however	 data	 was	 extracted	 and	 analysed	 based	 upon	 waveform	 shape	 (See	
2.5.4).	 This	 allowed	 several	 cells	 to	 be	 analysed	 in	 tandem,	 for	 example	 both	 the	 visually	identified	ON-cell	and	a	neighbouring	neutral	cell.	
The	effect	of	each	stimulus,	the	maximum	change	in	rate	of	firing,	was	calculated	as:	
Rate	of	Firing	During/After	stimulus	-	Mean	Baseline	Rate	
Where	baseline	was	calculated	as	the	mean	rate	of	firing	for	the	20	seconds	directly	preceding	the	stimulus;	Rate	of	firing	during	was	calculated	as	the	mean	rate	of	firing	for	the	20seconds	during	von	Frey	or	clamp	application;	and	the	rate	of	firing	after	stimulus	was	the	mean	rate	in	the	20seconds	after	 the	 stimulus.	The	greatest	 change	 in	 rate	of	 firing	over	 the	 three	 rounds	was	 used	 for	 analysis.	 This	measure	 of	 after	 stimulus	 change	 in	 rate	 of	 firing	was	 calculated	following	 observations	 that	 the	 increase	 or	 pause	 in	 firing	 sometimes	 followed	 the	
release/removal	of	the	more	noxious	stimuli,	namely	the	knee	clamp	and	60	and	100g	von	Frey	hairs.		
Change	 in	 rate	 of	 firing	 was	 analysed	 using	 column	 statistics,	 namely	 to	 calculate	 the	 25	percentiles,	 mean	 and	 standard	 deviation,	 alongside	 a	 One-sample	 t-test	 to	 determine	 if	 the	mean	 change	 in	 rate	 of	 firing	 was	 significantly	 different	 from	 0,	 denoting	 no	 change,	 and	 a	Wilcoxon	Signed	rank	test	to	determine	if	the	median	change	in	rate	of	firing	was	significantly	different	from	0.	
As	 described	 in	 Sikandar	 et	 al(Sikandar,	 Bannister	 et	 al.	 2012),	 ON-cells	 were	 then	 formally	reclassified	 by	 their	 response	 to	 paw	 and	 knee	 stimulation.	 Briefly,	 the	 mean	 percentage	change	in	firing	in	response	to	a	stimulus	was	calculated	using	the	formula:		
((Mean	rate	of	firing	after	the	stimulus	/	mean	baseline	rate	of	firing)*100)-100	
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where	 percentage	 changes	 >15%	 identified	 ON-like	 responses;	 >	 negative	 15%	 identified	 an	OFF-like	response;	and	responses	between	15%	to	-15%	identified	neutral-like	responses.		
In	 all	 graphs,	 data	 is	 expressed	 as	 the	 change	 in	 rate	 of	 firing,	 spikes	 per	 second,	 plotted	 as	either	scatter	plot;	box	and	whisker;	or	as	the	mean	change	in	rate	of	firing	(spikes	per	second)	±	SEM.	Significant	differences	in	the	extent	of	change	in	rate	of	firing	between	groups	and	sides	(i.e.	 MIA	 vs.	 Sham	 animal;	 Ispi	 vs.	 contra)	 was	 determined	 using	 a	 non-parametric	 Mann-Whitney	U	test.	
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5.3		 		 Results	
5.3.1				 Recording	Sites	
Bearing	 in	 mind	 the	 limitations	 of	 assuming	 that	 the	 recording	 site	 coordinates	 truthfully	correspond	to	the	rat	atlas	defined	location	without	histological	confirmation,	it	appears	likely	that	 a	 large	 number	 of	 cells	 fall	 within	 the	 nucleus	 reticularis	 gigantocellularis,	 commonly	abbreviated	to	either	RGC,	NGC,	or	Gi	–	as	it	is	referred	to	in	this	copy	of	the	rat	atlas	–	and	not	the	 desired	 RVM	 nuclei	 of	 the	 NRM,	 nucleus	 reticularis	 paragigantocellularis,	 or	 nucleus	reticularis	gigantocellularis	pars	alpha	(NGCα).	
Analysis	 within	 this	 chapter,	 and	 a	 large	 portion	 of	 the	 discussion,	 proceeds	 from	 the	perspective	of	the	expected	cell	types	found	in	the	RVM,	on	the	understanding	that	ON	cells	as	defined	in	the	RVM	have	also	previously	been	characterized	in	the	NGC(Fields,	Bry	et	al.	1983).	The	limitations	and	contrary	implications	of	potentially	having	recorded	from	the	NGC	will	also	be	considered	throughout,	and	in	greater	depth	in	sections	5.4.1	and	5.4.5.	
	
i	
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Figure	 5.2	 -	 A	 diagrammatic	 representation	 of	 coronal	 sections	 corresponding	 to	 RVM	 nuclei	 with	 recording	 sites	
indicated.	 Coronal	 depth	 is	 evaluated	 by	 the	 dorsoventral	 distance	 from	 the	 horizontal	 plane	 passing	 through	 bregma	 and	lambda	on	the	surface	of	the	skull.	Red	 circles	 indicate	recording	sites	in	MIA	rats.	Orange	 triangles	 indicate	recording	sits	in	sham	rats 
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5.3.2	Confirmation	of	behavioural	hypersensitivity		
The	50%	mechanical	paw	withdrawal	threshold	(PWT)	of	the	ipsilateral	and	contralateral	paw	was	assessed	in	rats	14days	after	the	intra-articular	injection	of	1mg	MIA	and	compared	to	the	sham	control,	which	received	saline.	 The	 significant	reduction	 in	 the	 50%	 PWT	on	the	ipsilateral	side	in	MIA	animals,	 versus	 both	contralateral	 paw	 and	 sham	control	 animals,	 indicate	 the	development	 of	 a	 marked	ipsilateral	 mechanical	hypersensitivity	 (Figure	 5.3;	n=15-16;	 Unpaired	 Students	T-test;	***	p≤0.001).	
While	 no	 significant	difference	 is	 observed,	 there	is	 similarly	 an	 interesting	trend	towards	a	reduction	in	the	 MIA	 contralateral	 paw	WT	compared	to	the	sham	ipsilateral	and	contralateral	PWT’s,	for	example	MIA	CL:	6.4	±	0.6g	versus	 Sham	 CL:	 8.1	 ±	 0.8g.	 Similarly,	 no	 difference	 in	 PWT	 was	 observed	 between	 Sham	ipsilateral	and	contralateral	paws.	
5.3.3			Electrophysiological	Recordings	in	MIA	and	Sham	Rats		
A	total	of	13	MIA	and	15	Sham	animals	were	used,	from	which	20	and	24	ON	cells,	1	and	6	OFF	cells	and	12	and	9	neutral	cells	were	characterised	respectively	(Table	5.1).		The	number	of	OFF	cells	is	in	contrast	extremely	low,	notably	in	the	MIA	group,	following	continuing	difficulties	in	
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Figure	 5.3	 –	 Monosodium	 Iodoacetate	 induced	 OA	 produced	 significant	
mechanical	 hypersensitivity	 in	 the	 ipsilateral	 paw	 versus	 both	
contralateral	paws	and	sham	animal	controls.		At	Day	14	following	injection,	MIA	animals	exhibit	a	significant	reduction	in	the	50%	withdrawal	threshold	to	vF	hairs	applied	to	the	paw,	versus	both	contralateral	paw	and	sham	ipsilateral	paw	WT	(MIA	n=13,	Sham	n=15;	***	p≤0.001)	
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identifying	OFF	cells	in	the	MIA	animals,	despite	perseverance,	and	so	the	decision	was	made	to	discontinue	the	search,	in	line	with	our	3Rs	obligations.	However,	given	the	volume	of	ON	cells	characterised	it	was	felt	this	would	be	sufficient	to	identify	any	alterations	in	firing	patterns	in	these	animals,	and	thus	ON	cells	are	the	focus	on	the	analysis	in	this	study.	
Example	electrophysiological	recordings	 in	Figure	5.4	 illustrate	selected	ON,	OFF,	and	neutral	cells	 showing	 characteristic	 changes	 in	 reflex-related	 firing	 following	 the	 application	 of	 the	noxious	heat	stimulus	to	tail.	Those	identified	as	ON-cells	increased	reflex-related	firing	(Figure	5.4A);	 OFF-cells	 paused	 reflex-related	 firing	 (Figure	 5.4B);	 and	 neutral	 cells	 show	 no	observable	meaningful	change	in	reflex-related	activity	(Figure	5.4C).	
Following	the	initial	electrophysiological	identification	of	the	ON,	OFF	or	Neutral	cell	type,	the	baseline	rate	of	firing,	change	in	rate	of	reflex	related	firing	and	time	delay	(latency)	to	tail	flick	following	immersion	in	hot	water	were	characterized	(Figure	5.5).	No	significant	difference	was	observed	between	the	baseline	rate	of	firing	of	either	ON	or	Neutral	cells	in	MIA	vs.	Sham	(OFF	could	 not	 be	 assessed)	 (Figure	 5.5	 A).	 However,	 there	 is	 a	 visible	 trend	 towards	 decreased	baseline	 firing	 rates	 in	 both	 MIA	 ON	 and	 MIA	 neutral	 cells	 in	 comparison	 to	 Sham	 ON	 and	neutral	cells:	for	example	ON	cell	rate	of	firing	2.8±1.0	spikes	per	second	vs.	7.2±2.2	spikes	per	second	in	MIA	vs.	Sham.	Similarly,	no	significant	difference	was	observed	in	the	latency	to	tail	flick	 following	 the	 8cm	 immersion	 of	 the	 tail	 in	 50*C	 water	 (Figure	 5.5B),	 nor	 significant	difference	in	the	mean	change	in	rate	of	firing	in	in	ON	or	neutral	cells	in	relation	to	the	reflex	tail	flick	(Figure	5.5	C)	between	sham	and	MIA	animals.	
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Figure	5.4	-	ON,	OFF,	and	neutral	cells	display	characteristic	changes	in	reflex-
related	firing	following	a	noxious	somatic	stimulus.	A)	Example	trace	of	an	RVM	ON-cell	 that	 increases	 reflex-related	 firing	 following	 noxious	 tail	 heat	 (êHeat	 =	application	of	heat	stimulus,	êTail	flick	=	visible	initiation	of	tail	flick).	B)	Example	trace	of	an	RVM	OFF-cell	that	pauses	reflex-related	firing	(spikes)	following	noxious	tail	heat.	C)	Example	trace	of	a	NEUTRAL-cell	that	displays	no	consistent	change	in	reflex-related	activity	following	noxious	tail	heat.	
A	
B	
C	
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A	 B	
C	 Figure	5.5	 –	The	baseline	rate	of	 firing,	 latency	 to	tail	
flick	 following	 application	 of	 noxious	 tail	 heat,	 and	
change	 in	 rate	 of	 reflex	 related	 firing	 of	 ON,	 OFF	 and	
Neutral	 cells	 did	not	 significantly	 differ	 between	MIA	
and	Sham	animals	14-16days	following	injection.	A)	No	significant	 difference	was	 observed	 between	 the	 baseline	rate	 of	 firing	 of	 ON,	 OFF	 and	 neutral	 cells	 (Mean	 over	 a	15minute	 period)	 in	 MIA	 versus	 sham	 animals.	 B)	 No	significant	difference	was	observed	in	the	mean	change	in	rate	of	 firing,	out	of	 three	responses,	upon	tail	 flick	reflex	response	 in	 ON,	 OFF	 and	 neutral	 cells	 in	 MIA	 and	 Sham	animals.	 C)	 No	 significant	 difference	 was	 observed	between	MIA	 and	sham	animals’	 latency	 to	 tail	 flick	upon	the	8cm	immersion	in	50*C	water.		
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5.3.4	Characterization	of	ON	cell	responses	to	somatic	stimulation		
The	change	in	rate	of	firing	of	previously	identified	ON	cells	was	then	characterized	following	the	application	of	noxious	and	non-noxious	stimuli	to	the	IL	and	CL	paw	and	knee	in	MIA	and	Sham	animals.	 	The	change	in	rate	in	the	20s	following	the	release	of	the	stimuli	was	used	for	further	analysis	as	both	through	experimental	observation	and	data	(See	Appendix)	this	often	produced	the	greatest	change	in	nociception-related	firing.	
In	 contrast	 to	 the	 responses	 to	 noxious	 tail	 heat,	 these	 mechanical	 somatic	 stimuli	 did	 not	produce	 consistent	 changes	 in	 activity	 following	 noxious	 and	 non-noxious	 mechanical	stimulation	of	the	paw	and	knee,	 in	both	MIA	and	sham	animals.	As	can	be	seen	in	Figure	5.6	and	 5.7,	 while	 the	 large	 proportion	 of	 cells	 increased	 their	 firing,	 a	 small	 number	 exhibited	reduction	 in	 firing,	 clearly	 observed	 in	 response	 to	 ipsilateral	 knee	 pinch	 in	 MIA	 animals	(Figure	5.6A	and	5.7A).	
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MIA Contralateral Firing Responses - ON Cell
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Sham Ispilateral Firing Responses - ON Cell
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Figure	5.6	–	The	response	of	ON-cells	to	mechanical	stimulation	to	the	knee	and	paw	following	MIA	and	saline	
produced	divergent	responses,	with	a	minority	of	cells	responding	in	an	OFF	like	manner	to	reduce	the	rate	of	
firing.	A+C)	Response	of	ON-cells	in	MIA	animals	to	ipsilateral	(A)	and	contralateral	(C)	knee	pinch	and	vF	application	to	 the	 paw,	 in	 which	 only	 the	 responses	 to	 100g	 in	 IL	 and	 15g	 vF	 in	 IL	 and	 CL	 were	 significant	 different	 from	 0	(significant	change	in	rate).	B+D)	Change	in	rate	of	firing	in	ON-cells	in	Sham	animals	to	ipsilateral	(B)	and	contralateral	
(D)	stimulation,	where	only	the	knee	pinch	evoked	a	significant	change	in	firing.		(*	p≤0.05).	
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	Across	all	groups,	column	statistics	were	performed,	box-and-whisker	diagrams	generated	and	the	significance	of	 change	 in	rate	of	 firing	versus	0,	or	no	change,	 calculated	(Figure	5.6;	One	sample	T-test;	*	p≤0.05).	 	 In	MIA	animals,	no	significant	change	in	rate	of	firing	was	observed	across	most	stimulus	groups,	with	the	exception	of	15g	vF	in	both	IL	and	CL	paw	and	to	100g	vF	in	 IL	paw.	The	 stimulation	of	 the	 IL	 side	 trended	 towards	 a	 greater	 increase	 in	 firing,	with	 a	firing	pattern	similar	to	a	stimulus	intensity	coding	in	the	MIA	IL	group	(Figure	5.6A)	–	where	the	less	noxious	and	non-noxious	stimuli	responses	cluster	closer	to	zero,	with	the	exception	of	15g	vF,	such	that	more	noxious	stimuli	evoke	greater	changes	in	the	rate	of	firing.	
In	Sham	animals,	a	significant	change	in	the	rate	of	firing	is	only	observed	in	response	to	knee	pinch	in	both	IL	and	CL	stimulation,	though	there	is	a	trend	towards	an	increased	rate	of	firing	in	response	to	both	60g	and	26g	vF	(60g:	IL	p=0.11,	CL	p=0.09;	26g	IL	p=0.07;	One	sample	T-test).		
Overall	the	change	in	rate	of	firing	is	smaller	in	the	sham	animals	than	MIA	animals,	and	on	the	contralateral	 side	 versus	 the	 ipsilateral	 side.	 Change	 in	 firing	 to	 the	 non-noxious	 and	 less	noxious	stimuli	clustered	near	0	–	indicating	a	lack	in	response	to	stimulation	(Figure	5.6	and	5.7).		
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Figure	5.7	–	The	response	of	ON-cells	to	mechanical	stimulation	to	the	knee	and	paw	14-16days	 	following	
injection	of	either	1mg	MIA	or	saline	produced	divergent	responses	within	groups,	with	a	minority	of	cells	
responding	in	an	OFF-like	manner	to	reduce	the	rate	of	firing.	A)	Knee	Pinch	B)	100g	vF	C)	60g	vF	D)	26g	vF	E)	15g	vF	F)	8g	vF	
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5.3.5	 		 Reclassification	and	ON:ON-like	cell	analysis	
As	can	be	observed	 in	Figure	5.6	and	5.7,	 a	proportion	of	ON	cells	 (classified	earlier	by	 their	response	 to	noxious	heat	 induced	 tail	 flick)	altered	 their	 firing	 in	a	manner	 inconsistent	with	this	classification.	
	
Table	5.2	–	Changes	in	activity	of	ON-cells	following	the	application	of	8-100g	vF	hairs	or	knee	pinch	(KP)	to	
the	 ipsilateral	or	 contralateral	paw	14-16days	after	 the	 injection	of	MIA	or	Saline:	Responses	were	either	
classified	 as	ON-like	 (>15%	 increase	 in	 firing),	 OFF-like	 (>15%	decrease	 in	 firing)	 or	Neutral-like	 (<15%	
change	in	either	direction)	based	on	the	change	in	rate	of	firing	following	stimulus	compared	to	baseline	
		
MIA	IPSILATERAL	 MIA	CONTRALATERAL	
8	 15	 26	 60	 100	 KP	 8	 15	 26	 60	 100	 KP	
ON-LIKE	 7	 12	 7	 8	 16	 14	 8	 13	 9	 7	 8	 11	
OFF-LIKE	 4	 2	 9	 9	 0	 3	 9	 5	 9	 7	 5	 4	
NEUTRAL	 8	 5	 3	 2	 3	 2	 2	 1	 1	 5	 6	 4	
		
SHAM	IPSILATERAL	 SHAM	CONTRALATERAL	
8	 15	 26	 60	 100	 KP	 8	 15	 26	 60	 100	 KP	
ON-LIKE	 12	 6	 12	 13	 14	 18	 9	 7	 8	 14	 9	 14	
OFF-LIKE	 5	 9	 7	 5	 2	 3	 5	 7	 9	 6	 8	 6	
NEUTRAL	 6	 8	 4	 5	 7	 2	 9	 9	 6	 3	 6	 3		
Using	 analysis	 previously	 described	 by	 Sikandar	 et	 al(Sikandar,	 Bannister	 et	 al.	 2012),	 these	cells	 were	 reclassified	 based	 on	 the	 </>15%	 change	 in	 the	 rate	 of	 firing	 following	 the	application	of	noxious	and	non-noxious	stimuli	 to	the	knee	and	paw,	such	that	cells	would	be	described	as	ON-like,	OFF-like	or	neutral.		
As	described	in	Table	5.2,	this	resulted	in	a	proportion	of	ON	cells	being	classified	as	OFF-like	or	neutral-like	in	their	responses	to	stimulation	of	the	paw	or	knee,	though	the	majority	were	ON-like	responses.	The	total	number	of	ON-like	responses	is	consistent	across	groups,	such	that	56%,	49%,	54%	and	44%	of	responses	are	classified	as	ON-like	in	MIA	IL,	MIA	CL,	Sham	IL	and	Sham	 CL	 respectively.	 This	 proportion	 is	 marginally	 higher	 in	 response	 to	 ipsilateral	stimulation,	where	fewer	OFF-like	responses	are	similarly	observed.	
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ON	cell	 responses	were	most	 consistent	 in	 response	 to	 the	most	noxious	 stimuli,	 such	 that	 a	greater	proportion	of	cell	responses	were	classified	as	ON-like	in	response	to	60g,	100g	vF	and	knee	pinch,	with	relatively	 few	OFF-like	responses	observed	 to	 these	most	noxious	stimuli	 in	ipsilateral	 knee	 and	 paw	 (both	MIA	 and	 Sham).	 Overall,	 the	 greatest	 number	 of	 neutral-like	responses	were	observed	in	response	to	the	non-noxious	and	mildly	noxious	stimuli	of	8g	and	15g	vF	–	with	the	exception	of	MIA	CL	–	however,	this	is	to	be	expected	since	ON-like	responses	would	 only	 be	 expected	 to	 stimuli	 sufficient	 to	 evoke	 a	 reflex	 withdrawal,	 where	 a	 lack	 of	response	results	in	a	Neutral-like	classification.		
The	 magnitude	 of	 change	 in	 rate	 of	 firing	 in	 ON	 cells	 responding	 in	 an	 ON-like	 manner	 to	mechanical	stimulation	of	 the	paw	and	knee	are	outlined	 in	Figure	5.8	and	5.9.	No	significant	differences	are	observed	between	either	group	(MIA	vs.	Sham),	side	(IL	vs.	CL)	or	stimulation	force	(8-100g	vF	hairs)	respectively	across	these	figures,	however	trends	are	apparent.	
A	 B	
C	 D	
Figure	5.8	–	Change	in	the	rate	of	firing	of	ON-Cells	exhibiting	ON-like	changes	in	the	rate	of	firing	following	
the	application	of	von	Frey	hairs	or	knee	pinch	to	the	ipsilateral	or	contralateral	hind	limb	14-16days	after	
the	injection	of	1mg	MIA	or	saline	(Sham).	A+B)	ON-like	changes	in	rate	of	firing	in	RVM	ON-cells	in	MIA	animas	following	 mechanical	 stimulation	 of	 ipsilateral	 (A)	 and	 contralateral	 (B)	 paw	 and	 knee;	 and	 in	 sham	 animals	following	ipsilateral	(C)	and	contralateral	(D)	stimulation	
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Consider	Figures	5.8A	and	Figure	5.9A	and	C.	Though	not	significant,	there	is	an	apparent	trend	towards	a	greater	increase	in	the	rate	of	firing	following	ipsilateral	MIA	knee	pinch,	60g,	100g	and	15g	vF	hair	application	to	the	paw	versus	contralateral	and	sham	stimulation.	
In	contrast	with	a	relatively	homogenous	extent	of	change,	the	response	to	ipsilateral	15g	vF	in	MIA	 animals	 equivalent	 to	 that	 of	 the	 knee	 pinch.	 While	 15g	 vF	 wouldn’t	 traditionally	 be	considered	as	strongly	noxious,	this	is	beyond	the	50%	withdrawal	threshold	observed	in	these	animals	(Figure	5.3)	and	thus	sufficiently	noxious	to	MIA	animals	to	evoke	a	strong	withdrawal,	the	behavioural	correlate	of	changes	in	ON	cell	firing.		
	 	
MIA Only
0 20 40 60 80 100 120
0
5
10
15
20
von Frey (g)
C
ha
ng
e 
in
 R
at
e 
of
 F
iri
ng
 
(s
pi
ke
s 
pe
r s
ec
on
d)
0 20 40 60 80 100 120
0
5
10
15
20
von Frey (g)
C
ha
ng
e 
in
 R
at
e 
of
 F
iri
ng
 
(s
pi
ke
s 
pe
r s
ec
on
d)
Combined View
Sham only
0 20 40 60 80 100 120
0
5
10
15
von Frey (g)
C
ha
ng
e 
in
 R
at
e 
of
 F
iri
ng
 
(s
pi
ke
s 
pe
r s
ec
on
d)
Knee Pinch
MI
A I
ps
i
MI
A C
on
tra
Sh
am
 Ip
si
Sh
am
 C
on
tra
 
0
5
10
15
20
C
ha
ng
e 
in
 R
at
e 
of
 F
iri
ng
 
(s
pi
ke
s 
pe
r s
ec
on
d)
MIA Ipsi MIA Contra Sham Ipsi Sham Contra 
Figure	5.9	 -	The	ON-like	response	of	recorded	ON-cells	 to	mechanical	stimulation	to	the	knee	and	paw	14-
16days	after	injection	of	either	1mg	MIA	or	saline.	Evoked	responses	of	MIA	(A)	and	sham	(B)	treated	animals	to	ipsilateral	and	contralateral	von	Frey	to	the	paw,	and	in	merged	view	(C).	D)	Evoked	response	to	knee	pinch	
A	 B	
C	 D	
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5.4				 Discussion	
Changes	to	the	rate	of	firing	of	ON	and	OFF	cells	in	the	RVM	are	by	now	well	characterized,	such	that	we	expect	distinctive	pauses	in	firing	from	OFF	cells	and	a	rapid	enhancement	in	the	rate	of	firing	 from	ON	 cells	 after	 the	 application	 of	 a	 nociceptive	 stimuli	 sufficient	 to	 evoke	 a	 reflex	withdrawal	 (Fields,	 Bry	 et	 al.	 1983,	 Heinricher,	 Barbaro	 et	 al.	 1989).	 	 It	 is	 similarly	 well	characterized	 through	 spinal	 electrophysiology	 and	 pharmacology	 that	 monoamine	 controls	descending	from	the	brainstem,	including	the	RVM,	act	to	modulate	nociceptive	transmission	in	the	spinal	cord(Stanfa	and	Dickenson	1994,	Green,	Lyons	et	al.	1998,	Green,	Scarth	et	al.	2000,	Suzuki,	Rygh	et	al.	2004,	Rahman,	Bauer	et	al.	2009,	Sikandar,	Bannister	et	al.	2012,	Burnham	and	Dickenson	2013,	Bannister,	Patel	et	al.	2015).	The	plasticity	in	brainstem	processing	during	chronic	 pain	 conditions,	 and	 the	 roles	 in	 determining	 the	 severity,	 profile,	 time	 course	 and	spatial	 mapping	 of	 the	 pain	 profile,	 are	 increasingly	 understood	 in	 neuropathic	 nerve	injuries(Burgess,	Gardell	et	al.	2002,	Vanegas	and	Schaible	2004,	Chen,	Oatway	et	al.	2009,	De	Felice,	Sanoja	et	al.	2011,	Hughes,	Hickey	et	al.	2013,	Wang,	King	et	al.	2013).	However,	less	well	understood	 is	 what	 these	 changes,	 if	 changes	 are	 apparent	 at	 all,	 might	 look	 like	 in	 an	 OA	animal.		
Clinical	studies	have	put	forward	evidence	that	central	sensitisation	spreads	beyond	the	spinal	cord	to	encompass	the	brainstem	during	OA	in	patients(Gwilym,	Keltner	et	al.	2009).		While	the	work	 presented	 herein	 fails	 to	 classify	 significant	 changes	 in	 nociceptive	 processing	 in	 the	brainstem	 of	 1mg	 MIA	 animals,	 apparent	 trends	 within	 the	 data	 may	 suggest	 more	 subtle	adaptations	in	this	model	of	OA	pain.	
	
5.4.1	 	 Implications	of	recording	from	NGC	
The	RVM	 in	 the	 rat	 is	 composed	 of	 the	 nucleus	 raphe	magnus	 (NRM)	 and	 adjacent	 reticular	areas,	 namely	 the	 nucleus	 reticularis	 gigantocellularis	 pars	 alpha	 (NGCα)	 and	 the	 nucleus	paragigantocellularis	 lateralis(Fields,	 Bry	 et	 al.	 1983,	 Bouhassira,	 Bing	 et	 al.	 1993).	 Directly	adjacent	to	the	NGCα	sits	the	NGC.	As	alluded	to	in	section	5.3.1,	it	is	clear	from	the	recording	plots	 in	 Figure	 5.2	 that	 a	majority	 of	 cells	 recorded	 in	 this	 study	 likely	 fell	within	 this	 latter	nucleus,	thus	recording	outside	of	the	RVM.	
The	NGC	 is	 sometimes	misquoted	 as	 forming	part	 of	 the	RVM(Zhuo	 and	Gebhart	 1992,	 Zhuo	and	Gebhart	1997),	 in	part	due	the	number	of	similarities	between	the	NGC	and	nuclei	of	 the	RVM.	For	example,	NGC	neurones	respond	to	noxious	simulation	with	increasing,	decreasing,	or	
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no	change	to	the	rate	of	 firing(Pearl	and	Anderson	1978,	Harris	and	Sinclair	1981,	Mohrland,	McManus	et	al.	1982,	Morrow	and	Casey	1983).	Indeed,	Fields	et	al	1983	recorded	from	what	he	 referred	 to	 as	 ON-cells	 within	 the	 NGC,	 though	 no	 OFF	 cells	 were	 identified	 during	 the	study(Fields,	 Bry	 et	 al.	 1983).	 	 Studies	 have	 similarly	 documented	 the	 effects	 of	 ES,	pharmacological	 and	 lesioning	 interventions	 that	 highlight	 a	 role	 for	 the	 NGC	 in	 descending	facilitation	of	spinal	processing(Zhuo	and	Gebhart	1991,	Zhuo	and	Gebhart	1997,	Wei,	Dubner	et	 al.	 1999,	 Terayama,	 Dubner	 et	 al.	 2002,	 Da	 Silva,	 DeSantana	 et	 al.	 2010),	 though	 studies	disagree	 over	 the	 exact	 role	 of	 NGC.	 These	 include	 theories	 of	 direct,	 to	 lamina	 VII,	 VIII	 and	IX,(Matsuyama,	Ohta	et	al.	1988)	and	indirect	to	lamina	I,	II	and	V(Basbaum,	Ralston	et	al.	1986,	Jones	and	Light	1990)	via	RVM(Beitz	1982,	Zagon	and	Bacon	1991),	influences	on	spinal	cord	excitability;	 tonic	 inhibition	of	NRM	OFF	cells	via	 local	GABA	 interneurons(Wei,	Dubner	et	al.	1999);	 and	 disinhibition	 of	 the	 A7	 noradrenergic	 descending	 inhibitory	 system(Clark	 and	Proudfit	1991,	Wei,	Dubner	et	al.	1999).	However,	in	contrast	to	the	RVM	the	NGC	additionally	has	 a	 role	 in	 escape	 behaviour(Casey	 1971),	 and	 the	 incidence	 of	 OFF-like	 cells	 is	 much	smaller(Pearl	and	Anderson	1978,	Harris	and	Sinclair	1981,	Fields,	Bry	et	al.	1983).		
What	is	the	impact	to	this	work	of	potentially	having	recorded	largely	from	the	NGC?	The	study	remains	 relevant,	 given	 the	 previously	 mentioned	 influence	 of	 NGC	 in	 pain	 and	 spinal	excitability.	 Similarly,	 the	 previously	 established	 presence	 of	 ON	 cells	 in	 the	 NGC	 by	 Fields	allows	the	current	analysis	 to	proceed.	However	expectations	 for	 the	potential	adaptations	 in	neuronal	activity	may	differ	–	for	example,	in	contrast	to	RVM	it	is	less	clear	if	the	NGC	‘s	cells	adapt	 their	 baseline	 firing	 patterns	 during	 pain	 conditions(Pertovaara	 and	 Tukeva	 1989,	Robinson,	Calejesan	et	al.	2002).	
	
5.4.2			 The	Baseline	Rate	of	Firing	and	Latency	to	Tail	Flick	in	MIA	Rats		
In	line	with	the	trend	towards	a	greater	latency	to	tail	flick,	the	baseline	spontaneous	activity	of	the	 ON-cells	 identified	 in	 these	 1mg	 MIA	 animal’s	 trends	 towards	 decreased	 rate	 of	 firing	versus	 sham	 animals.	 Though	 not	 significant,	 at	 p=0.119,	 this	 baseline	 activity	 is	 noticeably	different	and	could	be	taken	to	indicate	a	mild	resting	state	of	anti-nociception	in	comparison	to	sham	animals	that	had	not	received	1mg	MIA	to	the	knee	14-16days	prior.		
Considered	 from	 the	 perspective	 of	 recording	 in	 the	 RVM,	 the	 precedent	 for	 changes	 in	 the	baseline	 rate	 of	 firing	 of	 ON	 and	 OFF	 cells,	 and	 the	 tangible	 impact	 upon	 reflexes	 and	nociceptive	 thresholds,	 is	 clear.	Changes	 to	 the	 spontaneous	baseline	 rate	of	 firing	 in	 chronic	pain	 have	 been	 observed	 in	 animals	 during	 both	 inflammatory	 and	 neuropathic	 pain	
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models(Khasabov,	Brink	et	al.	2012,	Silva,	Amorim	et	al.	2013),	 though	this	 is	not	universally	observed(Carlson,	Maire	et	al.	2007).	It	 is	 likely	that	these	changes	in	the	spontaneous	rate	of	firing	 of	 ON	 cells	 are	 time	 sensitive,	 much	 like	 the	 changes	 in	 the	 balance	 of	 descending	inhibition	and	facilitation(Terayama,	Guan	et	al.	2000,	Terayama,	Dubner	et	al.	2002,	Vanegas	and	Schaible	2004),	since	Gonçalves	et	al	2007	demonstrated	enhanced	spontaneous	activity	of	RVM	 ON	 cells	 at	 weeks	 1	 but	 not	 8	 in	 rats	 following	 the	 SNI	 model	 of	 neuropathic	pain(Gonçalves,	 Almeida	 et	 al.	 2007).	 Similarly,	 the	most	 powerful	 analgesic	 agents,	 opiates,	causes	 significant	 reduction	 in	 the	 baseline	 firing	 of	 ON	 cells	while	 enhancing	 the	 activity	 of	OFF	cells(Heinricher,	Morgan	et	al.	1994).	Both	the	systemic	or	iontophoretic	administration	of	morphine	reduce	spontaneous	and	nocifensive	reflex	related	firing	of	ON-cells	at	doses	which	inhibit	noxious	heat	related	tail	flick(Barbaro,	Heinricher	et	al.	1986,	Heinricher,	Morgan	et	al.	1992).	As	such,	the	concept	of	adaptations	in	the	basal	rate	of	 firing	in	ON	cells,	or	that	those	reductions	may	result	in	tonic	anti-nociception	and	prolong	the	latency	to	tail	flick	are	not	new	ideas.	 However,	 three	 issues	 are	 clear	 here.	 The	 first,	 that	 observed	 adaptations	 in	 ON	 cell	spontaneous	 activity	 are	 largely	 enhancements	 of	 ON-cell	 firing	 in	 both	 inflammation	 and	neuropathy(Gonçalves,	 Almeida	 et	 al.	 2007,	 Khasabov,	 Brink	 et	 al.	 2012,	 Silva,	 Amorim	 et	 al.	2013),	 while	 these	 1mg	 MIA	 animals	 are	 exhibiting	 reductions	 in	 the	 basal	 rate	 of	 ON	 cell	activity.	 Second,	 these	 changes	 are	 not	 themselves	 significant,	 nor	 are	 the	 behavioural	correlates.	Thirdly,	conclusions	are	limited	severely	without	the	ability	to	draw	conclusions	on	OFF	cell	activity.	Notably,	the	first	and	last	of	these	may	in	part	be	addressed	by	analysis	of	this	data	as	NGC,	not	RVM.	
On	the	first:	though	increases	in	ON	cell	firing	in	the	RVM	is	most	commonly	observed	during	pain	 states,	 as	 already	 described	 above	 and	 discussed	 in	 Chapter	 4,	 these	 changes	 and	 the	balance	 between	 descending	 facilitation	 and	 inhibition	 have	 been	 shown	 to	 be	 time	dependent(Gonçalves,	Almeida	et	al.	2007).	This	trend	towards	decreased	firing	in	the	1mg	MIA	model	 at	 14-16days	 after	 injection	 by	 ON-cells	may	 reflect	 a	 time	 sensitive,	 disease	 severity	specific	point	of	minor	(non-	significant)	tonic	analgesia.	This	idea	aligns	well	to	previous	work	which	 shows	 a	 time	 sensitive	 effect	 of	 5HT7	 antagonism	 on	 the	 reversal	 of	 the	 effects	 of	milnacipran	 in	 the	2mg	MIA	model(Burnham	and	Dickenson	2013)	 It	may	be	 that	 significant	pharmacological	 effects	 are	 observed	 by	 Burnham	 et	 al	 2013,	 indicating	 descending	serotonergic	 inhibitions,	 due	 to	 differences	 in	 the	 severity	 of	 the	 1mg	 and	 2mg	models	 (See	discussion	in	Chapter	3&4).		Conversely,	this	may	simply	relate	to	recording	site	expectations.	While	RVM	cell	adaptations	during	pain	states	are	well	characterized(Gonçalves,	Almeida	et	al.	2007,	Khasabov,	Brink	et	 al.	 2012,	 Silva,	Amorim	et	 al.	 2013),	 it	may	be	 that	 the	NGC	adapts	differently.	By	recording	from	NGC,	ES	studies	have	previously	established	that	the	responses	
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of	 NGC	 cells	 are	 inhibited	 when	 PAG	 is	 stimulated(Harris	 and	 Sinclair	 1981,	 Mohrland,	McManus	et	al.	1982,	Morrow	and	Casey	1983)	Given	the	monosynaptic	pathway	between	PAG	and	 NGC(Harris	 and	 Sinclair	 1981),it	 is	 possible	 that	 in	 this	 1mg	 model	 the	 PAG	 has	 been	recruited	 and	 is	 providing	 some	 minor	 tonic	 inhibition,	 reflective	 of	 a	 similar	 spinal	 effect	observed	by	Burnham	in	the	2mg	MIA	model(Burnham	2012).	
That	no	significant	difference	 is	observed	 in	 the	 latency	to	 tail	 flick	 in	MIA	and	sham	animals	does	 not	 necessarily	 discredit	 or	 rule	 out	 the	 presence	 of	 a	 tonic	 descending	 inhibitory	influence	 in	 these	 animals.	 Spinal	 excitability,	 a	 crucial	 determinant	 of	 reflex	 latency,	 is	 a	complex	outcome	of	several	factors,	not	least	peripheral	inputs,	a	state	of	central	sensitization	and	a	balance	between	descending	facilitation	and	inhibition.		It	has	previously	been	suggested	that	during	inflammation,	while	a	minor	descending	inhibitory	drive	may	exist	to	neuron	pools	serving	 secondary	 sites,	 facilitation	 predominate(Vanegas	 and	 Schaible	 2004).	 It	 is	 similarly	understood	 that	 while	 inhibition	 from	 noradrenergic	 nuclei	 curb	 nociception	 initially,	 this	effect	diminishes	over	time(Burnham	and	Dickenson	2013,	Hughes,	Hickey	et	al.	2013),	which	could	render	descending	modulation	mediated	by	the	RVM	and	NGC	(Zhuo	and	Gebhart	1990,	Zhuo	and	Gebhart	1991,	Zhuo	and	Gebhart	1992)	less	physiologically	relevant.	It	may	similarly	be	the	case	that	 there	 is	no	trend	at	all,	and	to	 look	for	one	 is	 to	over	 interpret	no	significant	work.	It	may	well	be	that,	be	this	the	RVM	or	the	NGC,	there	is	no	significant	change	in	the	basal	activity	of	these	neurones	and	so	no	significant	behavioural	correlate,	in	the	form	of	latency	to	tail	flick,	would	be	expected.	
Thus,	 the	 final	 issue	 is	 the	 strength	 of	 any	 conclusions	 drawn	 from	 this	 study	 without	 the	analysis	of	OFF	cell	changes	between	MIA	and	Sham	rats.	As	outlined	in	Table	5.1,	while	a	total	of	20	and	23	ON	cells	were	identified	in	MIA	and	sham	rats	respectively,	only	1	and	6	OFF	cells	were	 identified	 in	 these	 animals	 –	 despite	 the	 use	 of	 28	 animals	 in	 total.	 The	 difficulty	 in	identifying	 OFF	 cells	 may	 be	 attributed	 to	 the	 likely	 recording	 location,	 within	 the	 NGC.		Previous	work	by	Fields	et	al	1983	concluded	that	while	ON	cells	are	relatively	wide	spread	in	the	 NGC,	 no	 OFF	 cells	 could	 be	 identified	 (Fields,	 Bry	 et	 al.	 1983).	 	 In	 work	 by	 Pearl	 and	Anderson	 et	 al	 1978,	 in	 which	 the	 response	 patterns	 of	 162	 neurones	 in	 the	 NGC	 of	 31	anaesthetized	 cats	 were	 characterized,	 only	 6%	 (5	 cells)	 were	 characterized	 as	 suppressing	activity	 following	 the	 application	 of	 spinal	 noxious	 stimuli,	 in	 contrast	 to	 76%	 which	demonstrated	 some	 form	of	 clear	 excitatory	 response(Pearl	 and	Anderson	1978).	Harris	 and	Sinclair	 1981	 concluded	 similarly	 in	 the	 rat,	 where	 single	 unit	 recordings	 in	 the	 NGC	characterizing	 the	 response	 of	 cells	 to	 noxious	 radiant	 heat	 provided	 to	 the	 tail.	 The	 study	categorized	 just	 17	 of	 128	 neurones	 as	 responding	 to	 the	 radiant	 heat	 with	 a	 reduction	 of	activity,	versus	62	excitatory	and	44	none	(neutral	 like)	responses(Harris	and	Sinclair	1981).	
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As	 such	 it	 seems	 likely	 that	 in	 NGC	 the	 expected	 ratio	 of	 ON:OFF:Neutral	 like	 cells	 favours	neurones	with	a	profile	similar	to	ON	Cells,	as	has	been	characterized	in	this	study.	
	
5.4.3			 Physiological	Responses	Of	ON-Cells	To	Mechanical	Stimulation	Of	The	Paw	
And	Knee		
Following	the	classification	of	cells	as	ON	based	upon	the	change	in	firing	before	heat	evoked	tail-flick,	the	responses	of	these	cells	to	escalating	force	von	Frey	hairs	and	noxious	knee	pinch	were	 shown	 to	 be	 more	 variable	 than	 uniform	 ON-like	 responses.	 While	 reflex	 related	responses	were	not	expected	to	all	these	stimuli,	given	the	innocuous	nature	of	the	lower	force	von	Frey	hairs,	it	was	expected	that	tail	flick	classified	ON	cells	would	similarly	exhibit	stimulus	related	enhancements	 in	 the	 rate	of	 firing	 to	noxious	stimulation	 like	knee	pinch	or	100g	vF.	However,	 as	 demonstrated	 in	 Figure	 5.5	 and	5.6,	 this	was	 not	 the	 case.	 Though	 the	majority	demonstrated	increases	in	the	rate	of	ON-cell	firing,	subgroups	of	cells	either	did	not	respond	or	in	fact	decreased	the	rate	of	firing.	Using	a	classification	based	on	15%	changes	in	the	rate	of	firing,	 as	 previously	 used	 in	 Sikandar	 et	 al(Sikandar	 and	 Dickenson	 2011),	 these	 previously	identified	ON-cells	 could	be	 reclassified	 into	neutral	 like	and	OFF-like	 cells,	 as	 seen	 in	Figure	5.4.	
While	 the	absence	of	change	 in	rate	of	 firing	 in	some	neurones	and	the	resultant	Neutral-like	classification	is	explained	simply,	the	OFF-like	behaviour	is	less	simply	explained.	This	original	definition	of	an	ON,	OFF	or	neutral	cell	relate	to	the	change	or	lack	there	of	in	the	rate	of	firing	just	prior	 to	 the	 initiation	of	nociceptive	 reflex	 (such	as	 tail	 flick	or	paw	withdrawal)	 (Fields,	Bry	 et	 al.	 1983,	 Heinricher,	 Barbaro	 et	 al.	 1989).	 	 As	 such,	 changes	 in	 firing	 relate	 to	 the	application	of	stimuli	noxious	enough	to	provoke	a	reflex	withdrawal,	where	this	threshold	will	naturally	vary	between	animals	and	depend	on	both	the	extent	of	sensitization	caused	by	the	1mg	MIA	injection	and	response	to	anaesthesia.	As	in	previous	chapters,	these	considerations	and	conclusion	are	limited	by	the	failure	to	characterize	the	histopathology	of	animals	used	–	as	there	can	be	no	certainty	of	an	OA	condition	driving	changes	in	thresholds	in	any	one	rat.	
Previous	work	has	demonstrated	the	effect	of	both	chronic	pain	conditions	and	anaesthesia	on	withdrawal	 thresholds	 and	 activation	 of	 RVM	 ON-cell	 firing	 in	 response	 to	 peripheral	stimulation.	Carlson	et	al	2007	demonstrates	this	clearly	in	a	neuropathic	model	of	pain.	While	sham	 animals	 would	 only	 exhibit	 EMG	 and	 ON	 cell	 responses	 to	 60g	 vF	 and	 upwards,	 SNL	animals	 exhibited	 both	 EMG	 and	 ON	 cell	 responses	 to	 6g	 vF(Carlson,	 Maire	 et	 al.	 2007).	Similarly,	PWT	were	significantly	 increased	in	anaesthetized	animals,	 though	the	reduction	in	
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the	threshold	in	neuropathic	pain	animals	remained(Carlson,	Maire	et	al.	2007).	Similar	studies	have	demonstrated	in	rats	5	days	after	CFA	injection	to	the	paw	that	the	magnitude	of	the	ON	cell	 response	 relative	 to	 the	 vF	 force	 increased	during	 inflammation.	This	 study	 also	 showed	that	the	threshold	for	ON	cell	evoked	responses	was	greater	than	15g,	since	this	force	evoked	no	change	in	ON	cell	firing(Khasabov,	Brink	et	al.	2012).	This	aligns	to	the	fact	that	within	this	study,	the	greatest	number	of	Neutral-like	responses	 is	observed	following	the	8g	and	15g	vF	hairs.	
However,	 this	 fails	 to	 account	 for	 the	 Neutral-like	 responses	 to	 noxious	 stimuli	 sufficient	 to	provoke	withdrawal	of	the	paw	or	twitching	within	the	leg	muscles.	It	similarly	fails	to	account	for	the	OFF-like	behaviours	of	cells	that	have	behaved	as	ON-cells	to	noxious	tail	heat	evoked	flick.	One	possible	explanation	is	that	the	responses	of	cells	in	the	NGC,	much	like	the	RVM,	are	more	fluid	than	a	simple	ON,	OFF	or	Neutral	designation	and	instead	that	responses	may	differ	as	a	result	of	location	or	tissue	type	(e.g.	cutaneous	vs.	joint	vs.	viscera).			
This	 is	not	the	first	time	such	observations	have	been	made.	 In	work	recording	from	the	NGC	while	stimulating	either	 the	upper	and	 lower	canine	 teeth,	 radial	nerve	or	sciatic	nerve	Pearl	and	Anderson	classified	a	group	of	cells	they	terms	M	cells,	or	mixed	cells.	These	cells	response	depended	on	the	site	of	stimulation,	including	an	ON	like	response	to	one	site	with	an	OFF	like	at	 another	 –	 though	 unfortunately	 the	 study	 does	 not	 discuss	 which	 stimulation	 site	corresponded	to	which	result,	if	a	clear	relationship	was	seen	at	all(Pearl	and	Anderson	1978).	Similar	 such	 observations	 were	 made	 by	 Guilbaud	 el	 al	 1973,	 who	 identified	 both	 “mixed”	responder	cells	following	IA	bradykinin	when	recording	from	NGC,	but	additionally	found	that,	of	 the	 73%	 of	 112	 cells	 that	 responded	 to	 IA	 BK	 with	 excitation	 43%	 did	 not	 response	 to	noxious	 pinch	 or	 pressure	 to	 the	 paw,	 but	 did	 response	 to	 light	 touch	 or	 tapping(Guilbaud,	Besson	et	al.	1973).	As	such	it	seems	clear	that	while	the	cells	of	the	NGC	are	responsive	to	both	noxious	 and	 non-noxious	 stimuli,	 including	 mechanical,	 chemical	 and	 electrical	stimulation(Casey	1969,	Casey	1971,	Guilbaud,	Besson	et	 al.	 1973,	Morrow	and	Casey	1983),	the	response	profile	depends	on	the	site	and	type	of	stimulation	presented.	
Within	 the	 RVM,	 previous	 studies	 have	 demonstrated	 a	 clear	 dissociation	 between	 the	responses	of	neurones	to	colorectal	or	bladder	distension,	such	that	classification	by	tail	 flick	activity	did	not	predict	the	response	to	distension	stimulation	(Chandler,	Oh	et	al.	1994,	Brink	and	Mason	2003,	Sikandar	and	Dickenson	2011).	Further	to	this,	Sikandar	et	al	2011	observed	that	 RVM	 neurones	 exhibited	 changes	 in	 activity	 to	 innocuous	 stimulation,	 specifically	 a	20mmHg	 colorectal	 distension,	 suggesting	 this	 represented	 the	 encoding	 of	 mechanical	
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distension	 by	 afferent	 capable	 of	 encoding	 through	 the	 range	 of	 mechanical	 stimulation:	Innocuous	through	to	noxious(Sikandar	and	Dickenson	2011).		
Further	back,	studies	have	looked	to	compare	the	responses	of	RVM	cells	to	differing	modalities	of	nociceptive	stimulation.	Leung	and	Mason	1998	demonstrated	that	of	17	ON	cells,	classified	by	the	response	to	heat	evoked	tail	flick,	1	did	not	change	firing	to	tail	clamp;	2	were	not	excited	by	pinches	to	the	paw;	while	6	were	activated	by	innocuous	brushing	of	at	least	one	site(Leung	and	Mason	1998).	Similarly,	8	of	12	cells	defined	as	Neutral	to	noxious	tail	heat	either	increased	or	decreased	their	firing	in	an	ON	or	OFF	like	manner	to	tail	clamp(Leung	and	Mason	1998).	In	another,	 the	 noxious	 stimulation	 of	 extremities	 including	 pinch	 of	 the	 tail,	 the	 hindpaw,	 the	forepaw,	the	ear,	the	nose,	the	forehead,	and	to	light	tactile	stimuli	applied	by	gentle	brushing	of	the	cornea	revealed	divergent	responses	in	3/13	ON-cells	and	11/23	OFF	cells	identified	by	their	 response	 to	noxious	 tail	heat(Ellrich,	Ulucan	et	al.	2001).	 	More	recently	Khasabov	et	al	2015	 demonstrated	 that	 RVM	 cells	 classified	 by	 cutaneous	 paw	 pinch	 did	 not	 universally	respond	 as	 classified	 to	 the	 pinching	 of	 the	 skin	 overlying	 the	 temporomandibular	joint(Khasabov,	Malecha	et	 al.	 2015).	This	 suggests	 that	 certain	 subpopulations	of	RVM	cells,	much	 like	 NGC,	 behave	 differently	 depending	 on	 the	 somatotopic	 location	 of	 the	 cutaneous	nociceptive	 stimulus	 or	 the	modality	 of	 the	 stimulus.	 It	 is	 suggested	 that	 of	 these	 diverging	responses,	 the	 differences	 are	 most	 common	 to	 neutral	 cell	 populations,	 though	 not	exclusively(Schnell,	Ulucan	et	al.	2002).		
The	suggestion	of	such	studies	is	that	NGC	and	RVM	cells	do	not	respond	universally,	regardless	of	stimulus	location	or	nature	(thermal,	pinch,	brush),	underlining	our	previous	understandings	of	the	complexity	of	the	pain	control	systems.	It	similarly	explains	how	cells	defined	by	noxious	tail	heat	could	behave	differently	to	noxious	and	innocuous	mechanical	stimulation	of	the	paw	and	knee,	as	observed	here.	
	
5.4.4			 Is	the	MIA	Model	insufficiently	severe	to	evoke	a	change	in	firing?	
Comparison	of	the	evoked	responses	of	ON	cells	behaving	in	an	ON-like	manner	to	mechanical	stimulation	of	the	paw	and	knee	in	1mg	MIA	and	sham	animals	reveals	no	significant	difference	in	 the	magnitude	of	 firing.	This	 suggests	 that	while	 the	 injection	of	1mg	MIA	 to	 the	 left	 knee	results	in	significant	differences	in	ipsilateral	and	contralateral	PWT,	there	is	not	a	significant	change	in	the	response	magnitude	in	the	NGC.	This	aligns	to	results	discussed	in	Chapter	4,	in	which	 no	 significant	 effect	 of	 5HT3	 receptor	 antagonism	 is	 observed	 in	 either	 the	 1mg	MIA	model	or	shams,	suggesting	an	absence	of	descending	serotonergic	facilitation.	
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There	 is	 no	 clear	 consensus	 on	 the	 expectations	 of	ON	 cell	 responses	during	pain	 conditions	such	as	neuropathy	or	inflammation.	While	both	Carlson	et	at	2007	and	Silva	et	al	2003	failed	to	identify	any	difference	in	the	rate	of	firing	of	ON	cells	in	response	to	noxious	stimulation	in	SNL	 or	 diabetic	 neuropathy	 rats	 respectively(Carlson,	 Maire	 et	 al.	 2007),	 studies	 in	inflammatory	 pain	 4days	 after	 CFA	 injection	 showed	 a	 significant	 increase	 in	 the	 number	 of	impulses	 evoked	 in	 ON	 cells	 to	 both	 mechanical	 and	 thermal	 stimuli(Khasabov,	 Brink	 et	 al.	2012).	 	 While	 such	 differences	 could	 be	 attributed	 to	 different	 etiology	 of	 neuropathic	 and	inflammatory	pain	models,	other	studies	highlight	time	specific	differences	in	neuropathic	pain	such	 that	 noxious	 pinch	 or	 CRD	 evoke	 significantly	 greater	 increases	 in	ON	 cell	 firing	 in	 SNI	animals	at	8	weeks,	but	with	no	significant	different	to	shams	at	1	week(Gonçalves,	Almeida	et	al.	2007).		
Taken	together,	this	could	suggest	that	such	changes	in	evoked	activity	are	dependent	upon	the	extent	of	changes	driven	by	the	peripheral	insult,	likely	the	combination	of	both	peripheral	and	central	 sensitization,	 which	 will	 also	 be	 time	 dependent.	 As	 such,	 this	 would	 attribute	 the	significantly	 greater	 increase	 in	 ON	 cell	 evoked	 responses	 following	 CFA,	 as	 observed	 by	Khasabov	et	al	2012,	to	enhanced	recruitment	of	the	RVM	as	a	result	of	the	extent	of	peripheral	sensitization	in	inflammation.	Similarly,	that	significant	differences	are	only	observed	8	weeks	into	 nerve	 injury	 models	 may	 suggest	 that	 neuropathy	 must	 reach	 a	 certain	 severity	 of	ascending	 drive.	 Such	 stimulus	 severity	 dependence	 for	 the	 recruitment	 descending	 controls	form	the	RVM	have	previously	been	described(Green,	Scarth	et	al.	2000,	Peters,	Hayashida	et	al.	2010,	Bardin	2011),	and	are	discussed	in	more	depth	in	Chapter	4.	Further	work,	using	a	large	dose	of	MIA	and	 later	 time	points	may	 reveal	 significant	differences	 in	evoked	activity	of	ON	cells	 versus	 shams.	 This	 would	 align	 with	 previously	 discussed	 results	 and	 conclusions,	 in	which	 no	 significant	 descending	 serotonergic	 facilitation	 is	 observed	 in	 the	 1mg	MIA	model,	using	 spinal	 cord	 electrophysiology,	 while	 adaptive	 changes	 in	 descending	 facilitation	 are	observed	in	the	2mg	model(Rahman,	Bauer	et	al.	2009).		
Conversely	 however,	 the	 failure	 to	 characterize	 a	 shift	 in	 the	 response	 properties	 of	 the	neurones	 recorded	 may	 instead	 relate	 the	 predominance	 of	 NGC	 in	 these	 recordings.	 For	example,	Robinson	et	al	2002	argue	that	the	differing	observations	of	work	by	Pertobaara	and	Tukeva	with	those	of	Robinson	can	largely	attributed	to	the	relative	number	of	NGC	neurones	recorded(Robinson,	 Calejesan	 et	 al.	 2002).	 In	 Robinson’s	 RVM	 study,	 4	 recorded	 cells	 were	within	the	NGC	with	the	majority	in	the	NRM	–	with	the	study	identifying	decreased	activity	of	neutral	 cells	and	 the	awakening	of	previously	silent	cells	 in	 the	second	phase	of	 the	 formalin	model	(Pertovaara	and	Tukeva	1989,	Robinson,	Calejesan	et	al.	2002).	Conversely,	Pertobraara	largely	 recorded	 in	 the	 NGC	 and	 characterized	 no	 change	 in	 the	 firing	 patterns	 in	 the	
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bulbospinal	 neurones	 in	 the	 second	 phase	 of	 the	 Formalin	 model(Pertovaara	 and	 Tukeva	1989).	 As	 such	 it	 may	 not	 be	 that	 the	 1mg	 MIA	 model	 was	 insufficiently	 severe	 to	 recruit	changes	in	the	brainstem,	but	instead	that	the	NGC	is	less	prone	to	adaptations	in	evoked	and	basal	activity	during	ongoing	pain.	
Such	 electrophysiological	 differences	 between	 the	 potential	 response	 of	 RGC	 and	 RVM	 in	chronic	pain	conditions	are	underlined	by	previously	defined	functional	differences.	Wei	et	al	1999,	by	lesioning	either	the	NGC/NCGα	or	NRM,	demonstrated	that	while	lesions	of	the	former	reduced	chronic	inflammation	induced	hyperalgesia	and	spinal	c-Fos	expression,	lesions	of	the	latter	increased	thermal	hyperalgesia	and	spinal	c-Fos(Wei,	Dubner	et	al.	1999).		Using	a	NMDA	receptor	 antagonism	 da	 Silva	 et	 al	 2010	 similarly	 identified	 such	 functional	 differences,	 in	which	antagonism	in	the	RVM	reversed	both	muscle	and	cutaneous	hypersensitivity	following	repeated	 intramuscular	 injections	 of	 acidic	 saline,	 whereas	 antagonism	 in	 the	 NGC	 only	reversed	cutaneous	sensitivity(Da	Silva,	DeSantana	et	al.	2010).	Interestingly	this	suggests	that	NGC	makes	a	notable	contribution	to	the	development	of	a	cutaneous	secondary	hyperalgesia,	potentially	explaining	the	unexpected	greater	(though	not	significant)	magnitude	of	change	in	firing	to	vF	15g	in	MIA	animals	(Figure	5.8	and	5.9).		
Greater	clarity	overall,	on	the	effect	of	MIA	on	the	behaviour	of	the	cells	of	the	RVM	and/or	NGC	would	be	gained	by	the	study	of	both	more	cells,	including	the	effect	of	MIA	on	OFF	cells,	more	time	points	later	into	the	MIA	model,	as	well	as	naïve	and	2mg	MIA	animals.	This	would	allow	greater	 understanding	 of	 the	 role	 of	 knee	 pathophysiological	 changes	 upon	 the	 RVM.	 At	present,	 current	 data	 indicated	 that	 limited	 sensitization	 occurs	 during	 the	 1mg	MIA	model,	similar	to	conclusions	in	chapter	4	suggesting	limited	descending	control.	
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5.4.5			 Study	Limitations	
In	considering	the	results	and	potential	conclusions	of	this	chapter,	it	is	important	to	consider	the	 limitations	 of	 the	 present	 study’s	 design	 –	 both	 to	 provide	 context	 that	 will	 inform	 the	conclusions,	 but	 also	 suggest	 potential	 modifications	 to	 the	 study	 that	 would	 have	 allowed	greater	clarity.	
Evidence	of	Structural	Pathology	
As	 is	 discussed	 in	more	 detail	 in	 other	 chapters,	 a	 major	 limitation	 in	 the	 discussion	 of	 the	results	presented	in	this	chapter,	as	in	all	the	chapters	of	this	thesis,	is	the	absence	of	analysis	of	 the	 structural	 pathology	 of	 these	 animals.	 While	 previous	 literature	 has	 established	 the	histopathological	changes	associated	with	this	stage	of	the	1mg	MIA	model	(Ivanavicius,	Ball	et	al.	2007,	Kelly,	Dunham	et	al.	2012,	Thakur	2012),	 it	would	be	a	 fallacy	 to	assume	that	every	injection	of	MIA	was	successfully	delivered.	Even	 in	a	 clinical	 setting,	 IA	 therapies	 commonly	miss	 their	 mark	 (in	 much	 larger	 knees)	 without	 ultrasound	 guidance(Berkoff,	 Miller	 et	 al.	2012).	 Please	 refer	 to	 Section	 3.4.3	 for	 greater	 discussion	 of	 the	 limitations	 associated	with	failing	to	characterize	the	presence	of	OA.	
Confirmation	of	Recording	Site	
As	has	been	discussed	throughout	this	chapter,	it	is	likely	that	the	recordings	presented	herein	are	 of	 cells	 residing	 in	 the	 NGC.	 Though	 the	 NGC	 is	 a	 nucleus	 of	 interest	 in	 the	 descending	control	of	pain,	with	many	studies	documenting	the	potential	role	on	hyperalgesia	and	spinal	excitability(Zhuo	and	Gebhart	1990,	Zhuo	and	Gebhart	1991,	Zhuo	and	Gebhart	1992,	Zhuo	and	Gebhart	1997,	Wei,	Dubner	et	al.	1999,	Da	Silva,	DeSantana	et	al.	2010),	no	confidence	can	be	assigned	 to	 the	 true	 location	 of	 the	 cells	 recorded	 from	 given	 the	 absence	 of	 histology	 to	conform	the	recording	site.	
Most	 studies	 recording	 from	 the	 brain	mark	 the	 recording	 site	 at	 the	 end	 of	 the	 experiment	with	a	small	 lesion,	 is	made	by	sending	current	back	down	the	electrode.	The	rat	can	then	be	perfused	 with	 formalin,	 the	 brain	 frozen,	 and	 sections	 cut	 and	 stained	 to	 reconstructed	 the	recording	site.	The	failure	to	do	so,	and	instead	basing	location	assumptions	on	the	recording	coordinates	relative	to	bregma	and	lambda,	means	no	definite	conclusions	can	be	taken.	While	the	rat	atlas	and	these	coordinates	provide	a	guide,	the	individual	variability	of	rats	by	weight	may	leave	the	recording	location	uncertain.	While	it	 is	clear	the	recording	site	contained	cells	responsive	to	nociceptive	and	non-noxious	inputs,	confidant	conclusions	cannot	be	made.	
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5.4.6	 	 Overall	Implications	
Herein	 I	 sought	 to	 investigate	 any	 adaptation	 to	 the	 electrophysiology	 of	 cells	 in	 the	 RVM	during	the	1mg	MIA	model	of	OA.	While	no	confident	conclusions	can	be	taken	in	the	absence	of	recording	histology,	 it	 appears	 the	majority	 of	 recordings	 took	place	 in	 the	NGC	without	 any	significant	 adaptations	 observed.	 I	 have	 suggested	 that	 the	 classifications	 of	 cells	 by	 the	response	 based	upon	heat	 evoked	 tail	 flick	may	be	 too	 simplistic	 an	 understanding,	 as	 these	responses	may	vary	based	upon	the	form	and	location	of	the	stimulation.	I	have	also	postulated	that	the	lack	of	difference	in	the	evoked	responses	between	MIA	and	Sham	animals	may	suggest	a	 lack	 of	 recruitment	 of	 descending	 facilitation	 in	 the	 MIA	 model,	 in	 agreement	 with	pharmacology	work	presented	in	Chapter	4.	
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Chapter	6	–Peripheral	Contributions	to	Osteoarthritis	Pain	
In	the	previous	Chapters	of	this	work,	I	have	raised	questions	about	the	contributions	of	descending	controls	 in	 the	 pain	 associated	 with	 osteoarthritis	 during	 the	 1mg	 MIA	 model.	 The	 failure	 to	characterize	a	descending	drive	places	further	emphasis	on	the	role	of	the	periphery	in	the	generation	of	 pain	 during	 joint	 pathology.	 This	 work	 aimed	 to	 use	 mouse	 lines,	 which	 had	 previously	 been	characterized	as	having	deficits	in	their	pain	or	mechanosensory	profiles,	to	identify	possible	sensory	afferent	 populations	 or	 channels	 which	 may	 underlie	 the	 peripheral	 transmission	 of	 noxious	mechanical	 stimuli	 or	 mechanical	 sensitization	 during	 OA	 and	 thus	 represent	 future	 avenues	 for	analgesia	in	OA.	
	
6.1			 	The	 Use	 Of	 Mouse	 Models	 To	 Identify	 The	 Contribution	 Of	 Specific	 Proteins	 In	
Healthy	And	Pathological	Sensation	
In	 much	 the	 same	 way	 that	 the	 MIA	 model	 is	 used	 as	 a	 tool	 to	 study	 the	 physiological	 processes	underlying	OA	pain,	transgenic	mice	that	have	been	genetically	manipulated	and	bred	to	lack,	under	express,	over	express	or	de	novo	express	certain	genes	to	allow	a	better	understanding	of	the	specific	contributions	of	 the	 encoded	proteins	 in	healthy	 and	pathological	 functioning.	The	 first	 use	of	 such	techniques	by	Mario	R.	Capecchi,	 Sir	Martin	 J.	Evans	and	Oliver	Smithies	earned	 the	Nobel	Prize	 for	Physiology	 and	 Medicine	 in	 2007(Manis	 2007),	 and	 has	 since	 become	 common	 lab	 practice,	representing	 the	 fasting	 growing	 use	 of	 lab	 animals	 to	 date(HomeOffice	 2013).	 For	 a	 full	 review	of	both	the	history,	significance	and	techniques	used,	see	Hall	et	al	2009(Hall,	Limaye	et	al.	2009).	
	
6.1.1			 Voltage	Gated	Sodium	Channels	
As	mention	 in	Section	1.4.2.2,	voltage	gated	sodium	channels	 (VGSC)	define	 the	electrophysiological	properties	of	primary	afferents.	These	channels	are	crucial	to	the	initiation	and	propagation	of	action	potentials,	and	consequentially	are	pivotal	in	the	transmission	of	peripheral	sensation	and	pain.	
The	VGSC	have	distinct	properties	and	locations	that	define	both	their	function	but	also	the	properties	of	 the	 tissues	 in	which	 they	 reside.	While	 specific	VGSC	populate	 cardiac	 tissue,	namely	Nav1.5	and	1.1,	others	are	restricted	to	nervous	tissue(Wood,	Boorman	et	al.	2004).	Nav	1.7,	1.8	and	1.9	are	found	throughout	the	DRG	and	have	been	implicated	in	determining	pain	thresholds	and	the	development	of	pathological	pain	conditions(Momin	and	Wood	2008,	Minett,	Nassar	et	al.	2012).		
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Nav1.7,	 the	 VGSC	 which	 regulates	 release	 of	 peptide	 transmitters	 from	 central	 terminals	 and	consequently	 wind-up,	 is	 also	 key	 to	 initiating	 action	 potentials	 following	 a	 sensory	 depolarizing	potential,	 and	 has	 been	 demonstrated	 to	 exert	 a	 key	 role	 in	 ectopic	 firing	 in	 neuromas(Dib-Hajj,	Cummins	 et	 al.	 2010,	Minett,	 Nassar	 et	 al.	 2012).	 	 In	 studies	 in	which	 the	 Nav1.7	 gene	 (SCN9A)	 is	ablated	 in	 all	 sensory	 neurones	mice	 loose	 all	mechanical	 and	 inflammatory	 pain,	 as	well	 as	 reflex	withdrawal	 to	 heat,	 while	maintaining	 neuropathic	 pain	 capabilities(Minett,	 Nassar	 et	 al.	 2012).	 In	contrast,	 deletion	of	 SCN9A	 in	 both	 sensory	 and	 sympathetic	 fibers	 now	abolishes	 this	 neuropathic	pain(Minett,	 Nassar	 et	 al.	 2012).	 Interestingly,	 because	 Nav1.7	 is	 pivotal	 to	 the	 conversion	 of	 a	receptor	 potential	 to	 action	 potential,	 bridging	 the	 gap	 between	 building	 depolarization	 and	 the	activation	 of	 Nav1.8	 VGSC,	 the	 knock	 out	 of	 SCN9A	 from	 the	 subset	 of	 afferents	 utilizing	 Nav1.8	 is	greater	than	would	perhaps	have	been	expected	as	it	essentially	silences	Nav1.8	too(Nassar,	Stirling	et	al.	 2004,	 Minett,	 Nassar	 et	 al.	 2012).	 The	 effect	 of	 this	 nociceptor-specific	 gene	 deletion	 is	 a	 lost	sensitivity	 to	 noxious	 grade	 mechanical	 stimuli	 and	 deficits	 in	 inflammatory	 pain,	 but	 maintained	thermosensation(Nassar,	 Stirling	 et	 al.	 2004,	 Minett,	 Nassar	 et	 al.	 2012).	 Additionally,	 such	 mice	showed	 that	 loss	 of	 SCN9A	 reduced	 the	 release	 of	 peptides	 at	 the	 central	 terminals,	 blocking	windup(Minett,	Nassar	et	al.	2012).		This	underlies	the	threefold	role	of	Nav1.7	in	pain	sensation	–	to	initiate	 the	 action	 potential	 by	 recruiting	Nav1.8(Momin	 and	Wood	 2008);	 propagating	 nociceptive	signals	to	the	spinal	cord;	and	regulating	central	sensitisation	through	control	of	transmitter	release	at	central	terminals(Minett,	Nassar	et	al.	2012).	
Various	gain	of	 function	genetic	mutations	 in	Nav1.7	have	been	characterized	as	producing	primary	erythromyalgia	and	paroxysmal	extreme	pain	disorder	(PEPD)	(Yang,	Wang	et	al.	2004,	Dib-Hajj,	Rush	et	 al.	 2005,	 Fertleman,	 Baker	 et	 al.	 2006),	 while	 a	 loss	 of	 function	 mutation	 has	 produced	 entire	families	with	 congenital	 insensitivity	 to	 pain	 (CIP)(Weiss,	 Pyrski	 et	 al.	 2011).	 Similarly,	 SCN9A,	 the	gene	for	Nav1.7,	is	one	of	only	5	genes	directly	linked	to	OA	pain(Thakur,	Dawes	et	al.	2013).		As	such,	there	is	a	clear	clinical	justification	for	targeting	this	Nav1.7	in	an	attempt	to	block	the	transmission	of	pain	 from	 the	 periphery	 –	 a	 pharmacological	 target	 experiencing	mixed	 success	 in	 clinical	 trials	 at	present,	with	 success	 in	 trigeminal	neuralgia(Zakrzewska,	Palmer	et	 al.	2013)	but	 recent	 failures	 in	OA	pain(Ltd.	2015).		
Nav1.8	 is	 also	 understood	 to	 play	 a	 crucial	 role	 in	 nociception	 and	 pain	 conditions.	 Nav1.8	 is	 a	tetrodotoxin	(TTX)	resistant	VGSC	which	has	an	all-or-nothing	role	 in	action	potential	generation	 in	sensory	afferents(Liu	and	Wood	2011),	 through	 the	action	potential	upstroke,	and	exhibits	 the	 rare	ability	 to	 transmit	 sensory	 information	 to	 the	 CNS	 at	 cold	 temperatures,	 unlike	 the	 other	 8	VGSCs(Zimmermann,	Leffler	et	al.	2007,	Liu	and	Wood	2011).			
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Crucially,	 this	VGSC	has	a	 restricted	expression	compared	 to	Nav1.7,	with	Nav1.7	 found	 throughout	sensory	and	sympathetic	fibers	while	Nav1.8	is	restricted	to	a	subset	of	sensory	afferents.	Specifically,	75%	of	DRG	 cells	 from	 L4-5	 express	Nav1.8,	 of	which	 this	 includes	 the	majority	 of	 the	 nociceptive	afferents	serving	this	area	(~90%,	accounting	for	60%	of	the	total	Nav1.8+	population)(Shields,	Ahn	et	al.	2012).	Beyond	the	nociceptors,	Nav1.8	is	also	expressed	in	the	C-low	threshold	mechanosensors	as	 well	 as	 rapidly	 adapting	 Aβ	 low	 threshold	 mechanosensory	 afferents.	 In	 other	 words,	 Nav1.8	underlies	 the	electrical	activity	of	multiple	sensory	modalities,	both	noxious	and	 innocuous,	notably	mechanical	and	cold.	
Nav1.8	 knock	 out	mice	 demonstrate	 a	 loss	 of	 noxious	mechanical	 sensation,	 impaired	 but	 not	 lost	noxious	thermoreception	and	delayed	development	of	inflammatory	hyperalgesia(Akopian,	Souslova	et	 al.	 1999),	 however	mice	maintained	 normal	 sensorimotor	 coordination	 and	 otherwise	 appeared	healthy,	 though	 a	 counterbalancing	 increase	 in	 Nav1.7	 expression	 was	 observed.	 Further	 studies	similarly	showed	loss	of	cold	sensitivity	and	mechanosensation	during	the	cold(Zimmermann,	Leffler	et	 al.	 2007).	 Such	 work	 highlighted	 the	 importance	 of	 Nav1.8	 to	 mechanical	 hyperalgesia,	 pain	sensation	during	 cold	and	cold	pain,	 as	well	 as	development	of	 inflammatory	pain.	The	 latter	 is	 the	result	 of	 the	 fact	 Nav1.8	 becomes	 heavily	 phosphorylated	 by	 inflammatory	 mediators,	 causing	 a	potentiation	 of	 the	 ion	 current	 and	 altered	 expression,	 both	 in	 terms	 of	 protein	 levels	 and	distribution(Vijayaragavan,	Boutjdir	et	al.	2004).		
Crucially	 for	 the	 investigation	 of	 mechanisms	 underlying	 OA	 pain,	 these	 studies	 have	 outlined	 the	importance	 of	 Nav1.8	 in	 the	 transmission	 of	 noxious	 mechanosensation	 and	 development	 of	inflammatory	pain.	As	such,	Nav1.8	is	a	logical	candidate	in	the	development	of	OA	pain	therapeutics.	The	first	part	of	this	study	is	 looking	to	characterize	the	MIA	pain	profile	of	a	mouse	line	previously	described	 in	Abrahamsen	et	 al	2008,	 the	DTA	mouse(Abrahamsen,	Zhao	et	 al.	 2008).	 In	 this	mouse	line	 all	 the	 post-mitotic	 sensory	 neurones	 containing	 Nav1.8	 have	 died	 through	 the	 expression	 of	diphtheria	toxin	A	(DTA)(Abrahamsen,	Zhao	et	al.	2008).		These	DTA	mice	were	generated	by	crossing	heterozygous	 Nav1.8	 knock-in	 Cre-expressing	mice	with	 homozygous	 DTA	 floxed	mice,	 to	 produce	equal	numbers	of	 control	mice	 (wild	 type,	WT)	and	DTA	expressing	mice,	whose	Nav1.8	 containing	neurones	die	as	a	result	of	toxicity	of	DTA.	Similarly	to	mice	where	Nav1.7	is	knocked	out	of	Nav1.8	containing	 neurones,	 these	 mice	 exhibit	 a	 loss	 of	 sensitivity	 to	 noxious	 mechanical,	 cold	 and	inflammatory	pain(Abrahamsen,	Zhao	et	al.	2008).	Herein	I	have	tested	the	hypothesis	that	such	mice,	which	lack	noxious	mechanical	and	inflammatory	pain,	would	be	resistant	to	the	development	of	OA	like	pain	from	the	MIA	model.	
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6.1.2			 Transient	Receptor	Potential	Channels	
The	microarray	data	for	the	DRG	cells	of	the	DTA	mice	show	a	significant	loss	of	TRP	family	receptors,	notably	TRPC6	and	TRPC3,	as	a	result	of	the	ablation	of	the	Nav1.8	containing	neurones(Abrahamsen,	Zhao	 et	 al.	 2008).	 Given	 differences	 observed	 between	 wild	 type	 (WT)	 and	 DTA	 mice	 in	 pain	behavioural	profiles,	 the	TRPC	family	was	proposed	as	a	possible	contributor	to	these	differences	in	mechanosensation.		
The	Transient	Receptor	Potential	 (TRP)	 channels	are	a	 family	of	non-selective	 cation	channels	with	roles	across	olfaction,	taste,	chemosensation,	thermosensation	and	mechanosensation.	As	discussed	in	Section	 1.4.2.1,	 these	 6	 transmembrane	 structures	 form	 pores	 by	 associating	 into	 homo	 or	heterotetrameric	 structures(Christensen	 and	 Corey	 2007).	 The	 TRPC	 (canonical)	 family	 have	 been	implicated	 heavily	 in	 the	 detection	 of	 mechanical	 stimuli,	 both	 through	 direct	 membrane	 stretch	activation	and	through	second	messenger	systems,	 largely	through	the	conversion	of	PIP2	to	DAG	in	the	neighbouring	membrane(Spassova,	Hewavitharana	 et	 al.	 2006).	 TRPC6	 is	 found	 throughout	 cell	populations	 responding	 to	 hydrostatic	 pressure	 changes,	 such	 as	 podocytes	 in	 the	 glomerulus	 and	vascular	smooth	muscle,	implicating	them	in	pressure	regulated	processes(Spassova,	Hewavitharana	et	al.	2006,	Quick,	Zhao	et	al.	2012).	TRPC3	on	 the	other	hand	has	only	 recently	been	 implicated	 in	mechanosensation	–	where	TRPC6-/-	mice	fail	to	show	any	behavioural	deficits	in	mechanosensation	they	 do	 display	 elevated	 blood	 pressure,	 linked	 to	 a	 compensatory	 overexpression	 of	TRPC3(Spassova,	Hewavitharana	 et	 al.	 2006).	 Similarly,	 the	TRPC3-/-	mouse	 shows	no	 behavioural	deficits,	but	the	DKO	mouse	show	a	consistent	loss	in	sensitivity	to	innocuous	punctate	stimuli(Quick,	Zhao	et	 al.	 2012).	 	Both	TRPC3	and	TRPC6	are	expressed	 in	 small	diameter	 sensory	neurons	of	 the	DRG(Elg,	Marmigere	et	al.	2007),	where	these	channels	have	previously	been	shown	to	associate(Goel,	Sinkins	et	al.	2002).		
Previous	 work	 investigating	 the	 possible	 role	 of	 these	 TRPC	 channels	 has	 shown	 that	 the	transcriptionally	regulated,	slowly-adapting	mechanosensitive	current	observed	in	this	population	of	Nav1.8+	neurones	is	regulated	by	TRPC	channels,	as	confirmed	by	a	TRPC3	and	TRPC6	double	knock	out	 (DKO)	mouse(Quick,	 Zhao	et	 al.	 2012).	These	DKO	mice	 show	a	 consistent	 loss	of	 sensitivity	 to	innocuous	mechanical	pressure,	while	maintaining	normal	thermal	and	noxious	mechanical	sensation.	In	these	mice	~50%	of	the	rapidly	adapting	mechanosensitive	currents	 in	small	diameter	cells	were	silenced(Quick,	 Zhao	 et	 al.	 2012),	 where	 C-LTMs	 have	 been	 shown	 to	 be	 necessary	 for	mechanical	allodynia	during	inflammation,	nerve	injury	and	trauma	previously(Seal,	Wang	et	al.	2009).		
Given	the	important	role	of	sensitized	mechanosensory	systems	in	OA	pain,	these	channels	represent	an	 interesting	 candidate	 in	 the	 search	 for	 mechanosensory	 machinery	 whose	 sensitization	 may	
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underlies	 the	 development	 of	 mechanical	 hypersensitivities	 during	 OA.	 Herein	 I	 have	 tested	 the	hypothesis	that	such	mice,	either	DKO	for	TRPC3	and	TRPC6,	or	SKO	for	one	of	either	TRCP3	or	TRPC6	may	exhibit	differences	in	the	mechanosensitive	profiles	observed	during	the	MIA	model	of	OA	pain,	compared	to	WT	mice.	
	
6.1.3	 	 Chapter	Aims	
For	 patients	 with	 symptomatic	 OA	 the	 unmet	 needs	 are	 still	 clear	 –	 efficacious,	 safe	 and	 tolerable	analgesia.	If	we	are	to	address	these	to	provide	superior	quality	of	life	for	patients,	it	is	crucial	that	we	continue	 to	 expand	our	 knowledge	of	 the	mechanisms	underlying	pain	during	OA	 so	we	 can	better	manipulate	and	target	these	mechanisms	to	mitigate	their	impact.	
The	purpose	of	 the	work	presented	 in	this	chapter	was	to	confirm	whether:	 first,	 the	subpopulation	characterized	 by	 the	 expression	 of	 Nav1.8	 were	 a	 requirement	 for	 the	 expression	 of	 pain	 in	osteoarthritis,	and	thus	whether	Nav1.8	blockade	would	represent	a	viable	target	for	the	management	of	 OA	 pain;	 and	 second,	 whether	 TRPC3	 and	 TRPC6	 channels	 contribute	 to	 the	 development	 of	mechanical	hypersensitivity	during	OA,	and	 thus	 themselves	may	similarly	act	as	a	viable	 target	 for	analgesia	 in	 OA.	 By	 understanding	 the	 contributions	 of	 these	 specific	 receptors	 and	 neuron	populations,	there	is	hope	of	defining	new	and	more	specific	targets	for	the	management	of	OA	pain.	
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6.2			 	 Methods	
NB:	This	project	was	performed	in	partnership	with	Michael	Minett	and	Jane	Sexton,	post-doc	and	PhD	candidates	
respectively	in	the	John	Wood	lab	at	UCL.	
6.2.1			 Animals	
All	 work	 was	 conducted	 in	 male	 and	 female	 transgenic	 mice	 and	 their	 WT	 littermates,	 bred	 and	housed	in	the	Cruciform	Biological	Services	unit	at	University	College	London.	As	described	in	Chapter	2,	behaviour	was	conducted	over	the	21days	of	the	MIA	model	in	the	following	mouse	lines:	
• “DTA	Mice”:	This	mouse	line	was	generated	by	crossing	heterozygous	Nav1.8	Cre	mice	with	homozygous	eGFP-DTA	mice.	This	generated	a	litter	of	half	controls	(wild	type,	WT)	and	half	DTA	mice,	 where	 DTA	mice	 have	 all	 the	 post-mitotic	 sensory	 neurons	 containing	 Nav1.8	eradicated	 through	 the	 expression	 of	 diphtheria	 toxin	 A(Ivanova,	 Signore	 et	 al.	 2005,	Stirling,	Forlani	et	al.	2005,	Abrahamsen,	Zhao	et	al.	2008).	A	full	sensory	profile	is	described	in	Abrahamsen	et	al	2008.	
• TRPC	knock	out	mice:	Quick	et	al	2012	generated	three	mouse	lines	for	use(Quick,	Zhao	et	al.	2012):	
o TRPC3	SKO	
o TRPC6	SKO	
o TRPC3/6	DKO	
A	double	knock	out	mouse	had	originally	been	generated	by	Birnbaumer	and	colleagues	at	the	 NIEHS.	 Their	 DKO	 mice	 were	 crossed	 with	 C57BL/6	 mice	 to	 create	 heterozygous	TRPC3+/-;TRPC6+/-	mice.	These	could	then	be	crossed	together	to	create	DKOs,	single	KOs	and	WT	controls.	A	full	sensory	profile	is	described	by	Quick	et	al.	
	
6.2.2			 Induction	of	the	model	
As	detailed	in	Section	2.2,	OA	was	induced	using	0.5mg	monosodium	iodoacetate	in	5μl	of	0.9%	saline	using	a	30G	needle.	Mice	were	aged	6-8	weeks,	weighing	between	20-35g	depending	on	gender	and	mouse	strain.	
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6.2.3			 Behavioural	Assessment	
Mice	were	assessed	on	day	0,	on	the	morning	prior	to	injection,	and	on	the	mornings	of	day	3,	7,	14	and	21	there	after.	 If,	at	any	time	point,	mice	displayed	obvious	pain	or	physical	damage	relating	to	fighting	or	over-scratching	(as	appeared	in	a	minority	of	D	mice)	these	animals	were	excluded.		
As	described	in	Section	2.3,	before	measurements	began,	all	mice	were	given	a	period	of	1hr	in	which	to	 acclimatize	 to	 their	 new	 settings.	 The	 PWT	was	 then	 assessed	 using	 the	 “up-down	method”,	 as	described	 by	 Chaplan	 et	 al(Chaplan,	 Bach	 et	 al.	 1994).	 In	 brief,	 vF	 hairs	 of	 sequential	 increasing	 or	decreasing	force	are	applied,	based	on	the	response	to	the	previous	stimuli	(withdrawal	or	lack	there	of).	The	statistical	 formula	described	by	Dixon	et	al	 is	then	utilized	to	calculate	the	50%	withdrawal	threshold(Dixon	 1980)	 –	which	 describes	 the	 force	 at	which	 the	 animal	will	 withdraw	 50%	 of	 the	time.		
Following	the	assessment	of	PWT,	incapacitance	was	assessed	as	described	in	Section	2.3.	
	
6.2.4			 Data	Analysis	
All	data	is	presented	as	the	mean	±	SEM.	
• Punctate	mechanical	hypersensitivity:	Data	expressed	as	the	50%	paw	withdrawal	threshold.	Differences	 between	 transgenic	 mouse	 groups	 were	 analysed	 using	 a	 two	 way	 ANOVA	followed	by	Bonferroni	post-hoc	tests.	
• Incapacitance:	Data	expressed	as	the	percentage	of	total	weight	borne	on	the	ipsilateral	side.		Differences	 between	 transgenic	 mouse	 groups	 were	 analysed	 using	 a	 two	 way	 ANOVA	followed	by	Bonferroni	post-hoc	tests.	
	
Values	were	deemed	significant	at	p<0.05.	
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6.3	 		 Results	
6.3.1	 		 Behavioural	Hypersensitivity	in	the	MIA	model	in	WT	and	DTA	mice	
Punctate	mechanical	 hypersensitivity	 and	 incapacitance	 was	 assessed	 in	 DTA	mice	 and	 their	WT	littermates	following	the	intra-articular	injection	of	0.5mg	MIA	at	days	0,	3,	7,	14	and	21.	These	tests	revealed	 the	 gradual	 development	 of	 a	 significant	 punctate	 mechanical	 hypersensitivity	 and	reduction	in	percentage	weight	borne	on	the	ipsilateral	paw	over	time	in	WT	mice.	While	the	effects	of	time	were	similarly	significant	in	the	DTA	mice,	the	behavioural	profiles	following	MIA	were	not	identical	to	those	of	the	WT	mice.	
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Figure	 6.1	 –	 Monosodium	 Iodoacetate	 induced	 OA	
produced	 significant	 punctate	 mechanical	
hypersensitivity	 and	 a	 reduction	 in	 ipsilateral	 weight	
bearing	in	both	WT	and	DTA	mice,	however	differences	
in	 the	 time	 course	 of	 the	 behavioural	 profile	 are	
apparent:	 A)	 The	 differences	 in	 the	 punctate	mechanical	hypersensitivity	 profile	 of	 DTA	 and	 WT	 mice	 neared	significant,	 at	 p=	 0.0687,	 with	 DTA	 mice	 exhibiting	 a	delayed	 profile	 compared	 to	 WT	 mice.	 Notably	 WT	 mice	exhibit	a	significantly	smaller	50%	PWT	versus	DTA	mice	at	Day	7	 following	0.5mg	MIA	 (C)	 (**	P≤0.01)	(WT	n=8,	DTA	n=7).	 	 B)	 There	 is	 no	 significant	 difference	 in	 the	 time	course	of	the	shift	in	weight	bearing	of	observed	in	WT	and	DTA	mice	following	0.5mg	MIA	(WT	n=8;	DTA	n=7)	
A	 B
C	
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While	the	effect	of	time	was	highly	significant	in	both	WT	and	DTA	Mice	(Figure	6.1A;	2-Way	ANOVA;	p<0.0001),	 indicating	 a	 significant	 decline	 in	PWT	 following	MIA	 injection	 in	 both	 animals,	 a	 near	significant	 difference	 is	 observed	 in	 the	 time	 course	 of	 the	 developing	 hypersensitivity	 between	these	mouse	groups,	at	p=0.0687.	This	difference	reflects	the	delayed	time	course	of	decreasing	50%	PWT	 in	 the	DTA	mice	 versus	WT,	with	 the	 greatest	 effect	 of	 this	 delay	 observed	 at	 day	 7	 (Figure	6.1C;	 Bonferroni	 posttests;	 **	 P≤0.01).	 This	 delayed	 punctate	mechanical	 hypersensitivity	 in	 DTA	mice	is	temporary,	with	very	similar	50%	PWT	of	0.14±0.04g	and	0.06±0.02g	for	WT	and	DTA	mice	respectively,	demonstrating	a	strong,	similar	mechanical	hypersensitivity	 in	both	lines	by	this	time	point.		
Though	a	significant	effect	of	time	was	observed	for	the	weight	borne	on	the	ipsilateral	paw	following	MIA	in	WT	and	DTA	mice,	no	significant	difference	was	observed	between	the	two	mouse	lines,	with	both	 showing	 a	 maximum	 change	 to	 any	 given	 time	 point	 of	 roughly	 ~10%	 (Figure	 6.1B;	 2-way	ANOVA).	However,	the	differences	in	time	course	of	the	change	is	interesting,	given	the	WT	mice	show	a	gradual	increase	in	incapacitance	to	day	21	while	the	DTA	mice	exhibit	the	greatest	incapacitance	at	day	7,	with	a	slight	recovery	there	after.		
As	 such,	 DTA	mice	 appear	 to	 show	 no	 difference	 in	 incapacitance	 behaviour	 to	WT	mice,	 however	there	 is	 an	 apparent	 delay	 in	 the	 time	 course	 of	 punctate	mechanical	 hypersensitivity,	 which	may	reflect	the	protective	effects	of	loss	of	Nav1.8	containing	neurones.	
	
6.3.2	 	 Behavioural	hypersensitivity	during	the	MIA	model	in	WT,	SKO	and	DKO	mice	
Punctate	 mechanical	 hypersensitivity	 and	 incapacitance	 was	 assessed	 in	 TRPC3	 SKO,	 TRPC6	 SKO,	their	WT	 littermates	 and	 TRPC3/6	 DKO	mice	 over	 the	 21days	 following	 injection	 of	 0.5mg	MIA.	 A	significant	effect	of	time	was	observed	across	all	groups	to	both	behavioural	measures,	indicating	the	development	of	significant	mechanical	hypersensitivity	and	shifts	 in	weight	bearing	following	0.5mg	MIA.	However	no	significant	difference	was	observed	between	these	mouse	groups	(Figure	6.2;	2-Way	ANOVA).		
All	mice	exhibited	a	rapid	decline	in	the	50%	PWT	to	day	3,	plateauing	across	all	groups	between	50%	PWTs	of	roughly	0.1	and	0.25g	from	days	7	to	21	(Figure	6.2A).	No	differences	were	detected	either	statistically	or	are	visually	apparent.	Similarly,	the	shape	of	the	time	course	of	change	for	these	mice	is	broadly	similar	to	those	observed	in	the	DTA	mice’s	WT	littermates	in	Figure	6.1.		
A	 broadly	 similar	 time	 course	 in	 the	 shift	 of	 weight	 bearing	 following	 injection	 of	MIA	 is	 similarly	observed	across	these	four	groups	of	mice	(Figure	6.2).	Mice	exhibit	a	rapid	shift	in	weight	bearing	of	
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roughly	10%,	seen	in	SKO	and	DKO	mice	to	Day	3	and	slightly	slower	to	develop	in	WT	mice	to	Day	7,	followed	 by	 a	 rebounding	 of	 weight	 bearing	 by	 day	 14	 onwards,	 reflecting	 the	 development	 of	 a	sensitivity	 in	 the	 knees	which	 recovers	 after	 this	 initial	 early	 flare	 in	 the	 first	week.	 	No	 significant	differences	between	these	four	groups	of	mice	were	observed.	
As	 such	 these	 SKO	and	DKO	mice	 appear	 to	 show	no	difference	 in	 the	behavioural	 hypersensitivity	profile	versus	WT	mice	during	the	MIA	model	of	OA,	indicating	that	the	loss	of	TRPC3	and/or	TRPC6	dose	not	protect	against	OA	pain.	
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Figure	 6.2	 -	 Monosodium	 Iodoacetate	 induced	 OA	 produced	 significant	 punctate	 mechanical	
hypersensitivity	and	a	reduction	in	ipsilateral	weight	bearing	in	both	WT,	TRPC3	SKO,	TRPC6	SKO	and	
TRPC3/6	DKO	mice,	 with	 no	 significant	 differences	 in	 the	 behavioural	 profiles	 of	 these	 four	mouse	
lines.	A)	All	four	mouse	lines	exhibit	a	rapid	decline	in	the	50%	PWT	to	Day	3	and	7,	which	is	maintained	to	day	21	following	0.5mg	MIA		(WT	n=10;	TRPC3	SKO	n=10;	TRPC6	SKO	n=10;	TRPC3/6	DKO	n=10).		B)	All	four	mouse	 lines	exhibit	a	rapid	decline	 in	weight	bourne	on	the	 ipsilateral	 limb	 in	 the	3-7days	 following	0.5mg	MIA	injection,	but	rebound	to	near	original	distribution	of	weight	to	days14	and	21.	MIA		(WT	n=10;	TRPC3	SKO	n=10;	TRPC6	SKO	n=10;	TRPC3/6	DKO	n=10)	
A	 B	
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6.4	 		 Discussion	
The	use	of	transgenic	mice	has	enabled	the	characterization	of	the	roles	of	specific	proteins	in	healthy	somatosensation	 and	 pathological	 pain	 conditions.	 Previous	 work	 has	 established,	 through	 the	generation	 of	 a	 number	 of	 different	 mouse	 lines,	 both	 the	 role	 of	 Nav1.8	 containing	 neurones	 in	noxious	 mechanosensation	 and	 inflammatory	 pain,	 and	 for	 TRPC3	 and	 TRPC6	 in	 innocuous	mechanical	pressure.		
The	work	 presented	 here	 has	 demonstrated	 that	while	 the	 ablation	 of	 Nav1.8	 containing	 neurones	may	 protect	 against	 the	 initial	 stages	 of	 the	 MIA	 model	 in	 these	 DTA	 mice,	 this	 does	 not	 provide	protection	from	the	punctate	mechanical	sensitivity	which	develops	in	WT	MIA	mice	in	the	later	days	of	the	model.	This	work	has	similarly	demonstrated	that	while	TRPC3	and	TRPC6	may	have	a	role	in	innocuous	pressure	sensation,	these	channels	do	not	play	a	part	in	the	punctate	mechanical	threshold	or	weight	bearing	changes	observed	during	this	model	of	OA	pain.	
	
6.4.1			 Behavioural	hypersensitivity	in	a	murine	model	of	MIA	induced	OA	pain	
As	discussed	in	Section	3.4.1,	behavioural	hypersensitivity	following	a	dose	of	MIA	to	the	knee	is	well	characterized	as	including	both	shifts	in	weight	bearing	and	punctate	mechanical	hypersensitivity	in	the	rat(Bove	2003,	Fernihough,	Gentry	et	al.	2004,	Pomonis,	Boulet	et	al.	2005,	Rahman,	Bauer	et	al.	2009,	Vonsy,	Ghandehari	et	al.	2009,	Sagar,	Staniaszek	et	al.	2010,	Kelly,	Dunham	et	al.	2012,	Thakur,	Rahman	et	al.	2012,	Burnham	and	Dickenson	2013).	Similar	efforts	have	been	made	 to	characterize	these	changes	in	mice,	given	the	opportunity	transgenic	mice	offer	to	the	study	of	OA	pain.	However,	the	translation	of	this	model	to	mice	is	difficult	to	scale.	The	smaller	size	of	mice	raise	questions	about	injection	volume,	needle	gage	and	most	 importantly,	 the	dose	of	MIA	to	be	used	–	not	 least	because	some	 of	 the	 doses	 used	 in	 rats,	 namely	 >1mg,	 have	 been	 lethal	 in	 mice	 (unpublished	 –	 known	experience	of	several	UK	labs,	including	Nottingham,	UCL	and	KCL).	As	a	result,	the	dose	used	in	the	MIA	model	in	mice	has	varied	broadly,	from	0.025	to	1mg	per	knee,	in	volumes	between	5-10μl(van	der	 Kraan,	 Vitters	 et	 al.	 1989,	 Van	 Osch,	 Van	 Der	 Kraan	 et	 al.	 1994,	 Harvey	 and	 Dickenson	 2009,	Ogbonna,	Clark	et	al.	2012,	Bowles,	Mata	et	al.	2014).	However	in	those	studies	that	tested	pain-like	behaviours,	 using	 the	 upper	 and	 lower	 doses	 described,	 all	 doses	 induced	 significant	 mechanical	threshold	 and	 weight	 bearing	 changes(Harvey	 and	 Dickenson	 2009,	 Ogbonna,	 Clark	 et	 al.	 2012,	Bowles,	Mata	et	al.	2014,	Horváth,	Tékus	et	al.	2016).	
In	 line	with	 these	prior	 studies,	 this	work	presented	 in	Figure	6.1A	and	6.2A	demonstrates	 that	 the	injection	of	a	0.5mg	dose	of	MIA	 to	WT	mice	results	 in	a	 rapid	decline	and	plateau	 in	 the	50%	paw	
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withdrawal	threshold	to	roughly	0.2g.	 In	Ogbonna	et	al	2013,	where	one	of	three	doses	investigated	included	the	same	0.5mg	dose,	a	very	similar	decline	and	plateau	 is	observed,	 through	the	extent	of	the	reduction	in	PWT	is	greater	–	at	<0.1g	by	day	14(Ogbonna,	Clark	et	al.	2012).		
Slightly	 less	 aligned	 are	 the	 effects	 of	MIA	 on	 the	 percentage	weight	 borne	 on	 the	 ipsilateral	 paw.	While	in	Figure	6.1B	the	WT	mice	exhibit	a	slow	but	steady	shift	in	the	weight	borne	by	roughly	10%	to	the	final	day,	the	mice	in	Figure	6.2B	decline	more	rapidly	to	days	3-7,	by	a	similar	10%,	but	then	regain	to	settle	at	a	less	severe	shift.	This	suggest	the	development	of	a	hypersensitivity	at	the	knee	in	both	mouse	strains,	suggesting	a	pain/discomfort	at	rest	that	may	relate	to	increased	spontaneous	C	fibre	activity	 (Kelly,	Dunham	et	al.	2012)	 (As	discussed	 in	Section	3.4.1).	However	 the	 time	courses	differ.	 Interestingly,	 the	DTA	mice	 themselves	show	a	weight	distribution	profile	over	 time	which	 is	far	more	similar	 to	 that	seen	 in	mice	 in	Figure	6.2B.	Such	differences	 in	weight	distribution	profiles	may	be	an	artefact	of	the	mouse	strains,	since	the	WT	mice	in	Figure	6.1B	are	different	from	those	in	Figure	6.2B	–	where	previous	work	has	identified	differences	in	pain	profiles	between	different	mouse	or	rat	strains(Mogil,	Wilson	et	al.	1999,	Yoon,	Lee	et	al.	1999,	Lovell,	Stuesse	et	al.	2000,	Felice,	Sanoja	et	al.	2011).	
Previous	murine	OA	studies	have	characterised	a	“recovery”	profile	of	incapacitance	in	the	MIA	model,	in	 which	 the	 mice	 recovered	 back	 to	 the	 baseline	 weight	 distribution	 observed	 in	 comparator	animals(Bowles,	Mata	et	al.	2014,	Horváth,	Tékus	et	al.	2016).	In	one	of	the	studies	this	was	explained	by	 the	 author	 as	 a	 likely	 artefact	 of	 the	 low	dose,	 given	 just	 0.05mg	of	MIA	was	 used	 to	model	OA	pain(Bowles,	Mata	 et	 al.	 2014)	 .	 The	 initial	 drop	 in	weight	 bearing	was	 attributed	 to	 inflammation,	which	 recovered;	 where	 a	 chronic	 shift	might	 eventually	 have	 been	 seen	 as	 pathology	 in	 the	 knee	progressed(Bowles,	Mata	et	al.	2014).	However,	Horvath’s	work	using	the	same	dose	as	used	in	this	chapter	also	reported	a	recovery	in	the	shift	 in	weight	distribution	by	day	14	in	WT	mice,	similar	to	that	observed	in	figures	6.2B(Horváth,	Tékus	et	al.	2016).	It	is	worth	noting	however	that	a	recovery	profile	 is	not	seen	 in	high	dose	models	 like	 the	1mg	murine	model	used	by	Ogbonna	et	al(Ogbonna,	Clark	 et	 al.	 2012).	 The	 shift	 reported	 in	 Ogbonna	 et	 al	 2012	 is	 maintained	 up	 to	 the	 28th	 day	 of	observation,	much	like	the	profiles	reported	in	rats	by	Bove	et	al	2003(Bove	2003).	As	such,	it	may	be	that	 across	 all	 the	 doses	 of	MIA	 used	 a	 change	 to	 the	weight	 bearing	 profile,	 indicative	 of	 primary	hypersensitivity,	is	observed	in	the	initial~10days,	but	only	in	the	larger	1mg	dose	is	this	maintained.	It	could	be	suggested	that	the	initial	shift	in	weight	bourne,	across	all	doses,	could	be	attributed	to	an	early	inflammation,	and	at	latter	time	points	(14days	onwards)	is	driven	by	a	more	chronic	pathology	at	the	joint	that	is	potentially	more	pronounced	in	the	higher	dose	model.	
While	 these	 suggested	 explanations	 are	 limited	by	 the	 failure	 to	 characterise	 inflammation,	 such	 as	synovitis	or	joint	volume,	in	the	work	presented	here	(and	these	limitations	will	be	discussed	in	more	
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detail	 in	 6.4.3),	 other	 studies	 in	 the	mouse	model	 of	MIA	 have	 investigated	 these	 characters	 of	 the	model	to	support	the	proposal.	Recent	work	by	Horvath	et	al	has	characterised	a	significant	increase	in	both	the	mediolateral	and	anteroposterior	knee	diameter,	most	notably	in	the	first	3days	of	a	0.5mg	MIA	model(Horváth,	Tékus	et	al.	2016).	This	study	went	so	far	as	to	call	the	inflammation	“remarkable	oedema”.	 Others	 have	 captured	 similar	 changes,	 with	 early	 work	 by	 van	 der	 Kraan	 capturing	significant	swelling	in	the	initial	days	of	the	model(van	der	Kraan,	Vitters	et	al.	1989),	and	Uchimura	suggesting	 that	 a	 degree	 of	 synovitis	 persists	 to	 day	 10	 even	 with	 a	 much	 lower	 dose	 of	MIA(Uchimura,	 Foote	 et	 al.	 2016).	 	Meanwhile	 Ogbonna	 et	 al	 suggest	 that,	 given	 the	 absence	 of	 an	ATF-3	 profile	 at	 day	 10	 in	 their	 1mg	MIA	mouse	model,	 that	 the	microgliosis	 observed	 at	 day	 7	 is	driven	by	 inflammation	 instead	of	neuronal	damage	at	 this	 time(Ogbonna,	Clark	et	al.	2012).	 	While	this	is	not	as	a	large	a	body	of	evidence	as	is	available	in	the	rat	MIA	model,	this	certainly	supports	the	potential	of	an	initial	inflammatory	phase	driving	sensitization	in	the	first	week	after	MIA	injection.		
In	contrast	to	the	recovery	observed	in	WB,	the	decline	in	PWT,	which	occurs	in	the	first	3-7days,	 is	maintained	 instead.	 This	 suggests	 that	 secondary	 sensitization,	 indicative	 of	 the	 development	 of	central	 sensitization,	 does	 not	 recover	 after	 this	 postulated	 initial	 inflammatory	 stage.	 It	 seems	plausible	that	this	difference	may	be	a	result	of	the	size	of	the	MIA	dose	selected	in	this	protocol,	such	that	 joint	 pathology	 may	 already	 be	 sufficient	 at	 Day	 7-14	 to	 maintain	 central	 sensitization.	 It	 is	certainly	 the	 case	 that	 in	 both	 mouse	 models	 or	 rat	 models	 using	 larger	 doses,	 ≥0.5mg	 or	 ≥2mg	respectively,	 the	 changes	 in	 50%	 PWT	 plateau	 across	 a	 time	 course(Combe,	 Bramwell	 et	 al.	 2004,	Ogbonna,	 Clark	 et	 al.	 2012).	 	 That	 larger	 doses	 could	 institute	 changes	 of	 this	 severity	 of	 joint	pathology	 so	 rapidly	 can	 be	 understood	 from	 the	 comparative	 time	 course	 and	 locations	 of	 lost	proteoglycan	synthesis,	where	larger	doses	have	a	significant	effect	across	both	central	and	peripheral	patella	cartilage,	with	the	greatest	effect	 in	the	first	week,	while	 lower	doses	fail	to	effect	peripheral	cartilage	(Guingamp,	Gegout-Pottie	et	al.	1997).		
However,	 given	 the	 hypothesis	 that	 the	 >2mg	 dose	 in	 rats	 triggers	 neuropathic	mechanisms	 in	 the	MIA	model,	it	is	also	valid	to	question	at	what	scaled	down	dose	this	“tipping	point”	occurs	in	the	mice.	It	 is	 plausible	 that	 this	may	 have	 happened	 already	 in	mice	 at	 0.5mg,	 not	 least	 given	 the	 systemic	lethality	of	the	1mg	dose	in	some	mice.	While	not	on	a	scale	equivalent	to	the	PNL	model,	it	has	been	shown	that	1mg	MIA	in	mice	results	in	a	significant	increase	in	the	expression	of	activated	ATF-3,	with	the	author	concluding	that	the	possibility	of	axonal	injury	could	not	be	excluded	in	theses	MIA	mice	–	though	 it	 was	 felt	 that	 inflammation	 was	 more	 likely	 the	 underlying	 driver(Ogbonna,	 Clark	 et	 al.	2012).	 This	 aligns	 to	 observation	 of	 axonal	 injury	 and	 neuropathic	 components	 to	 high	 dose	 MIA	induced	hypersensitivities	in	rats(Ivanavicius,	Ball	et	al.	2007,	Thakur,	Rahman	et	al.	2012).	As	such,	there	is	a	possibility	that	the	behavioural	hypersensitivity	exhibited	in	these	mice,	at	least	beyond	day	7	 of	 this	model,	may	 in	 part	 be	 attributed	 to	 axonal	 damage	by	 the	 large	dose	 of	MIA	 escaping	 the	
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synovial	 joint	 and	 affecting	 local	 sensory	 afferents	 terminals	 –	 though	 this	 has	 not	 been	 verified	 in	these	animals.	Further	work	to	clarify	this	would	provide	valuable	insight	into	potential	explanations	for	this	maintained	decline	in	PWT.	
	
6.4.2			 Preserved	 punctate	 hypersensitivity	 at	 day	 14	 and	 onwards	 after	 0.5mg	MIA	 in	
mice	lacking	Nav1.8	neurones		
The	data	presented	in	Figure	6.1A,	in	which	near	significant	differences	in	the	time	course	of	changes	in	 50%	 PWT	 threshold	 are	 observed	 between	 WT	 and	 DTA	 mice	 following	 IA	 injection	 of	 MIA	(p=0.0687,	 Figure	 6.1A),	 suggests	 that	 the	 loss	 of	 Nav1.8	 containing	 neurones	 provides	 protection	from	behavioural	hypersensitivity	in	the	paw	in	the	first	but	not	later	weeks	of	this	OA	pain	model.	
It	has	previously	been	demonstrated	that	the	loss	of	Nav1.8	containing	neurones	protects	against	the	development	of	inflammatory	pain	but	not	neuropathic	pain	associated	with	the	SNL,	oxaliplatin	and	cancer	induced	bone	pain	models(Abrahamsen,	Zhao	et	al.	2008,	Minett,	Falk	et	al.	2014).		In	light	of	this,	 the	 results	 presented	here	 could	 suggest	 a	 potential	 timeline	 of	 pain	mechanisms	 following	 IA	injection	of	MIA.	Namely	that	 in	the	first	7	days,	where	a	significant	resistance	to	hypersensitivity	 is	observed	 in	 DTA	mice,	 pain	 is	 driven	 by	 the	 previously	 discussed	 inflammation,	 where	 the	 loss	 of	Nav1.8	containing	neurones	provides	protection	from	punctate	mechanical	sensitivity	provided	in	the	DTA	mice.	However,	beyond	 this	point,	 the	 resurgence	of	 the	punctate	mechanical	 sensitivity	 in	 the	DTA	mice	suggests	that	the	pain	mechanisms	have	evolved	beyond	inflammation.	Given	the	profile	of	DTA	mice	similarly	include	deficits	in	noxious	mechanical	sensation(Abrahamsen,	Zhao	et	al.	2008),	it	is	 possible	 to	 interpret	 these	 results	 as	 suggestive	 of	 neuropathic	 mechanisms	 at	 these	 later	 time	points.	Unfortunately	this	work	did	not	seek	to	classify	this	(and	these	limitations	will	be	discussed	in	more	detail	in	6.4.3)	
As	 discussed	 earlier,	 previous	work	 in	mice	 following	 the	 injection	 of	 1mg	MIA	 have	 characterized	changes	 that	 could	 reflect	 neuropathic	 mechanisms(Ogbonna,	 Clark	 et	 al.	 2012).	 Such	 changes	 are	similarly	characterized	in	rats	at	doses	of	2mg	MIA	and	upwards	(Ivanavicius,	Ball	et	al.	2007,	Thakur,	Rahman	et	al.	2012).	As	such,	the	possibility	of	neuropathic	changes	during	the	MIA	model	of	OA	pain	is	established.	The	pertinent	questions	are	whether	the	rebounding	punctate	mechanical	sensitivity	in	these	DTA	mice	is	a	genuine	indicator	of	neuropathy.	
The	 first	 question	 is	 addressed	 by	 our	 understanding	 of	 the	 role	 of	 Nav1.8	 containing	 neurones	 in	differing	pain	 conditions,	 both	 inflammatory	 and	neuropathic.	Nav1.8	 is	distinct	 from	other	 sodium	channels	 in	 two	 major	 ways:	 this	 channel	 is	 the	 only	 channel	 which	 functions	 at	 cold	
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temperatures(Zimmermann,	Leffler	et	al.	2007),	but	crucially	this	channel	is	the	only	channel	whose	expression	 is	 restricted	 to	 a	 subpopulation	 of	 sensory	 fibers,	 namely	 nociceptors,	 C-LTMs	 and	 A-LTMs(Shields,	Ahn	et	al.	2012).		Nav1.8	works	in	concert	with	Nav1.7	channels	expressed	in	this	same	population,	 where	 Nav1.7	 bridges	 the	 gap	 between	 building	 depolarization	 and	 the	 activation	 of	Nav1.8	 for	 neuronal	 transmission.	 By	 interrupting	 the	 activity	 of	 these	 neurones,	 through	 various	genetic	and	pharmacological	techniques,	attempts	have	been	made	to	classify	a	specialized	population	of	sensory	afferents.	However,	whether	Nav1.8	and	thus	this	population	have	a	role	in	the	generation	of	pain	during	neuropathy	is	not	entirely	clear-cut.	
Initial	 work	 using	 Nav1.8	 knock	 out	 mice	 revealed	 no	 difference	 in	 the	 change	 in	 mechanical	withdrawal	threshold	of	KO	mice	and	WT	mice	following	peripheral	nerve	injury(Kerr,	Souslova	et	al.	2001),	which	was	 corroborated	 in	 later	 studies(Nassar,	 Levato	 et	 al.	 2005).	 This	 suggests	 that	 this	Nav1.8	containing	fiber	population	is	not	required	for	the	generation	or	maintenance	of	neuropathic	pain.	 However,	 given	 the	 expression	 of	 Nav1.7	 in	 these	 fibers,	 it	 is	 conceivable	 that	 Nav1.7	compensates	 for	 the	 loss	of	Nav1.8	 to	maintain	 the	response	of	 this	 fiber	population	 to	neuropathic	pain,	 especially	 given	 Nav1.7	 expression	 is	 increased	 in	 Nav1.8	 KO	 mice(Akopian,	 Souslova	 et	 al.	1999).	 That	 this	 Nav1.8	 containing	 population	 of	 sensory	 afferents	 is	 neither	 a	 requirement	 nor	 a	major	 contributor	 to	 neuropathic	 pain	 was	 further	 suggested	 by	 work	 in	 which	 both	 Nav1.7	 was	knock	 out	 from	 the	 Nav1.8	 positive	 fibers,	 in	 addition	 to	 the	 knock	 out	 of	 Nav1.8.	 This	 double	 KO	mouse	developed	mechanical	 allodynia	 following	SNL	 that	was	 indistinguishable	 from	either	WT	or	Nav1.8	single	KO	mice(Nassar,	Levato	et	al.	2005).	Later	work	has	similarly	demonstrated	that	Nav1.8	KO	mice	develop	SNT	and	CCI	induced	mechanical	allodynia	normally(Minett,	Falk	et	al.	2014),	while	DTA	mice	 develop	 SNL,	 oxaliplatin	 and	 cancer	 induced	 bone	 pain	mechanical	 and	 cold	 allodynia	 to	both	the	same	degree	and	time	course	as	WT	mice(Abrahamsen,	Zhao	et	al.	2008,	Minett,	Falk	et	al.	2014).	 The	 overarching	 suggestion	 of	 such	 studies	 is	 that	 peripheral	 neuropathic	 pain	 can	 develop	independently	of	the	Nav1.8	containing	population	of	sensory	afferents.		
However,	 it	 is	 important	to	consider	the	body	of	work	that	contradicts	this,	citing	the	importance	of	Nav1.8	as	a	target	for	the	management	of	neuropathic	pain	–	and	thus	the	role	of	this	neuronal	sub-population.	Changes	in	Nav1.8	expression	patterns	and	sensitivity	during	neuropathic	pain	have	been	described,	 where	 these	 changes	 to	 the	 Nav1.8	 channel	 population	 are	 described	 as	 enabling	 the	development	 of	 neuropathic	 pain(Gold	 MS	 2003,	 Thakor,	 Lin	 et	 al.	 2009).	 Further,	 treatment	 with	anti-sense	 oligonucleotides	 and	 selective	 antagonists	 such	 as	 A803467	 were	 shown	 to	 prevent	 or	reverse	 hypersensitivities	 caused	 by	 peripheral	 nerve	 damage(Lai,	 Gold	 et	 al.	 2002,	 Gold	MS	 2003,	Jarvis,	Honore	et	al.	2007).	That	targeting	Nav1.8	could	provide	such	clear	reversal	of	hypersensitivity	counters	 the	 suggestion	 that	 Nav1.8	 containing	 neurones	 are	 not	 required	 for	 neuropathic	 pain.	However,	it	is	plausible	that	both	antisense	and	Nav1.8	antagonists	could	be	having	off	target	effects	
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that	underlie	 this	 analgesia.	 It	 is	 similarly	possible	 that	 the	persistence	of	neuropathic	pain	 in	mice	lacking	Nav1.8	populations	may	be	an	artifact	of	the	broad	redundancy	in	sensation	and	nociceptive	systems	–	such	that	in	the	absence	of	Nav1.8	other	systems	make	up	the	difference,	while	in	normal	animals	 Nav1.8	 contributes	 both	 through	 redistribution	 and	 phosphorylation.	 This	 would	 certainly	explain	 the	 ability	 of	 Nav1.8	 antagonism	 to	 reduce	 mechanically	 evoked	 responses	 in	 spinal	 cord	electrophysiology	in	MIA	but	not	sham	animals(Rahman	and	Dickenson	2015).	Considering	these	two	possibilities,	it	seems	more	likely	that	counterbalancing	adaptations	in	other	ion	channel	systems	may	allow	 neuropathy	 to	 proceed	 uninterrupted	 in	DTA	 animals.	 As	 such,	 the	 punctate	 hypersensitivity	observed	at	day	14	onwards	in	the	DTA	mice	may	be	driven	by	peripheral	nerve	damage.		
The	alternative	explanation	is	that	joint	pathology	by	this	time	point	is	severe	enough	that	it	is	driving	central	 sensitization	 and	 the	 consequential	 expansion	 of	 receptive	 fields	 and	 referral	 of	 pain	associated(Bajaj,	Graven-Nielsen	et	al.	2001).	However,	this	theory	is	reliant	on	an	ongoing	barrage	of	mechanical	nociception	from	the	joint(Schaible,	Schmidt	et	al.	1987),	which	is	understood	to	be	absent	in	DTA	mice,	which	lack	noxious	mechanosensation(Abrahamsen,	Zhao	et	al.	2008).	This	absence	and	disruption	of	noxious	mechanosensation	 is	similarly	observed	 in	Nav1.8	KO	mice(Akopian,	Souslova	et	 al.	 1999,	 Nassar,	 Levato	 et	 al.	 2005),	 mice	 in	 which	 Nav1.7	 have	 been	 deleted	 from	 all	 Nav1.8	expressing	neurones(Minett,	Nassar	et	al.	2012),	and	double	KO	mice	where	Nav1.8	are	additionally	deleted(Nassar,	Levato	et	al.	2005).	Further	more,	as	previously	discussed,	the	results	of	Figured	6.1	and	6.2B	suggest	that	at	this	time	point	a	recovery	from	previous	shifts	in	weight	bearing	has	occurred	–	 suggestive	 in	 itself	 that	 the	 joint	 is	 less	 likely	 to	 be	 causing	 pain/discomfort	 at	 rest,	 potentially	interpreted	as	a	recovery	from	increased	spontaneous	C	fibre	activity	(Kelly,	Dunham	et	al.	2012).	
We	must	 similarly	 consider	 that	 the	 ablation	 of	 this	 population	 of	Nav1.8	 expressing	neurones	will	have	 dramatically	 reduced	 innervation	 of	 the	 knee	 joint.	 We	 know	 that	 approximately	 80%	 of	afferents	 serving	 the	 joint	 are	 unmyelinated(Grubb	 2004),	where	 previous	work	 has	 demonstrated	that	up	to	90%	of	these	would	be	Nav1.8	containing	neurones(Shields,	Ahn	et	al.	2012).	We	similarly	know	that	roughly	50%	of	 joint	afferents	are	CGRP	positive	neurones(Edoff,	Grenegard	et	al.	2000),	where	 CGRP	 expression	 is	 increased	 during	 painful	 OA	 (Fernihough,	 Gentry	 et	 al.	 2005)–	 however,	only	12%	of	CGRP	containing	 fibers	were	spared	 in	 the	DTA	mouse(Abrahamsen,	Zhao	et	al.	2008).	This	 suggests	 that	 not	 only	 is	 noxious	 mechanosensation	 undermined	 in	 these	 animals,	 but	 there	would	be	a	considerable	loss	of	input	from	the	joint	regardless	of	the	extent	of	pathophysiology.	It	is	questionable	if,	even	in	the	presence	of	inflammatory	sensitization	or	noxious	mechanical	stimuli,	this	restricted	population	of	remaining	afferents	could	provoke	equivalent	behavioural	sensitivity	to	that	seen	 in	WT	mice,	 suggesting	 that	 chronic	 joint	 pathophysiology	 alone	 is	 not	 the	 only	 force	 driving	central	sensitization.	
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While	these	considerations	suggest	to	me	that	the	drop	in	the	50%	withdrawal	threshold	observed	in	DTA	mice	at	days	14	onwards	of	 this	0.5mg	MIA	murine	model	 could,	 at	 least	 in	part,	be	driven	by	neuropathic	mechanisms	 I	 have	 no	 conclusive	 evidence	 of	 neuropathy	 in	 the	murine	MIA	model	 of	osteoarthritis.	 This	 remains	 one	 potential	 explanation	 of	 a	 behavioural	 profile	 that	 is	 difficult	 to	explain.	 	 In	 addition	 to	 further	work	 in	 the	mouse	MIA	model	 to	 characterize	 neuropathy,	 such	 as	characterization	of	intra-epidermal	nerve	fibre	density	in	plantar	hindpaw	skin,	or	spinal	cord	dorsal	and	ventral	horn	microgliosis,	the	use	of	another	model	of	OA	may	be	considered	in	this	mouse	line	to	compare	 the	 behavioural	 profile,	 such	 as	 an	 anterior	 cruciate	 ligament	 transection.	 This	 would	eliminate	the	possibility	of	neurotoxicity	 from	MIA	and	if	 the	DTA	mice	go	on	to	develop	a	punctate	mechanical	sensitivity	following	this	model,	potentially	over	a	similar	or	slower	time	course,	a	more	confident	 conclusion	 could	be	drawn	about	 the	 feasibility	 of	Nav1.8	blockade	 to	 treat	OA	pain.	 The	results	 presented	 within	 do	 not	 suggest	 Nav1.8	 blockade	 would	 be	 successful	 in	 OA	 pain	 without	inflammation/synovitis,	 though	 pharmacology	 work	 in	 previous	 MIA	 rat	 studies	 have	 suggested	otherwise(Schuelert	and	McDougall	2012).	
The	lack	of	a	significant	difference	between	the	ipsilateral	weight	bearing	in	DTA	and	WT	mice	(Figure	6.1B)	suggests	that,	even	in	the	absence	of	the	Nav1.8	containing	population	of	sensory	afferents,	DTA	mice	 experience	 discomfort	 from	 the	 knee	 joint	 sufficient	 to	 shift	 their	 weight	 to	 the	 contralateral	paw.	As	discussed,	we	would	expect	a	drastic	reduction	in	the	nociceptors	population	serving	the	joint	in	these	DTA	mice.	However,	these	DTA	mice	would	still	retain	a	large	proportion	of	the	roughly	20%	myelinated	 fibers	 serving	 the	 joint	whose	 sensitization	and	chronic	 activation	 could	be	 sufficient	 to	encourage	a	 shift	 in	weight	bearing,	 reflecting	perhaps	more	a	discomfort	 than	ongoing	pain.	These	raise	 important	questions	however	about	 the	extent	and	nature	of	 the	remaining	 innervation	of	 the	joint	 in	 DTA	mice,	 since	 it	 is	 clear	 that	 the	 loss	 of	 Nav1.8	 containing	 neurones	 is	 not	 sufficient	 to	alleviate	the	pain	or	discomfort	motivating	shifts	in	weight	bearing.		
	
6.4.3			 The	behavioural	profile	of	TRPC3	and	TRPC6	SKO	and	DKO	mice		
By	both	measures,	punctate	mechanical	sensitivity	and	weight	distribution,	the	KO	of	either	TRPC3	or	TRPC6	 or	 both	 fails	 to	 affect	 the	 behavioural	 profile	 evoked	 by	 the	 IA	 injection	 of	 0.5mg	MIA.	 This	suggests	that	these	SKO	and	DKO	mice	have	either	developed	a	counterbalancing	increase	in	another	mechanosensitive	 receptor	 to	 compensate	 for	 these	 deletions,	 or	 that	 TRPC3	 and	 TRPC6	 are	 not	involved	 in	 the	mechanosensitization	observed	 in	mice	 following	 in	 the	 injection	of	MIA	 into	 the	 IA	space.		
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The	 original	 hypothesis	 was	 that	 these	 mechanoceptors	 might	 be	 involved	 in	 the	 generation	 of	inflammation	related	mechanical	sensitization,	becoming	sensitized	during	the	early	phase	of	the	MIA	model	to	underlie	primary	hypersensitivity	reflected	in	weight	bearing	changes.	This	hypothesis	was	driven	by	understandings	from	previous	studies,	which	suggested	both	the	 localization	and	function	of	these	receptors	could	lend	themselves	to	mechanical	sensation	and	allodynia.	
During	 the	 study	of	 the	DTA	mice	by	Abrahmasen	et	 al	 2008,	 it	was	demonstrated	 that	TRPC3	and	TRPC6	 expression	 in	 the	 DRG	 was	 significantly	 diminished	 in	 DTA	 mice	 versus	 WT	 littermates,	suggesting	 these	 ion	 channels	 may	 be	 most	 commonly	 expressed	 in	 small	 diameter	 sensory	afferents(Abrahamsen,	Zhao	et	al.	2008).	This	is	corroborated	by	work	using	real	time	PCR	to	examine	the	presence	of	TRPC1-C7	in	DRG,	which	characterised	the	expression	of	TRPC3	in	roughly	30%	of	the	DRG	in	exclusively	in	the	non-peptidergic	IB4+	TRPV1-	small	diameter	afferents(Elg,	Marmigere	et	al.	2007).	 This	 study	 similarly	 characterised	TRPC3	and	TRPC6	as	 the	most	 abundant	 of	 this	 family	 of	receptors.		
A	range	of	work	had	similarly	characterised	a	role	for	TRPC	channels	in	mechanosensation.	While	the	impact	 is	 lesser	 in	 SKO	 mice,	 due	 to	 corresponding	 compensatory	 increases	 in	 related	 TRPC	receptors(Spassova,	 Hewavitharana	 et	 al.	 2006),	 DKO	 mice	 exhibited	 selective	 deficits	 in	 touch	response	and	cultured	DRGs	electrophysiology	revealed	deficits	in	mechanotransduction(Quick,	Zhao	et	al.	2012).	These	channels,	in	concert	with	other	TRPs	through	the	formation	of	heteromeric	calcium	channels,	 have	 similarly	 been	 identified	 for	 their	 roles	 in	 the	 development	 of	 mechanical	hypersensitivity	 and	 nociceptors	 sensitization	 during	 inflammation(Alessandri-Haber,	 Dina	 et	 al.	2009,	Ding,	Xiao	et	al.	2011),	leading	to	speculation	that	this	family	of	TRPC	channels	may	contribute	to	mechanical	 allodynia	during	disease	models	 such	as	OA(Eijkelkamp,	Linley	 et	 al.	 2013,	 Lolignier,	Eijkelkamp	et	al.	2015),	especially	in	light	of	the	sensory	profile	and	inflammatory	pain	deficits	in	DTA	mice(Abrahamsen,	Zhao	et	al.	2008).		
However,	 the	 suggestion	 of	 the	 results	 in	 Figure	 6.2	 is	 that	 TRPC3	 and	 TRPC6	 are	 not	 involved	 in	either	the	initial	suggested	inflammatory	period,	nor	the	later	phase	of	mechanical	hypersensitivity	in	these	mice.		The	most	likely	explanation	for	this	is	a	compensatory	rebound	in	the	population	of	other	mechanically	sensitive	TRP	channel	populations,	as	already	observed	in	SKO	populations.	These	may	not	 just	 be	 within	 TRPC,	 but	 extend	 across	 the	 whole	 family	 of	 previously	 characterised	mechanosensitive	 TRP	 receptors,	 including	 TRPV4	 and	 TRPA1(Suzuki,	 Mizuno	 et	 al.	 2003,	 Kwan,	Allchorne	 et	 al.	 2006,	 Alessandri-Haber,	 Dina	 et	 al.	 2009,	 Vilceanu	 and	 Stucky	 2010).	 TRPA1	 has	similarly	 already	been	 suggested	as	 candidates	 for	 the	 generation	of	mechanical	hypersensitivity	 in	OA(McGaraughty,	Chu	et	 al.	 2010,	Chen,	 Joshi	 et	 al.	 2011,	Bautista,	Pellegrino	et	 al.	 2013,	Moilanen,	Hämäläinen	et	al.	2015),	though	failure	of	other	antagonist	candidates	make	this	picture	less	clear(*A.	
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OKUN1	2011).	It	is	also	possible	that	KO	or	antagonism	of	just	one	mechanosensitive	TRP	will	always	remain	 insufficient	 to	 provide	 meaningful	 analgesia	 due	 to	 the	 extent	 of	 redundancy	 within	 this	system,	and	especially	considering	the	associations	and	heteromeric	ion	channels	that	may	form(Goel,	Sinkins	et	al.	2002).	
It	 is	 similarly	 possible	 that	 mechanosensory	 machinery	 other	 than	 the	 TRP	 channel	 underlie	 the	development	of	mechanical	hypersensitivity	during	OA.	For	example,	increasingly	evidence	is	pointing	to	 proteins	 such	 as	 Piezo2,	 found	 through	 out	 subsets	 of	 myelinated	 and	 unmyelinated	afferents(Delmas	and	Coste	2013).	While	the	KO	of	this	protein	is	deadly(Dubin,	Schmidt	et	al.	2012),	the	 use	 of	 antisense	 oligonucleotides	 have	 established	 the	 contribution	 of	 this	 protein	 to	 both	inflammatory	and	neuropathic	mechanical	allodynia(Eijkelkamp,	Linley	et	al.	2013).		
	
6.4.4	 	 Study	Limitations	
In	 considering	 the	 results	 and	 potential	 conclusions	 of	 this	 chapter,	 it	 is	 important	 to	 consider	 the	limitations	of	the	present	study’s	design	–	both	to	provide	context	that	will	inform	the	conclusions,	but	also	suggest	potential	modifications	to	the	study	that	would	have	allowed	greater	clarity.		
Evidence	of	Structural	Pathology	
A	major	limitation	in	the	discussion	of	the	results	presented	in	this	chapter,	as	in	all	the	chapters	of	this	thesis,	 is	 the	absence	of	 analysis	of	 the	 structural	pathology	of	 these	animals.	Previous	 literature	has	established	 the	histopathological	 changes	associated	with	 this	doses(Horváth,	Tékus	et	al.	2016),	and	lower	doses(Yoon,	Won	et	al.	2015,	Uchimura,	Foote	et	al.	2016),	of	MIA	at	the	time	points	investigated	in	mice.	As	seen	in	the	rat,	these	studies	describe	roughened	cartilage	surface,	disorganization	and	cell	loss,	reduced	matrix	staining,	and	disrupted	tidemark	integrity	with	0.5mg	at	day	22(Horváth,	Tékus	et	al.	 2016).	 With	 a	 dose	 of	 0.2mg	 one	 study	 reported	 observable	 necrotic	 clefts	 in	 the	 cartilage	 at	14days(Yoon,	Won	et	al.	2015),	while	at	doses	as	low	as	62.5μg	OARSI	scores	of	4	were	reported	at	day	10(Uchimura,	Foote	et	al.	2016).	
However,	it	would	be	a	fallacy	to	assume	that	every	injection	of	MIA	was	successfully	delivered.	Even	in	a	 clinical	 setting,	 IA	 therapies	 commonly	miss	 their	mark	 (in	much	 larger	knees)	without	ultrasound	guidance(Berkoff,	 Miller	 et	 al.	 2012).	 There	 are	 similarly	 considerations	 of	 the	 potential	 off-target	effects	 of	 MIA,	 such	 as	 leaking	 from	 the	 synovial	 joint	 to	 affect	 surrounding	 tissues	 and	 drive	 pain	independently	 of	OA-like	pathology	 –	 including	potential	 uptake	by	 local	 neuronal	 endings	 to	 trigger	neuropathic	 pain.	 These	 possibilities	 undermine	 the	 assumption	 that	 a	 pain	 profile	 necessarily	demonstrates	a	successful	injection	and	the	presence	of	OA-like	changes	in	the	knee	joint.		
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The	 conclusions	 drawn	 in	 this	 study	 are	 based	 upon	 potential	 considerations	 of	 the	 extent	 of	histopathological	 changes	 and	 the	 development	 of	 an	 OA	 like	 condition	 of	 the	 knee	 –	 including	 the	potential	existence	of	an	inflammatory	phase	in	the	earlier	time	points.	These	conclusions	would	be	far	stronger	with	 a)	 evidence	 of	 such	 changes,	 on	which	 to	 base	 these	 conclusions	 and	 b)	 a	 correlation	analysis,	to	detect	any	potential	relationship	between	the	extent	of	structural	pathology	and	behaviour.	Such	 analysis	 could	 also	 allow	 the	 exclusion	 from	 analysis	 of	 animals	 in	 which	 OA	 had	 not	 been	successfully	 induced	 by	 the	 MIA	 model.	 It	 is	 possible	 that	 in	 so	 doing,	 more	 significant	 differences	between	groups	might	be	detected.	Conversely,	in	a	meta	analysis	of	studies	that	measured	behavioural	pain	 outcomes	 in	 small	 animal	models	 of	 OA,	 Suokas	 et	 al	 2014	 demonstrate	 that	 	 “Lack	of	 reported	
evidence	 that	OA	 structural	 change	was	 successfully	 induced	 in	 the	model	was	 strongly	 associated	with	
larger	effect	sizes”,	where	effect	size	refers	to	reported	analgesic	efficacy(Suokas,	Sagar	et	al.	2014).	This	analysis	 suggests	 that	 incomplete	 phenotyping	 of	 animals,	 including	 the	 failure	 to	 confirm	 structural	pathology,	may	 lead	 to	 false	 conclusions.	 In	 this	 instance,	 the	 false	 conclusion	would	 be	 to	 attribute	differences	in	the	response	to	the	different	genetic	profiles	of	these	mice,	when	these	differences	may	instead	related	to	off	target	effects	of	MIA	in	tissues	surrounding	the	joint	capsule.	
Evidence	of	inflammation	or	neuropathy	
The	informed	discussion	of	the	likely	mechanisms	underlying	the	timeline	of	the	changes	in	behavioural	profile	of	MIA	injected	mice	is	limited	by	my	failure	to	characterize	directly	any	inflammation	or	signs	of	neuropathy	in	this	model.		
As	mentioned	at	the	beginning	of	6.4.1,	while	we	know	much	about	the	rat	models	of	MIA	induced	OA,	and	extensive	work	has	been	published	 to	build	a	confident	picture	of	 the	histopathology,	behaviour,	inflammation	and	neuropathy	at	various	doses,	comparatively	much	less	work	has	been	performed	in	mice	 –	with	 a	degree	of	 variability	 in	 the	 exact	dose	 selected.	 	 It	would	be	misleading	 to	 assume	 the	initial	inflammation	seen	in	rats(Bove	2003,	Guzman,	Evans	et	al.	2003,	Fernihough,	Gentry	et	al.	2004,	Clements,	 Ball	 et	 al.	 2009,	Orita,	 Ishikawa	 et	 al.	 2011,	 Ahmed,	 Li	 et	 al.	 2012),	 or	 the	 development	 of	neuropathy	seen	in	rats	at	higher	doses,	would	translate	directly	into	a	mouse	MIA	model(Ivanavicius,	Ball	et	al.	2007,	Orita,	Ishikawa	et	al.	2011,	Thakur,	Rahman	et	al.	2012).	While	there	is	published	work	to	 suggest	 inflammation	 in	a	 contributor	 to	 the	mouse	MIA	model(van	der	Kraan,	Vitters	et	 al.	 1989,	Ogbonna,	 Clark	 et	 al.	 2012,	 Horváth,	 Tékus	 et	 al.	 2016,	 Uchimura,	 Foote	 et	 al.	 2016),	 relatively	 little	exists	to	support	the	presence	of	neuropathy	at	this	dose.	Indeed,	some	studies	have	suggested	this	is	unlikely	in	the	0.5mg	model(Ogbonna,	Clark	et	al.	2012).	
In	 order	 to	 validate	 the	 suggestions	 of	 this	 chapter	 future	 supplementary	 work	 would	 be	 required,	including	 the	 measurement	 of	 joint	 diameter,	 knee	 histology	 at	 days	 1,	 3	 and	 7-post	 MIA	 injection,	
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profiling	 of	 ATF-3,	 microgliosis,	 and	 intra-epidermal	 nerve	 fiber	 density.	 Much	 as	 with	 joint	histopathology	 above,	 this	 would	 allow	 a	 clearer	 picture	 of	 the	 timeline	 of	 pathology,	 how	 it	corresponded	with	the	hypersensitivity	observed,	and	the	differences	observed	between	WT	and	DTA	mice.	
Failure	to	use	sham,	saline	injected	mouse	controls	
While	 the	 genetic	 profile	 of	 the	mice	was	 the	 key	 experimental	 variable	 under	 investigation	 in	 the	above	 studies,	 with	 wild	 type	 littermates	 acting	 as	 controls,	 the	 failure	 to	 use	 a	 non-MIA,	 saline	injected	 control	 cohort	 of	mice	 can	 also	 be	 viewed	 as	 a	major	 limitation	 to	 the	 conclusions	 of	 this	study.			
The	 original	 decision	 not	 to	 conduct	 a	 saline	 injected	 control	 stemmed	 from	 a	 desire	 to	 limit	 the	number	of	experimental	animals	used.	Conscientious	animal	research	requires	experimenters	to	find	the	 balance	 between	 sufficiently	 powered	 experiments	 and	 the	 use	 of	 the	 minimum	 number	 of	animals	 required,	 to	 avoid	 unnecessary	 wastage	 of	 animal	 lives	 and	 suffering.	 The	 decision	 also	considered	the	challenges	of	breading	sufficient	mice	to	allow	appropriate	power	in	four		(instead	of	two)	 experimental	 arms	 in	 the	 DTA	 mouse	 experiments	 (DTA+MIA,	 DTA+Saline,	 WT+MIA,	WT+Saline),	and	in	the	case	of	the	TRP	mouse	lines	up	to	8	arms	versus	the	four	used.		
While	some	published	studies	clearly	draw	the	same	conclusion,	opting	to	not	use	a	sham	control	arm	in	their	pain	studies	in	genetically	manipulated	mouse	lines(Minett,	Nassar	et	al.	2012,	Horváth,	Tékus	et	al.	2016),	there	are	many	documented	MIA	mouse	studies	which	include	a	minimum	of	one	saline	sham	 control	 arm(So,	 Haraguchi	 et	 al.	 2015),	 as	 also	 seen	 in	 MIA	 studies	 in	 non	 genetically	manipulated	 mice(Harvey	 and	 Dickenson	 2009,	 Ogbonna,	 Clark	 et	 al.	 2012).	 These	 studies	demonstrate	 the	absence	of	effect	 from	a	saline	 injection	 to	 the	knee	over	 time,	confirming	 that	 the	injection	of	a	similar	volume	of	liquid	using	a	30G	needle	does	not	in	and	of	itself,	independent	of	the	effect	 of	 MIA	 on	 chondrocytes,	 induce	 pain	 in	 the	 knee	 at	 any	 time-point	 studied(Harvey	 and	Dickenson	2009,	Ogbonna,	Clark	et	al.	2012,	So,	Haraguchi	et	al.	2015).		It	would	however	have	been	valuable	 to	 establish,	 in	 a	 minimum	 of	 one	 arm	 (likely	 WT+Saline)	 that	 the	 injection	 procedure	performed	 with	 myself	 as	 the	 experimenter	 was	 not	 the	 key	 driver	 of	 the	 change	 in	 behaviour	observed	within	these	mice.			
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6.4.5			 Overall	Implications	
In	the	present	chapter	I	have	presented	results	that	demonstrate	that	this	0.5mg	MIA	model	induced	both	primary	and	secondary	hypersensitivity	in	wild	type,	DTA,	TRPC3	or	TRPC6	SKO	and	DKO	mouse	lines,	indicative	of	the	development	of	central	sensitization.		
The	absence	of	changes	in	punctate	mechanical	sensitivity	during	the	early	phase	of	this	MIA	model	in	the	 DTA	 mice	 could	 be	 viewed	 as	 further	 evidence	 of	 an	 initial	 inflammatory	 phase.	 It	 similarly	suggests	that	the	blockade	of	Nav1.8	may	provide	effective	analgesia	during	this	inflammatory	flares	or	synovitis	 in	patients	with	OA	pain.	 It	remains	unclear	what	mechanisms	may	drive	the	behaviour	observed	in	the	later	stages	of	this	mouse	model,	however	the	similarities	between	the	WT	and	DTA	mice	suggest	these	mechanisms	are	independent	of	Nav1.8	containing	neurones.	
Finally	this	work	has	suggested	that	the	TRPC3	and	TRPC6	receptors	are	not	crucial	contributors	to	the	development	of	mechanical	 sensitivity	 in	 this	model	of	OA	pain,	despite	 their	 role	 in	 innocuous	mechanosensation.	 Though	 these	 channels	 may	 become	 sensitized	 to	 contribute	 to	 mechanical	allodynia	during	OA,	 the	scale	of	 redundancy	 in	 the	TRP	mechanosensory	system	renders	 the	KO	of	any	one	or	two	channels	unlikely	to	effectively	protect	against	the	development	of	OA	pain.	 	
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Chapter	7	–	General	Discussion	
7.1	 	 General	Summary	Of	Findings		
The	 experiments	 performed	 and	 presented	 herein	 aimed	 to	 further	 understand	 the	 differing	contributions	of	peripheral	and	central	mechanisms	 in	the	development	and	maintenance	of	pain	 in	OA.	Particular	emphasis	was	placed	on	understanding	how	these	contributions	might	differ	with	time	and	 dose	 in	 a	 model	 of	 OA	 pain	 that	 has	 been	 demonstrated	 to	 involve	 dose	 and	 time	 dependent	inflammatory,	 chronic	 nociceptive	 and	 neuropathic	 pain	 aetiologies(Guzman,	 Evans	 et	 al.	 2003,	Fernihough,	Gentry	et	al.	2004,	Ivanavicius,	Ball	et	al.	2007,	Thakur,	Rahman	et	al.	2012).	
This	 thesis	has	demonstrated	 that	while	a	 significant	behavioural	profile	develops	 in	both	 the	early	and	 late	 stages	 of	 the	1mg	MIA	model	 of	OA	pain,	 these	 changes	 are	 only	 reflected	 in	 L5	Lamina	V	WDR	 evoked	 responses	 during	 the	 early,	 inflammatory	 stages	 of	 the	model.	 This	 suggests	 that	 the	punctate	 hypersensitivity	 at	 the	 paw	 observed	 at	 day	 3	 and	 day	 10	 are	 driven	 by	 different	 spinal	mechanisms,	in	the	absence	of	L5	central	sensitization	at	day	10.	
I	have	similarly	demonstrated	that	in	a	1mg	MIA	model	of	OA	pain,	at	both	early	and	late	stages,	there	is	an	absence	of	significant	descending	serotonergic	facilitation	and	noradrenergic	inhibition,	in	direct	contrast	 to	 previous	 work	 in	 the	 2mg	model(Rahman,	 Bauer	 et	 al.	 2009,	 Burnham	 and	 Dickenson	2013).		Recordings	in	the	brainstem,	which	failed	to	characterize	significant	adaptations	in	the	activity	of	ON	 cells,	 corroborated	 these	 conclusions	by	 suggesting	 that	 the	1mg	MIA	model	 failed	 to	 recruit	descending	controls.	
The	 overarching	 suggestion	 of	 this	 work	 with	 the	 1mg	 MIA	 model	 in	 rats	 is	 that	 OA	 pain	 lacking	neuropathic	components	fails	to	recruit	the	descending	control	of	spinal	cord	excitability.	At	days	10-14	it	seems	likely	that	joint	pathology	fails	to	drive	ongoing	nociception	from	the	knee	joint	or	inflict	consequential	 damage	 to	 local	 sensory	 endings,	 and	 subsequently	 neither	 drives	 spreading	 central	sensitization	 to	 the	 L5	 segment	 serving	 the	 paw,	 nor	 recruit	 the	 intensity	 dependent	 descending	controls.	As	such,	I	have	suggested	that	differences	in	the	aetiology	of	pain	in	the	1mg	and	2mg	models	should	directly	impact	the	extrapolation	of	results	to	the	clinic	for	development	of	pharmacotherapy	in	OA	patients.		
Finally,	 I	 have	 demonstrated	 a	 delay	 to	 the	 development	 of	 punctate	mechanical	 sensitivity	 in	DTA	mice	to	day	7	 in	a	0.5mg	MIA	model	of	OA	pain,	potentially	presenting	further	evidence	of	an	 initial	inflammatory	 phase	 in	 this	 model.	 It	 similarly	 suggests	 that	 the	 blockade	 of	 Nav1.8	 may	 provide	effective	 analgesia	during	 this	 inflammatory	 flares	or	 synovitis	 in	patients	with	OA	pain.	 It	 remains	unclear	what	mechanisms	may	drive	the	behaviour	observed	in	the	later	stages	of	this	mouse	model.	
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7.2		 	 Translational	Relevance	to	the	OA	Clinic	
The	value	of	work	conducted	at	the	bench	is	in	part	defined	by	how	it	can	inform	our	understanding	of	pain	in	a	real	world,	clinical	setting.	 	The	work	presented	within	raises	an	important	question	about	the	relevance	of	conclusions	drawn	from	pharmacology	studies	in	the	MIA	model	to	a	heterogeneous	condition	 like	OA	pain.	 It	 similarly	poses	 important	questions	around	 the	OA	patient	 segments	 that	may	best	respond	to	certain	interventions.	
	
7.2.1				 MIA	as	a	Model	of	OA	Pain	–	The	Question	of	Neuropathy?	
As	part	of	this	thesis,	clear	differences	in	the	pharmacological	profile	of	rats	10-14days	after	1mg	MIA	versus	 previous	 work	 in	 2mg	 MIA	 have	 been	 demonstrated.	 While	 the	 implied	 differences	 in	 the	recruitment	 of	 descending	 controls	 could	 be	 attributed	 to	 the	 differing	 extent	 of	 joint	 pathology,	questions	have	been	raised	about	the	possible	contribution	of	neuropathy	to	the	differences	observed	at	the	higher	dose.	The	pertinent	question	here	is	whether	neuropathy	is	driven	by	“on	target”	effect	of	MIA,	namely	joint	degeneration	damaging	sensory	endings	in	the	joint,	or	an	“off	target”	effect,	such	as	possible	leakage	of	MIA	from	the	synovial	joint	to	effect	neighbouring	endings	outside	the	joint.	
A	 simple	 proof	 of	 concept	 study	 is	 the	 injection	 of	 blue	 dye	 into	 the	 synovial	 joint	 of	 an	 adult	 rat	cadaver.	Working	on	the	assumption	of	a	similar	diffusion	pattern	between	the	dye	and	saline	solution	containing	MIA,	the	spread	of	this	dye	could	be	taken	to	model	the	reach	of	MIA	after	joint	injection	–	though	in	a	live	animal	this	would	be	expected	to	extend	further	given	both	joint	movement,	body	heat	and	bloody	 supply.	 It	 can	be	observed	 that	 the	dye	 is	 not	 entirely	 confined	 to	 the	 synovial	 capsule,	with	 spread	 into	 the	 neighbouring	 ligaments	 and	 muscle,	 all	 of	 which	 will	 be	 highly	 innervated.	However	it	has	previously	been	suggested	that	given	fastblue	is	not	taken	up	by	neurones	beyond	the	IA	space	 following	 it’s	 IA	 injection	that	perhaps	MIA	similarly	 fails	 to	effect	neurones	beyond	the	 IA	space(Thakur	2012).	Similarly	Ivanavicius	et	al	2007	suggest	that	the	time	course	of	ATF-3,	a	marker	of	neuropathy,	coincides	with	osteoclast	activity	which	may	drive	the	nerve	damage,	through	a	similar	mechanism	to	that	described	in	bone	cancer	pain(Ivanavicius,	Ball	et	al.	2007).	In	reality,	for	each	rat	injected	with	MIA	 there	may	be	 small	 contributions	of	 the	 former	and	small	 contributions	 from	 the	latter	to	drive	an	overall	pain	profile.	There	is	no	definitive	answer	on	the	origins	of	the	neuropathy.	
While	 there	 is	 no	 clear-cut	 conclusion	 regarding	 the	 origins	 of	 neuropathy	 in	 the	MIA	model,	 it	 is	questionable	how	important	this	is	given	the	aetiology	of	neuropathy	does	not	directly	determine	the	pain	profile	of	patients.	Previous	work	characterizing	the	neuropathic	pain	profiles	 into	distinct	sub	groups,	based	upon	patters	of	gain	and	loss	of	function,	have	shown	that	while	certain	profiles	may	be	
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more	common	to	certain	diseases	they	are	not	exclusive(Baron,	Tölle	et	al.	2009,	Maier,	Baron	et	al.	2010,	 Baron,	 Förster	 et	 al.	 2012).	 As	 such	 the	 question	 is	 not	what	 causes	 neuropathy	 in	 the	 2mg	model	of	MIA,	but	whether	neuropathy	itself	is	reflective	of	the	clinical	reality,	and	how	differences	in	the	pharmacology	between	1mg	and	2mg	models	may	be	similarly	reflected	in	patient	populations.		
As	discussed	briefly	 in	Section	3.1.5,	while	not	reflective	of	the	majority	there	is	a	sub	population	of	OA	patients	with	pain	characteristics	and	sensory	changes	indicative	of	neuropathy(Hurley,	Scott	et	al.	1997,	 Sharma	1999,	Hawker,	 Stewart	 et	 al.	 2008,	 Shakoor,	 Agrawal	 et	 al.	 2008,	 Felson,	 Gross	 et	 al.	2009,	Gwilym,	Keltner	et	al.	2009,	Shigemura,	Ohtori	et	al.	2011,	Hochman,	Davis	et	al.	2013,	Oteo‐Álvaro,	Ruiz‐Ibán	et	al.	2014).	The	use	of	modified	pain	questionnaires	and	QST	has	suggested	that	~20%	of	OA	patients	may	have	neuropathic	contributions	to	their	pain(Hochman,	Davis	et	al.	2013),	though	some	predictions	are	as	high	as	33%(Oteo‐Álvaro,	Ruiz‐Ibán	et	al.	2014).	 	As	reviewed	by	Thakur	 et	 al	 2014,	 nerve	 lesions,	 denervation	 and	 de	 novo	 innervation	 in	 OA	 patients	 have	 been	characterized	following	samples	during	joint	replacement	surgery(Thakur,	Dickenson	et	al.	2014).	As	such	it	can	be	argued	that	use	of	data	from	rats	which	have	received	doses	of	MIA	≥2mg,	at	roughly	day	14	onwards,	may	model	pain	reflective	of	this	not	unsubstantial	group	of	neuropathic	OA	patients	–	this	could	be	estimated	to	be	as	many	as	1.7million	people	in	the	UK	alone(Smith	2012).	Meanwhile	data	from	rats	that	have	received	doses	<2mg	may	be	a	more	representative	model	for	the	majority	of	patients,	whose	pain	is	driven	by	a	mixture	of	inflammation	and	chronic	nociception.		
Thus,	it	could	be	postulated	that	the	MIA	model	may	provide	a	useful	tool	for	investigating	differences	in	 the	 pain	 properties	 and	 pharmacological	 response	 profiles	 of	 patients	with	 neuropathic	 or	 non-neuropathic	 characteristics.	 This	 could	 allow	 the	 optimization	 of	 pharmacotherapy	 for	 more	successful	 analgesia	 in	 OA,	 such	 that	 prescriptions	 could	 become	 personalized	 to	 the	 individual	patient	 profile.	 	 Examples	 of	 the	 relevance	 can	 be	 seen	 from	 the	 failure	 of	 gabapentinoids	 in	 OA	Pain(Vedula,	 Bero	 et	 al.	 2009).	 Previous	 work	 using	 the	 MIA	 model	 has	 shown	 that	 pregabalin	 is	effective	in	the	2mg	but	not	the	1mg	model	(Thakur,	Rahman	et	al.	2012)–	as	such	it	may	be	the	case	that	if	patients	had	been	segmented	by	the	qualities	of	the	pain,	using	QST	or	a	modified	PainDETECT	questionnaire,	the	end	points	may	have	been	met	in	the	smaller	neuropathic	sub	group.	This	concept	has	 been	 demonstrated	 in	 a	 small	 trial	 of	 89	 patients	 using	 a	 combination	 of	 pregabalin	 and	meloxicam,	 which	 demonstrated	 that	 patients	 with	 higher	 PainDETECT	 scores	 reported	 greater	analgesia	than	those	whose	pain	had	fewer	neuropathic	qualities(Ohtori,	Inoue	et	al.	2013).			
At	present	the	use	of	pain	questionnaires,	QST	and	enriched	enrollment	 is	 incredibly	rare	 in	clinical	trials	 of	 OA	 pain.	 At	 present,	 Clinicaltrials.gov	 lists	 just	 two	 OA	 trials	 testing	 pharmacological	intervention	that	utilize	PainDETECT	or	QST	as	an	end	point,	and	one	of	these	was	terminated	prior	to	completion.	Given	the	differences	observed	in	pregabalin	sensitivity	depending	on	the	dosage	of	MIA,	
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it	is	possible	that	we	will	continue	to	experience	clinical	failures	in	OA	pain	unless	we	segment	patient	groups.	
	
7.2.2			 Manipulating	 Descending	 Controls	 to	 Achieve	 Analgesia	 In	 OA	 Patients	 with	
Neuropathic	Pain	Qualities	
The	results	presented	within	this	thesis	have	suggested	that	while	previous	work	has	demonstrated	that	 descending	 noradrenaline	 and	 serotonin	may	 be	 recruited	 to	 the	 control	 of	 spinal	 excitability	during	a	2mg	MIA	model	of	OA(Rahman,	Bauer	et	al.	2009,	Burnham	and	Dickenson	2013),	this	is	not	the	case	during	the	1mg	model.	The	broad	implication	to	the	clinic	is	that	interventions	like	duloxetine	(Cymbalta),	an	SNRI	used	for	both	the	management	of	mood	and	pain	conditions,	might	provide	more	effective	analgesia	in	those	patients	classified	as	having	pain	with	neuropathic	like	qualities.	Cymbalta	is	 licensed	 in	 the	US	 for	musculoskeletal	 pain	 (including	 the	management	 of	 OA)	 but	 failed	 to	 gain	approval	 in	 the	 EU	 after	 “unfavourable	 risk-benefit	 balance”	 because	 “the	 clinical	 relevance	 of	 the	effect	 is	 not	 established”((EMA)	 2012).	 It	 is	 interesting	 to	 consider	 whether,	 had	 Lilly	 opted	 to	segment	 patients	 using	 QST	 or	 questionnaires,	 whether	 they	 would	 have	 defined	 a	 sub	 group	 of	patients	in	which	efficacy	was	“clinically	relevant”	as	per	the	reviewer’s	requirements.		
	
7.2.3			 Viability	of	Nav1.8	for	Analgesia	in	OA	Pain	
The	 translation	 of	 the	 implications	 of	 the	 MIA	 induced	 pain	 profile	 in	 DTA	 mice	 is	 a	 little	 less	straightforward.	 The	 results	 of	 this	 study	 suggest	 that	Nav1.8	 antagonism	might	 provide	 successful	analgesia	 to	 patients	 in	 the	 earlier,	 inflammatory	 stage	 of	 OA	 pain,	where	 pain	 is	 driven	mostly	 by	inflammation	and	mechanical	nociception.	
However,	the	ablation	of	a	complete	population	of	neurones	based	on	the	expression	of	Nav1.8	is	not	the	equivalent	of	successful	pharmacological	blockade	of	Nav1.8.	While	antagonizing	 these	channels	should	theoretically	provide	a	degree	of	disruption	of	transmission	in	this	population,	the	expression	and	 action	 of	 Nav1.7	 could	 be	 postulated	 to	 be	 sufficient	 to	 maintain	 the	 transmission	 of	 noxious	mechanical	sensation	and	inflammatory	pain,	based	on	work	comparing	the	profiles	of	Nav1.8	KO	and	Nav1.7-Nav1.8	 DKO	 mice(Nassar,	 Levato	 et	 al.	 2005).	 While	 the	 neuropathic	 pain	 profile	 was	indistinguishable	across	 these	 two	mouse	populations	and	WT	mice,	only	 the	DKO	mouse	exhibited	increased	noxious	mechanical	thresholds	and	resistance	to	inflammatory	pain,	while	the	Nav1.8	single	KO	mouse	 had	 a	 largely	 similar	 profile	 to	 the	WT	mice(Nassar,	 Levato	 et	 al.	 2005).	 As	 such,	 there	appears	 to	 be	 a	 critical	 role	 of	 the	 combined	 loss	 of	 Nav1.7	 and	 Nav1.8	 transmission	 to	 achieve	
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analgesia,	which	may	suggest	that	an	antagonist	that	shows	selectivity	for	just	Nav1.8	may	fail	where	a	dual	antagonist	succeeds.	
Similarly,	consideration	must	also	be	paid	 to	 the	effect	of	chronic	use	of	any	pharmacological	agent.	Namely	 we	must	 consider	 whether	 chronic	 antagonism	 of	 any	 sodium	 channel	might	 result	 in	 the	compensatory	 up-regulation	 of	 the	 target	 channel,	 to	 drive	 the	 development	 of	 tolerance	 such	 that	larger	doses	are	required,	increasing	the	risk	that	effects	are	seen	at	off	target	channels	in	the	heart,	but	 also	 compensatory	 up-regulation	 or	 down-regulation	 of	 other	 channels	 and	 proteins.	 As	 has	already	 been	mentioned,	 the	 KO	 of	Nav1.8	 results	 in	 a	 compensatory	 increase	 in	 the	 expression	 of	Nav1.7(Akopian,	Souslova	et	al.	1999).	 In	a	chronic	disease	 like	OA,	where	dosing	could	conceivable	continue	for	a	matter	of	years	with	a	well-tolerated	drug,	such	modifications	must	also	be	considered.	These	 adaptations	 are	 seen	 within	 opiate	 and	 monoamine	 systems(Pan	 2007,	 Fava	 and	 Offidani	2011),	where	it	would	be	interesting	to	characterize	if	this	is	the	case	for	sodium	channels.	
Finally,	 consideration	 must	 also	 be	 given	 to	 those	 Nav1.8	 antagonists	 already	 in	 development.	 In	direct	 contrast	 to	 the	 conclusions	 I	 draw	 from	KO	animals,	 these	 studies	 claim	analgesic	 efficacy	 of	
selective	Nav1.8	antagonists	in	both	inflammatory	and	neuropathic	pain	conditions	in	animal	models,	in	direct	contrast	to	expectations	from	genetic	studies(Jarvis,	Honore	et	al.	2007,	Payne,	Brown	et	al.	2015).	 However,	 the	 newest	 compound	 is	 yet	 to	 demonstrate	 efficacy	 in	 a	 clinical	 setting,	 where	translation	between	animal	models	into	patients	have	presented	challenging	–	with	recent	failures	in	post-surgical	 dental	 pain(Skerratt	 and	West	 2015).	 It	 is	 possible	 that	while	 blockade	 of	Nav1.8	 can	provide	 some	degree	of	 relief	 that	 this	analgesia	will	only	achieve	 clinical	 relevance	 in	 combination	with	a	Nav1.7	blocker	–	also	in	extensive	clinical	development	at	present.	
	
	 	
		 247	
7.3	 		 Methodological	Considerations	
No	 experimental	 technique	 for	 the	 pre-clinical	 investigation	 of	 pain	 mechanisms	 is	 a	 perfect	representation	 of	 clinical	 reality,	 however	 our	 awareness	 of	 the	 limitations	 give	 context	 to	 the	conclusions	we	draw.	
	
7.3.1	 		 Further	considerations	when	using	the	MIA	model		
Beyond	 considerations	 of	 the	 contributions	 of	 neuropathy	 to	 the	 pain	 profile	 of	 rats	 following	 the	injection	of	different	doses	of	MIA,	it	is	important	to	understand	in	more	depth	the	ultimate	relevance	of	observations	 from	the	MIA	model	 to	 the	clinical	 reality	of	OA.	As	discussed	briefly	 in	Section	3,	a	large	body	of	work	suggests	the	MIA	model	effectively	simulates	the	histopathology,	hypersensitivity	and	disease	progression	observed	in	patients.		
Common	 to	 both	 patients	 and	 rats	 are	 periods	 of	 inflammation(Fernandez-Madrid,	 Karvonen	 et	 al.	1994,	Bove	2003,	Guzman,	Evans	et	al.	2003,	Fernihough,	Gentry	et	al.	2004,	Bonnet	and	Walsh	2005,	Clements,	 Ball	 et	 al.	 2009);	 cartilage	 loss,	 fibrillation	 and	 compositional	 changes(Dunham,	 Hoedt-Schmidt	et	al.	1992,	Poole	1993,	Guingamp,	Gegout-Pottie	et	al.	1997,	Eyre	2004);	and	eventual	bone	remodeling,	 including	osteophyte	 formation,	cysts,	and	 lost	density(Kean,	Kean	et	al.	2004,	Wieland,	Michaelis	 et	 al.	 2005,	 Mohan,	 Perilli	 et	 al.	 2011).	 However	 while	 the	 similarities	 between	 these	structural	 changes	 are	 clear,	 the	 differences	 in	 the	 time	 course	 and	 aetiology	must	 be	 considered.	While	 the	 MIA	 model	 presents	 a	 time	 course	 with	 an	 established	 initial	 week	 of	 inflammation,	synovitis	in	patients	can	be	episodic	–	observed	in	both	the	early	years	and	severe,	late	stages(Benito,	Veale	 et	 al.	 2005,	 D’Agostino,	 Conaghan	 et	 al.	 2005).	 As	 such,	 testing	 during	 the	 second	week	 and	beyond	in	MIA	animals	may	fail	to	characterize	inflammatory	components	observed	in	the	general	OA	population,	which	 themselves	may	 be	 an	 important	 contributor	 to	 pain.	 Periods	 of	 synovitis	would	similarly	 show	 different	 response	 properties	 to	 pharmacotherapy	 –	 perhaps	 this	may	 explain	 how	NSAID	efficacy	is	lost	during	the	late	stages	of	the	MIA	model	yet	NSAID	pharmacotherapy	persists	in	the	clinic(Fernihough,	Gentry	et	al.	2004,	Pomonis,	Boulet	et	al.	2005).		
Given	 a	 role	 for	 descending	 controls	 in	 inflammatory	 pain	 has	 previously	 been	 established(Green,	Lyons	et	al.	1998,	Green,	Scarth	et	al.	2000,	Rahman,	Suzuki	et	al.	2004),	the	impact	of	this	on	this	on	the	 conclusions	 I	 have	 drawn,	 that	 pharmacotherapies	 manipulating	 descending	 controls	 such	 as	duloxetine	may	 not	 be	 effective	 in	 non	 neuropathic	 OA	 pain,	may	 be	 too	 simplistic.	 It	may	 be	 that	SSRIs	 and	 SNRIs	 may	 be	 effective	 in	 patients	 with	 either	 inflammatory	 flares	 or	 neuropathic	 pain	characteristics,	but	not	those	patients	in	a	period	where	pain	is	driven	by	neither	of	the	above.		
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There	 similarly	 remain	questions	 about	 the	presence	or	not	 of	 central	 sensitization	during	 the	MIA	model.	As	was	highlighted	in	the	discussions	of	Section	3,	there	is	no	clear-cut	consensus	on	whether	the	injection	of	MIA	enhances	the	evoked	responses	of	WDR	cells	in	lamina	V.	While	3	studies	point	to	significant	increases	in	the	responses	evoked	by	vF(Harvey	and	Dickenson	2009,	Rahman,	Bauer	et	al.	2009,	 Burnham	2012),	 another	 3	 failed	 to	 replicate	 this(Vonsy	 2008,	 Patel	 2012,	 Thakur	 2012).	 In	part,	 this	may	be	 attributed	 to	 the	 sample	 size,	where	 cell	 populations	of	 just	~n=7	per	 group	may	allow	one	or	two	very	active	cells	to	skew	the	data.	However,	in	the	case	of	both	Burnham	et	al	2012	and	Thakur	et	al	2012,	data	 for	a	number	of	studies	were	compiled	to	provide	study	populations	of	between	30-45	cells(Burnham	2012,	Thakur	2012),	which	statistically	would	be	expected	to	even	this	effect	 out.	 It	 would	 be	 revealing	 to	 pool	 the	 data	 across	 the	 5	 rat	 studies	 cited,	 along	 with	 other	historical	lab	data	to	create	a	stronger	consensus.	As	it	stands,	my	data	suggests	there	is	not	–	at	least	in	the	1mg	MIA	model	–	a	clear	spreading	central	sensitization	in	these	animals	 in	the	 late	stages	of	the	model.	This	creates	questions	about	 the	validity	of	a	1mg	model	 for	 investigating	OA	pain	given	the	clear	consensus	around	the	presence	of	central	sensitization	in	the	clinic.	This	may	again	link	back	to	 the	 question	 of	 inflammation,	 since	 I	 did	 demonstrate	 central	 sensitization	 during	 the	 early	inflammatory	 phase.	 Perhaps	 in	 the	 clinic,	 central	 sensitization	 is	 maintained	 by	 evolving	contributions	 of	 inflammation,	 mechanical	 nociception	 and	 neuropathy	 -	 whereas	 in	 the	 10-14day	period	of	the	1mg	MIA	model	there	is	not	sufficient	drive	to	maintain	central	sensitization	from	either	of	 these	mechanisms.	 It	 is	 possible	 instead	 that	 this	 time	 point	 in	 the	 1mg	MIA	model	may	 better	represent	 the	 very	 early	 stages	 of	 OA,	 before	 the	 patient	 seeks	 medical	 assistance	 or	 progresses	beyond	paracetamol	for	the	management	of	their	pain.	
	
7.3.2	 		 Limitations	of	in	vivo	Electrophysiology	
in	vivo	 electrophysiology	 is	an	exceptionally	valuable	 tool,	providing	quantitative	 information	of	 the	responses	 of	 neurones	 in	 the	 PNS	 and	 CNS	 to	 suprathreshold	 stimuli,	 both	 in	 healthy	 animals	 and	pathological	 conditions.	 The	 value	 of	 these	 techniques	 above	 behaviour,	 though	 the	 information	 is	complimentary,	 is	 allowing	 experimenters	 to	 develop	 an	 understanding	 of	 changes	 that	 would	otherwise	be	unobservable	 from	behaviour,	or	even	unethical	 to	pursue	–	namely	hyperalgesia.	For	example,	 that	a	drug	may	quench	the	responses	of	a	 lamina	V	WDR	to	50*C	water	may	be	observed	using	 spinal	 electrophysiology,	 however	 if	 the	 evoked	 response	 is	 still	 greater	 than	 the	withdrawal	threshold	this	may	not	be	observed	with	behaviour.		
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However,	 there	are	 limitations	 to	 the	 technique,	which	are	applicable	 for	both	 the	 recordings	made	from	 the	 spinal	 cord	 and	 the	 RVM.	 The	 process	 of	 cell	 searching,	 which	 crudely	 involves	 the	application	 of	 a	 stimulus	while	 listening	 and	 looking	 for	 responses	 on	 an	 oscilloscope	while	 gently	altering	 the	electrodes	position,	 is	heavily	biased	by	experimenter	 selection	and	 “low	hanging	 fruit”	cells,	 which	 may	 skew	 cell	 sample	 demographics.	 The	 first	 is	 demonstrated	 by	 the	 differences	 in	baseline	 responses	 observed	 in	 naïve	 animals	 between	 different	 experimenters	 –	 take	Thakur	 et	 al	2012,	which	characterized	a	mean	response	to	60g	vF	>1100	action	potentials,	while	Burnham	et	al	characterized	 a	 mean	 nearer	 800	 action	 potentials(Burnham	 2012,	 Thakur	 2012),	 despite	 study	populations	 of	 n=21	 and	 n=39	 respectively.	 Such	 differences	 are	 understood	 to	 be	 driven	 by	 the	experimenter	selection	process,	where	one	individual	may	be	more	likely	to	characterize	more	“noisy”	and	active	cells	than	another,	for	a	variety	of	reasons.	In	a	similar	vane,	the	concept	of	“low	hanging	fruit”	 cells	 –	 cells	which	 are	more	 active,	with	 larger	 evoked	 responses	or	 a	 degree	of	 spontaneous	activity	will	be	easier	 to	 identify	and	perhaps	more	attractive	 to	 follow,	 to	 the	disadvantage	of	 cells	with	a	more	phasic	or	 sedate	 response	profile.	As	 such,	 the	conclusions	drawn	 from	any	study	may	only	apply	to	one	population	of	many	within	both	the	spinal	cord	and	the	brain.	
This	 limitation	 especially	 holds	 true	 for	 characterization	 of	 cells	 in	 the	 RVM,	where	 the	 search	 for	specific	 response	 profiles	may	 cause	 the	 experimenter	 to	 fail	 to	 identify	 cells	 or	move	 on	 because	during	that	particular	 time	period	the	cell	was	silent	or	unresponsive.	 	This	 is	especially	relevant	 to	the	study	of	chronic	pain	conditions,	since	there	would	be	huge	value	in	knowing	if	perhaps	chronic	pain	silences	or	causes	identity	switched	in	cells	of	the	RVM.	While	population	studies	may	seem	like	a	viable	alternate,	they	may	be	misleading	given	these	too	are	inherently	biased	by	the	search	strategy	and	operator	choice.			
	
7.3.3	 	 Limitations	of	KO	Mice	for	the	Study	of	Pain	Mechanisms	
The	use	of	knock	out	mice	for	the	study	of	healthy	and	pathological	pain	has	been	a	valuable	tool	for	experimenters,	where	the	deletion	of	genes	may	allow	direct	inferences	about	function	based	on	the	resulting	phenotype.	However,	the	tool	is	not	perfect	–	the	deletion	of	one	gene	can	commonly	have	no	effect	 at	 all,	 unexpected	 effects	 in	 out	 of	 scope	 systems	 or	 simply	 result	 in	 death	 of	 the	 mouse	(Barbaric,	Miller	et	al.	2007)–	as	was	the	case	for	Nav1.7	global	KO	mice(Minett,	Nassar	et	al.	2012).	Relevant	 to	 this	 work	 is	 the	 lack	 of	 effect	 on	 mouse	 phenotype,	 where	 failing	 to	 characterize	 a	difference	following	double	KO	of	TRPC3	and	TRPC6	does	not	necessarily	exclude	these	proteins	from	the	 generation	 of	 allodynia	 during	OA.	 Another	 functional	mechnoceptor	 “steps	 in”	 to	make	 up	 the	difference,	 as	 is	 seen	 in	 SKO	mice	 and	 blood	 pressure(Spassova,	 Hewavitharana	 et	 al.	 2006).	 This	
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functional	 redundancy	 may	 hide	 the	 involvement	 of	 TRPC3	 and	 TRPC6	 in	 the	 development	 of	mechanical	allodynia	 in	 the	MIA	model	of	OA	pain	–	 though	regardless	 it	may	suggest	 this	 is	a	poor	pharmacological	target	for	the	treatment	of	allodynia.	
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7.4	 	 Further	Research	
A	continuing	 suggestion	and	question	 following	 these	 studies	 is	whether	 the	 failure	 to	demonstrate	central	 sensitization	 and	 recruitment	 of	 descending	 controls	 from	 the	 brainstem	at	 days	 10-16	 is	 a	time	 sensitive	 conclusion.	 In	 previous	 studies	 in	which	28+	day	 end	points	 are	 used,	 after	 doses	 of	both	1mg	or	2mg	MIA,	 this	model	 of	OA	 is	 demonstrated	 to	be	more	pronounced.	 Sagar	 et	 al	 2010	similarly	 failed	 to	 demonstrate	 any	 alterations	 in	 spinal	 cord	 excitability	 at	 days	 14-17	 to	 punctate	stimulation,	 but	 characterizing	 a	 significant	 sensitivity	 at	 days	 28-31	 to	mid-range	 punctate	 stimuli	that	 correlated	 strongly	 to	 joint	 pathology(Sagar,	 Staniaszek	 et	 al.	 2010).	 A	 similar	 time	 dependent	recruitment	of	descending	control	has	been	observed	from	the	“unmasking”	effect	of	spinalizations	at	the	28th	day	of	a	1mg	MIA	model(Kelly,	Dobson	et	al.	2013),	and	the	time	dependent	efficacy	of	a	NA	re-uptake	 inhibition	 to	 resolve	 incapacitance	 at	 week	 3	 of	 the	 1mg	model(Whiteside,	 Dwyer	 et	 al.	2010).	As	such,	it	would	be	interesting	to	characterize	if	later	days	in	the	1mg	model,	perhaps	at	days	28	 and	 35,	 enhancements	 of	 evoked	 responses	 of	 WDR	 neurones	 and	 recruitment	 of	 descending	serotonergic	 and	 noradrenergic	 controls	 can	 be	 observed.	 This	 would	 further	 support	 conclusions	made	within	 that	 at	days	10-14	of	 the	1mg	model	 that	 the	drive	 from	 the	arthritic	knees	 is	not	yet	sufficient	to	recruit	descending	controls,	as	the	2mg	MIA	model	does.	It	would	be	similarly	interesting	to	characterize	the	RVM	at	these	 later	days	of	the	1mg	MIA	model,	and	extend	RVM	studies	 into	the	2mg	 MIA	 model	 to	 demonstrate	 any	 differences	 in	 the	 activity	 of	 RVM	 neurones	 in	 both	 a	 more	advanced	joint	pathology	and	a	mildly	neuropathic	OA	pain	model.	
These	 studies	 have	 similarly	 only	 looked	 to	 characterize	 descending	 serotonergic	 facilitation	 in	 the	1mg	 MIA	 model.	 Previous	 work	 has	 demonstrated	 that	 at	 the	 late	 stages	 of	 the	 2mg	 MIA	 model	descending	5HT	acting	 at	 the	5HT7	 receptor	provided	 a	 tonic	 regulation	of	 thermal	 processing	 that	was	 increased	 versus	 naïve	 animals,	 likely	 as	 a	 consequence	 of	 differing	 joint	 pathology(Burnham	2012).	Conversely,	the	tonic	inhibition	of	mechanically	evoked	responses	through	5HT	at	this	receptor	was	 much	 smaller	 in	 the	 MIA	 animals	 than	 in	 naïve	 animals.	 This	 suggests	 that	 in	 addition	 to	adaptations	in	facilitatory	serotonergic	systems(Rahman,	Bauer	et	al.	2009),	similar	adaptations	may	occur	 in	 the	serotonergic	 inhibitory	system.	 In	parallel	 the	above	suggested	studies,	 there	would	be	value	n	completing	the	picture	by	gaining	an	understanding	of	the	contribution	of	5HT	acting	at	5HT7	at	days	3,	14	and	28	of	the	1mg	MIA	model.	
Finally	there	may	be	value	in	exploring	these	changes	to	descending	control	systems	in	a	model	of	OA	pain	that	does	not	 involve	the	introduction	of	a	toxin	into	the	knee,	but	 instead	follows	an	aetiology	more	 similar	 to	OA	 in	 the	 clinic	with	 the	more	 ongoing	 presence	 of	 inflammation	 discussed	 above,	such	 as	 the	meniscal	 transection	model.	 This	model	maintains	 a	 greater	 inflammation	 score	 across	time	points(Mapp,	Sagar	et	al.	2013),	unlike	MIA,	where	the	study	of	descending	controls	and	Nav1.8	
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blockers	 following	 meniscal	 transection	 may	 provide	 greater	 insight	 to	 the	 monoaminergic	contributions	to	pain	in	those	patients	experiencing	synovitis/inflammatory	flares.	
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7.5			 	 Closing	Remarks	
The	work	I	have	presented	in	this	thesis,	when	considered	in	the	context	of	previous	work	from	this	lab	 and	 others	 in	 the	 MIA	 model	 of	 OA	 pain,	 suggests	 that	 pain	 mechanisms,	 notably	 descending	control	of	pain,	will	 vary	considerably	between	 the	different	 stages	of	OA,	where	 the	extent	of	 joint	pathology,	 inflammatory	 flares	 or	 neuropathy,	 themselves	 a	 factor	 of	 time	 from	 induction,	 will	determine	 to	what	 extent	descending	 controls	 are	 recruited.	The	 impact	 of	 these	 conclusions	 is	 the	suggestion	that	successful	analgesia	in	OA	may	rely	on	patient	segmentation	–	sorting	patients	using	QST	and	pain	questionnaires	and	prescribing	based	on	the	pain	profile,	where	the	conclusions	within	suggest	 that	 those	patients	with	 the	most	 neuropathic	 like	 qualities	 to	 their	 pain	may	benefit	most	from	 SNRI	 therapy,	while	 those	 patients	with	 inflammatory	 flares	might	 benefit	more	 from	Nav1.8	blockade.	
	
It	 is	 my	 hope	 that	 the	 studies	 presented	 within	 this	 thesis	 have	 contributed	 further	 to	 our	understanding	 of	 the	 contributions	 to	 pain	 in	 OA,	 particularly	 with	 reference	 to	 the	 utility	 of	manipulating	descending	controls	to	provide	analgesia,	and	will	help	shape	future	approaches	to	pain	management	in	OA	pain.	
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Chapter	8	–	Appendix	
Appendix	1:	Spinal	Cord	Electrophysiology	–	Saline	Controls	in	Naïve	Rats	
		
The	evoked	responses	of	Lamina	V	WDR	cells	following	the	application	of	vF	hairs,	thermal	water	jet	or	electrical	stimulation	to	the	paw	in	naïve	rats	is	unchanged	following	the	application	of	saline	to	the	spinal	cord.	Evoked	responses	exhibit	a	stimulus	intensity	dependent	increase	in	the	number	of	action	potentials	with	increasingly	noxious	mechanical	or	thermal	stimulation.	This	stimulus	dependent	relationship	is	unchanged	following	saline.				 	
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Appendix	1	–	Mechanical,	thermal	and	electrically	evoked	responses	of	Lamina	V	WDR	cells	in	naive	rats	are	unchanged	
following	the	spinal	cord	application	of	saline	(n=5)	
		 256	
Appendix	2:	Comparison	of	ON	Cell	Responses	To	Somatic	Simulation	in	MIA	rats	–	
During	and	After	Stimulus	
Appendix	2	-	The	response	of	RVM	ON-cells	to	mechanical	stimulation	of	the	knee	and	paw	in	rats	14-16days	after	
the	 IA	 injection	of	1mg	MIA	–	Maximum	rate	of	change	of	firing	of	pre-characterized	ON	cells	either	during	the	20second	application	or	for	the	20seconds	after	the	removal	of	a	mechanical	stimuli	–	knee	pinch,	100g,	60g,	26g,	15g	or	8g	von	Frey.	The	greatest	change	 in	 the	rate	of	 firing	was	observed	 in	 the	“after”	responses,	which	exhibit	a	greater	SD	 in	10	out	of	12	comparisons.	 	
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